<html xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns:m="http://schemas.microsoft.com/office/2004/12/omml"
xmlns="http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 15">
<meta name=Originator content="Microsoft Word 15">
<link rel=File-List href="thesis-github_files/filelist.xml">
<link rel=Edit-Time-Data href="thesis-github_files/editdata.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:OfficeDocumentSettings>
  <o:RemovePersonalInformation/>
  <o:RemoveDateAndTime/>
 </o:OfficeDocumentSettings>
</xml><![endif]-->
<link rel=themeData href="thesis-github_files/themedata.thmx">
<link rel=colorSchemeMapping href="thesis-github_files/colorschememapping.xml">
<!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:TrackMoves>false</w:TrackMoves>
  <w:TrackFormatting/>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>EN-US</w:LidThemeOther>
  <w:LidThemeAsian>JA</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:UseWord2010TableStyleRules/>
   <w:DontGrowAutofit/>
   <w:SplitPgBreakAndParaMark/>
   <w:EnableOpenTypeKerning/>
   <w:DontFlipMirrorIndents/>
   <w:OverrideTableStyleHps/>
   <w:UseFELayout/>
  </w:Compatibility>
  <w:DoNotOptimizeForBrowser/>
  <m:mathPr>
   <m:mathFont m:val="Cambria Math"/>
   <m:brkBin m:val="before"/>
   <m:brkBinSub m:val="&#45;-"/>
   <m:smallFrac m:val="off"/>
   <m:dispDef/>
   <m:lMargin m:val="0"/>
   <m:rMargin m:val="0"/>
   <m:defJc m:val="centerGroup"/>
   <m:wrapIndent m:val="1440"/>
   <m:intLim m:val="subSup"/>
   <m:naryLim m:val="undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="false"
  DefSemiHidden="false" DefQFormat="false" DefPriority="99"
  LatentStyleCount="371">
  <w:LsdException Locked="false" Priority="0" QFormat="true" Name="Normal"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 1"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 2"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 3"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 4"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 5"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 6"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 7"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 8"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 9"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 6"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 7"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 8"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 9"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 1"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 2"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 3"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 4"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 5"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 6"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 7"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 8"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 9"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Normal Indent"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="footnote text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="annotation text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="header"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="footer"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index heading"/>
  <w:LsdException Locked="false" Priority="35" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="caption"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="table of figures"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="envelope address"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="envelope return"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="footnote reference"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="annotation reference"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="line number"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="page number"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="endnote reference"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="endnote text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="table of authorities"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="macro"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="toa heading"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number 5"/>
  <w:LsdException Locked="false" Priority="10" QFormat="true" Name="Title"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Closing"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Signature"/>
  <w:LsdException Locked="false" Priority="1" SemiHidden="true"
   UnhideWhenUsed="true" Name="Default Paragraph Font"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text Indent"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Message Header"/>
  <w:LsdException Locked="false" Priority="11" QFormat="true" Name="Subtitle"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Salutation"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Date"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text First Indent"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text First Indent 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Note Heading"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text Indent 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text Indent 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Block Text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Hyperlink"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="FollowedHyperlink"/>
  <w:LsdException Locked="false" Priority="22" QFormat="true" Name="Strong"/>
  <w:LsdException Locked="false" Priority="20" QFormat="true" Name="Emphasis"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Document Map"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Plain Text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="E-mail Signature"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Top of Form"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Bottom of Form"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Normal (Web)"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Acronym"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Address"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Cite"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Code"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Definition"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Keyboard"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Preformatted"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Sample"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Typewriter"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Variable"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Normal Table"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="annotation subject"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="No List"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Outline List 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Outline List 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Outline List 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Simple 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Simple 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Simple 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Colorful 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Colorful 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Colorful 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 6"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 7"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 8"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 6"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 7"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 8"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table 3D effects 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table 3D effects 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table 3D effects 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Contemporary"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Elegant"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Professional"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Subtle 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Subtle 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Web 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Web 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Web 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Balloon Text"/>
  <w:LsdException Locked="false" Priority="39" Name="Table Grid"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Theme"/>
  <w:LsdException Locked="false" SemiHidden="true" Name="Placeholder Text"/>
  <w:LsdException Locked="false" Priority="1" QFormat="true" Name="No Spacing"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 1"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 1"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 1"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 1"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 1"/>
  <w:LsdException Locked="false" SemiHidden="true" Name="Revision"/>
  <w:LsdException Locked="false" Priority="34" QFormat="true"
   Name="List Paragraph"/>
  <w:LsdException Locked="false" Priority="29" QFormat="true" Name="Quote"/>
  <w:LsdException Locked="false" Priority="30" QFormat="true"
   Name="Intense Quote"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 1"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 1"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 1"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 1"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 1"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 1"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 2"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 2"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 2"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 2"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 2"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 2"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 2"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 2"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 3"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 3"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 3"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 3"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 3"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 3"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 3"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 3"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 4"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 4"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 4"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 4"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 4"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 4"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 4"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 4"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 5"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 5"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 5"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 5"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 5"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 5"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 5"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 5"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 6"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 6"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 6"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 6"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 6"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 6"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 6"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 6"/>
  <w:LsdException Locked="false" Priority="19" QFormat="true"
   Name="Subtle Emphasis"/>
  <w:LsdException Locked="false" Priority="21" QFormat="true"
   Name="Intense Emphasis"/>
  <w:LsdException Locked="false" Priority="31" QFormat="true"
   Name="Subtle Reference"/>
  <w:LsdException Locked="false" Priority="32" QFormat="true"
   Name="Intense Reference"/>
  <w:LsdException Locked="false" Priority="33" QFormat="true" Name="Book Title"/>
  <w:LsdException Locked="false" Priority="37" SemiHidden="true"
   UnhideWhenUsed="true" Name="Bibliography"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="TOC Heading"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark"/>
  <w:LsdException Locked="false" Priority="51" Name="Grid Table 6 Colorful"/>
  <w:LsdException Locked="false" Priority="52" Name="Grid Table 7 Colorful"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 1"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 1"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 1"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 1"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 2"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 2"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 2"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 2"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 3"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 3"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 3"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 3"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 4"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 4"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 4"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 4"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 5"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 5"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 5"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 5"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 6"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 6"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 6"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 6"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 6"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 6"/>
  <w:LsdException Locked="false" Priority="46" Name="List Table 1 Light"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark"/>
  <w:LsdException Locked="false" Priority="51" Name="List Table 6 Colorful"/>
  <w:LsdException Locked="false" Priority="52" Name="List Table 7 Colorful"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 1"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 1"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 1"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 1"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 2"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 2"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 2"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 2"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 3"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 3"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 3"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 3"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 4"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 4"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 4"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 4"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 5"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 5"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 5"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 5"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 6"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 6"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 6"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 6"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 6"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 6"/>
 </w:LatentStyles>
</xml><![endif]-->
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 5 4 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;
	mso-font-charset:0;
	mso-generic-font-family:modern;
	mso-font-format:other;
	mso-font-pitch:fixed;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;
	mso-font-alt:"\FF2D\FF33 \660E\671D";
	mso-font-charset:128;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-536870145 1791491579 18 0 131231 0;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;
	mso-font-alt:\BC14\D0D5;
	mso-font-charset:129;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-1342176593 1775729915 48 0 524447 0;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;
	mso-font-alt:\5B8B\4F53;
	mso-font-charset:134;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:3 680460288 22 0 262145 0;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 2 5 0 0 0 0 0 0 0;
	mso-font-alt:\65B0\7D30\660E\9AD4;
	mso-font-charset:136;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-1610611969 684719354 22 0 1048577 0;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;
	mso-font-alt:"\FF2D\FF33 \30B4\30B7\30C3\30AF";
	mso-font-charset:128;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-536870145 1791491579 18 0 131231 0;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;
	mso-font-alt:\B3CB\C6C0;
	mso-font-charset:129;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1342176593 1775729915 48 0 524447 0;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 9 6 1 1 1 1 1;
	mso-font-alt:\9ED1\4F53;
	mso-font-charset:134;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-2147482945 953122042 22 0 262145 0;}
@font-face
	{font-family:MingLiU;
	panose-1:2 2 5 9 0 0 0 0 0 0;
	mso-font-alt:\7D30\660E\9AD4;
	mso-font-charset:136;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-1610611969 684719354 22 0 1048577 0;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;
	mso-font-alt:\660E\671D;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:fixed;
	mso-font-signature:1 134676480 16 0 131072 0;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;
	mso-font-alt:\AD74\B9BC;
	mso-font-charset:129;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1342176593 1775729915 48 0 524447 0;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 4 5 5 5 2 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2130706429 0 0 0 65537 0;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2130706429 0 0 0 65537 0;}
@font-face
	{font-family:Mangal;
	panose-1:2 4 5 3 5 2 3 3 2 2;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:32771 0 0 0 1 0;}
@font-face
	{font-family:Latha;
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:1048579 0 0 0 1 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:67110535 0 0 0 159 0;}
@font-face
	{font-family:Vrinda;
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:65539 0 0 0 1 0;}
@font-face
	{font-family:Raavi;
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:131075 0 0 0 1 0;}
@font-face
	{font-family:Shruti;
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:262147 0 0 0 1 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:1;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:2097155 0 0 0 1 0;}
@font-face
	{font-family:Tunga;
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:4194307 0 0 0 1 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	panose-1:3 8 6 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:-2147475389 0 128 0 1 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 1107305727 0 0 415 0;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-134238209 -371195905 63 0 4129279 0;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1610611985 1073750139 0 0 415 0;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 1073786111 1 0 415 0;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-520084737 -1073683329 41 0 479 0;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 1073743103 0 0 415 0;}
@font-face
	{font-family:"Lucida Grande";
	mso-font-alt:Arial;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 1342218751 0 0 447 0;}
@font-face
	{font-family:"Adobe Caslon Pro Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:7 1 0 0 147 0;}
@font-face
	{font-family:"Adobe Caslon Pro";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:7 1 0 0 147 0;}
@font-face
	{font-family:"Adobe Fangsong Std R";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:519 168761360 22 0 393223 0;}
@font-face
	{font-family:"\@Adobe Fangsong Std R";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:519 168761360 22 0 393223 0;}
@font-face
	{font-family:"Adobe Fan Heiti Std B";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:515 437197056 22 0 1179653 0;}
@font-face
	{font-family:"\@Adobe Fan Heiti Std B";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:515 437197056 22 0 1179653 0;}
@font-face
	{font-family:"Adobe Gothic Std B";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:515 701967376 16 0 2752517 0;}
@font-face
	{font-family:"\@Adobe Gothic Std B";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:515 701967376 16 0 2752517 0;}
@font-face
	{font-family:"Adobe Heiti Std R";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:519 168761360 22 0 393223 0;}
@font-face
	{font-family:"\@Adobe Heiti Std R";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:519 168761360 22 0 393223 0;}
@font-face
	{font-family:"Adobe Kaiti Std R";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:519 168761360 22 0 393223 0;}
@font-face
	{font-family:"\@Adobe Kaiti Std R";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:519 168761360 22 0 393223 0;}
@font-face
	{font-family:"Adobe Naskh Medium";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:modern;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:8195 0 0 0 65 0;}
@font-face
	{font-family:"Adobe Garamond Pro Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:7 1 0 0 147 0;}
@font-face
	{font-family:"Adobe Garamond Pro";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:7 1 0 0 147 0;}
@font-face
	{font-family:"Birch Std";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Blackoak Std";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Brush Script Std";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Chaparral Pro";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:7 1 0 0 147 0;}
@font-face
	{font-family:"Chaparral Pro Light";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:7 1 0 0 147 0;}
@font-face
	{font-family:"Charlemagne Std";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Cooper Std Black";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Giddyup Std";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Hobo Std";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Kozuka Gothic Pro B";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:643 717691921 18 0 131077 0;}
@font-face
	{font-family:"\@Kozuka Gothic Pro B";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:643 717691921 18 0 131077 0;}
@font-face
	{font-family:"Kozuka Gothic Pro EL";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:643 717691921 18 0 131077 0;}
@font-face
	{font-family:"\@Kozuka Gothic Pro EL";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:643 717691921 18 0 131077 0;}
@font-face
	{font-family:"Kozuka Gothic Pro H";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:643 717691921 18 0 131077 0;}
@font-face
	{font-family:"\@Kozuka Gothic Pro H";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:643 717691921 18 0 131077 0;}
@font-face
	{font-family:"Kozuka Gothic Pro L";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:643 717691921 18 0 131077 0;}
@font-face
	{font-family:"\@Kozuka Gothic Pro L";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:643 717691921 18 0 131077 0;}
@font-face
	{font-family:"Kozuka Gothic Pro M";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:643 717691921 18 0 131077 0;}
@font-face
	{font-family:"\@Kozuka Gothic Pro M";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:643 717691921 18 0 131077 0;}
@font-face
	{font-family:"Kozuka Gothic Pro R";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:643 717691921 18 0 131077 0;}
@font-face
	{font-family:"\@Kozuka Gothic Pro R";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:643 717691921 18 0 131077 0;}
@font-face
	{font-family:"Kozuka Mincho Pro B";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:643 717691921 18 0 131077 0;}
@font-face
	{font-family:"\@Kozuka Mincho Pro B";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:643 717691921 18 0 131077 0;}
@font-face
	{font-family:"Kozuka Mincho Pro EL";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:643 717691921 18 0 131077 0;}
@font-face
	{font-family:"\@Kozuka Mincho Pro EL";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:643 717691921 18 0 131077 0;}
@font-face
	{font-family:"Kozuka Mincho Pro H";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:643 717691921 18 0 131077 0;}
@font-face
	{font-family:"\@Kozuka Mincho Pro H";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:643 717691921 18 0 131077 0;}
@font-face
	{font-family:"Kozuka Mincho Pro L";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:643 717691921 18 0 131077 0;}
@font-face
	{font-family:"\@Kozuka Mincho Pro L";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:643 717691921 18 0 131077 0;}
@font-face
	{font-family:"Kozuka Mincho Pro M";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:643 717691921 18 0 131077 0;}
@font-face
	{font-family:"\@Kozuka Mincho Pro M";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:643 717691921 18 0 131077 0;}
@font-face
	{font-family:"Kozuka Mincho Pro R";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:643 717691921 18 0 131077 0;}
@font-face
	{font-family:"\@Kozuka Mincho Pro R";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:643 717691921 18 0 131077 0;}
@font-face
	{font-family:"Lithos Pro Regular";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:135 0 0 0 155 0;}
@font-face
	{font-family:"Mesquite Std";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Minion Pro Cond";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:1610613383 1 0 0 415 0;}
@font-face
	{font-family:"Minion Pro Med";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:1610613383 1 0 0 415 0;}
@font-face
	{font-family:"Minion Pro SmBd";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:1610613383 1 0 0 415 0;}
@font-face
	{font-family:"Myriad Arabic";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:modern;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:8199 0 0 0 67 0;}
@font-face
	{font-family:"Nueva Std";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Nueva Std Cond";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"OCR A Std";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:modern;
	mso-font-format:other;
	mso-font-pitch:fixed;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Orator Std";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:modern;
	mso-font-format:other;
	mso-font-pitch:fixed;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Poplar Std";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Prestige Elite Std";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:modern;
	mso-font-format:other;
	mso-font-pitch:fixed;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Rosewood Std Regular";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Stencil Std";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Tekton Pro";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:7 1 0 0 147 0;}
@font-face
	{font-family:"Tekton Pro Cond";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:7 1 0 0 147 0;}
@font-face
	{font-family:"Tekton Pro Ext";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:7 1 0 0 147 0;}
@font-face
	{font-family:"Trajan Pro";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:7 0 0 0 147 0;}
@font-face
	{font-family:"Adobe Arabic";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:-2147475409 -2147442614 8 0 65 0;}
@font-face
	{font-family:"Adobe Devanagari";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:-1610579729 1073750090 0 0 1 0;}
@font-face
	{font-family:"Adobe Hebrew";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:-2147481489 1073750090 0 0 33 0;}
@font-face
	{font-family:"Adobe Ming Std L";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:515 437197056 22 0 1179653 0;}
@font-face
	{font-family:"\@Adobe Ming Std L";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:515 437197056 22 0 1179653 0;}
@font-face
	{font-family:"Adobe Myungjo Std M";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:515 701967376 16 0 2752517 0;}
@font-face
	{font-family:"\@Adobe Myungjo Std M";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:515 701967376 16 0 2752517 0;}
@font-face
	{font-family:"Adobe Song Std L";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:519 168761360 22 0 393223 0;}
@font-face
	{font-family:"\@Adobe Song Std L";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:519 168761360 22 0 393223 0;}
@font-face
	{font-family:"Kozuka Gothic Pr6N B";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:727 717691921 18 0 131231 0;}
@font-face
	{font-family:"\@Kozuka Gothic Pr6N B";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:727 717691921 18 0 131231 0;}
@font-face
	{font-family:"Kozuka Gothic Pr6N EL";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:727 717691921 18 0 131231 0;}
@font-face
	{font-family:"\@Kozuka Gothic Pr6N EL";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:727 717691921 18 0 131231 0;}
@font-face
	{font-family:"Kozuka Gothic Pr6N H";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:727 717691921 18 0 131231 0;}
@font-face
	{font-family:"\@Kozuka Gothic Pr6N H";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:727 717691921 18 0 131231 0;}
@font-face
	{font-family:"Kozuka Gothic Pr6N L";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:727 717691921 18 0 131231 0;}
@font-face
	{font-family:"\@Kozuka Gothic Pr6N L";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:727 717691921 18 0 131231 0;}
@font-face
	{font-family:"Kozuka Gothic Pr6N M";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:727 717691921 18 0 131231 0;}
@font-face
	{font-family:"\@Kozuka Gothic Pr6N M";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:727 717691921 18 0 131231 0;}
@font-face
	{font-family:"Kozuka Gothic Pr6N R";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:727 717691921 18 0 131231 0;}
@font-face
	{font-family:"\@Kozuka Gothic Pr6N R";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:727 717691921 18 0 131231 0;}
@font-face
	{font-family:"Kozuka Mincho Pr6N B";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:727 717691921 18 0 131231 0;}
@font-face
	{font-family:"\@Kozuka Mincho Pr6N B";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:727 717691921 18 0 131231 0;}
@font-face
	{font-family:"Kozuka Mincho Pr6N EL";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:727 717691921 18 0 131231 0;}
@font-face
	{font-family:"\@Kozuka Mincho Pr6N EL";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:727 717691921 18 0 131231 0;}
@font-face
	{font-family:"Kozuka Mincho Pr6N H";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:727 717691921 18 0 131231 0;}
@font-face
	{font-family:"\@Kozuka Mincho Pr6N H";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:727 717691921 18 0 131231 0;}
@font-face
	{font-family:"Kozuka Mincho Pr6N L";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:727 717691921 18 0 131231 0;}
@font-face
	{font-family:"\@Kozuka Mincho Pr6N L";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:727 717691921 18 0 131231 0;}
@font-face
	{font-family:"Kozuka Mincho Pr6N M";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:727 717691921 18 0 131231 0;}
@font-face
	{font-family:"\@Kozuka Mincho Pr6N M";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:727 717691921 18 0 131231 0;}
@font-face
	{font-family:"Kozuka Mincho Pr6N R";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:727 717691921 18 0 131231 0;}
@font-face
	{font-family:"\@Kozuka Mincho Pr6N R";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:727 717691921 18 0 131231 0;}
@font-face
	{font-family:"Letter Gothic Std";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:modern;
	mso-font-format:other;
	mso-font-pitch:fixed;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Minion Pro";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:1610613383 1 0 0 415 0;}
@font-face
	{font-family:"Myriad Hebrew";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:modern;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:2055 1073741824 0 0 35 0;}
@font-face
	{font-family:"Myriad Pro";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:536871559 1 0 0 415 0;}
@font-face
	{font-family:"Myriad Pro Cond";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:536871559 1 0 0 415 0;}
@font-face
	{font-family:"Myriad Pro Light";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:536871559 1 0 0 415 0;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"\@Batang";
	panose-1:2 3 6 0 0 1 1 1 1 1;
	mso-font-charset:129;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-1342176593 1775729915 48 0 524447 0;}
@font-face
	{font-family:BatangChe;
	panose-1:2 3 6 9 0 1 1 1 1 1;
	mso-font-charset:129;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-1342176593 1775729915 48 0 524447 0;}
@font-face
	{font-family:"\@BatangChe";
	panose-1:2 3 6 9 0 1 1 1 1 1;
	mso-font-charset:129;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-1342176593 1775729915 48 0 524447 0;}
@font-face
	{font-family:Gungsuh;
	panose-1:2 3 6 0 0 1 1 1 1 1;
	mso-font-charset:129;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-1342176593 1775729915 48 0 524447 0;}
@font-face
	{font-family:"\@Gungsuh";
	panose-1:2 3 6 0 0 1 1 1 1 1;
	mso-font-charset:129;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-1342176593 1775729915 48 0 524447 0;}
@font-face
	{font-family:GungsuhChe;
	panose-1:2 3 6 9 0 1 1 1 1 1;
	mso-font-charset:129;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-1342176593 1775729915 48 0 524447 0;}
@font-face
	{font-family:"\@GungsuhChe";
	panose-1:2 3 6 9 0 1 1 1 1 1;
	mso-font-charset:129;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-1342176593 1775729915 48 0 524447 0;}
@font-face
	{font-family:DaunPenh;
	panose-1:1 1 1 1 1 1 1 1 1 1;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:3 0 65536 0 1 0;}
@font-face
	{font-family:DokChampa;
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:50331651 0 0 0 65537 0;}
@font-face
	{font-family:Euphemia;
	panose-1:2 11 5 3 4 1 2 2 1 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483537 74 8192 0 1 0;}
@font-face
	{font-family:Vani;
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:2097155 0 0 0 1 0;}
@font-face
	{font-family:"\@Gulim";
	panose-1:2 11 6 0 0 1 1 1 1 1;
	mso-font-charset:129;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1342176593 1775729915 48 0 524447 0;}
@font-face
	{font-family:GulimChe;
	panose-1:2 11 6 9 0 1 1 1 1 1;
	mso-font-charset:129;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-1342176593 1775729915 48 0 524447 0;}
@font-face
	{font-family:"\@GulimChe";
	panose-1:2 11 6 9 0 1 1 1 1 1;
	mso-font-charset:129;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-1342176593 1775729915 48 0 524447 0;}
@font-face
	{font-family:"\@Dotum";
	panose-1:2 11 6 0 0 1 1 1 1 1;
	mso-font-charset:129;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1342176593 1775729915 48 0 524447 0;}
@font-face
	{font-family:DotumChe;
	panose-1:2 11 6 9 0 1 1 1 1 1;
	mso-font-charset:129;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-1342176593 1775729915 48 0 524447 0;}
@font-face
	{font-family:"\@DotumChe";
	panose-1:2 11 6 9 0 1 1 1 1 1;
	mso-font-charset:129;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-1342176593 1775729915 48 0 524447 0;}
@font-face
	{font-family:Impact;
	panose-1:2 11 8 6 3 9 2 5 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"Iskoola Pota";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:3 0 512 0 1 0;}
@font-face
	{font-family:Kalinga;
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:524291 0 0 0 1 0;}
@font-face
	{font-family:Kartika;
	panose-1:2 2 5 3 3 4 4 6 2 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:8388611 0 0 0 1 0;}
@font-face
	{font-family:"Khmer UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 8266 65536 0 1 0;}
@font-face
	{font-family:"Lao UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:33554435 0 0 0 1 0;}
@font-face
	{font-family:"Lucida Console";
	panose-1:2 11 6 9 4 5 4 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-2147482993 6144 0 0 31 0;}
@font-face
	{font-family:"Malgun Gothic";
	panose-1:2 11 5 3 2 0 0 2 0 4;
	mso-font-charset:129;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1879047505 165117179 18 0 524289 0;}
@font-face
	{font-family:"\@Malgun Gothic";
	panose-1:2 11 5 3 2 0 0 2 0 4;
	mso-font-charset:129;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1879047505 165117179 18 0 524289 0;}
@font-face
	{font-family:Meiryo;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-520027393 -355991553 65554 0 131231 0;}
@font-face
	{font-family:"\@Meiryo";
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-520027393 -355991553 65554 0 131231 0;}
@font-face
	{font-family:"Meiryo UI";
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-520027393 -355991553 65554 0 131231 0;}
@font-face
	{font-family:"\@Meiryo UI";
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-520027393 -355991553 65554 0 131231 0;}
@font-face
	{font-family:"Microsoft Himalaya";
	panose-1:1 1 1 0 1 1 1 1 1 1;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-2147483645 65536 64 0 1 0;}
@font-face
	{font-family:"Microsoft JhengHei";
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:136;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:135 680476672 22 0 1048585 0;}
@font-face
	{font-family:"\@Microsoft JhengHei";
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:136;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:135 680476672 22 0 1048585 0;}
@font-face
	{font-family:"Microsoft YaHei";
	panose-1:2 11 5 3 2 2 4 2 2 4;
	mso-font-charset:134;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 672087122 22 0 262175 0;}
@font-face
	{font-family:"\@Microsoft YaHei";
	panose-1:2 11 5 3 2 2 4 2 2 4;
	mso-font-charset:134;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 672087122 22 0 262175 0;}
@font-face
	{font-family:"\@MingLiU";
	panose-1:2 2 5 9 0 0 0 0 0 0;
	mso-font-charset:136;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-1610611969 684719354 22 0 1048577 0;}
@font-face
	{font-family:"\@PMingLiU";
	panose-1:2 2 5 0 0 0 0 0 0 0;
	mso-font-charset:136;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-1610611969 684719354 22 0 1048577 0;}
@font-face
	{font-family:MingLiU_HKSCS;
	panose-1:2 2 5 0 0 0 0 0 0 0;
	mso-font-charset:136;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-1610611969 953154810 22 0 1048577 0;}
@font-face
	{font-family:"\@MingLiU_HKSCS";
	panose-1:2 2 5 0 0 0 0 0 0 0;
	mso-font-charset:136;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-1610611969 953154810 22 0 1048577 0;}
@font-face
	{font-family:MingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;
	mso-font-charset:136;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 168296456 16 0 1048577 0;}
@font-face
	{font-family:"\@MingLiU-ExtB";
	panose-1:2 2 5 0 0 0 0 0 0 0;
	mso-font-charset:136;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 168296456 16 0 1048577 0;}
@font-face
	{font-family:PMingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;
	mso-font-charset:136;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 168296456 16 0 1048577 0;}
@font-face
	{font-family:"\@PMingLiU-ExtB";
	panose-1:2 2 5 0 0 0 0 0 0 0;
	mso-font-charset:136;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 168296456 16 0 1048577 0;}
@font-face
	{font-family:MingLiU_HKSCS-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;
	mso-font-charset:136;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 168296456 16 0 1048577 0;}
@font-face
	{font-family:"\@MingLiU_HKSCS-ExtB";
	panose-1:2 2 5 0 0 0 0 0 0 0;
	mso-font-charset:136;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 168296456 16 0 1048577 0;}
@font-face
	{font-family:"Mongolian Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:-2147483613 0 131072 0 1 0;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;
	mso-font-charset:128;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-536870145 1791491579 18 0 131231 0;}
@font-face
	{font-family:"MS PGothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 1791491579 18 0 131231 0;}
@font-face
	{font-family:"\@MS PGothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 1791491579 18 0 131231 0;}
@font-face
	{font-family:"MS UI Gothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 1791491579 18 0 131231 0;}
@font-face
	{font-family:"\@MS UI Gothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 1791491579 18 0 131231 0;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;
	mso-font-charset:128;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-536870145 1791491579 18 0 131231 0;}
@font-face
	{font-family:"MS PMincho";
	panose-1:2 2 6 0 4 2 5 8 3 4;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 1791491579 18 0 131231 0;}
@font-face
	{font-family:"\@MS PMincho";
	panose-1:2 2 6 0 4 2 5 8 3 4;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 1791491579 18 0 131231 0;}
@font-face
	{font-family:"MV Boli";
	panose-1:2 0 5 0 3 2 0 9 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:3 0 256 0 1 0;}
@font-face
	{font-family:"Microsoft New Tai Lue";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:3 0 -2147483648 0 1 0;}
@font-face
	{font-family:Nyala;
	panose-1:2 0 5 4 7 3 0 2 0 3;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610612625 0 2048 0 147 0;}
@font-face
	{font-family:"Microsoft PhagsPa";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:3 0 134217728 0 1 0;}
@font-face
	{font-family:"Plantagenet Cherokee";
	panose-1:2 2 6 2 7 1 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 4096 0 1 0;}
@font-face
	{font-family:"Segoe Script";
	panose-1:2 11 5 4 2 0 0 0 0 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:655 0 0 0 159 0;}
@font-face
	{font-family:"Segoe UI Semibold";
	panose-1:2 11 7 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 1073783931 1 0 415 0;}
@font-face
	{font-family:"Segoe UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 1073783931 1 0 415 0;}
@font-face
	{font-family:"Segoe UI Symbol";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483537 302054383 6602752 0 1 0;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;
	mso-font-charset:134;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:3 680460288 22 0 262145 0;}
@font-face
	{font-family:NSimSun;
	panose-1:2 1 6 9 3 1 1 1 1 1;
	mso-font-charset:134;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:3 680460288 22 0 262145 0;}
@font-face
	{font-family:"\@NSimSun";
	panose-1:2 1 6 9 3 1 1 1 1 1;
	mso-font-charset:134;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:3 680460288 22 0 262145 0;}
@font-face
	{font-family:SimSun-ExtB;
	panose-1:2 1 6 9 6 1 1 1 1 1;
	mso-font-charset:134;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:3 168689664 16 0 262145 0;}
@font-face
	{font-family:"\@SimSun-ExtB";
	panose-1:2 1 6 9 6 1 1 1 1 1;
	mso-font-charset:134;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:3 168689664 16 0 262145 0;}
@font-face
	{font-family:"Microsoft Tai Le";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:3 0 1073741824 0 1 0;}
@font-face
	{font-family:"Shonar Bangla";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:65539 0 0 0 1 0;}
@font-face
	{font-family:"Microsoft Yi Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:-2147483645 66562 524290 0 1 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-520081665 -1073717157 41 0 66047 0;}
@font-face
	{font-family:"Microsoft Sans Serif";
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-520082689 -1073741822 8 0 66047 0;}
@font-face
	{font-family:Aparajita;
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:32771 0 0 0 1 0;}
@font-face
	{font-family:Ebrima;
	panose-1:2 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610612641 33554497 0 0 147 0;}
@font-face
	{font-family:Gisha;
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147481593 1073741890 0 0 33 0;}
@font-face
	{font-family:Kokila;
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:32771 0 0 0 1 0;}
@font-face
	{font-family:Leelawadee;
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:16777219 0 0 0 65537 0;}
@font-face
	{font-family:"Microsoft Uighur";
	panose-1:2 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-2147475421 -2147483646 8 0 65 0;}
@font-face
	{font-family:MoolBoran;
	panose-1:2 11 1 0 1 1 1 1 1 1;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483633 8266 65536 0 1 0;}
@font-face
	{font-family:Utsaah;
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:32771 0 0 0 1 0;}
@font-face
	{font-family:Vijaya;
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:1048579 0 0 0 1 0;}
@font-face
	{font-family:Andalus;
	panose-1:2 2 6 3 5 4 5 2 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:8195 -2147483648 8 0 65 0;}
@font-face
	{font-family:"Arabic Typesetting";
	panose-1:3 2 4 2 4 4 6 3 2 3;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:-1610604433 -1073741824 8 0 211 0;}
@font-face
	{font-family:"Simplified Arabic";
	panose-1:2 2 6 3 5 4 5 2 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:8195 0 0 0 65 0;}
@font-face
	{font-family:"Simplified Arabic Fixed";
	panose-1:2 7 3 9 2 2 5 2 4 4;
	mso-font-charset:0;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:8195 0 0 0 65 0;}
@font-face
	{font-family:"Sakkal Majalla";
	panose-1:2 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610604417 -1073733557 8 0 211 0;}
@font-face
	{font-family:"Traditional Arabic";
	panose-1:2 2 6 3 5 4 5 2 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:8195 -2147483648 8 0 65 0;}
@font-face
	{font-family:Aharoni;
	panose-1:2 1 8 3 2 1 4 3 2 3;
	mso-font-charset:177;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:2049 0 0 0 32 0;}
@font-face
	{font-family:David;
	panose-1:2 14 5 2 6 4 1 1 1 1;
	mso-font-charset:177;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:2049 0 0 0 32 0;}
@font-face
	{font-family:FrankRuehl;
	panose-1:2 14 5 3 6 1 1 1 1 1;
	mso-font-charset:177;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:2049 0 0 0 32 0;}
@font-face
	{font-family:"Levenim MT";
	panose-1:2 1 5 2 6 1 1 1 1 1;
	mso-font-charset:177;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:2049 0 0 0 32 0;}
@font-face
	{font-family:Miriam;
	panose-1:2 11 5 2 5 1 1 1 1 1;
	mso-font-charset:177;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:2049 0 0 0 32 0;}
@font-face
	{font-family:"Miriam Fixed";
	panose-1:2 11 5 9 5 1 1 1 1 1;
	mso-font-charset:177;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:2049 0 0 0 32 0;}
@font-face
	{font-family:Narkisim;
	panose-1:2 14 5 2 5 1 1 1 1 1;
	mso-font-charset:177;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:2049 0 0 0 32 0;}
@font-face
	{font-family:Rod;
	panose-1:2 3 5 9 5 1 1 1 1 1;
	mso-font-charset:177;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:2049 0 0 0 32 0;}
@font-face
	{font-family:FangSong;
	panose-1:2 1 6 9 6 1 1 1 1 1;
	mso-font-charset:134;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-2147482945 953122042 22 0 262145 0;}
@font-face
	{font-family:"\@FangSong";
	panose-1:2 1 6 9 6 1 1 1 1 1;
	mso-font-charset:134;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-2147482945 953122042 22 0 262145 0;}
@font-face
	{font-family:"\@SimHei";
	panose-1:2 1 6 9 6 1 1 1 1 1;
	mso-font-charset:134;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-2147482945 953122042 22 0 262145 0;}
@font-face
	{font-family:KaiTi;
	panose-1:2 1 6 9 6 1 1 1 1 1;
	mso-font-charset:134;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-2147482945 953122042 22 0 262145 0;}
@font-face
	{font-family:"\@KaiTi";
	panose-1:2 1 6 9 6 1 1 1 1 1;
	mso-font-charset:134;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-2147482945 953122042 22 0 262145 0;}
@font-face
	{font-family:AngsanaUPC;
	panose-1:2 2 6 3 5 4 5 2 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2130706429 0 0 0 65537 0;}
@font-face
	{font-family:"Browallia New";
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2130706429 0 0 0 65537 0;}
@font-face
	{font-family:BrowalliaUPC;
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2130706429 0 0 0 65537 0;}
@font-face
	{font-family:CordiaUPC;
	panose-1:2 11 3 4 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2130706429 0 0 0 65537 0;}
@font-face
	{font-family:DilleniaUPC;
	panose-1:2 2 6 3 5 4 5 2 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2130706393 2 0 0 65537 0;}
@font-face
	{font-family:EucrosiaUPC;
	panose-1:2 2 6 3 5 4 5 2 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2130706393 2 0 0 65537 0;}
@font-face
	{font-family:FreesiaUPC;
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:16777223 2 0 0 65537 0;}
@font-face
	{font-family:IrisUPC;
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:16777223 2 0 0 65537 0;}
@font-face
	{font-family:JasmineUPC;
	panose-1:2 2 6 3 5 4 5 2 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:16777223 2 0 0 65537 0;}
@font-face
	{font-family:KodchiangUPC;
	panose-1:2 2 6 3 5 4 5 2 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:16777223 2 0 0 65537 0;}
@font-face
	{font-family:LilyUPC;
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:16777223 2 0 0 65537 0;}
@font-face
	{font-family:DFKai-SB;
	panose-1:3 0 5 9 0 0 0 0 0 0;
	mso-font-charset:136;
	mso-generic-font-family:script;
	mso-font-pitch:fixed;
	mso-font-signature:3 135135232 22 0 1048577 0;}
@font-face
	{font-family:"\@DFKai-SB";
	panose-1:3 0 5 9 0 0 0 0 0 0;
	mso-font-charset:136;
	mso-generic-font-family:script;
	mso-font-pitch:fixed;
	mso-font-signature:3 135135232 22 0 1048577 0;}
@font-face
	{font-family:"Lucida Sans Unicode";
	panose-1:2 11 6 2 3 5 4 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147480833 14699 0 0 191 0;}
@font-face
	{font-family:"Arial Black";
	panose-1:2 11 10 4 2 1 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:Candara;
	panose-1:2 14 5 2 3 3 3 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1610611985 1073783883 0 0 415 0;}
@font-face
	{font-family:"Comic Sans MS";
	panose-1:3 15 7 2 3 3 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-520092929 1073806591 9 0 415 0;}
@font-face
	{font-family:Constantia;
	panose-1:2 3 6 2 5 3 6 3 3 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-1610611985 1073750091 0 0 415 0;}
@font-face
	{font-family:Corbel;
	panose-1:2 11 5 3 2 2 4 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1610611985 1073783883 0 0 415 0;}
@font-face
	{font-family:"Franklin Gothic Medium";
	panose-1:2 11 6 3 2 1 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:Gabriola;
	panose-1:4 4 6 5 5 16 2 2 13 2;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:-536870161 1342185547 0 0 159 0;}
@font-face
	{font-family:Georgia;
	panose-1:2 4 5 2 5 4 5 2 3 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"Palatino Linotype";
	panose-1:2 4 5 2 5 5 5 3 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-536870265 1073741843 0 0 415 0;}
@font-face
	{font-family:"Segoe Print";
	panose-1:2 0 6 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:655 0 0 0 159 0;}
@font-face
	{font-family:"Trebuchet MS";
	panose-1:2 11 6 3 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1593833729 1073750107 16 0 415 0;}
@font-face
	{font-family:Webdings;
	panose-1:5 3 1 2 1 5 9 6 7 3;
	mso-font-charset:2;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"Nirmala UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2130739165 74 512 0 1 0;}
@font-face
	{font-family:"MT Extra";
	panose-1:5 5 1 2 1 2 5 2 2 2;
	mso-font-charset:2;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"Agency FB";
	panose-1:2 11 5 3 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Algerian;
	panose-1:4 2 7 5 4 10 2 6 7 2;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Book Antiqua";
	panose-1:2 4 6 2 5 3 5 3 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 6 6 2 2 2 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:647 2048 0 0 159 0;}
@font-face
	{font-family:"\@Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-134238209 -371195905 63 0 4129279 0;}
@font-face
	{font-family:"Arial Rounded MT Bold";
	panose-1:2 15 7 4 3 5 4 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Baskerville Old Face";
	panose-1:2 2 6 2 8 5 5 2 3 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Bauhaus 93";
	panose-1:4 3 9 5 2 11 2 2 12 2;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Bell MT";
	panose-1:2 2 5 3 6 3 5 2 3 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Bernard MT Condensed";
	panose-1:2 5 8 6 6 9 5 2 4 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Bodoni MT";
	panose-1:2 7 6 3 8 6 6 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Bodoni MT Black";
	panose-1:2 7 10 3 8 6 6 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Bodoni MT Condensed";
	panose-1:2 7 6 6 8 6 6 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Bodoni MT Poster Compressed";
	panose-1:2 7 7 6 8 6 1 5 2 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:7 0 0 0 17 0;}
@font-face
	{font-family:"Bookman Old Style";
	panose-1:2 5 6 4 5 5 5 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"Bradley Hand ITC";
	panose-1:3 7 4 2 5 3 2 3 2 3;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Britannic Bold";
	panose-1:2 11 9 3 6 7 3 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Berlin Sans FB";
	panose-1:2 14 6 2 2 5 2 2 3 6;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Berlin Sans FB Demi";
	panose-1:2 14 8 2 2 5 2 2 3 6;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Broadway;
	panose-1:4 4 9 5 8 11 2 2 5 2;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Brush Script MT";
	panose-1:3 6 8 2 4 4 6 7 3 4;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Bookshelf Symbol 7";
	panose-1:5 1 1 1 1 1 1 1 1 1;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"Californian FB";
	panose-1:2 7 4 3 6 8 11 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Calisto MT";
	panose-1:2 4 6 3 5 5 5 3 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Castellar;
	panose-1:2 10 4 2 6 4 6 1 3 1;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Century Schoolbook";
	panose-1:2 4 6 4 5 5 5 2 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:Centaur;
	panose-1:2 3 5 4 5 2 5 2 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Chiller;
	panose-1:4 2 4 4 3 16 7 2 6 2;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Colonna MT";
	panose-1:4 2 8 5 6 2 2 3 2 3;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Cooper Black";
	panose-1:2 8 9 4 4 3 11 2 4 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Copperplate Gothic Bold";
	panose-1:2 14 7 5 2 2 6 2 4 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Copperplate Gothic Light";
	panose-1:2 14 5 7 2 2 6 2 4 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Curlz MT";
	panose-1:4 4 4 4 5 7 2 2 2 2;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Elephant;
	panose-1:2 2 9 4 9 5 5 2 3 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Engravers MT";
	panose-1:2 9 7 7 8 5 5 2 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Eras Bold ITC";
	panose-1:2 11 9 7 3 5 4 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Eras Demi ITC";
	panose-1:2 11 8 5 3 5 4 2 8 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Eras Light ITC";
	panose-1:2 11 4 2 3 5 4 2 8 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Eras Medium ITC";
	panose-1:2 11 6 2 3 5 4 2 8 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Felix Titling";
	panose-1:4 6 5 5 6 2 2 2 10 4;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Forte;
	panose-1:3 6 9 2 4 5 2 7 2 3;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Franklin Gothic Book";
	panose-1:2 11 5 3 2 1 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"Franklin Gothic Demi";
	panose-1:2 11 7 3 2 1 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"Franklin Gothic Demi Cond";
	panose-1:2 11 7 6 3 4 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"Franklin Gothic Heavy";
	panose-1:2 11 9 3 2 1 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"Franklin Gothic Medium Cond";
	panose-1:2 11 6 6 3 4 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"Freestyle Script";
	panose-1:3 8 4 2 3 2 5 11 4 4;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"French Script MT";
	panose-1:3 2 4 2 4 6 7 4 6 5;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Footlight MT Light";
	panose-1:2 4 6 2 6 3 10 2 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Gadugi;
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:3 0 12288 0 1 0;}
@font-face
	{font-family:Garamond;
	panose-1:2 2 4 4 3 3 1 1 8 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:Gigi;
	panose-1:4 4 5 4 6 16 7 2 13 2;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Gill Sans MT";
	panose-1:2 11 5 2 2 1 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:7 0 0 0 3 0;}
@font-face
	{font-family:"Gill Sans MT Condensed";
	panose-1:2 11 5 6 2 1 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:7 0 0 0 3 0;}
@font-face
	{font-family:"Gill Sans Ultra Bold Condensed";
	panose-1:2 11 10 6 2 1 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:7 0 0 0 3 0;}
@font-face
	{font-family:"Gill Sans Ultra Bold";
	panose-1:2 11 10 2 2 1 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:7 0 0 0 3 0;}
@font-face
	{font-family:"Gloucester MT Extra Condensed";
	panose-1:2 3 8 8 2 6 1 1 1 1;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Gill Sans MT Ext Condensed Bold";
	panose-1:2 11 9 2 2 1 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:7 0 0 0 3 0;}
@font-face
	{font-family:"Century Gothic";
	panose-1:2 11 5 2 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"Goudy Old Style";
	panose-1:2 2 5 2 5 3 5 2 3 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Goudy Stout";
	panose-1:2 2 9 4 7 3 11 2 4 1;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Harlow Solid Italic";
	panose-1:4 3 6 4 2 15 2 2 13 2;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Harrington;
	panose-1:4 4 5 5 5 10 2 2 7 2;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Haettenschweiler;
	panose-1:2 11 7 6 4 9 2 6 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"High Tower Text";
	panose-1:2 4 5 2 5 5 6 3 3 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Imprint MT Shadow";
	panose-1:4 2 6 5 6 3 3 3 2 2;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Informal Roman";
	panose-1:3 6 4 2 3 4 6 11 2 4;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Blackadder ITC";
	panose-1:4 2 5 5 5 16 7 2 13 2;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Edwardian Script ITC";
	panose-1:3 3 3 2 4 7 7 13 8 4;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Kristen ITC";
	panose-1:3 5 5 2 4 2 2 3 2 2;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Jokerman;
	panose-1:4 9 6 5 6 13 6 2 7 2;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Juice ITC";
	panose-1:4 4 4 3 4 10 2 2 2 2;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Kunstler Script";
	panose-1:3 3 4 2 2 6 7 13 13 6;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Wide Latin";
	panose-1:2 10 10 7 5 5 5 2 4 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Lucida Bright";
	panose-1:2 4 6 2 5 5 5 2 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Lucida Calligraphy";
	panose-1:3 1 1 1 1 1 1 1 1 1;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Lucida Fax";
	panose-1:2 6 6 2 5 5 5 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Lucida Handwriting";
	panose-1:3 1 1 1 1 1 1 1 1 1;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Lucida Sans";
	panose-1:2 11 6 2 3 5 4 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Lucida Sans Typewriter";
	panose-1:2 11 5 9 3 5 4 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Magneto;
	panose-1:4 3 8 5 5 8 2 2 13 2;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Maiandra GD";
	panose-1:2 14 5 2 3 3 8 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Matura MT Script Capitals";
	panose-1:3 2 8 2 6 6 2 7 2 2;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Mistral;
	panose-1:3 9 7 2 3 4 7 2 4 3;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"Modern No\. 20";
	panose-1:2 7 7 4 7 5 5 2 3 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Microsoft JhengHei UI";
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:136;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:135 680476672 22 0 1048585 0;}
@font-face
	{font-family:"\@Microsoft JhengHei UI";
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:136;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:135 680476672 22 0 1048585 0;}
@font-face
	{font-family:"Microsoft YaHei UI";
	panose-1:2 11 5 3 2 2 4 2 2 4;
	mso-font-charset:134;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 684670034 22 0 262175 0;}
@font-face
	{font-family:"\@Microsoft YaHei UI";
	panose-1:2 11 5 3 2 2 4 2 2 4;
	mso-font-charset:134;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 684670034 22 0 262175 0;}
@font-face
	{font-family:"Monotype Corsiva";
	panose-1:3 1 1 1 1 2 1 1 1 1;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"Niagara Engraved";
	panose-1:4 2 5 2 7 7 3 3 2 2;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Niagara Solid";
	panose-1:4 2 5 2 7 7 2 2 2 2;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"OCR A Extended";
	panose-1:2 1 5 9 2 1 2 1 3 3;
	mso-font-charset:0;
	mso-generic-font-family:modern;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Old English Text MT";
	panose-1:3 4 9 2 4 5 8 3 8 6;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Onyx;
	panose-1:4 5 6 2 8 7 2 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"MS Outlook";
	panose-1:5 1 1 0 1 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"Palace Script MT";
	panose-1:3 3 3 2 2 6 7 12 11 5;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Papyrus;
	panose-1:3 7 5 2 6 5 2 3 2 5;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Parchment;
	panose-1:3 4 6 2 4 7 8 4 8 4;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Perpetua;
	panose-1:2 2 5 2 6 4 1 2 3 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Perpetua Titling MT";
	panose-1:2 2 5 2 6 5 5 2 8 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Playbill;
	panose-1:4 5 6 3 10 6 2 2 2 2;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Poor Richard";
	panose-1:2 8 5 2 5 5 5 2 7 2;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Pristina;
	panose-1:3 6 4 2 4 4 6 8 2 4;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Rage Italic";
	panose-1:3 7 5 2 4 5 7 7 3 4;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Ravie;
	panose-1:4 4 8 5 5 8 9 2 6 2;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"MS Reference Sans Serif";
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:536871559 0 0 0 415 0;}
@font-face
	{font-family:"MS Reference Specialty";
	panose-1:5 0 5 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"Rockwell Condensed";
	panose-1:2 6 6 3 5 4 5 2 1 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Rockwell;
	panose-1:2 6 6 3 2 2 5 2 4 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Rockwell Extra Bold";
	panose-1:2 6 9 3 4 5 5 2 4 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Script MT Bold";
	panose-1:3 4 6 2 4 6 7 8 9 4;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Segoe UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-469750017 -1073683329 9 0 511 0;}
@font-face
	{font-family:"Showcard Gothic";
	panose-1:4 2 9 4 2 1 2 2 6 4;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Snap ITC";
	panose-1:4 4 10 7 6 10 2 2 2 2;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Stencil;
	panose-1:4 4 9 5 13 8 2 2 4 4;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Tw Cen MT";
	panose-1:2 11 6 2 2 1 4 2 6 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:7 0 0 0 3 0;}
@font-face
	{font-family:"Tw Cen MT Condensed";
	panose-1:2 11 6 6 2 1 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:7 0 0 0 3 0;}
@font-face
	{font-family:"Tw Cen MT Condensed Extra Bold";
	panose-1:2 11 8 3 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:7 0 0 0 3 0;}
@font-face
	{font-family:"Tempus Sans ITC";
	panose-1:4 2 4 4 3 13 7 2 2 2;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Viner Hand ITC";
	panose-1:3 7 5 2 3 5 2 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Vivaldi;
	panose-1:3 2 6 2 5 5 6 9 8 4;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Vladimir Script";
	panose-1:3 5 4 2 4 4 7 7 3 5;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Wingdings 2";
	panose-1:5 2 1 2 1 5 7 7 7 7;
	mso-font-charset:2;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"Wingdings 3";
	panose-1:5 4 1 2 1 8 7 7 7 7;
	mso-font-charset:2;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"Buxton Sketch";
	panose-1:3 8 5 0 0 5 0 0 0 4;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:-1610612049 1073750235 0 0 159 0;}
@font-face
	{font-family:"Segoe Marker";
	panose-1:3 8 6 2 4 3 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 1073750091 0 0 1 0;}
@font-face
	{font-family:"SketchFlow Print";
	panose-1:2 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610612561 1073750090 0 0 403 0;}
@font-face
	{font-family:ZWAdobeF;
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:536881799 0 0 0 511 0;}
@font-face
	{font-family:AcadEref;
	panose-1:2 0 5 0 0 0 0 2 0 3;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:AIGDT;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:AmdtSymbols;
	panose-1:2 0 5 0 0 0 0 2 0 4;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:GENISO;
	panose-1:2 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:536881799 0 64 0 511 0;}
@font-face
	{font-family:AMGDT;
	panose-1:2 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-2147483645 268435456 0 0 1 0;}
@font-face
	{font-family:"BankGothic Lt BT";
	panose-1:2 11 6 7 2 2 3 6 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:135 0 0 0 27 0;}
@font-face
	{font-family:"BankGothic Md BT";
	panose-1:2 11 8 7 2 2 3 6 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:135 0 0 0 27 0;}
@font-face
	{font-family:CityBlueprint;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"CommercialPi BT";
	panose-1:5 2 1 2 1 2 6 8 8 2;
	mso-font-charset:2;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"CommercialScript BT";
	panose-1:3 3 8 3 4 8 7 9 12 4;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:135 0 0 0 27 0;}
@font-face
	{font-family:CountryBlueprint;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"Dutch801 Rm BT";
	panose-1:2 2 6 3 6 5 5 2 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:135 0 0 0 27 0;}
@font-face
	{font-family:"Dutch801 XBd BT";
	panose-1:2 2 9 3 6 5 5 2 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:135 0 0 0 27 0;}
@font-face
	{font-family:EuroRoman;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"Monospac821 BT";
	panose-1:2 11 6 9 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:135 0 0 0 27 0;}
@font-face
	{font-family:PanRoman;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:Romantic;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:RomanS;
	panose-1:2 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:536881799 0 0 0 511 0;}
@font-face
	{font-family:SansSerif;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"Stylus BT";
	panose-1:2 14 4 2 2 2 6 2 3 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:135 0 0 0 27 0;}
@font-face
	{font-family:SuperFrench;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"Swis721 BT";
	panose-1:2 11 5 4 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:135 0 0 0 27 0;}
@font-face
	{font-family:"Swis721 BdOul BT";
	panose-1:4 2 7 5 2 11 3 4 2 3;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:135 0 0 0 27 0;}
@font-face
	{font-family:"Swis721 Cn BT";
	panose-1:2 11 5 6 2 2 2 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:135 0 0 0 27 0;}
@font-face
	{font-family:"Swis721 BdCnOul BT";
	panose-1:4 2 7 4 3 11 3 4 2 3;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:135 0 0 0 27 0;}
@font-face
	{font-family:"Swis721 BlkCn BT";
	panose-1:2 11 8 6 3 5 2 4 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:135 0 0 0 27 0;}
@font-face
	{font-family:"Swis721 LtCn BT";
	panose-1:2 11 4 6 2 2 2 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:135 0 0 0 27 0;}
@font-face
	{font-family:"Swis721 Ex BT";
	panose-1:2 11 6 5 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:135 0 0 0 27 0;}
@font-face
	{font-family:"Swis721 BlkEx BT";
	panose-1:2 11 9 7 4 5 2 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:135 0 0 0 27 0;}
@font-face
	{font-family:"Swis721 LtEx BT";
	panose-1:2 11 5 5 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:135 0 0 0 27 0;}
@font-face
	{font-family:"Swis721 Blk BT";
	panose-1:2 11 9 4 3 5 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:135 0 0 0 27 0;}
@font-face
	{font-family:"Swis721 BlkOul BT";
	panose-1:4 2 9 5 3 11 3 4 2 3;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:135 0 0 0 27 0;}
@font-face
	{font-family:"Swis721 Lt BT";
	panose-1:2 11 4 3 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:135 0 0 0 27 0;}
@font-face
	{font-family:TechnicBold;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:TechnicLite;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:Technic;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"UniversalMath1 BT";
	panose-1:5 5 1 2 1 2 5 2 6 2;
	mso-font-charset:2;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"Vineta BT";
	panose-1:4 2 9 6 5 6 2 7 2 2;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:135 0 0 0 27 0;}
@font-face
	{font-family:ISOCPEUR;
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:ISOCTEUR;
	panose-1:2 11 6 9 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:Complex;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:536881799 6144 0 0 511 0;}
@font-face
	{font-family:GDT;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-2147483645 268435456 0 0 1 0;}
@font-face
	{font-family:GothicE;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:536881799 0 0 0 511 0;}
@font-face
	{font-family:GothicG;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:536881799 0 0 0 511 0;}
@font-face
	{font-family:GothicI;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:536881799 0 0 0 511 0;}
@font-face
	{font-family:GreekC;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:536881799 0 0 0 511 0;}
@font-face
	{font-family:GreekS;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:536881799 0 0 0 511 0;}
@font-face
	{font-family:ISOCP2;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:536881799 0 0 0 511 0;}
@font-face
	{font-family:ISOCP3;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:536881799 0 0 0 511 0;}
@font-face
	{font-family:ISOCP;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:536881799 0 64 0 511 0;}
@font-face
	{font-family:ISOCT2;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:536881799 0 0 0 511 0;}
@font-face
	{font-family:ISOCT3;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:536881799 0 0 0 511 0;}
@font-face
	{font-family:ISOCT;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:536881799 0 0 0 511 0;}
@font-face
	{font-family:ItalicC;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:536881799 0 0 0 511 0;}
@font-face
	{font-family:ItalicT;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:536881799 0 0 0 511 0;}
@font-face
	{font-family:Italic;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:536881799 0 0 0 511 0;}
@font-face
	{font-family:Monotxt;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610601849 0 0 0 511 0;}
@font-face
	{font-family:"Proxy 1";
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610601817 0 0 0 511 0;}
@font-face
	{font-family:"Proxy 2";
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610601817 0 0 0 511 0;}
@font-face
	{font-family:"Proxy 3";
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610601817 0 0 0 511 0;}
@font-face
	{font-family:"Proxy 4";
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610601817 0 0 0 511 0;}
@font-face
	{font-family:"Proxy 5";
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610601817 0 0 0 511 0;}
@font-face
	{font-family:"Proxy 6";
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610601817 0 0 0 511 0;}
@font-face
	{font-family:"Proxy 7";
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610601817 0 0 0 511 0;}
@font-face
	{font-family:"Proxy 8";
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610601817 0 0 0 511 0;}
@font-face
	{font-family:"Proxy 9";
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610601817 0 0 0 511 0;}
@font-face
	{font-family:RomanC;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:536881799 0 0 0 511 0;}
@font-face
	{font-family:RomanD;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:536881799 0 0 0 511 0;}
@font-face
	{font-family:RomanT;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:536881799 0 0 0 511 0;}
@font-face
	{font-family:ScriptC;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:536881799 0 0 0 511 0;}
@font-face
	{font-family:ScriptS;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:536881799 0 0 0 511 0;}
@font-face
	{font-family:Simplex;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:536881799 0 0 0 511 0;}
@font-face
	{font-family:Syastro;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:536881799 0 0 0 511 0;}
@font-face
	{font-family:Symap;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:536881799 0 0 0 511 0;}
@font-face
	{font-family:Symath;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:536881799 0 0 0 511 0;}
@font-face
	{font-family:Symeteo;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:536881799 0 0 0 511 0;}
@font-face
	{font-family:Symusic;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:536881799 0 0 0 511 0;}
@font-face
	{font-family:Txt;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610601817 0 0 0 511 0;}
@font-face
	{font-family:DengXian;
	panose-1:3 0 5 9 0 0 0 0 0 0;
	mso-font-charset:134;
	mso-generic-font-family:script;
	mso-font-pitch:fixed;
	mso-font-signature:-2147482945 953122042 22 0 262145 0;}
@font-face
	{font-family:"\@DengXian";
	panose-1:3 0 5 9 0 0 0 0 0 0;
	mso-font-charset:134;
	mso-generic-font-family:script;
	mso-font-pitch:fixed;
	mso-font-signature:-2147482945 953122042 22 0 262145 0;}
@font-face
	{font-family:"Microsoft MHei";
	panose-1:2 11 4 2 4 2 4 2 2 3;
	mso-font-charset:136;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1610612033 986709243 22 0 1048735 0;}
@font-face
	{font-family:"\@Microsoft MHei";
	panose-1:2 11 4 2 4 2 4 2 2 3;
	mso-font-charset:136;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1610612033 986709243 22 0 1048735 0;}
@font-face
	{font-family:"Microsoft NeoGothic";
	panose-1:2 11 4 2 4 2 4 2 2 3;
	mso-font-charset:129;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1342176577 420962555 16 0 524447 0;}
@font-face
	{font-family:"\@Microsoft NeoGothic";
	panose-1:2 11 4 2 4 2 4 2 2 3;
	mso-font-charset:129;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1342176577 420962555 16 0 524447 0;}
@font-face
	{font-family:"Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147482897 1791491322 18 0 131077 0;}
@font-face
	{font-family:"\@Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147482897 1791491322 18 0 131077 0;}
@font-face
	{font-family:"Segoe WP Black";
	panose-1:2 11 10 2 4 5 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1610612033 268435707 0 0 159 0;}
@font-face
	{font-family:"Segoe WP";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-469750017 -1073683329 9 0 511 0;}
@font-face
	{font-family:"Segoe WP Semibold";
	panose-1:2 11 7 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-469750017 -1073683329 9 0 511 0;}
@font-face
	{font-family:"Segoe WP Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-469750017 -1073683329 9 0 511 0;}
@font-face
	{font-family:"Segoe WP SemiLight";
	panose-1:2 11 4 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-469750017 -1073683329 9 0 511 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:"";
	margin:0in;
	margin-bottom:.0001pt;
	text-indent:.3in;
	line-height:200%;
	mso-pagination:none;
	font-size:12.0pt;
	mso-bidi-font-size:11.0pt;
	font-family:"Georgia",serif;
	mso-fareast-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;}
h1
	{mso-style-priority:9;
	mso-style-qformat:yes;
	mso-style-parent:"";
	mso-style-link:"Heading 1 Char";
	mso-style-next:Normal;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:200%;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:12.0pt;
	mso-bidi-font-size:11.0pt;
	font-family:"Georgia",serif;
	mso-fareast-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	mso-font-kerning:0pt;
	mso-bidi-font-weight:normal;}
h2
	{mso-style-priority:9;
	mso-style-qformat:yes;
	mso-style-parent:"";
	mso-style-link:"Heading 2 Char";
	mso-style-next:Normal;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:200%;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:2;
	font-size:12.0pt;
	mso-bidi-font-size:11.0pt;
	font-family:"Georgia",serif;
	mso-fareast-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	mso-bidi-font-weight:normal;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{mso-style-update:auto;
	mso-style-priority:39;
	mso-style-next:Normal;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:0in;
	line-height:107%;
	mso-pagination:none;
	font-size:12.0pt;
	mso-bidi-font-size:11.0pt;
	font-family:"Georgia",serif;
	mso-fareast-font-family:"MS Mincho";
	mso-fareast-theme-font:minor-fareast;
	mso-bidi-font-family:"Times New Roman";}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{mso-style-update:auto;
	mso-style-priority:39;
	mso-style-next:Normal;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:11.0pt;
	line-height:107%;
	mso-pagination:none;
	font-size:12.0pt;
	mso-bidi-font-size:11.0pt;
	font-family:"Georgia",serif;
	mso-fareast-font-family:"MS Mincho";
	mso-fareast-theme-font:minor-fareast;
	mso-bidi-font-family:"Times New Roman";}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{mso-style-update:auto;
	mso-style-priority:39;
	mso-style-next:Normal;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:22.0pt;
	line-height:107%;
	mso-pagination:none;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:"MS Mincho";
	mso-fareast-theme-font:minor-fareast;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-priority:99;
	mso-style-link:"Comment Text Char";
	margin:0in;
	margin-bottom:.0001pt;
	text-indent:.3in;
	mso-pagination:none;
	font-size:12.0pt;
	font-family:"Georgia",serif;
	mso-fareast-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;}
span.MsoCommentReference
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-ansi-font-size:9.0pt;
	mso-bidi-font-size:9.0pt;}
a:link, span.MsoHyperlink
	{mso-style-priority:99;
	color:#0563C1;
	mso-themecolor:hyperlink;
	text-decoration:underline;
	text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
	{mso-style-noshow:yes;
	mso-style-priority:99;
	color:#954F72;
	mso-themecolor:followedhyperlink;
	text-decoration:underline;
	text-underline:single;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"Comment Text";
	mso-style-link:"Comment Subject Char";
	mso-style-next:"Comment Text";
	margin:0in;
	margin-bottom:.0001pt;
	text-indent:.3in;
	mso-pagination:none;
	font-size:10.0pt;
	font-family:"Georgia",serif;
	mso-fareast-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-link:"Balloon Text Char";
	margin:0in;
	margin-bottom:.0001pt;
	text-indent:.3in;
	mso-pagination:none;
	font-size:9.0pt;
	font-family:"Lucida Grande";
	mso-fareast-font-family:Georgia;
	color:black;}
p.MsoNoSpacing, li.MsoNoSpacing, div.MsoNoSpacing
	{mso-style-priority:1;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:"";
	margin:0in;
	margin-bottom:.0001pt;
	text-indent:.3in;
	mso-pagination:none;
	font-size:12.0pt;
	mso-bidi-font-size:11.0pt;
	font-family:"Georgia",serif;
	mso-fareast-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-parent:"";
	margin:0in;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	mso-bidi-font-size:11.0pt;
	font-family:"Georgia",serif;
	mso-fareast-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;}
p.MsoTocHeading, li.MsoTocHeading, div.MsoTocHeading
	{mso-style-priority:39;
	mso-style-qformat:yes;
	mso-style-parent:"Heading 1";
	mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:107%;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	font-size:12.0pt;
	mso-bidi-font-size:16.0pt;
	font-family:"Georgia",serif;
	mso-fareast-font-family:"MS Gothic";
	mso-fareast-theme-font:major-fareast;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Heading 1";
	mso-ansi-font-size:12.0pt;
	font-family:"Georgia",serif;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Heading 2";
	mso-ansi-font-size:12.0pt;
	font-family:"Georgia",serif;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Balloon Text";
	mso-ansi-font-size:9.0pt;
	mso-bidi-font-size:9.0pt;
	font-family:"Lucida Grande";
	mso-ascii-font-family:"Lucida Grande";
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:"Lucida Grande";
	mso-bidi-font-family:"Lucida Grande";
	color:black;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Comment Text";
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	font-family:"Georgia",serif;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"Comment Text Char";
	mso-style-link:"Comment Subject";
	mso-ansi-font-size:10.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Georgia",serif;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	font-weight:bold;}
span.msoIns
	{mso-style-type:export-only;
	mso-style-name:"";
	text-decoration:underline;
	text-underline:single;
	color:teal;}
span.msoDel
	{mso-style-type:export-only;
	mso-style-name:"";
	text-decoration:line-through;
	color:red;}
.MsoChpDefault
	{mso-style-type:export-only;
	mso-default-props:yes;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:"MS Mincho";
	mso-fareast-theme-font:minor-fareast;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
.MsoPapDefault
	{mso-style-type:export-only;
	margin-bottom:8.0pt;
	line-height:107%;}
 /* Page Definitions */
 @page
	{mso-footnote-separator:url("thesis-github_files/header.htm") fs;
	mso-footnote-continuation-separator:url("thesis-github_files/header.htm") fcs;
	mso-endnote-separator:url("thesis-github_files/header.htm") es;
	mso-endnote-continuation-separator:url("thesis-github_files/header.htm") ecs;
	mso-facing-pages:yes;}
@page WordSection1
	{size:8.5in 11.0in;
	margin:74.9pt 46.3pt 87.4pt 1.5in;
	mso-header-margin:.5in;
	mso-footer-margin:51.4pt;
	mso-page-numbers:roman-lower 1;
	mso-even-header:url("thesis-github_files/header.htm") eh1;
	mso-header:url("thesis-github_files/header.htm") h1;
	mso-even-footer:url("thesis-github_files/header.htm") ef1;
	mso-footer:url("thesis-github_files/header.htm") f1;
	mso-first-header:url("thesis-github_files/header.htm") fh1;
	mso-first-footer:url("thesis-github_files/header.htm") ff1;
	mso-paper-source:0;}
div.WordSection1
	{page:WordSection1;}
@page WordSection2
	{size:8.5in 11.0in;
	margin:74.9pt 1.0in 51.4pt 1.5in;
	mso-header-margin:.5in;
	mso-footer-margin:.5in;
	mso-page-numbers:1;
	mso-title-page:yes;
	mso-even-header:url("thesis-github_files/header.htm") eh2;
	mso-header:url("thesis-github_files/header.htm") h2;
	mso-even-footer:url("thesis-github_files/header.htm") ef2;
	mso-footer:url("thesis-github_files/header.htm") f2;
	mso-first-header:url("thesis-github_files/header.htm") fh2;
	mso-first-footer:url("thesis-github_files/header.htm") ff2;
	mso-paper-source:0;}
div.WordSection2
	{page:WordSection2;}
@page WordSection3
	{size:8.5in 11.0in;
	margin:74.9pt 1.0in 51.4pt 1.5in;
	mso-header-margin:.5in;
	mso-footer-margin:.5in;
	mso-title-page:yes;
	mso-even-header:url("thesis-github_files/header.htm") eh3;
	mso-header:url("thesis-github_files/header.htm") h3;
	mso-even-footer:url("thesis-github_files/header.htm") ef3;
	mso-footer:url("thesis-github_files/header.htm") f3;
	mso-first-header:url("thesis-github_files/header.htm") fh3;
	mso-first-footer:url("thesis-github_files/header.htm") ff3;
	mso-paper-source:0;}
div.WordSection3
	{page:WordSection3;}
@page WordSection4
	{size:8.5in 11.0in;
	margin:74.85pt 1.0in 94.5pt 1.5in;
	mso-header-margin:55.05pt;
	mso-footer-margin:.5in;
	mso-even-header:url("thesis-github_files/header.htm") eh4;
	mso-header:url("thesis-github_files/header.htm") h4;
	mso-even-footer:url("thesis-github_files/header.htm") ef4;
	mso-footer:url("thesis-github_files/header.htm") f4;
	mso-first-header:url("thesis-github_files/header.htm") fh4;
	mso-first-footer:url("thesis-github_files/header.htm") ff4;
	mso-paper-source:0;}
div.WordSection4
	{page:WordSection4;}
@page WordSection5
	{size:8.5in 11.0in;
	margin:72.1pt 1.0in 44.7pt 1.5in;
	mso-header-margin:.5in;
	mso-footer-margin:.5in;
	mso-title-page:yes;
	mso-even-header:url("thesis-github_files/header.htm") eh5;
	mso-header:url("thesis-github_files/header.htm") h5;
	mso-even-footer:url("thesis-github_files/header.htm") ef5;
	mso-footer:url("thesis-github_files/header.htm") f5;
	mso-first-header:url("thesis-github_files/header.htm") fh5;
	mso-first-footer:url("thesis-github_files/header.htm") ff5;
	mso-paper-source:0;}
div.WordSection5
	{page:WordSection5;}
@page WordSection6
	{size:8.5in 11.0in;
	margin:72.4pt 1.0in 51.4pt 1.5in;
	mso-header-margin:.5in;
	mso-footer-margin:.5in;
	mso-title-page:yes;
	mso-even-header:url("thesis-github_files/header.htm") eh6;
	mso-header:url("thesis-github_files/header.htm") h6;
	mso-even-footer:url("thesis-github_files/header.htm") ef6;
	mso-footer:url("thesis-github_files/header.htm") f6;
	mso-first-header:url("thesis-github_files/header.htm") fh6;
	mso-first-footer:url("thesis-github_files/header.htm") ff6;
	mso-paper-source:0;}
div.WordSection6
	{page:WordSection6;}
@page WordSection7
	{size:8.5in 11.0in;
	margin:74.9pt 1.0in 51.4pt 1.5in;
	mso-header-margin:.5in;
	mso-footer-margin:.5in;
	mso-title-page:yes;
	mso-even-header:url("thesis-github_files/header.htm") eh7;
	mso-header:url("thesis-github_files/header.htm") h7;
	mso-even-footer:url("thesis-github_files/header.htm") ef7;
	mso-footer:url("thesis-github_files/header.htm") f7;
	mso-first-header:url("thesis-github_files/header.htm") fh7;
	mso-first-footer:url("thesis-github_files/header.htm") ff7;
	mso-paper-source:0;}
div.WordSection7
	{page:WordSection7;}
@page WordSection8
	{size:8.5in 11.0in;
	margin:55.05pt 1.0in 51.4pt 121.45pt;
	mso-header-margin:.5in;
	mso-footer-margin:.5in;
	mso-even-header:url("thesis-github_files/header.htm") eh8;
	mso-header:url("thesis-github_files/header.htm") h8;
	mso-even-footer:url("thesis-github_files/header.htm") ef8;
	mso-footer:url("thesis-github_files/header.htm") f8;
	mso-first-header:url("thesis-github_files/header.htm") fh8;
	mso-first-footer:url("thesis-github_files/header.htm") ff8;
	mso-paper-source:0;}
div.WordSection8
	{page:WordSection8;}
 /* List Definitions */
 @list l0
	{mso-list-id:396318809;
	mso-list-type:hybrid;
	mso-list-template-ids:787495040 192730680 -1084442218 1157514540 -3492886 -912459380 1024071110 -1031490242 -1040259054 -1646495186;}
@list l0:level1
	{mso-level-start-at:3;
	mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:17.95pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l0:level2
	{mso-level-number-format:alpha-lower;
	mso-level-text:%2;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.75in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l0:level3
	{mso-level-number-format:roman-lower;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.25in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l0:level4
	{mso-level-text:%4;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.75in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l0:level5
	{mso-level-number-format:alpha-lower;
	mso-level-text:%5;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l0:level6
	{mso-level-number-format:roman-lower;
	mso-level-text:%6;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.75in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l0:level7
	{mso-level-text:%7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.25in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l0:level8
	{mso-level-number-format:alpha-lower;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.75in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l0:level9
	{mso-level-number-format:roman-lower;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:4.25in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l1
	{mso-list-id:550963460;
	mso-list-type:hybrid;
	mso-list-template-ids:323413178 858556772 1655340194 -602249384 582901540 1951443690 1929548190 -1058139674 491010720 -1776376430;}
@list l1:level1
	{mso-level-start-at:8;
	mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:45.45pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l1:level2
	{mso-level-number-format:alpha-lower;
	mso-level-text:%2;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.75in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l1:level3
	{mso-level-number-format:roman-lower;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.25in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l1:level4
	{mso-level-text:%4;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.75in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l1:level5
	{mso-level-number-format:alpha-lower;
	mso-level-text:%5;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l1:level6
	{mso-level-number-format:roman-lower;
	mso-level-text:%6;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.75in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l1:level7
	{mso-level-text:%7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.25in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l1:level8
	{mso-level-number-format:alpha-lower;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.75in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l1:level9
	{mso-level-number-format:roman-lower;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:4.25in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l2
	{mso-list-id:559950322;
	mso-list-type:hybrid;
	mso-list-template-ids:-1110959964 -1163615280 46672590 1854548042 301660004 1592528548 -160380454 804440904 849920904 -237234850;}
@list l2:level1
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:15.85pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l2:level2
	{mso-level-number-format:alpha-lower;
	mso-level-text:%2;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:54.55pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l2:level3
	{mso-level-number-format:roman-lower;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:90.55pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l2:level4
	{mso-level-text:%4;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:126.55pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l2:level5
	{mso-level-number-format:alpha-lower;
	mso-level-text:%5;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:162.55pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l2:level6
	{mso-level-number-format:roman-lower;
	mso-level-text:%6;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:198.55pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l2:level7
	{mso-level-text:%7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:234.55pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l2:level8
	{mso-level-number-format:alpha-lower;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:270.55pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l2:level9
	{mso-level-number-format:roman-lower;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:306.55pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l3
	{mso-list-id:617490824;
	mso-list-type:hybrid;
	mso-list-template-ids:-313381940 -1462322456 -853927374 913756502 1858864508 -771613914 -146259062 1921442648 1597520498 2025461172;}
@list l3:level1
	{mso-level-start-at:11;
	mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:27.5pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l3:level2
	{mso-level-number-format:alpha-lower;
	mso-level-text:%2;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.75in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l3:level3
	{mso-level-number-format:roman-lower;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.25in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l3:level4
	{mso-level-text:%4;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.75in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l3:level5
	{mso-level-number-format:alpha-lower;
	mso-level-text:%5;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l3:level6
	{mso-level-number-format:roman-lower;
	mso-level-text:%6;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.75in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l3:level7
	{mso-level-text:%7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.25in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l3:level8
	{mso-level-number-format:alpha-lower;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.75in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l3:level9
	{mso-level-number-format:roman-lower;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:4.25in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l4
	{mso-list-id:720177034;
	mso-list-type:hybrid;
	mso-list-template-ids:-746409150 -1975205052 -1975192626 -1285789328 1244536122 -1811149926 1433957502 1912213786 1872420466 1064699274;}
@list l4:level1
	{mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:45.45pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l4:level2
	{mso-level-number-format:alpha-lower;
	mso-level-text:%2;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.75in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l4:level3
	{mso-level-number-format:roman-lower;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.25in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l4:level4
	{mso-level-text:%4;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.75in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l4:level5
	{mso-level-number-format:alpha-lower;
	mso-level-text:%5;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l4:level6
	{mso-level-number-format:roman-lower;
	mso-level-text:%6;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.75in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l4:level7
	{mso-level-text:%7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.25in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l4:level8
	{mso-level-number-format:alpha-lower;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.75in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l4:level9
	{mso-level-number-format:roman-lower;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:4.25in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l5
	{mso-list-id:740062010;
	mso-list-type:hybrid;
	mso-list-template-ids:-1471896738 -238918188 -69961194 529463918 398351694 -61467288 -1187585984 2092363456 55746740 -2016279100;}
@list l5:level1
	{mso-level-start-at:119;
	mso-level-text:"\[%1\]";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:36.8pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l5:level2
	{mso-level-start-at:19;
	mso-level-number-format:alpha-upper;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:47.45pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l5:level3
	{mso-level-number-format:roman-lower;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:87.85pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l5:level4
	{mso-level-text:%4;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:123.85pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l5:level5
	{mso-level-number-format:alpha-lower;
	mso-level-text:%5;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:159.85pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l5:level6
	{mso-level-number-format:roman-lower;
	mso-level-text:%6;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:195.85pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l5:level7
	{mso-level-text:%7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:231.85pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l5:level8
	{mso-level-number-format:alpha-lower;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:267.85pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l5:level9
	{mso-level-number-format:roman-lower;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:303.85pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l6
	{mso-list-id:742601464;
	mso-list-type:hybrid;
	mso-list-template-ids:150268938 -39966934 -595835534 1913426156 1393090040 -146509726 -529479690 -939503012 54923202 -185049960;}
@list l6:level1
	{mso-level-start-at:3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.75pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l6:level2
	{mso-level-number-format:alpha-lower;
	mso-level-text:%2;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:151.0pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l6:level3
	{mso-level-number-format:roman-lower;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:187.0pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l6:level4
	{mso-level-text:%4;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:223.0pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l6:level5
	{mso-level-number-format:alpha-lower;
	mso-level-text:%5;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:259.0pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l6:level6
	{mso-level-number-format:roman-lower;
	mso-level-text:%6;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:295.0pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l6:level7
	{mso-level-text:%7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:331.0pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l6:level8
	{mso-level-number-format:alpha-lower;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:367.0pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l6:level9
	{mso-level-number-format:roman-lower;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:403.0pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l7
	{mso-list-id:1210146005;
	mso-list-type:hybrid;
	mso-list-template-ids:1747853740 1106645112 778318196 -1243857082 -1110651962 624440278 -35255220 852770338 27159900 33333132;}
@list l7:level1
	{mso-level-text:"\[%1\]";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:41.1pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l7:level2
	{mso-level-start-at:10;
	mso-level-number-format:alpha-upper;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:46.9pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l7:level3
	{mso-level-number-format:roman-lower;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:82.9pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l7:level4
	{mso-level-text:%4;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:118.9pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l7:level5
	{mso-level-number-format:alpha-lower;
	mso-level-text:%5;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:154.9pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l7:level6
	{mso-level-number-format:roman-lower;
	mso-level-text:%6;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:190.9pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l7:level7
	{mso-level-text:%7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:226.9pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l7:level8
	{mso-level-number-format:alpha-lower;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:262.9pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l7:level9
	{mso-level-number-format:roman-lower;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:298.9pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l8
	{mso-list-id:1212883853;
	mso-list-type:hybrid;
	mso-list-template-ids:149574678 749102984 1375508218 1814461246 2006631844 -1563929978 1465395400 205540426 753167118 -1822787396;}
@list l8:level1
	{mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:17.95pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l8:level2
	{mso-level-number-format:alpha-lower;
	mso-level-text:%2;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.75in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l8:level3
	{mso-level-number-format:roman-lower;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.25in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l8:level4
	{mso-level-text:%4;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.75in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l8:level5
	{mso-level-number-format:alpha-lower;
	mso-level-text:%5;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l8:level6
	{mso-level-number-format:roman-lower;
	mso-level-text:%6;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.75in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l8:level7
	{mso-level-text:%7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.25in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l8:level8
	{mso-level-number-format:alpha-lower;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.75in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l8:level9
	{mso-level-number-format:roman-lower;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:4.25in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l9
	{mso-list-id:1268929281;
	mso-list-type:hybrid;
	mso-list-template-ids:233214914 89587326 -1067547760 -1990001598 1015441500 -417939870 1446048052 461256362 2067060364 1250477938;}
@list l9:level1
	{mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:15.85pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l9:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.75in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l9:level3
	{mso-level-number-format:bullet;
	mso-level-text:\25AA;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.25in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l9:level4
	{mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.75in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l9:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l9:level6
	{mso-level-number-format:bullet;
	mso-level-text:\25AA;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.75in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l9:level7
	{mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.25in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l9:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.75in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l9:level9
	{mso-level-number-format:bullet;
	mso-level-text:\25AA;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:4.25in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l10
	{mso-list-id:1596522808;
	mso-list-type:hybrid;
	mso-list-template-ids:-387799522 2106862964 812384852 -1423156958 -265517178 -2055201886 -1813229374 -2086604968 -2081116258 -561465444;}
@list l10:level1
	{mso-level-start-at:6;
	mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:17.95pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l10:level2
	{mso-level-number-format:alpha-lower;
	mso-level-text:%2;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.75in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l10:level3
	{mso-level-number-format:roman-lower;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.25in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l10:level4
	{mso-level-text:%4;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.75in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l10:level5
	{mso-level-number-format:alpha-lower;
	mso-level-text:%5;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l10:level6
	{mso-level-number-format:roman-lower;
	mso-level-text:%6;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.75in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l10:level7
	{mso-level-text:%7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.25in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l10:level8
	{mso-level-number-format:alpha-lower;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.75in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l10:level9
	{mso-level-number-format:roman-lower;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:4.25in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l11
	{mso-list-id:1830439016;
	mso-list-type:hybrid;
	mso-list-template-ids:-27391994 253948062 -1851471746 342917898 -1245401180 -877604740 -1422856476 686032790 2134138960 1116254010;}
@list l11:level1
	{mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:29.25pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l11:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:78.9pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l11:level3
	{mso-level-number-format:bullet;
	mso-level-text:\25AA;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:114.9pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l11:level4
	{mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:150.9pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l11:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:186.9pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l11:level6
	{mso-level-number-format:bullet;
	mso-level-text:\25AA;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:222.9pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l11:level7
	{mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:258.9pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l11:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:294.9pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l11:level9
	{mso-level-number-format:bullet;
	mso-level-text:\25AA;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:330.9pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l12
	{mso-list-id:2065640440;
	mso-list-type:hybrid;
	mso-list-template-ids:-288879896 -1238846452 -1465341566 1792033496 -1184488144 514123312 1794561256 -2100147138 1341291178 1225418832;}
@list l12:level1
	{mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:45.45pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l12:level2
	{mso-level-number-format:alpha-lower;
	mso-level-text:%2;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.75in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l12:level3
	{mso-level-number-format:roman-lower;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.25in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l12:level4
	{mso-level-text:%4;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.75in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l12:level5
	{mso-level-number-format:alpha-lower;
	mso-level-text:%5;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l12:level6
	{mso-level-number-format:roman-lower;
	mso-level-text:%6;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.75in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l12:level7
	{mso-level-text:%7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.25in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l12:level8
	{mso-level-number-format:alpha-lower;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.75in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l12:level9
	{mso-level-number-format:roman-lower;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:4.25in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l13
	{mso-list-id:2074500999;
	mso-list-type:hybrid;
	mso-list-template-ids:-241392314 163983264 1444676538 1431476204 -477597290 259191846 180262968 175164074 1377500946 -273767092;}
@list l13:level1
	{mso-level-start-at:13;
	mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:27.5pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l13:level2
	{mso-level-number-format:alpha-lower;
	mso-level-text:%2;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.75in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l13:level3
	{mso-level-number-format:roman-lower;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.25in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l13:level4
	{mso-level-text:%4;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.75in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l13:level5
	{mso-level-number-format:alpha-lower;
	mso-level-text:%5;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l13:level6
	{mso-level-number-format:roman-lower;
	mso-level-text:%6;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.75in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l13:level7
	{mso-level-text:%7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.25in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l13:level8
	{mso-level-number-format:alpha-lower;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.75in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l13:level9
	{mso-level-number-format:roman-lower;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:4.25in;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l14
	{mso-list-id:2100366604;
	mso-list-type:hybrid;
	mso-list-template-ids:1732812812 -1978889068 -1873670090 969807264 -518366708 -653208086 523913266 284869642 717405586 63466914;}
@list l14:level1
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:16.55pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l14:level2
	{mso-level-number-format:alpha-lower;
	mso-level-text:%2;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:54.45pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l14:level3
	{mso-level-number-format:roman-lower;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:90.45pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l14:level4
	{mso-level-text:%4;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:126.45pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l14:level5
	{mso-level-number-format:alpha-lower;
	mso-level-text:%5;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:162.45pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l14:level6
	{mso-level-number-format:roman-lower;
	mso-level-text:%6;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:198.45pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l14:level7
	{mso-level-text:%7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:234.45pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l14:level8
	{mso-level-number-format:alpha-lower;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:270.45pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l14:level9
	{mso-level-number-format:roman-lower;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:306.45pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l15
	{mso-list-id:2127119304;
	mso-list-type:hybrid;
	mso-list-template-ids:41346972 -650890414 1332107238 1928469962 1362887368 231604352 -1570326242 781094134 843226422 -1940734514;}
@list l15:level1
	{mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:15.85pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l15:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:56.1pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l15:level3
	{mso-level-number-format:bullet;
	mso-level-text:\25AA;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:92.1pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l15:level4
	{mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:128.1pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l15:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:164.1pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l15:level6
	{mso-level-number-format:bullet;
	mso-level-text:\25AA;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:200.1pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l15:level7
	{mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:236.1pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l15:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:272.1pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
@list l15:level9
	{mso-level-number-format:bullet;
	mso-level-text:\25AA;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:308.1pt;
	text-indent:0in;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	mso-ascii-font-family:Georgia;
	mso-fareast-font-family:Georgia;
	mso-hansi-font-family:Georgia;
	mso-bidi-font-family:Georgia;
	color:black;
	border:none;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-underline:black;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;
	vertical-align:baseline;}
ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Table Normal";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"";
	mso-padding-alt:0in 5.4pt 0in 5.4pt;
	mso-para-margin-top:0in;
	mso-para-margin-right:0in;
	mso-para-margin-bottom:8.0pt;
	mso-para-margin-left:0in;
	line-height:107%;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;}
table.MsoTableGrid
	{mso-style-name:"Table Grid";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-priority:39;
	mso-style-unhide:no;
	border:solid windowtext 1.0pt;
	mso-border-alt:solid windowtext .5pt;
	mso-padding-alt:0in 5.4pt 0in 5.4pt;
	mso-border-insideh:.5pt solid windowtext;
	mso-border-insidev:.5pt solid windowtext;
	mso-para-margin:0in;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;}
table.TableGrid
	{mso-style-name:TableGrid;
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-unhide:no;
	mso-style-parent:"";
	mso-padding-alt:0in 0in 0in 0in;
	mso-para-margin:0in;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext="edit" spidmax="2049"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext="edit">
  <o:idmap v:ext="edit" data="1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=EN-US link="#0563C1" vlink="#954F72" style='tab-interval:.5in'>

<div class=WordSection1>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:46.4pt;
margin-bottom:13.8pt;margin-left:15.4pt;text-align:center;line-height:110%'>BOSTON
UNIVERSITY</p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:46.4pt;
margin-bottom:57.15pt;margin-left:15.4pt;text-align:center;line-height:110%'>DIVISION
OF GRADUATE MEDICAL SCIENCES</p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:46.1pt;
margin-bottom:55.0pt;margin-left:15.8pt;text-align:center;text-indent:-.7pt;
line-height:110%'>Dissertation</p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:13.8pt;
margin-left:12.65pt;line-height:110%'><b style='mso-bidi-font-weight:normal'>A
MURINE MODEL OF GLUCOCORTICOID MYOPATHY</b></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:31.7pt;
margin-bottom:.75in;margin-left:.7pt;text-align:center;text-indent:-.7pt;
line-height:110%'><b style='mso-bidi-font-weight:normal'>ALLEVIATION USING
ANDROGEN THERAPY</b></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:46.35pt;
margin-bottom:57.15pt;margin-left:15.4pt;text-align:center;line-height:110%'>by</p>

<p class=MsoNormal align=center style='text-align:center'><b style='mso-bidi-font-weight:
normal'>NICOLAE LUCIAN SANDOR<o:p></o:p></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:.75pt;margin-bottom:0in;
margin-left:1.25pt;margin-bottom:.0001pt;line-height:107%'><span lang=IT
style='mso-ansi-language:IT'>B.M./M.D., Universitatea de Medicina si Farmacie
Carol Davila, 2002<o:p></o:p></span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:46.1pt;
margin-bottom:92.0pt;margin-left:15.8pt;text-align:center;text-indent:-.7pt;
line-height:110%'>B.S., Universitatea Bucuresti, 2005</p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:80.95pt;
margin-bottom:.15pt;margin-left:50.0pt;text-align:center;line-height:210%'>Submitted
in partial fulfillment of the requirements for the degree of</p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:46.4pt;
margin-bottom:13.8pt;margin-left:15.4pt;text-align:center;line-height:110%'>Doctor
of Philosophy</p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:46.4pt;
margin-bottom:13.8pt;margin-left:15.4pt;text-align:center;line-height:110%'>2015<br
clear=all style='mso-special-character:line-break;page-break-before:always'>
</p>

<p class=MsoNormal align=center style='text-align:center;text-indent:0in;
mso-pagination:widow-orphan'><span style='mso-bidi-font-size:12.0pt;line-height:
200%;font-family:"Times New Roman",serif;mso-fareast-font-family:"MS Mincho";
color:windowtext'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal align=center style='text-align:center;text-indent:0in;
mso-pagination:widow-orphan'><span style='mso-bidi-font-size:12.0pt;line-height:
200%;font-family:"Times New Roman",serif;mso-fareast-font-family:"MS Mincho";
color:windowtext'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal align=center style='text-align:center;text-indent:0in;
mso-pagination:widow-orphan'><span style='mso-bidi-font-size:12.0pt;line-height:
200%;font-family:"Times New Roman",serif;mso-fareast-font-family:"MS Mincho";
color:windowtext'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal align=center style='text-align:center;text-indent:0in;
mso-pagination:widow-orphan'><span style='mso-bidi-font-size:12.0pt;line-height:
200%;font-family:"Times New Roman",serif;mso-fareast-font-family:"MS Mincho";
color:windowtext'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal align=center style='text-align:center;text-indent:0in;
line-height:normal;mso-pagination:widow-orphan'><span style='mso-bidi-font-size:
12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"MS Mincho";
color:windowtext'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal align=center style='text-align:center;text-indent:0in;
line-height:normal;mso-pagination:widow-orphan'><span style='mso-bidi-font-size:
12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"MS Mincho";
color:windowtext'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal align=center style='text-align:center;text-indent:0in;
line-height:normal;mso-pagination:widow-orphan'><span style='mso-bidi-font-size:
12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"MS Mincho";
color:windowtext'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal align=center style='text-align:center;text-indent:0in;
line-height:normal;mso-pagination:widow-orphan'><span style='mso-bidi-font-size:
12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"MS Mincho";
color:windowtext'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal align=center style='text-align:center;text-indent:0in;
line-height:normal;mso-pagination:widow-orphan'><span style='mso-bidi-font-size:
12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"MS Mincho";
color:windowtext'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal align=center style='text-align:center;text-indent:0in;
line-height:normal;mso-pagination:widow-orphan'><span style='mso-bidi-font-size:
12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"MS Mincho";
color:windowtext'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal align=center style='text-align:center;text-indent:0in;
line-height:normal;mso-pagination:widow-orphan'><span style='mso-bidi-font-size:
12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"MS Mincho";
color:windowtext'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal align=center style='text-align:center;text-indent:0in;
line-height:normal;mso-pagination:widow-orphan'><span style='mso-bidi-font-size:
12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"MS Mincho";
color:windowtext'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal align=center style='text-align:center;text-indent:0in;
line-height:normal;mso-pagination:widow-orphan'><span style='mso-bidi-font-size:
12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"MS Mincho";
color:windowtext'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal align=center style='text-align:center;text-indent:0in;
line-height:normal;mso-pagination:widow-orphan'><span style='mso-bidi-font-size:
12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"MS Mincho";
color:windowtext'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal align=center style='text-align:center;text-indent:0in;
line-height:normal;mso-pagination:widow-orphan'><span style='mso-bidi-font-size:
12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"MS Mincho";
color:windowtext'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal align=center style='text-align:center;text-indent:0in;
line-height:normal;mso-pagination:widow-orphan'><span style='mso-bidi-font-size:
12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"MS Mincho";
color:windowtext'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal align=center style='text-align:center;text-indent:0in;
line-height:normal;mso-pagination:widow-orphan'><span style='mso-bidi-font-size:
12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"MS Mincho";
color:windowtext'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal align=center style='text-align:center;text-indent:0in;
line-height:normal;mso-pagination:widow-orphan'><span style='mso-bidi-font-size:
12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"MS Mincho";
color:windowtext'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal align=center style='text-align:center;text-indent:0in;
line-height:normal;mso-pagination:widow-orphan'><span style='mso-bidi-font-size:
12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"MS Mincho";
color:windowtext'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-indent:0in;line-height:normal;mso-pagination:
widow-orphan'><span style='mso-bidi-font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"MS Mincho";color:windowtext'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-indent:0in;line-height:normal;mso-pagination:
widow-orphan'><span style='mso-bidi-font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"MS Mincho";color:windowtext'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-indent:0in;line-height:normal;mso-pagination:
widow-orphan'><span style='mso-bidi-font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"MS Mincho";color:windowtext'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-indent:0in;line-height:normal;mso-pagination:
widow-orphan'><span style='mso-bidi-font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"MS Mincho";color:windowtext'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-indent:0in;line-height:normal;mso-pagination:
widow-orphan'><span style='mso-bidi-font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"MS Mincho";color:windowtext'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-indent:0in;line-height:normal;mso-pagination:
widow-orphan'><span style='mso-bidi-font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"MS Mincho";color:windowtext'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-indent:0in;line-height:normal;mso-pagination:
widow-orphan'><span style='mso-bidi-font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"MS Mincho";color:windowtext'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-indent:0in;line-height:normal;mso-pagination:
widow-orphan'><span style='mso-bidi-font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"MS Mincho";color:windowtext'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-indent:0in;line-height:normal;mso-pagination:
widow-orphan'><span style='mso-bidi-font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"MS Mincho";color:windowtext'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-indent:0in;line-height:normal;mso-pagination:
widow-orphan'><span style='mso-bidi-font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"MS Mincho";color:windowtext'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-indent:0in;line-height:normal;mso-pagination:
widow-orphan'><span style='mso-bidi-font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"MS Mincho";color:windowtext'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-indent:0in;line-height:normal;mso-pagination:
widow-orphan'><span style='mso-bidi-font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"MS Mincho";color:windowtext'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-indent:0in;line-height:normal;mso-pagination:
widow-orphan'><span style='mso-bidi-font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"MS Mincho";color:windowtext'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-indent:0in;line-height:normal;mso-pagination:
widow-orphan'><span style='mso-bidi-font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"MS Mincho";color:windowtext'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-indent:0in;line-height:normal;mso-pagination:
widow-orphan'><span style='mso-bidi-font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"MS Mincho";color:windowtext'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-indent:0in;line-height:normal;mso-pagination:
widow-orphan'><span style='mso-bidi-font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"MS Mincho";color:windowtext'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-indent:0in;line-height:normal;mso-pagination:
widow-orphan'><span style='mso-bidi-font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"MS Mincho";color:windowtext'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-indent:0in;line-height:normal;mso-pagination:
widow-orphan'><span style='mso-bidi-font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"MS Mincho";color:windowtext'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:.75pt;margin-bottom:0in;
margin-left:245.05pt;margin-bottom:.0001pt;text-indent:-29.05pt;line-height:
107%'> 2015</p>

<p class=MsoNormal style='margin-top:0in;margin-right:.75pt;margin-bottom:0in;
margin-left:245.05pt;margin-bottom:.0001pt;text-indent:-29.05pt;line-height:
107%'>NICOLAE LUCIAN SANDOR</p>

<p class=MsoNormal style='margin-top:0in;margin-right:.75pt;margin-bottom:0in;
margin-left:245.05pt;margin-bottom:.0001pt;text-indent:-29.05pt;line-height:
107%'>All rights reserved</p>

<span style='font-size:12.0pt;mso-bidi-font-size:11.0pt;line-height:107%;
font-family:"Georgia",serif;mso-fareast-font-family:Georgia;mso-bidi-font-family:
Georgia;color:black;mso-ansi-language:EN-US;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA'><br clear=all style='mso-special-character:line-break;
page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:8.0pt;text-indent:0in;line-height:107%'><o:p>&nbsp;</o:p></p>

<p class=MsoNormal style='margin-top:0in;margin-right:.75pt;margin-bottom:0in;
margin-left:245.05pt;margin-bottom:.0001pt;line-height:107%'><o:p>&nbsp;</o:p></p>

<p class=MsoNormal style='margin-top:0in;margin-right:.75pt;margin-bottom:180.4pt;
margin-left:151.05pt;line-height:107%'>Approved by</p>

<table class=TableGrid border=0 cellspacing=0 cellpadding=0 width=583
 style='width:437.1pt;margin-left:16.6pt;border-collapse:collapse;mso-yfti-tbllook:
 1184;mso-padding-alt:0in 0in 0in 0in'>
 <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;height:70.85pt'>
  <td width=142 valign=top style='width:106.5pt;padding:0in 0in 0in 0in;
  height:70.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>First Reader</p>
  </td>
  <td width=441 valign=top style='width:330.6pt;padding:0in 0in 0in 0in;
  height:70.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:105%'>___________________________________________
  Monty Montano, Ph.D.</p>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>Assistant
  Professor of Medicine</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1;mso-yfti-lastrow:yes;height:70.85pt'>
  <td width=142 style='width:106.5pt;padding:0in 0in 0in 0in;height:70.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>Second Reader</p>
  </td>
  <td width=441 valign=bottom style='width:330.6pt;padding:0in 0in 0in 0in;
  height:70.85pt'>
  <p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
  text-indent:0in;line-height:107%'>___________________________________________</p>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>Shalender Bhasin,
  MD</p>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>Professor of
  Medicine</p>
  </td>
 </tr>
</table>

<h1 style='margin-top:0in;margin-right:25.7pt;margin-bottom:0in;margin-left:
.5pt;margin-bottom:.0001pt'><i style='mso-bidi-font-style:normal'><span
style='font-weight:normal'><o:p>&nbsp;</o:p></span></i></h1>

<b style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
style='font-size:12.0pt;mso-bidi-font-size:11.0pt;line-height:107%;font-family:
"Georgia",serif;mso-fareast-font-family:Georgia;mso-bidi-font-family:Georgia;
color:black;mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:
AR-SA'><br clear=all style='mso-special-character:line-break;page-break-before:
always'>
</span></i></b>

<p class=MsoNormal style='margin-bottom:8.0pt;text-indent:0in;line-height:107%'><i
style='mso-bidi-font-style:normal'><o:p>&nbsp;</o:p></i></p>

<h1 style='margin-top:0in;margin-right:25.7pt;margin-bottom:0in;margin-left:
.5pt;margin-bottom:.0001pt'><a name="_Toc421412235">Acknowledgments</a></h1>

<p class=MsoNormal>I am deeply indebted to the members of my committee, Profs.
Caroline Apovian, Shalender Bhasin, Isabel Dominguez, Konstantin Kandror, Monty
Montano, and Carlo Serra. It was a privilege to receive insights from so many
angles of expertise. I am grateful to the leaders of the graduate programs at
Boston University School of Medicine, Profs. William Cruikshank, David
Atkinson, and Mary Jo Murnane. I am commending the assistance I received from
Drs. Wen Guo, Mikhail Zakharov, and Michael Panichas. I am also obliged to Mary
Kathleen Deloge, who helped me deal with limiting conditions. I am also
thanking my past mentors, Profs. Vasile Munteanu, Alex Babes, Gordon Reid, Anne
Treisman, and Assen Marintchev.</p>

<p class=MsoNormal>Congratulations are due to my spouse who, all these years,
took an unreasonably positive view, managed many of the household businesses,
and published as many papers as me.</p>

<p class=MsoNormal>I am dedicating this work to those who were taken away
untimely during these years. My mother spent her life in the most important
frontline, as an EMT. My first lab mate, the prodigious Iurie Barbu, MD, died
before his defense. We spent long weekend afternoons, manually switching
polarizers in the Cotroceni lab, and dark winter nights, moonlighting in the
pediatric ER at the Alexandrescu Hospital. This world is poorer without them.</p>

<p class=MsoNormal>This work would not have existed, were it not for the kind
financial support of the American nation, through the National Institute of
Health and Boston University.</p>

<b style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;
mso-bidi-font-size:11.0pt;line-height:107%;font-family:"Georgia",serif;
mso-fareast-font-family:Georgia;mso-bidi-font-family:Georgia;color:black;
mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><br
clear=all style='mso-special-character:line-break;page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;text-indent:0in;line-height:107%'><b
style='mso-bidi-font-weight:normal'><o:p>&nbsp;</o:p></b></p>

<p class=MsoNormal align=center style='text-align:center'><b style='mso-bidi-font-weight:
normal'>A MURINE MODEL OF GLUCOCORTICOID MYOPATHY<o:p></o:p></b></p>

<p class=MsoNormal align=center style='text-align:center'><b style='mso-bidi-font-weight:
normal'>ALLEVIATION USING ANDROGEN THERAPY<o:p></o:p></b></p>

<p class=MsoNormal align=center style='text-align:center'><b style='mso-bidi-font-weight:
normal'>NICOLAE LUCIAN SANDOR<o:p></o:p></b></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:40.55pt;
margin-bottom:20.45pt;margin-left:15.4pt;text-align:center;line-height:110%'>Boston
University School/Division of Graduate Medical Sciences, 2015</p>

<p class=MsoNormal style='margin-top:0in;margin-right:.75pt;margin-bottom:20.75pt;
margin-left:22.1pt'>Major Professor: Monty Montano, PhD, Assistant Professor of
Medicine</p>

<h1 style='margin-top:0in;margin-right:25.7pt;margin-bottom:0in;margin-left:
.5pt;margin-bottom:.0001pt'><a name="_Toc421412236">Abstract</a></h1>

<p class=MsoNormal>Glucocorticoids (GC) are used widely for the treatment of a
large number of inflammatory conditions. A loss in muscle mass and increases in
muscle weakness are common complications of GC therapy. Androgen therapy has
been suggested to reverse GC-associated muscle loss (GAML), but evidence of its
effectiveness is inconsistent. Herein, I established a mouse model of GAML.
Young adult male mice receiving 0.25 mg/kg/day of the GC dexamethasone (D) s.c.
daily, for a week, lost 3% of their total body weight. Based on NMR lean body
mass quantification and muscle dissection, more than 10% of their muscle mass
was lost. More than half of the D-induced muscle loss could be reversed by
co-administration of 0.7 mg/kg/day of testosterone (T). To my knowledge, this
is the first mouse model of GAML demonstrating alleviation by T.</p>

<p class=MsoNormal>D-upregulated intramuscular atrogene expression and
proteasome catalytic activity were suppressed by T co-administration. D
downregulated cathepsin L enzymatic activity and beclin expression, indicating
that lysosome was not a major effector of GAML. Changes in calpain 1 and in
translation factors 4E-BP, eIF3f and eIF2, following T treatment, were
inconclusive. The changes in proteasome activity and atrogene expression were
correlated with changes in expression of Foxo 1, 3a, and 4. Pro-catabolic
factors REDD1 and Klf15 were repressed by T co-administration.</p>

<p class=MsoNormal>C2C12 differentiated myotubes were used to model GAML in
vitro. Myotube diameter and total protein were reduced by D, and restored by T
co-administration. Changes in C2C12 total protein were correlated with changes
in protein degradation. D-induced proteolysis was inhibited by the proteasome
inhibitor MG132.</p>

<p class=MsoNormal>In vivo, D reduced intramuscular IGF-I expression, an effect
reversed by T co-administration. In C2C12, inhibition of IGF-1R signaling with
picropodophyllin did not modify T protective effect. Mechanisms potentially
explaining these observations are discussed.</p>

<p class=MsoNormal>In summary, my model demonstrates that T protective effect
in GAML is mainly anti-catabolic, through the reversal of proteasome upregulation
induced by D. In vivo, T stimulates a potentially protective intramuscular
IGF-I response. The roles of protein synthesis and IGF-I in anabolic
myoprotection could not be addressed in these models, and require further
investigations.</p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<span style='font-size:12.0pt;mso-bidi-font-size:11.0pt;line-height:107%;
font-family:"Georgia",serif;mso-fareast-font-family:Georgia;mso-bidi-font-family:
Georgia;color:black;mso-ansi-language:EN-US;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA'><br clear=all style='mso-special-character:line-break;
page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:8.0pt;text-indent:0in;line-height:107%'><b
style='mso-bidi-font-weight:normal'><o:p>&nbsp;</o:p></b></p>

<h1 style='margin-top:0in;margin-right:25.7pt;margin-bottom:10.4pt;margin-left:
.5pt'><a name="_Toc421412237">Contents</a></h1>

<p class=MsoNormal style='margin-bottom:8.0pt;text-indent:0in;line-height:107%;
tab-stops:center 209.85pt 430.25pt'><span style='font-size:11.0pt;line-height:
107%;font-family:"Calibri",sans-serif;mso-fareast-font-family:Calibri;
mso-bidi-font-family:Calibri'><span style='mso-tab-count:1'> </span></span></p>

<w:Sdt SdtDocPart="t" DocPartType="Table of Contents" DocPartUnique="t"
 ID="-278875544">
 <p class=MsoTocHeading>Table of Contents<span style='mso-bidi-font-size:11.0pt;
 line-height:107%;mso-fareast-font-family:Georgia;mso-bidi-font-family:Georgia;
 color:black'><w:sdtPr></w:sdtPr></span></p>
 <p class=MsoToc1 style='tab-stops:right dotted 6.35in'><!--[if supportFields]><span
 style='mso-element:field-begin'></span><span
 style='mso-spacerun:yes'></span>TOC \o &quot;1-3&quot; \h \z \u <span
 style='mso-element:field-separator'></span><![endif]--><a href="#_Toc421412235"><span
 style='mso-no-proof:yes'>Acknowledgments</span><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412235 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>iv<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200330035000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc1 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412236"><span
 style='mso-no-proof:yes'>Abstract</span><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412236 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>v<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200330036000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc1 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412237"><span
 style='mso-no-proof:yes'>Contents</span><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412237 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>vii<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200330037000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc1 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412238"><span
 style='mso-no-proof:yes'>List of Tables</span><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412238 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>x<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200330038000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc1 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412239"><span
 style='mso-no-proof:yes'>List of Figures</span><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412239 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>xi<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200330039000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc1 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412240"><span
 style='mso-no-proof:yes'>Abbreviations</span><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412240 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>xiii<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200340030000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc1 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412241"><span
 style='font-family:"Times New Roman",serif;mso-fareast-font-family:"MS Gothic";
 mso-fareast-theme-font:major-fareast;mso-bidi-font-weight:bold;mso-no-proof:
 yes'>1. CLINICAL QUESTIONS AND EVIDENCE</span><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-tab-count:1 dotted'>.. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412241 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>1<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200340031000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412242"><span
 style='mso-no-proof:yes'>Cushings syndrome</span><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412242 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>1<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200340032000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412243"><span
 style='mso-no-proof:yes'>Glucocorticoid therapy</span><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412243 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>3<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200340033000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412244"><span
 style='mso-no-proof:yes'>Hypercortisolism-induced muscle loss</span><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412244 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>10<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200340034000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412245"><span
 style='mso-no-proof:yes'>Muscle protection with androgen therapy</span><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412245 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>21<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200340035000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412246"><span
 style='mso-no-proof:yes'>Hypercortisolism-induced changes in endogenous
 androgens levels</span><span style='color:windowtext;display:none;mso-hide:
 screen;mso-no-proof:yes;text-decoration:none;text-underline:none'><span
 style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412246 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>30<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200340036000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412247"><span
 style='mso-no-proof:yes'>Molecular mechanisms of androgenic myoprotection in
 humans</span><span style='color:windowtext;display:none;mso-hide:screen;
 mso-no-proof:yes;text-decoration:none;text-underline:none'><span
 style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412247 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>34<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200340037000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc1 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412248"><span
 style='mso-no-proof:yes'>2. BIOLOGICAL PREMISES</span><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412248 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>40<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200340038000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412249"><span
 style='mso-no-proof:yes'>Skeletal muscle histology</span><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412249 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>40<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200340039000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412250"><span
 style='mso-no-proof:yes'>Preadult muscle development</span><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412250 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>43<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200350030000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412251"><span
 style='mso-no-proof:yes'>Physiological muscle metabolism</span><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-tab-count:1 dotted'>... </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412251 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>46<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200350031000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412252"><span
 style='mso-no-proof:yes'>Adult muscle remodeling</span><span style='color:
 windowtext;display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;
 text-underline:none'><span style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412252 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>50<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200350032000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412253"><span
 style='mso-no-proof:yes'>Hormonal control of muscle mass</span><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412253 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>52<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200350033000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412254"><span
 style='mso-no-proof:yes'>Interaction of muscle mass and vascularization</span><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-tab-count:1 dotted'>.. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412254 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>55<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200350034000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412255"><span
 style='mso-no-proof:yes'>Control of muscle mass through innervation</span><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-tab-count:1 dotted'>.. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412255 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>57<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200350035000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412256"><span
 style='mso-no-proof:yes'>Animal models of glucocorticoid myopathy</span><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412256 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>62<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200350036000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412257"><span
 style='mso-no-proof:yes'>Glucocorticoid stimulation of ubiquitin-proteasome
 system</span><span style='color:windowtext;display:none;mso-hide:screen;
 mso-no-proof:yes;text-decoration:none;text-underline:none'><span
 style='mso-tab-count:1 dotted'>... </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412257 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>66<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200350037000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412258"><span
 style='mso-no-proof:yes'>Glucocorticoid-induced loss of sensitivity on the IRS
 - Akt axis</span><span style='color:windowtext;display:none;mso-hide:screen;
 mso-no-proof:yes;text-decoration:none;text-underline:none'><span
 style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412258 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>71<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200350038000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412259"><span
 style='mso-no-proof:yes'>Glucocorticoid inhibition of mTOR</span><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-tab-count:1 dotted'>.. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412259 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>77<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200350039000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412260"><span
 style='mso-no-proof:yes'>Glucocorticoid activation of Foxo transcriptional
 program</span><span style='color:windowtext;display:none;mso-hide:screen;
 mso-no-proof:yes;text-decoration:none;text-underline:none'><span
 style='mso-tab-count:1 dotted'>... </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412260 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>81<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200360030000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412261"><span
 style='mso-no-proof:yes'>Glucocorticoid activation of myostatin</span><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-tab-count:1 dotted'>.. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412261 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>85<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200360031000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412262"><span
 style='mso-no-proof:yes'>Glucocorticoid modulation of protein synthesis</span><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412262 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>87<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200360032000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412263"><span
 style='mso-no-proof:yes'>The effects of glucocorticoids on autophagy</span><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412263 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>92<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200360033000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412264"><span
 style='mso-no-proof:yes'>Other proteolytic systems modulated by
 glucocorticoids</span><span style='color:windowtext;display:none;mso-hide:
 screen;mso-no-proof:yes;text-decoration:none;text-underline:none'><span
 style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412264 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>94<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200360034000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412265"><span
 style='mso-no-proof:yes'>Alleviation of glucocorticoid myopathy by IGF-I</span><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412265 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>95<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200360035000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412266"><span
 style='mso-no-proof:yes'>Alleviation of glucocorticoid myopathy by anabolic
 steroids</span><span style='color:windowtext;display:none;mso-hide:screen;
 mso-no-proof:yes;text-decoration:none;text-underline:none'><span
 style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412266 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>98<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200360036000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc1 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412267"><span
 style='mso-no-proof:yes'>3. HYPOTHESES</span><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412267 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>104<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200360037000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc1 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412268"><span
 style='mso-no-proof:yes'>4. METHODS</span><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412268 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>107<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200360038000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412269"><span
 style='mso-no-proof:yes'>Ethical considerations</span><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412269 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>107<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200360039000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412270"><span
 style='mso-no-proof:yes'>Animal studies</span><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412270 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>107<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200370030000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412271"><span
 style='mso-no-proof:yes'>Enzymatic assays</span><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412271 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>108<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200370031000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412272"><span
 style='mso-no-proof:yes'>Immunoblot</span><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412272 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>111<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200370032000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412273"><span
 style='mso-no-proof:yes'>Quantitative real-time polymerase chain reaction</span><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-tab-count:1 dotted'>.. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412273 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>115<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200370033000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412274"><span
 style='mso-no-proof:yes'>Cell culture studies</span><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412274 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>118<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200370034000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412275"><span
 style='mso-no-proof:yes'>Immunofluorescence microscopy</span><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412275 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>120<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200370035000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412276"><span
 style='mso-no-proof:yes'>Measurement of muscle protein synthesis and
 degradation</span><span style='color:windowtext;display:none;mso-hide:screen;
 mso-no-proof:yes;text-decoration:none;text-underline:none'><span
 style='mso-tab-count:1 dotted'>.. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412276 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>121<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200370036000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412277"><span
 style='mso-no-proof:yes'>Statistics</span><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412277 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>123<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200370037000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412278"><span
 style='mso-no-proof:yes'>Literature review</span><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-tab-count:1 dotted'>.. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412278 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>123<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200370038000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc1 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412279"><span
 style='mso-no-proof:yes'>5. IN VIVO EXPERIMENTS</span><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412279 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>125<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200370039000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412280"><span
 style='mso-no-proof:yes'>Testosterone reverses dexamethasone-induced muscle
 atrophy</span><span style='color:windowtext;display:none;mso-hide:screen;
 mso-no-proof:yes;text-decoration:none;text-underline:none'><span
 style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412280 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>125<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200380030000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412281"><span
 style='mso-no-proof:yes'>Testosterone reverses glucocorticoid-induced
 activation of the ubiquitin-proteasome system</span><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-tab-count:1'> </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412281 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>134<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200380031000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412282"><span
 style='mso-no-proof:yes'>Autophagy markers during dexamethasone and
 testosterone treatments</span><span style='color:windowtext;display:none;
 mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:none'><span
 style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412282 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>138<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200380032000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412283"><span
 style='mso-no-proof:yes'>Protein synthesis modulation during Dexa-induced
 muscle atrophy</span><span style='color:windowtext;display:none;mso-hide:screen;
 mso-no-proof:yes;text-decoration:none;text-underline:none'><span
 style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412283 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>142<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200380033000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412284"><span
 style='mso-no-proof:yes'>Foxo pathway response to dexamethasone and
 testosterone</span><span style='color:windowtext;display:none;mso-hide:screen;
 mso-no-proof:yes;text-decoration:none;text-underline:none'><span
 style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412284 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>145<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200380034000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412285"><span
 style='mso-no-proof:yes'>Akt pathway response to dexamethasone and
 testosterone</span><span style='color:windowtext;display:none;mso-hide:screen;
 mso-no-proof:yes;text-decoration:none;text-underline:none'><span
 style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412285 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>147<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200380035000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412286"><span
 style='mso-no-proof:yes'>IGF-I changes during dexamethasone and testosterone
 administration</span><span style='color:windowtext;display:none;mso-hide:screen;
 mso-no-proof:yes;text-decoration:none;text-underline:none'><span
 style='mso-tab-count:1 dotted'>.. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412286 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>149<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200380036000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412287"><span
 style='mso-no-proof:yes'>Protein synthesis in cultured cells treated with
 dexamethasone and testosterone</span><span style='color:windowtext;display:
 none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412287 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>155<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200380037000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412288"><span
 style='mso-no-proof:yes'>Testosterone prevents protein catabolism upregulation
 induced by dexamethasone</span><span style='color:windowtext;display:none;
 mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:none'><span
 style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412288 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>157<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200380038000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412289"><span
 style='mso-no-proof:yes'>Mechanisms of androgenic myoprotection in cultured
 myotubes</span><span style='color:windowtext;display:none;mso-hide:screen;
 mso-no-proof:yes;text-decoration:none;text-underline:none'><span
 style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412289 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>160<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200380039000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412290"><span
 style='mso-no-proof:yes'>treated with dexamethasone</span><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412290 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>160<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200390030000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc1 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412291"><span
 style='mso-no-proof:yes'>7. DISCUSSION</span><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-tab-count:1 dotted'>.. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412291 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>163<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200390031000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412292"><span
 style='mso-no-proof:yes'>Testosterone alleviates dexamethasone-induced muscle
 atrophy in mice</span><span style='color:windowtext;display:none;mso-hide:
 screen;mso-no-proof:yes;text-decoration:none;text-underline:none'><span
 style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412292 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>163<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200390032000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412293"><span
 style='mso-no-proof:yes'>Testosterones myoprotective action is based on the
 inhibition of the dexamethasone-induced proteasome upregulation</span><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-tab-count:1 dotted'>.. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412293 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>167<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200390033000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412294"><span
 style='mso-no-proof:yes'>Molecular mechanisms linking dexamethasone and
 testosterone to protein metabolism</span><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-tab-count:1'> </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412294 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>173<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200390034000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412295"><span
 style='mso-no-proof:yes'>Future directions</span><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412295 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>175<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200390035000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc2 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412296"><span
 style='mso-no-proof:yes'>Conclusions</span><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412296 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>176<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200390036000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc1 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412297"><span
 style='mso-no-proof:yes'>Bibliography</span><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-tab-count:1 dotted'>. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412297 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>177<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200390037000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoToc1 style='tab-stops:right dotted 6.35in'><a href="#_Toc421412298"><span
 style='mso-no-proof:yes'>8. CURRICULUM VITAE</span><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-tab-count:1 dotted'>.. </span></span><!--[if supportFields]><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'><span style='mso-element:field-begin'></span>
 PAGEREF _Toc421412298 \h <span style='mso-element:field-separator'></span></span><![endif]--><span
 style='color:windowtext;display:none;mso-hide:screen;mso-no-proof:yes;
 text-decoration:none;text-underline:none'>285<!--[if gte mso 9]><xml>
  <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F0054006F0063003400320031003400310032003200390038000000</w:data>
 </xml><![endif]--></span><!--[if supportFields]><span style='color:windowtext;
 display:none;mso-hide:screen;mso-no-proof:yes;text-decoration:none;text-underline:
 none'><span style='mso-element:field-end'></span></span><![endif]--></a><span
 style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
 mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
 "Times New Roman";mso-bidi-theme-font:minor-bidi;mso-no-proof:yes'><o:p></o:p></span></p>
 <p class=MsoNormal><!--[if supportFields]><b><span style='mso-no-proof:yes'><span
 style='mso-element:field-end'></span></span></b><![endif]--><o:p>&nbsp;</o:p></p>
</w:Sdt><span style='font-size:12.0pt;mso-bidi-font-size:11.0pt;line-height:
107%;font-family:"Georgia",serif;mso-fareast-font-family:Georgia;mso-bidi-font-family:
Georgia;color:black;mso-ansi-language:EN-US;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA'><br clear=all style='mso-special-character:line-break;
page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:8.0pt;text-indent:0in;line-height:107%'><o:p>&nbsp;</o:p></p>

<h1 style='margin-top:0in;margin-right:25.7pt;margin-bottom:32.7pt;margin-left:
.5pt'><a name="_Toc421412238">List of Tables</a></h1>

<p class=MsoNormal style='margin-top:0in;margin-right:25.7pt;margin-bottom:
10.45pt;margin-left:45.45pt;text-indent:-27.5pt;mso-list:l4 level1 lfo4'><![if !supportLists]><span
style='mso-bidi-font-size:12.0pt;line-height:200%'><span style='mso-list:Ignore'>1<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Pharmacological agents used in Cushings disease
of unidentified ectopic, or diffuse localization (reviewed in [1, 2])</p>

<p class=MsoNormal style='margin-top:0in;margin-right:25.7pt;margin-bottom:
0in;margin-left:45.45pt;margin-bottom:.0001pt;text-indent:-27.5pt;line-height:
107%;mso-list:l4 level1 lfo4'><![if !supportLists]><span style='mso-bidi-font-size:
12.0pt;line-height:107%'><span style='mso-list:Ignore'>2<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>List of RT-PCR primers</p>

<span style='font-size:12.0pt;mso-bidi-font-size:11.0pt;line-height:107%;
font-family:"Georgia",serif;mso-fareast-font-family:Georgia;mso-bidi-font-family:
Georgia;color:black;mso-ansi-language:EN-US;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA'><br clear=all style='mso-special-character:line-break;
page-break-before:always'>
</span>

<p class=MsoNormal style='margin-top:0in;margin-right:25.7pt;margin-bottom:
0in;margin-left:45.45pt;margin-bottom:.0001pt;text-indent:-27.5pt;line-height:
107%;mso-list:l4 level1 lfo4'><![if !supportLists]><span style='mso-bidi-font-size:
12.0pt;line-height:107%'><span style='mso-list:Ignore'>3<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><o:p>&nbsp;</o:p></p>

<h1 style='margin-top:0in;margin-right:25.7pt;margin-bottom:32.7pt;margin-left:
.5pt'><a name="_Toc421412239">List of Figures</a></h1>

<p class=MsoNormal>1<span style='mso-tab-count:1'> </span>Experimental
protocol for the in vivo studies</p>

<p class=MsoNormal>2<span style='mso-tab-count:1'> </span>Body weight at
sacrifice, following Dexa with / without Testo treatments.</p>

<p class=MsoNormal>3<span style='mso-tab-count:1'> </span>Time course of body
weight Dexa with / without Testo treatments.</p>

<p class=MsoNormal>4<span style='mso-tab-count:1'> </span>Changes in water,
lean, and fat body mass, after Dexa with / without Testo treatments </p>

<p class=MsoNormal>5<span style='mso-tab-count:1'> </span>Effects of Dexa
with / without Testo treatments on individual muscle weights</p>

<p class=MsoNormal>6<span style='mso-tab-count:1'> </span>Changes in
atrogenes MuRF-1 / Trim63 and MAFbx / Fbxo32 expression following Dexa with /
without Testo treatments</p>

<p class=MsoNormal>7 Changes in proteasome enzymatic activity following Dexa
and / or <span style='mso-tab-count:1'> </span>Testo treatments.</p>

<p class=MsoNormal><span style='mso-spacerun:yes'></span>8<span
style='mso-tab-count:1'> </span>Changes in autophagy-related genes following Dexa
with / without Testo treatments</p>

<p class=MsoNormal>9<span style='mso-tab-count:1'> </span>Changes in
cathepsin enzymatic activity following Dexa with / without Testo treatments</p>

<p class=MsoNormal>10<span style='mso-tab-count:1'> </span>Changes in LC3
lipidation status following Dexa with / without Testo treatments</p>

<p class=MsoNormal>11<span style='mso-tab-count:1'> </span>Calpain enzymatic
activity during Dexa with / without Testo treatments</p>

<p class=MsoNormal>12<span style='mso-tab-count:1'> </span>Levels of
phosphorylated eIF2&#945; following Dexa with / without Testo treatment</p>

<p class=MsoNormal>13<span style='mso-tab-count:1'> </span>Levels of eIF3f
following Dexa with / without Testo treatments</p>

<p class=MsoNormal>14<span style='mso-tab-count:1'> </span>Levels of total and
phosphorylated 4E-BP following Dexa with / without Testo treatments. </p>

<p class=MsoNormal>15<span style='mso-tab-count:1'> </span>Changes in the
expression of Foxo3a and Klf15 transcription factors during Dexa with / without
Testo treatments.</p>

<p class=MsoNormal>16<span style='mso-tab-count:1'> </span>Levels of total and
phosphorylated Akt following Dexa with / without Testo treatments</p>

<p class=MsoNormal>17<span style='mso-tab-count:1'> </span>Changes in the
expression of Redd1 during Dexa with / without Testo treatments.</p>

<p class=MsoNormal>18<span style='mso-tab-count:1'> </span>Changes in the
expression of IGF-I during Dexa with / without Testo treatments.<span
style='mso-tab-count:1'> </span></p>

<p class=MsoNormal>19<span style='mso-tab-count:1'> </span>Changes in C2C12
myotube diameter following Dexa with / without Testo treatments.</p>

<p class=MsoNormal>20<span style='mso-tab-count:1'> </span>Changes
in C2C12 myotube protein content following Dexa with / without Testo
treatments.</p>

<p class=MsoNormal>21<span style='mso-tab-count:1'> </span>Estimates of protein
synthesis rate in C2C12 myotubes treated with Dexa with / without Testo</p>

<p class=MsoNormal>22<span style='mso-tab-count:1'> </span>Estimates of protein
degradation rate in C2C12 myotubes treated with Dexa with / without Testo</p>

<p class=MsoNormal>23<span style='mso-tab-count:1'> </span>Interference of
protein degradation in C2C12 myotubes treated with Dexa with chemical
inhibitors</p>

<p class=MsoNormal>24<span style='mso-tab-count:1'> </span>Mechanisms of AAS
alleviation of GAML</p>

<span style='font-size:25.0pt;mso-bidi-font-size:11.0pt;line-height:107%;
font-family:"Georgia",serif;mso-fareast-font-family:Georgia;mso-bidi-font-family:
Georgia;color:black;mso-ansi-language:EN-US;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA'><br clear=all style='mso-special-character:line-break;
page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:8.0pt;text-indent:0in;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span style='font-size:25.0pt;mso-bidi-font-size:
11.0pt;line-height:107%'><o:p>&nbsp;</o:p></span></b></p>

<h1><a name="_Toc421412240">Abbreviations</a></h1>

<table class=TableGrid border=0 cellspacing=0 cellpadding=0 width=438
 style='width:328.85pt;border-collapse:collapse;mso-yfti-tbllook:1184;
 mso-padding-alt:0in 0in 0in 0in'>
 <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;height:22.75pt'>
  <td width=200 valign=top style='width:149.85pt;padding:0in 0in 0in 0in;
  height:22.75pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>24HUC</p>
  </td>
  <td width=239 valign=top style='width:179.0pt;padding:0in 0in 0in 0in;
  height:22.75pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>24-hour urine
  cortisol</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>3MH</p>
  </td>
  <td width=239 style='width:179.0pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>3-methylhistidine</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>4E-BP</p>
  </td>
  <td width=239 style='width:179.0pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>eIF4E binding
  protein</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>AAP</p>
  </td>
  <td width=239 style='width:179.0pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>adrenal androgen
  precursor</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>AAS</p>
  </td>
  <td width=239 style='width:179.0pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>anabolic
  androgenic steroids</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>ACTH</p>
  </td>
  <td width=239 style='width:179.0pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>adrenocorticotropic
  hormone;</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>ActRIIB</p>
  </td>
  <td width=239 style='width:179.0pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>activin A
  receptor, type IIB</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>AMPK</p>
  </td>
  <td width=239 style='width:179.0pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
  text-indent:0in;line-height:107%'>adenosine monophosphate kinase</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>ANOVA</p>
  </td>
  <td width=239 style='width:179.0pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>analysis of
  variance</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>AP-1</p>
  </td>
  <td width=239 style='width:179.0pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>activator protein
  1</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:10;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>AR</p>
  </td>
  <td width=239 style='width:179.0pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>androgen receptor</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:11;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>ATF4</p>
  </td>
  <td width=239 style='width:179.0pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>activating
  transcription factor 4</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:12;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>Atg12</p>
  </td>
  <td width=239 style='width:179.0pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>autophagy-related
  12</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:13;mso-yfti-lastrow:yes;height:22.75pt'>
  <td width=200 valign=bottom style='width:149.85pt;padding:0in 0in 0in 0in;
  height:22.75pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>BCA</p>
  </td>
  <td width=239 valign=bottom style='width:179.0pt;padding:0in 0in 0in 0in;
  height:22.75pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>bicinchoninic
  acid</p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-top:0in;margin-right:100.6pt;margin-bottom:
0in;margin-left:-1.5in;margin-bottom:.0001pt;text-indent:0in;line-height:107%'><o:p>&nbsp;</o:p></p>

<table class=TableGrid border=0 cellspacing=0 cellpadding=0 width=476
 style='width:357.05pt;border-collapse:collapse;mso-yfti-tbllook:1184;
 mso-padding-alt:0in 0in 0in 0in'>
 <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;height:22.75pt'>
  <td width=200 valign=top style='width:149.85pt;padding:0in 0in 0in 0in;
  height:22.75pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>BCAA</p>
  </td>
  <td width=276 valign=top style='width:207.2pt;padding:0in 0in 0in 0in;
  height:22.75pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>branched-chain
  amino acids</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>Bcl3</p>
  </td>
  <td width=276 style='width:207.2pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>B-cell
  leukemia/lymphoma 3</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>bFGF</p>
  </td>
  <td width=276 style='width:207.2pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>basic fibroblast
  growth factor</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>BSA</p>
  </td>
  <td width=276 style='width:207.2pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>bovine serum
  albumin</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>C/EBP</p>
  </td>
  <td width=276 style='width:207.2pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>CCAAT-enhancer-binding
  protein</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>Comb</p>
  </td>
  <td width=276 style='width:207.2pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>combination of
  Dexa and Testo</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>COPD</p>
  </td>
  <td width=276 style='width:207.2pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
  text-indent:0in;line-height:107%'>chronic obstructive pulmonary disease</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>CS</p>
  </td>
  <td width=276 style='width:207.2pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>Cushings
  syndrome</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>CSA</p>
  </td>
  <td width=276 style='width:207.2pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>cross-sectional
  area</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>CT</p>
  </td>
  <td width=276 style='width:207.2pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>computed
  tomography</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:10;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>Ct</p>
  </td>
  <td width=276 style='width:207.2pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>cycle threshold</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:11;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>D</p>
  </td>
  <td width=276 style='width:207.2pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>dexamethasone-only
  group</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:12;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>Dexa</p>
  </td>
  <td width=276 style='width:207.2pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>dexamethasone</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:13;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>DHEA</p>
  </td>
  <td width=276 style='width:207.2pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>dehydroepiandrosterone</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:14;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>DHEAS</p>
  </td>
  <td width=276 style='width:207.2pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>dehydroepiandrosterone
  sulfate</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:15;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>DHT</p>
  </td>
  <td width=276 style='width:207.2pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>dihydrotestosterone</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:16;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>DMEM</p>
  </td>
  <td width=276 style='width:207.2pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>Dulbeccos
  Modified Eagle Medium</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:17;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>DMSO</p>
  </td>
  <td width=276 style='width:207.2pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>dimethyl
  sulfoxide</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:18;mso-yfti-lastrow:yes;height:22.75pt'>
  <td width=200 valign=bottom style='width:149.85pt;padding:0in 0in 0in 0in;
  height:22.75pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>DT</p>
  </td>
  <td width=276 valign=bottom style='width:207.2pt;padding:0in 0in 0in 0in;
  height:22.75pt'>
  <p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
  text-indent:0in;line-height:107%'>dexamethasone and testosterone group</p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-top:0in;margin-right:88.85pt;margin-bottom:
0in;margin-left:-1.5in;margin-bottom:.0001pt;text-indent:0in;line-height:107%'><o:p>&nbsp;</o:p></p>

<table class=TableGrid border=0 cellspacing=0 cellpadding=0 width=492
 style='width:368.85pt;border-collapse:collapse;mso-yfti-tbllook:1184;
 mso-padding-alt:0in 0in 0in 0in'>
 <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;height:22.75pt'>
  <td width=200 valign=top style='width:149.85pt;padding:0in 0in 0in 0in;
  height:22.75pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>DTT</p>
  </td>
  <td width=292 valign=top style='width:219.0pt;padding:0in 0in 0in 0in;
  height:22.75pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>dithiothreitol</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>EC50</p>
  </td>
  <td width=292 style='width:219.0pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>half maximal
  effective concentration</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>EDTA</p>
  </td>
  <td width=292 style='width:219.0pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>ethylenediaminetetraacetate</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>eIF2</p>
  </td>
  <td width=292 style='width:219.0pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>eukaryotic
  initiation factor 2</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>eIF2B</p>
  </td>
  <td width=292 style='width:219.0pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>eukaryotic
  initiation factor 2B</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>eIF3-f</p>
  </td>
  <td width=292 style='width:219.0pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>eukaryotic
  initiation factor 3f</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>eIF4E</p>
  </td>
  <td width=292 style='width:219.0pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
  text-indent:0in;line-height:107%'>eukaryotic translation initiation factor 4E</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>eNOS</p>
  </td>
  <td width=292 style='width:219.0pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>endothelial
  nitric oxide synthase</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>FBS</p>
  </td>
  <td width=292 style='width:219.0pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>fetal bovine
  serum</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>FDA</p>
  </td>
  <td width=292 style='width:219.0pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>Food and Drug
  Administration</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:10;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>FSH</p>
  </td>
  <td width=292 style='width:219.0pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>follicle
  stimulating hormone</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:11;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>FSR</p>
  </td>
  <td width=292 style='width:219.0pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>fractional
  synthesis rate</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:12;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>Gadd45</p>
  </td>
  <td width=292 style='width:219.0pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>Growth Arrest and
  DNA Damage 45</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:13;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>GAML</p>
  </td>
  <td width=292 style='width:219.0pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>GC-associated
  muscle loss</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:14;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>GC</p>
  </td>
  <td width=292 style='width:219.0pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>glucocorticoid</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:15;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>GCN2</p>
  </td>
  <td width=292 style='width:219.0pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>General Control
  Nonderepressible 2</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:16;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>GFP</p>
  </td>
  <td width=292 style='width:219.0pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>green fluorescent
  protein</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:17;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>GH</p>
  </td>
  <td width=292 style='width:219.0pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>growth hormone</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:18;mso-yfti-lastrow:yes;height:22.75pt'>
  <td width=200 valign=bottom style='width:149.85pt;padding:0in 0in 0in 0in;
  height:22.75pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>GLUT</p>
  </td>
  <td width=292 valign=bottom style='width:219.0pt;padding:0in 0in 0in 0in;
  height:22.75pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>glucose
  transporter</p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-top:0in;margin-right:41.85pt;margin-bottom:
0in;margin-left:-1.5in;margin-bottom:.0001pt;text-indent:0in;line-height:107%'><o:p>&nbsp;</o:p></p>

<table class=TableGrid border=0 cellspacing=0 cellpadding=0 width=554
 style='width:415.8pt;border-collapse:collapse;mso-yfti-tbllook:1184;
 mso-padding-alt:0in 0in 0in 0in'>
 <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;height:22.75pt'>
  <td width=200 valign=top style='width:149.85pt;padding:0in 0in 0in 0in;
  height:22.75pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>GnRH</p>
  </td>
  <td width=355 valign=top style='width:265.95pt;padding:0in 0in 0in 0in;
  height:22.75pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>gonadotropin-releasing
  hormone</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>GR</p>
  </td>
  <td width=355 style='width:265.95pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>glucocorticoid
  receptor</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>Grb2</p>
  </td>
  <td width=355 style='width:265.95pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>Growth factor
  receptor-bound protein 2</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>GRE</p>
  </td>
  <td width=355 style='width:265.95pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>glucocorticoid
  responsive-elements</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>GSK3</p>
  </td>
  <td width=355 style='width:265.95pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>glycogen synthase
  kinase 3</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>HAT</p>
  </td>
  <td width=355 style='width:265.95pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>histone
  acetyltransferase</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>HDAC</p>
  </td>
  <td width=355 style='width:265.95pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>histone
  deacetylase</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>HEPES</p>
  </td>
  <td width=355 style='width:265.95pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>4-(2-hydroxyethyl)-1-piperazineethanesulfonate</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>HIF 1a</p>
  </td>
  <td width=355 style='width:265.95pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>hypoxia-induced
  factor 1a</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>HOMA-IR</p>
  </td>
  <td width=355 style='width:265.95pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
  text-indent:0in;line-height:107%'>homeostatic model assessment - insulin
  resistance</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:10;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>HPA</p>
  </td>
  <td width=355 style='width:265.95pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>hypothalamic -
  pituitary - adrenal</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:11;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>HS</p>
  </td>
  <td width=355 style='width:265.95pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>horse serum</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:12;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>HSD</p>
  </td>
  <td width=355 style='width:265.95pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>honest
  significant difference</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:13;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>IBMX</p>
  </td>
  <td width=355 style='width:265.95pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>3-isobutyl-1-methylxanthine</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:14;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>IGF-1R</p>
  </td>
  <td width=355 style='width:265.95pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>IGF-I receptor</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:15;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>IGF-I</p>
  </td>
  <td width=355 style='width:265.95pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>insulin-like
  growth factor I</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:16;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>IGF2</p>
  </td>
  <td width=355 style='width:265.95pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>insulin-like
  growth factor 2</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:17;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>IGFBP</p>
  </td>
  <td width=355 style='width:265.95pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>IGF-I binding
  protein</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:18;mso-yfti-lastrow:yes;height:22.75pt'>
  <td width=200 valign=bottom style='width:149.85pt;padding:0in 0in 0in 0in;
  height:22.75pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>IL-1</p>
  </td>
  <td width=355 valign=bottom style='width:265.95pt;padding:0in 0in 0in 0in;
  height:22.75pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>interleukin 1</p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-top:0in;margin-right:31.55pt;margin-bottom:
0in;margin-left:-1.5in;margin-bottom:.0001pt;text-indent:0in;line-height:107%'><o:p>&nbsp;</o:p></p>

<table class=TableGrid border=0 cellspacing=0 cellpadding=0 width=568
 style='width:426.15pt;border-collapse:collapse;mso-yfti-tbllook:1184;
 mso-padding-alt:0in 0in 0in 0in'>
 <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;height:22.75pt'>
  <td width=200 valign=top style='width:149.85pt;padding:0in 0in 0in 0in;
  height:22.75pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>IL-1RII</p>
  </td>
  <td width=368 valign=top style='width:276.3pt;padding:0in 0in 0in 0in;
  height:22.75pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>interleukin 1
  receptor type II</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>IL-2</p>
  </td>
  <td width=368 style='width:276.3pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>interleukin 2</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>IRS</p>
  </td>
  <td width=368 style='width:276.3pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>insulin receptor
  substrate</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>I&#954;B&#945;</p>
  </td>
  <td width=368 style='width:276.3pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>inhibitory
  &#954;B&#945;</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>Kd</p>
  </td>
  <td width=368 style='width:276.3pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>dissociation
  constant</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>Ki</p>
  </td>
  <td width=368 style='width:276.3pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>inhibitory
  constant</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>Klf15</p>
  </td>
  <td width=368 style='width:276.3pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>Krppel-like
  factor-15</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>LC3</p>
  </td>
  <td width=368 style='width:276.3pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>microtubule-associated
  protein 1 light chain 3</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>LH</p>
  </td>
  <td width=368 style='width:276.3pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>luteinizing
  hormone</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>LKB1</p>
  </td>
  <td width=368 style='width:276.3pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>Liver Kinase B1</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:10;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>MAFbx</p>
  </td>
  <td width=368 style='width:276.3pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>muscle atrophy
  F-box</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:11;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>MAPK</p>
  </td>
  <td width=368 style='width:276.3pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>mitogen-activated
  protein kinases</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:12;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>MEF2A</p>
  </td>
  <td width=368 style='width:276.3pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>myocyte enhancer
  factor 2A</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:13;height:57.8pt'>
  <td width=200 valign=top style='width:149.85pt;padding:0in 0in 0in 0in;
  height:57.8pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>MNK2</p>
  </td>
  <td width=368 style='width:276.3pt;padding:0in 0in 0in 0in;height:57.8pt'>
  <p class=MsoNormal style='margin-bottom:9.1pt;text-align:justify;text-justify:
  inter-ideograph;text-indent:0in;line-height:107%'>mitogen-activated protein
  kinaseinteracting kinase</p>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>2</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:14;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>MR</p>
  </td>
  <td width=368 style='width:276.3pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>mineralocorticoid
  receptor</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:15;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>MRF</p>
  </td>
  <td width=368 style='width:276.3pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>muscle regulatory
  factor</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:16;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>Mrf4</p>
  </td>
  <td width=368 style='width:276.3pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>myogenic
  regulatory factor 4</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:17;mso-yfti-lastrow:yes;height:22.75pt'>
  <td width=200 valign=bottom style='width:149.85pt;padding:0in 0in 0in 0in;
  height:22.75pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>mTOR</p>
  </td>
  <td width=368 valign=bottom style='width:276.3pt;padding:0in 0in 0in 0in;
  height:22.75pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>Mechanistic
  Target of Rapamycin</p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-top:0in;margin-right:58.2pt;margin-bottom:
0in;margin-left:-1.5in;margin-bottom:.0001pt;text-indent:0in;line-height:107%'><o:p>&nbsp;</o:p></p>

<table class=TableGrid border=0 cellspacing=0 cellpadding=0 width=533
 style='width:399.5pt;border-collapse:collapse;mso-yfti-tbllook:1184;
 mso-padding-alt:0in 0in 0in 0in'>
 <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;height:22.75pt'>
  <td width=200 valign=top style='width:149.85pt;padding:0in 0in 0in 0in;
  height:22.75pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>mTORC1</p>
  </td>
  <td width=333 valign=top style='width:249.65pt;padding:0in 0in 0in 0in;
  height:22.75pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>mTOR complex 1</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>MuRF1</p>
  </td>
  <td width=333 style='width:249.65pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>muscle RING
  finger 1</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>Myf</p>
  </td>
  <td width=333 style='width:249.65pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>myogenic factor</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>MyHC</p>
  </td>
  <td width=333 style='width:249.65pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>myosin heavy
  chain</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>NEFA</p>
  </td>
  <td width=333 style='width:249.65pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>non-esterified
  fatty acids</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5;height:57.8pt'>
  <td width=200 valign=top style='width:149.85pt;padding:0in 0in 0in 0in;
  height:57.8pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>NF-&#954;B</p>
  </td>
  <td width=333 style='width:249.65pt;padding:0in 0in 0in 0in;height:57.8pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>nuclear factor
  kappa - light-chain enhancer of activated B cells</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>NFAT</p>
  </td>
  <td width=333 style='width:249.65pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>nuclear factor of
  activated T-cells</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>NMJ</p>
  </td>
  <td width=333 style='width:249.65pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>neuro-muscular
  junction</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>NMR</p>
  </td>
  <td width=333 style='width:249.65pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>nuclear magnetic
  resonance</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>OMIM</p>
  </td>
  <td width=333 style='width:249.65pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>Online Mendelian
  Inheritance in Man</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:10;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>ORF</p>
  </td>
  <td width=333 style='width:249.65pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>open reading
  frame</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:11;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>p70-S6K</p>
  </td>
  <td width=333 style='width:249.65pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>ribosomal protein
  S6 kinase, 70 kDa</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:12;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>p90-RSK</p>
  </td>
  <td width=333 style='width:249.65pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>ribosomal protein
  S6 kinase, 90 kDa</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:13;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>PAGE</p>
  </td>
  <td width=333 style='width:249.65pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>polyacrylamide
  gel electrophoresis</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:14;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>PBS</p>
  </td>
  <td width=333 style='width:249.65pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>phosphate
  buffered saline</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:15;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>PDK1</p>
  </td>
  <td width=333 style='width:249.65pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
  text-indent:0in;line-height:107%'>3-phosphoinositide-dependent protein kinase
  1</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:16;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>PGC-1</p>
  </td>
  <td width=333 style='width:249.65pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>PPAR&#947;
  coactivator 1</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:17;mso-yfti-lastrow:yes;height:22.75pt'>
  <td width=200 valign=bottom style='width:149.85pt;padding:0in 0in 0in 0in;
  height:22.75pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>PI3K</p>
  </td>
  <td width=333 valign=bottom style='width:249.65pt;padding:0in 0in 0in 0in;
  height:22.75pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>phosphatidylinositol
  3-kinase</p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-top:0in;margin-right:49.05pt;margin-bottom:
0in;margin-left:-1.5in;margin-bottom:.0001pt;text-indent:0in;line-height:107%'><o:p>&nbsp;</o:p></p>

<table class=TableGrid border=0 cellspacing=0 cellpadding=0 width=545
 style='width:408.6pt;border-collapse:collapse;mso-yfti-tbllook:1184;
 mso-padding-alt:0in 0in 0in 0in'>
 <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;height:22.6pt'>
  <td width=200 valign=top style='width:149.85pt;padding:0in 0in 0in 0in;
  height:22.6pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>Pitx</p>
  </td>
  <td width=345 valign=top style='width:258.75pt;padding:0in 0in 0in 0in;
  height:22.6pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>paired-like
  homeodomain</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1;height:33.55pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.55pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>PLC</p>
  </td>
  <td width=345 style='width:258.75pt;padding:0in 0in 0in 0in;height:33.55pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>phospholipase C</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2;height:33.55pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.55pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>POMC</p>
  </td>
  <td width=345 style='width:258.75pt;padding:0in 0in 0in 0in;height:33.55pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>pro-opiomelanocortin</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3;height:33.55pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.55pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>PPAR</p>
  </td>
  <td width=345 style='width:258.75pt;padding:0in 0in 0in 0in;height:33.55pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>peroxisome
  proliferator-activated receptor</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4;height:33.55pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.55pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>PPP</p>
  </td>
  <td width=345 style='width:258.75pt;padding:0in 0in 0in 0in;height:33.55pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>picropodophyllin</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5;height:33.55pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.55pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>PRAS40</p>
  </td>
  <td width=345 style='width:258.75pt;padding:0in 0in 0in 0in;height:33.55pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>proline-rich Akt
  substrate of 40-kDa</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6;height:33.55pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.55pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>qRT-PCR</p>
  </td>
  <td width=345 style='width:258.75pt;padding:0in 0in 0in 0in;height:33.55pt'>
  <p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
  text-indent:0in;line-height:107%'>quantitative real-time polymerase chain
  reaction</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7;height:57.45pt'>
  <td width=200 valign=top style='width:149.85pt;padding:0in 0in 0in 0in;
  height:57.45pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>REDD1</p>
  </td>
  <td width=345 style='width:258.75pt;padding:0in 0in 0in 0in;height:57.45pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>regulated in
  development and DNA damage responses-1</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8;height:33.55pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.55pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>RIPA</p>
  </td>
  <td width=345 style='width:258.75pt;padding:0in 0in 0in 0in;height:33.55pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>radioimmunoprecipitation
  assay</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9;height:33.55pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.55pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>SDS</p>
  </td>
  <td width=345 style='width:258.75pt;padding:0in 0in 0in 0in;height:33.55pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>sodium dodecyl
  sulfate</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:10;height:57.45pt'>
  <td width=200 valign=top style='width:149.85pt;padding:0in 0in 0in 0in;
  height:57.45pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>SGKL</p>
  </td>
  <td width=345 style='width:258.75pt;padding:0in 0in 0in 0in;height:57.45pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>serum and
  glucocorticoid-inducible kinase-like kinase</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:11;height:33.55pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.55pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>Shc</p>
  </td>
  <td width=345 style='width:258.75pt;padding:0in 0in 0in 0in;height:33.55pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>Src homology 2
  domain containing</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:12;height:33.55pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.55pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>Sos</p>
  </td>
  <td width=345 style='width:258.75pt;padding:0in 0in 0in 0in;height:33.55pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>Son of sevenless
  homolog</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:13;height:33.55pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.55pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>Sp1</p>
  </td>
  <td width=345 style='width:258.75pt;padding:0in 0in 0in 0in;height:33.55pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>SV40
  promoter-specific 1</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:14;height:33.55pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.55pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>STAT</p>
  </td>
  <td width=345 style='width:258.75pt;padding:0in 0in 0in 0in;height:33.55pt'>
  <p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
  text-indent:0in;line-height:107%'>Signal Transducer and Activator of
  Transcription</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:15;height:33.55pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.55pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>T</p>
  </td>
  <td width=345 style='width:258.75pt;padding:0in 0in 0in 0in;height:33.55pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>testosterone-only
  group</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:16;height:33.55pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.55pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>Tbx</p>
  </td>
  <td width=345 style='width:258.75pt;padding:0in 0in 0in 0in;height:33.55pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>T-box</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:17;mso-yfti-lastrow:yes;height:22.6pt'>
  <td width=200 valign=bottom style='width:149.85pt;padding:0in 0in 0in 0in;
  height:22.6pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>TCA</p>
  </td>
  <td width=345 valign=bottom style='width:258.75pt;padding:0in 0in 0in 0in;
  height:22.6pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>trichloroacetic
  acid</p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-top:0in;margin-right:137.15pt;margin-bottom:
0in;margin-left:-1.5in;margin-bottom:.0001pt;text-indent:0in;line-height:107%'><o:p>&nbsp;</o:p></p>

<table class=TableGrid border=0 cellspacing=0 cellpadding=0 width=427
 style='width:320.55pt;border-collapse:collapse;mso-yfti-tbllook:1184;
 mso-padding-alt:0in 0in 0in 0in'>
 <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;height:22.75pt'>
  <td width=200 valign=top style='width:149.85pt;padding:0in 0in 0in 0in;
  height:22.75pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>TCF4</p>
  </td>
  <td width=228 valign=top style='width:170.7pt;padding:0in 0in 0in 0in;
  height:22.75pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>transcription
  factor 4</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>Testo</p>
  </td>
  <td width=228 style='width:170.7pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>testosterone</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>TGF-&#946;</p>
  </td>
  <td width=228 style='width:170.7pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
  text-indent:0in;line-height:107%'>transforming growth factor-beta</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>Tp</p>
  </td>
  <td width=228 style='width:170.7pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>testosterone
  propionate</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>TSC1</p>
  </td>
  <td width=228 style='width:170.7pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>Tuberous
  Sclerosis Complex 1</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>TSC2</p>
  </td>
  <td width=228 style='width:170.7pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>Tuberous
  Sclerosis Complex 2</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>ULK1</p>
  </td>
  <td width=228 style='width:170.7pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>UNC-51-like
  kinase 1</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7;height:33.85pt'>
  <td width=200 style='width:149.85pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>V</p>
  </td>
  <td width=228 style='width:170.7pt;padding:0in 0in 0in 0in;height:33.85pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>Vehicle-only</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8;mso-yfti-lastrow:yes;height:22.75pt'>
  <td width=200 valign=bottom style='width:149.85pt;padding:0in 0in 0in 0in;
  height:22.75pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>VEGFR</p>
  </td>
  <td width=228 valign=bottom style='width:170.7pt;padding:0in 0in 0in 0in;
  height:22.75pt'>
  <p class=MsoNormal style='text-indent:0in;line-height:107%'>VEGF receptor</p>
  </td>
 </tr>
</table>

</div>

<span style='font-size:12.0pt;mso-bidi-font-size:11.0pt;line-height:200%;
font-family:"Georgia",serif;mso-fareast-font-family:Georgia;mso-bidi-font-family:
Georgia;color:black;mso-ansi-language:EN-US;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA'><br clear=all style='page-break-before:always;
mso-break-type:section-break'>
</span>

<div class=WordSection2>

<h1><a name="_Toc421412241"><span style='mso-bidi-font-size:12.0pt;line-height:
200%;font-family:"Times New Roman",serif;mso-fareast-font-family:"MS Gothic";
mso-fareast-theme-font:major-fareast;color:windowtext;mso-bidi-font-weight:
bold'>1. CLINICAL QUESTIONS AND EVIDENCE</span></a><span style='mso-bidi-font-size:
12.0pt;line-height:200%;font-family:"Times New Roman",serif;mso-fareast-font-family:
"MS Gothic";mso-fareast-theme-font:major-fareast;color:windowtext;mso-bidi-font-weight:
bold'><o:p></o:p></span></h1>

<h2 style='margin-left:.5pt'><a name="_Toc421412242">Cushings syndrome</a> and
hints of an atrophy mechanism</h2>

<p class=MsoNormal>Maintenance of muscle mass and force is dependent on the
well-adjusted endocrine system. The first evidence for this muscle-hormones
interaction came from diseases, interpreted as natural experiments.
Interestingly, the role of adrenal hormones in muscle homeostasis was deduced
from perturbations of another gland, the pituitary.</p>

<p class=MsoNormal>Through the detailed case series written by Harvey Cushing [3],
the scientific and medical community became aware of an otherwise rare disease,
which bears his name. Unlike the earlier and better-studied deficiencies of the
thyroid and pancreas, pituitary defects are more variable in manifestation and
therefore harder to unify in a single clinical entity. Even when macroscopic
hypertrophy of pituitary was localized to a gland subdomain, pathological
mechanisms were ambiguous. Symptoms could have been attributed to a
hypersecretion from the hypertrophied sector, or to a deficiency in the
neighboring compressed structures. Pituitary extracts caused multiple, and even
opposite effects, in animal models [4], further proving the heterogeneous
nature of pituitary secretion.</p>

<p class=MsoNormal>Among 50 cases described by Cushing, about five stood out
due to the involvement of other glands. In each of them, and, to a lesser
extent, in a few more cases, hyperadrenalism was blamed for asthenia,
hyperpigmentation of skin, low blood pressure, and hypoglycemia. Histopathology
tests localized the adrenal abnormalities to the zona fasciculata of the
cortex. Cushing wrote that some of these abnormalities reflect current adrenal
hypoactivity, caused by exhaustion after preceding intense stimulation and
hyperactivity.</p>

<p class=MsoNormal>Twenty years later, Cushing narrowed the focus in an updated
case series of combined pituitary-adrenal pathology [5]. Cushing noted that
basophile adenomata of the pituitary and hypertrophy of the adrenal glands
often coexisted. Based on the curative effect of pituitary surgery, he
hypothesized that the adrenal defect is secondary to the pituitary abnormality.
In turn, he inferred that the adrenal changes mediate the disease phenotype,
which includes obesity with ectopic adipose deposits, kyphosis, amenorrhea /
impotence, hypertrichosis, lineae atrophicae, fatigability and weakness. Among
these disease manifestations, muscle impairment was a serious, if variable,
component. Cushing considered intense muscle loss the cause of death for one of
these cases.</p>

<p class=MsoNormal>Cushings work did little to elucidate mechanisms leading to
the phenotype. The variability in pituitary changes between the cases he
described meant that many scientists rejected his hypothesis of pituitary
primacy. A group at the Mayo Clinic was actively pursuing the opposite
hypothesis, with the adrenal as the primary site of impairment in
adrenal-pituitary combined afflictions [6]. On the clinical side, it was noted
that some of Cushings patients lacked observable pituitary changes. Moreover,
some of the Mayo patients were cured by adrenal surgery. From a theoretical
perspective, the adrenal hypothesis was more tempting because the adrenal
deficiency (termed Addisons disease) and its reversal by administration of
adrenal cortex extracts were better known than pituitary pathology [7].</p>

<p class=MsoNormal>Today, we know that the truth was more nuanced.
Hypersecretion of the adrenal cortex hormones cortisol and / or corticosterone
is termed hypercortisolism. One or more clinical signs listed by Cushing (see
above) suggest to the practitioner the activation of the hypothalamic -
pituitary - adrenal (HPA) axis. If concomitant hypercortisolism is confirmed by
an increase of urine free cortisol measurements, or by the effacement of the
evening trough in circulating cortisol, there is suspicion for Cushings
syndrome (CS) [8]. Some hypercortisolism cases, termed pseudo-Cushings
syndrome, are ascribed to causes outside the HPA axis, such as in depression,
morbid obesity, uncontrolled diabetes mellitus, and sleep apnea (reviewed in [9]).</p>

<p class=MsoNormal>True CS cases are further classified based on the role of
the adrenal-stimulating pituitary hormone corticotropin (adrenocorticotropic
hormone; ACTH). In some CS patients, hypercortisolism is paralleled by an
increase in ACTH. Their adrenals are usually responsive to further ACTH
stimulation tests, indicating that previously intact adrenals underwent
hyperplasia in response to a pathological overstimulation with ACTH. When
attributed to the pituitary, such ACTH hypersecretion, followed by secondary
hypercortisolism, is termed Cushings disease (reviewed in [10]). Cushings
disease remains a staple of physiology textbooks, because it provides an
excellent didactic example of a hormone hierarchy.</p>

<p class=MsoNormal>The remainder of CS cases consists of hypercortisolism
despite low ACTH. In primary hypercortisolism, ACTH is typically suppressed by
negative feedback.</p>

<p class=MsoNormal>Adrenal neoplasms are the most frequent cause of primary
hypercortisolism. Ectopic or diffuse unregulated sources of ACTH or cortisol
may cause hypercortisolism. In recent decades, overdose with synthetic
derivatives of cortisol became the most important cause of low-intensity CS
(discussed in the next section).</p>

<p class=MsoNormal>Although CS may originate in various HPA pathologies, muscle
impairment is one of its most common, unifying features.</p>

<h2><a name="_Toc421412243">Glucocorticoid therapy</a></h2>

<p class=MsoNormal>A series of historically serendipitous decisions brought
impressive knowledge about CS of non-pituitary etiology (reviewed in [11]).
First, during World War II, US intelligence learned that Germans were importing
large quantities of adrenal glands from neutral Argentina. This reignited US
government interest in corticoadrenal research, despite the lackluster results
with earlier adrenal extracts. At the end of the war, only a few grams of pure
adrenal steroids were manufactured, from endogenous sources and at a high cost.
The second opportunity was in the allocation of those scarce steroids. One of
them, cortisone, made by Merck, was shared by a few clinical researchers,
including Phillip Hench. Henchs request was based on his previous work on
rheumatoid arthritis. He observed that rheumatoid arthritis was alleviated in
jaundice, and hypothesized the existence of a steroidal anti-rheumatoid
factor. Third, Henchs choice of dose and route elicited an extraordinary
reversal in arthritic pain and dysfunction. In 1949, after treating only five
patients [12], impressive improvements in those cases reordered priorities in
corticosteroid research.</p>

<p class=MsoNormal>Previous work described multiple effects for adrenal
extracts. In fact, adrenal research was considered a dead end prior to
cortisone purification, because less pure extracts combined antagonistic
hormones in variable doses, seemingly lacking defined pharmacological or
endocrine relevance. Even with purified cortisone, Hench saw a very diverse set
of consequences for cortisone administration [13]. However, Henchs
observations were replicable, demonstrating the complex and vital role of the
adrenal.</p>

<p class=MsoNormal>First, cortisones action on metabolism was accessible even
to the less sophisticated clinical measurements used 60 years ago. Patients
receiving cortisone gained weight. Chronic cortisone therapy leads to
accumulation of adipose tissue, often in ectopic locations, such as the
interscapular buffalo hump. Cortisone also induces hyperglycemia, and
subsequent glycosuria. For this reason, cortisone and its endogenous and
synthetic analogs are grouped in the glucocorticoid (GC) family.</p>

<p class=MsoNormal>Hench and collaborators hypothesized that cortisones
protective action is not limited to rheumatoid arthritis. In his 1950 Nobel
lecture, Hench envisaged a role for alleviation of most inflammatory diseases.
GCs share the ability to reduce inflammation (reviewed in [14, 15]). Some of
these anti-inflammatory effects, such as reduction in the number of circulating
white blood cells, are ample and robust. Other aspects of GC action remain
under active study, facilitated by the rapid progress of immunology. The
questions still open illustrate the convoluted ways in which GC signals are
relayed in the cell. For example, GCs are often acting in a manner shared with
all steroid hormones, by binding and activating the glucocorticoid receptor
(GR). Activated GR translocates from cytosol to the nucleus, where it dimerizes
on specific DNA sequences, termed glucocorticoid responsive-elements (GRE) [16].
The classical effect of the GRE-GR interaction is increased transcription for
neighboring target genes (transactivation), as it is the case in
polymorphonucleate cells for interleukin 1 (IL-1) receptor type II (IL-1RII) [17],
a decoy inhibitor for the pro-inflammatory IL-1. In other circumstances, the
activated receptor inhibits transcription directly (transrepression), or by
interfering with transcription factors. For example, in human T lymphocytes,
GCs inhibit the transcription factor activator protein 1 (AP-1), thus causing a
reduction in their ability to synthesize pro-inflammatory interleukin 2 (IL-2)
[18]. GCs employ nongenomic mechanisms, such as mRNA stability and enzymatic
activity modulations. In airway epithelia, GCs reduce the half-life of the mRNA
for interleukin 8 (IL-8), the major chemoattractant for neutrophils [19].
Within minutes, GC administration induces vasodilation, through direct,
nongenomic activation of endothelial phosphatidylinositol 3-kinase (PI3K)
leading to activation of endothelial nitric oxide synthase (eNOS) [20].</p>

<p class=MsoNormal>Some GC effects may be limited to a range of doses,
durations, and frequencies of administration. Moreover, the example of
adrenalectomized rats re-supplemented with corticosterone, their most abundant
endogenous GC, illustrates how, at times, the same GC can induce or repress the
same cellular response, depending on the dose. A lower 5 mg<span
style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>/</span>kg
dose enhanced the immune skin delayed-type hypersensitivity, while a 40 mg<span
style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>/</span>kg
dose yielded the opposite, expected immunosuppressive response [21]. This
biphasic behavior, suggestive of a U- (or inverted-U) shaped curve, poses great
challenges, both to the investigative scientist, and to the clinician
attempting to establish a therapeutic regimen.</p>

<p class=MsoNormal>In 1950, endogenous GCs corticosterone and cortisol, were
synthesized at Merck [22], thus lowering the price and creating the opportunity
for large-scale trials. The Empire Rheumatism Council organized a randomized
trial comparing cortisone with acetylsalicylate, and concluded that there is no
benefit in cortisone [23]. While participants receiving cortisone claimed an
improvement in subjective well-being, they were afflicted more often with
deleterious side effects, including edema and hypertension. In retrospect, a
comparison between two palliative symptomatic therapies using cure-indicating
outcomes was likely misleading. Nevertheless, cortisone was deemed unfit for
therapeutic purposes, at least in Britain. This failure initiated a race for
improving endogenous GCs with chemical modifications (reviewed in [24]). While
synthesizing esters with a better half-life, Schering chemists introduced a
double bond in the A ring of cortisone, thus discovering prednisone, the first
widely used oral GC [25]. Prednisone was a better anti-inflammatory than
cortisone, but had a lower ability to cause edema. This was the first
suggestion that the many GC effects could be separated by chemical
modifications. In 1955, NIH researchers synthesized and characterized
prednisones active metabolite, prednisolone [26]. In a trial of prednisolone
versus acetylsalicylate in rheumatoid arthritis, the GC provided better
functional protection to the articulations [27], thus establishing prednisolone
as a standard of care and making GCs even more interesting for chemists.</p>

<p class=MsoNormal>Further improvements were made at Squibb, where it was found
that insertion of a halogen atom improves GCs anti-inflammatory effect [28,
29]. In 1958, Merck chemists led by Arth modified cortisol with the unsaturated
A ring (&#916;<sup>1</sup>), the fluoride addition at position 9&#945;, and
with a methyl group on the 16&#945; position to obtain dexamethasone (Dexa) [30,
31]. Dexa is the most effective and specific therapeutic synthetic GC to date,
with 170 times higher ability to inhibit the immune reaction to subcutaneous
foreign bodies (granuloma) compared to cortisol [32]. The other benefit of Dexa
is its virtual inability to cause edema and electrolyte imbalance.</p>

<p class=MsoNormal>In addition to being a strong anti-inflammatory, Dexa is 52
times more potent in suppressing endogenous GC secretion, and 35 times more
potent in causing hyperglycemia compared to cortisone [33, 34]. Efforts to
synthesize steroids with anti-inflammatory action that do not interfere with
metabolism have failed. Compounds such as A276575 [35] and RU 24858 [36] failed
in preclinical studies. Mapracorat [37] did not progress beyond phase II
clinical trials. These facts demonstrate that the anti-inflammatory and
hyperglycemic actions are intermediated by the same specific, Dexa-sensitive
receptor, whereas electrolyte changes are caused by cortisol through a
different pathway. Clinicians prescribing GCs in these five decades had to
balance therapeutic benefit with metabolic side effects, and, in the case of
less specific GCs, with the water retention.</p>

<p class=MsoNormal>Edema is an example of non-specific GC effect, caused by a
less typical interaction of the hormone with the mineralocorticoid receptor
(MR). The GC family spans tens of active principles and thousands of
formulations, from weak GCs with lower specificity, such as cortisone, to
strong, specific GCs, such as Dexa. When strong GR activation is desired,
clinicians have to use Dexa in order to avoid MR activation. When safety is
desired, such as in over-the-counter products, low-activity, low-specificity
compounds are preferred.</p>

<p class=MsoNormal>Chronic GC therapy causes glucose metabolism disturbance, osteoporosis,
and muscle loss, suggesting that their therapeutic use is limited. However,
their efficacy makes them some of the most commonly used drugs. The trivial
case for using GC therapy is in hormone replacement, such as in adrenocortical
insufficiency (reviewed in [38]). In addition, many other diseases are
alleviated by GCs to a degree that deleterious effects are outweighed. Based on
their ability to lower white blood cell count, GC are an important adjuvant in
the palliative and even etiologic treatment of leukemias and lymphomas [39, 40,
41]. On the balance of benefits and drawbacks, GCs are recommended for many
life threatening or impairing immune reactions, such as polymyositis (reviewed
in [42]), severe sarcoidosis (reviewed in [43]), and disseminated pulmonary
tuberculosis. GCs are relatively safe in topical applications in dermatological
conditions (pemphigus, psoriasis, most types of dermatitis; reviewed in [44]).
Similarly, GCs are commonly used in eye inflammatory conditions [45, 46], such
as diffuse posterior uveitis and optical neuritis. GC therapy is suitable for
brief administration in acute immune or allergic conditions, such as seasonal
rhinitis (reviewed in [38]). In chronic diseases, GCs are recommended for
short-term alleviation of exacerbations. Short-term GC therapy is recommended
for rheumatoid arthritis, gouty arthritis, psoriatic arthritis, ankylosing
spondylitis, asthma [47, 48], ulcerative colitis [49, 50], and idiopathic
nephrotic syndrome [51].</p>

<p class=MsoNormal>As envisaged by Hench in his Nobel Lecture, GCs do not
address disease causes, and are recommended for temporary respite. For many
immune diseases, more specific therapeutic alternatives have been developed.
The list of Food and Drug Administration (FDA)-approved indications for
cortisone, Dexa, and prednisone is often narrowed by additional precautions,
and by newly discovered drugs [52, 53, 54]. Nevertheless, off-label use of GCs
is very frequent. For example, GCs are perceived by physicians as a fallback
therapeutic alternative for cerebral hypertensive conditions, despite scarce
evidence for efficacy in any specific conditions. Small trials suggest GCs
reduce vasogenic cerebral edema [55] and prevent acute mountain sickness [56].
These studies have been carried although earlier systematic reviews showed
that, in fact, GCs worsen outcomes for acute brain trauma victims [57]. This
example illustrates how strongly rooted are off-label uses of GCs.</p>

<p class=MsoNormal>A similar, paradoxical situation is seen in ongoing clinical
research. As of 2015, the patent-free status of the GCs discourages trials for
new indications, while their de facto standard-of-care status makes them a
common comparator in clinical trials. The National Cancer Institute sponsors
311 ongoing clinical studies employing Dexa, mainly in the standard-of-care
arm, thus providing a plethora of data that have been, and may still be,
misconstrued as support for the use of GCs. Everyday practice may drift further
apart for the officially sanctioned label, thus providing new opportunities for
unjustifiable overdose.</p>

<p class=MsoNormal>This wide array of uses make GCs some of the most prescribed
and used drugs. Despite the low prevalence of the conditions proven to benefit
from GC therapy, every year, about 1% of the Americans and British receive some
form of GC [58, 59]. GCs are likely even more prescribed in the developing
world, due to affordability and lack of alternatives, poor access to health
care notwithstanding. Dexa and cortisol are the only drugs listed five times in
the World Health Organizations List of Essential Medicines [60]. Due to their
widespread use, GCs are likely to cause covert iatrogenic CS in a large
population, impairing muscle mass and quality of life to a certain and
understudied degree.</p>

<h2><a name="_Toc421412244">Hypercortisolism-induced muscle loss</a></h2>

<p class=MsoNormal>Primary and secondary endogenous hypercortisolism are rare
diseases (1-2 cases per million and year each [61]), despite a recent boost
from incidental imaging diagnoses. The symptomatology is non-specific, meaning
that, even today in the developed world, an average of 6 years pass from signs
onset until diagnosis is made and treatment is initiated [62]. Endogenous
hypercortisolism is a life-threatening disease, with untreated patients having
a median survival rate of 5 years after diagnosis [63]. Some of the changes
occurring in Cushings disease are irreversible, especially at the level of
brain, bone, adipose tissue, and liver levels (reviewed in [64]). Even after
surgical adjustments of the hyperactive pituitary, the quality of life for CS
patients lags behind that of the unaffected population.</p>

<p class=MsoNormal>About two thirds of Cushings syndrome patients acknowledge muscular
problems at presentation, with similar incidence among pituitary and adrenal
conditions [65]. Among patients diagnosed with endogenous CS, one fifth are
referred to the endocrinologist due to muscle weakness [66]. Two fifths of
those whose endogenous hypercortisolism is successfully corrected by surgery
still complain of fatigue [67].</p>

<p class=MsoNormal>On the other hand, therapy-induced (iatrogenic) CS is
common. The glut of GC indications and off-label uses makes them some of the
most used drugs in the developed countries, as described earlier. In most
cases, the cause of iatrogenic CS can be identified by careful history taking
and medication reviews. However, an increasing number of cases are not as
easily diagnosed, because the excess GC is not from prescription medicine. In
United States, FDA approved in 1979 over-the-counter sale of 0.5%
hydrocortisone cream for itching and minor skin inflammation. In 1990, 1%
hydrocortisone creams were also permitted [68]. In 1987, hydrocortisone creams
became over-the-counter in Great Britain. Regulated over-the-counter GC creams
rarely cause CS on their own, but have been frequently suspected to lower the
threshold for CS in patients who are also prescribed oral GC. Unregulated,
mislabeled, overdosing GC creams sold as skin-bleaching products pose a great
CS risk to patients from ethnic groups with darker skin. Half of the
respondents in a Nigeria poll admitted using GC-based skin bleaching products [69].
In 2015, the Ivory Coast government made illegal skin bleaching products, due
to worries about GC overdose side effects [70]. The side effects of skin
bleaching are well recognized by the sub-Saharan medical community.
Paradoxically, CS caused by bleaching products may be less identifiable to
practitioners who care for the African diaspora in the developed world, where
bleaching is more frequent, due to improved financial access and social
pressures [71, 72].</p>

<p class=MsoNormal>Other, less frequent causes of iatrogenic CS include the
interaction between low dose GC therapy and cytochrome P450 3A4 inhibitors,
such as the antiretroviral ritonavir [73]. Other steroid drugs may interact
with GR and cause CS when overdosed, as it is the case with the synthetic
progestin megestrol acetate [74].</p>

<p class=MsoNormal>Due to its insidious and erratic symptomatology, iatrogenic
CS is often diagnosed years after onset or completely unrecognized [62]. The
incidence of iatrogenic CS is difficult to estimate, because there is no
reporting requirement. In the developed world, iatrogenic CS could be as
frequent as one case per thousand and year [75].</p>

<p class=MsoNormal>Signs of iatrogenic CS are as varied as those of Cushings
disease. In a cohort of patients receiving for three months more than 0<i
style='mso-bidi-font-style:normal'><span style='mso-fareast-font-family:Cambria;
mso-bidi-font-family:Cambria'>.</span></i>4 mg<span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>/(</span>kg d<span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>) </span>prednisone, the most common
signs were development of ectopic adipose deposits (50%), hyperphagia (47%),
and muscle cramps (32%) [76]. In the same cohort, 15% complained of muscle
weakness. Patients stated that the most distressing signs of hypercortisolism
were, in order, body shape changes, neuropsychiatric disorders, muscle cramps,
and hand tremor. In 1982, the most common cause of iatrogenic muscle weakness
was GC therapy [77].</p>

<p class=MsoNormal>There are differences between GC-induced cardiovascular
changes, depending on the nature of the GC. Endogenous GCs, such as cortisol,
have hypertensive effects, while some synthetic GCs, Dexa included, lack such
non-specific MR-dependent action. Nevertheless, excess exogenous and endogenous
GC causes the same disabling effects on muscle [78], indicating that muscle damage
is mediated by GR. GCs differ quantitatively in their ability to cause
myopathy. Myopathy is invariably induced in two weeks by either 0<i
style='mso-bidi-font-style:normal'><span style='mso-fareast-font-family:Cambria;
mso-bidi-font-family:Cambria'>.</span></i>2 mg<span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>/(</span>kg d<span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>) </span>Dexa [79], or by 0<i
style='mso-bidi-font-style:normal'><span style='mso-fareast-font-family:Cambria;
mso-bidi-font-family:Cambria'>.</span></i>5 mg<span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>/(</span>kg d<span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>) </span>prednisone [80]. Based on animal
studies, it is likely that the catabolic potency ratio is even more tilted
towards Dexa than the referenced studies indicate. Modern human
pharmacodynamics and epidemiological studies are needed, in order to establish
actual safety thresholds.</p>

<p class=MsoNormal>In their 1958 case series, Muller and Kugelberg were the
first to describe muscle changes associated with long-term Cushings disease [81].
In their mixed, primary and secondary, endogenous hypercortisolic cohort, they
found that complaints of muscle weakness were primarily localized on the thigh.
Objective loss of muscle force was correlated with histopathological changes
indicative of a muscle fiber defect, such as degenerated fibers, at times
hyalinized or with loss of striation, muscle replacement with fat and
connective tissue, and rare hypertrophic fibers. Through electromyography, they
established that the number of motor units is unaffected. Together with lack of
changes in reflexes, their work negated a neurological component of CS. Muller
and Kugelberg noted faster extinction of the action potential, which is
typically caused by a reduction in the number of muscle fibers, or by fiber
atrophy [82]. Based on the evidence that CS is a muscle fiber disease, they
coined the phrase steroid myopathy (in opposition to a hypothetical
neuropathy). Similar electromyography changes are induced by long-term GC
therapy [83], making some authors reserve the term steroid myopathy to muscle
complaints of iatrogenic etiology. In 1966, DAgostino and Chiga, confirming
histological fiber changes in a rabbit model of iatrogenic CS, formulated the
more precise, yet less commonly used glucocorticoid myopathy [84]. Owing to
the fact that glucocorticoid myopathy is not a standalone disease or syndrome,
terminology has never been standardized. In the present work, the human
condition will be designated glucocorticoid myopathy, while its animal models
will be termed GC-associated muscle loss (GAML).</p>

<p class=MsoNormal>In exogenous CS, GC excess can be better quantified. In a
population with neurological maladies receiving long-term Dexa, the threshold
for manifest glucocorticoid myopathy appears to be 50 g<span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>/(</span>kg d<span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>)</span> [85]. However, the most
significant predictor of clinical GAML is total dose [79, 86]. When GAML
develops, the amplitude of electromyography changes (that is, the reduction in
action potential duration) is proportional with the total GC dose [87]. These
findings imply that glucocorticoid myopathy can be induced in shorter periods,
if the GC dose is extremely high. Foye and colleagues drew a distinction
between classic or chronic glucocorticoid myopathy, induced within weeks
to years, and acute glucocorticoid myopathy, induced in 5-7 days of
high-dose GC [88]. However, their description of the two forms of GAML is
almost identical, suggesting that the two clinical entities are largely
overlapping.</p>

<p class=MsoNormal>In a comparative study of patients receiving GC therapy for
asthma, half of the patients receiving more than 0<i style='mso-bidi-font-style:
normal'><span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>.</span></i>2
mg<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>/(</span>kg
d<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>) </span>prednisone
exhibited a reduction in hip flexor strength of 2 SD or more, compared with
healthy age- and sex-matched controls [80]. In a study of adults with brain or
spine cancer, 60% of the participants experienced loss of iliopsoas muscle
force in response to GC therapy for cerebral edema [79]. In a small cohort, 6
months of 0<i style='mso-bidi-font-style:normal'><span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>.</span></i>16 mg<span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>/(</span>kg d<span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>) </span>prednisone treatment was
associated with a 20% reduction in thigh muscle force, compared to healthy
controls [89]. Such findings suggest that GC-induced weakness has functional
consequences.</p>

<p class=MsoNormal>In a post-hoc analysis of a chronic obstructive pulmonary
disease (COPD) trial, the placebo arm was stratified in GC-treated and GC-naive
groups [90]. The maximal inspiratory mouth pressure, a proxy measurement for
respiratory muscle strength, was significantly better maintained over the 8
weeks of the trial in the GC-naive, compared to GC-treated participants. Involvement
of partly-involuntary muscles further proves that GC-induced weakness is caused
by an objective muscle disorder, and negate the alternative, neuropsychiatric
etiology.</p>

<p class=MsoNormal>Another investigative direction in the study of GC-induced
muscle weakness focused on muscle mass and volume. Although correlated, muscle
force, mass, and volume are not completely reflecting each other. The most
accessible proxy measurements of muscle mass, such as mid upper-arm or thigh
circumference, are not sensitive enough in monitoring GC-induced muscle loss,
even after subtracting skin fold, because GC stimulate intramuscular adipose
deposits [91]. The advent of modern imaging allowed non-invasive muscle
measurements. Chronic prednisone administration causes a 20% reduction in
mid-thigh muscle area measured by computed tomography, and a 36% increase in
the ratio of fat-to-muscle areas (CT) [92]. Psoas muscle area and density,
measured by computed tomography, are inversely correlated with GC levels
indicated by 24-hour urine cortisol (24HUC) [93].</p>

<p class=MsoNormal>Muscle fibers are classified in types, based on their
adaptation to either<span style='mso-spacerun:yes'> </span>endurance or brief
strong bursts. Fast-twitch fibers are further classified based on their
propensity for aerobic or anaerobic (glycolytic) metabolism. Differential
effects on fiber types and inter-type conversions have been observed in many
muscle-afflicting maladies. For example, gains in the ratio fast-to-slow twitch
fibers are associated with insulin resistance [94]. In contrast, aging is
correlated with preferential loss of fast fibers [scelsi1980histochemical]. Reports
of type-specific effects of GC are inconclusive. In one study, women with CS had
an increased proportion of type IIx (fast twitch, glycolytic) and a lower
proportion of type I (slow twitch, oxidative) fibers in their vastus lateralis
muscles [95]. Renal transplant patients receiving 25 mg<span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>/(</span>kg d<span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>) </span>prednisone over three months had
lower cross-sectional area (CSA) in type IIa (slow twitch, oxidative /
glycolytic) and I fibers [96]. Others found that all types of fibers are
uniformly affected by GC [97]. This hypothesis was further followed in animal
studies.</p>

<p class=MsoNormal>A set of muscle mononucleate cells, expressing the
paired-box transcription factor Pax7, are presumed to support muscle development
and regeneration, and are termed satellite cells (reviewed in [98]). There are
no definitive studies describing the effect of GC in human satellite cells.
Some or all satellite cells may be activated to proliferate, thus becoming
myoblasts. Many in vitro assays use proliferating cells from human muscle, at
times assumed to be myoblasts. These human myoblasts do not proliferate in
the absence of at least 1 M Dexa ([99], and personal observation; data not
shown). For comparison, maximum normal concentration of endogenous cortisol in
humans is 0<i style='mso-bidi-font-style:normal'><span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>.</span></i>78 M [100], that is, tens of
times less potent. Therefore, it is impossible to conceive an experiment where
human myoblasts in culture are subjected to meaningful manipulations of GC
concentration. The fact that GCs are vital for human muscle development in
vitro and maintenance suggests that cell lines that do not require GC may be
less accurate models of human muscle.</p>

<p class=MsoNormal>There are no published cases of increase in circulating
myoglobin or creatine kinase in response to GC monotherapy, or as a consequence
of Cushings disease. The absence of such intramuscular protein from the blood
flow suggests GC do not cause rhabdomyolysis, that is, loss of muscle through
uncontrolled rapid membrane leakage.</p>

<p class=MsoNormal>GC therapy induces a massive loss of nitrogen, a side effect
seen from its first trial [101]. The ample increase in urinary creatine and
creatinine is evidence for upregulated tissue protein breakdown. As little as
20 g<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>/</span>kg
cortisol infused over 8 hours increases by a quarter the rate of appearance of
leucine into the bloodstream, suggestive of acute proteolysis upregulation [102].
Leucines rate of appearance is even higher when the GC-induced
hyperinsulinemia is prevented, indicating that whole-body experiments do not
capture the amplitude of the GC-induced proteolysis [103]. More modern mass
spectrometric methods revealed that a single dose of 1 mg<span
style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>/</span>kg
prednisolone cause increases in all blood amino acids, presumably due to
mobilization from muscle sources [104]. The same acute treatment causes an
increase in 3-methylhistidine (3MH), a non-recyclable degradation product
specific to muscle actin and myosin [105]. Similar increases in 3MH are seen
with control diet in chronic GC excess of endogenous or exogenous nature [97].
These findings demonstrate that GC-induced loss of muscle mass is mediated by
stimulation of protein degradation.</p>

<p class=MsoNormal>The last three decades brought a better understanding of
protein degradative pathways and of muscle atrophy. Two distinct proteolytic
systems, the proteasome - ubiquitin system and the autophagosome (discussed in
later sections), have been discovered. Unfortunately, only one published trial
investigated the action of GC in human muscle biopsies, at a molecular level.
It failed to find a significant change in mRNA of ubiquitin and the C3 subunit
of the proteasome [106]. The result is unsurprising, given that the control of
the proteasome system may be exercised in other, unexplored ways. In animal
models, the genes most correlated with muscle loss, including GAML, are two E3
ubiquitin ligases, muscle atrophy F-box (MAFbx; gene known as Fbxo32) and
muscle RING finger 1 (MuRF1; gene known as Trim63), but no published studies
confirm or refute their modulation in humans (reviewed in [107]).</p>

<p class=MsoNormal>Recently, pharmacological inhibitors of the proteasome
became widely available. The first proteasome inhibitor, bortezomib, is
recommended by the FDA for multiple myeloma and mantle cell lymphoma [108]. The
second generation, irreversible proteasome blocker carfilzomib is also approved
for advanced myeloma therapy [109]. In the light of data from the animal models
of muscle loss, these drugs should have been useful in cachexia, but, to date,
no human trials investigated their ability to prevent muscle atrophy.</p>

<p class=MsoNormal>There are no trials comparing GC with the combination (GC +
bortezomib). However, an indirect comparison can be made. In a trial for
multiple myeloma, fatigue was a complaint of 32% of the participants receiving
40 mg Dexa, compared to 42% for bortezomib [110]. In another trial, addition of
20 mg Dexa to bortezomib lowered the rate of fatigue from 57% to 25% [111].
Neither finding is suggestive for superiority of that the combination (Dexa +
bortezomib) to Dexa alone. Clinical studies directly addressing this comparison
are recommended, given that the most commonly accepted hypothesis centers on
the proteasome as main effector of GC-induced muscle loss. Proving a beneficial
action of bortezomib in co-administration with GC will have major practice-changing
implications. Even proving the opposite, that bortezomib has no protective
action, will be very valuable in better understanding and eventually preventing
GC-induced muscle loss.</p>

<p class=MsoNormal>The inhibition of the other proteolytic system, the
autophagosome, is also the focus of clinical studies. Starting with the
inexpensive antimalarials chloroquine and hydroxychloroquine, autophagosome
inhibitors are now the focus of phase II clinical studies in many cancers [112].
Interestingly, hydroxychloroquine is also recommended for rheumatoid arthritis,
where it may be prescribed for up to six months [113]. However, to my
knowledge, no clinical trial compared hydroxychloroquine with GC. Chronic
hydroxychloroquine therapy is known to induce muscle weakness and sporadic
myopathy, through a distinct, vacuolar mechanism. The
hydroxychloroquine-induced myopathy is associated with an increase in
autophagosome markers in muscle, demonstrating the importance of autophagosome
in muscle regulation [114]. In two separate case reports, co-administration of
prednisone and hydroxychloroquine led to vacuolar myopathy, which could be
caused by the choice of doses, or could be indicative of true epistasis [115,
116]. Potential benefits of anti-lysosome co-therapy in glucocorticoid myopathy
remain the subject of speculation.</p>

<p class=MsoNormal>Another putative parallel mechanism for GC-induced loss of
muscle is downregulation of protein synthesis. Few human trials measured
directly the effect of GC on protein synthesis in healthy volunteers. Brillion
and colleagues [103] found that an 80 mg cortisol infusion over 13 hours led to
8% increase in non-oxidative leucine uptake, indicating an upregulation of
protein synthesis. However, using a 200 mg cortisol infusion in the same
protocol failed to cause a detectable change in protein synthesis compared to
placebo, indicating a biphasic response. Moreover, this finding was never
replicated. Lfberg and colleagues [106] found that three days of 65 mg / day
prednisolone caused a non-significant 21% increase in protein synthesis rate
and a statistically significant 52% increase in the rate of protein
degradation, based on the difference between arterial and venous levels of
tritiated phenylalanine at leg level. Short and colleagues employed fractional
synthesis rate (FSR), which describes the time rate of enrichment in muscle
tracer, normalized to the circulating tracer concentration. They concluded
repeatedly that, in leg muscles, 35 mg / day prednisone for 6 days has no
effect on [...] muscle protein metabolism or muscle function [117, 118]. Some
of these studies may have been underpowered (sample size n = 6-7) or may be
troubled by the use of a small dose. Nevertheless, their validity is confirmed
by the fact that, in each case, the expected hyperglycemic response to GC was observed.</p>

<p class=MsoNormal>The hypothesis that GC cause muscle loss by inhibition of
protein synthesis is still debated, due to a plethora of indirect evidence. In
Lfbergs study, biopsies revealed a prednisolone-induced loss of muscle
polyribosomes, interpreted as evidence for decrease in protein synthesis rate.
Even in studies where GC failed to elicit reductions in protein synthesis, they
inhibited translation-stimulating signals in muscle from anabolic factors such
as insulin [119], branched chain amino acids [120], and exercise [121].</p>

<p class=MsoNormal>At a molecular level, it appears that Dexa inhibits anabolic
signals centered on the Akt / mechanistic target of rapamycin (mTOR) axis.
Rather than directly repressing this axis, GCs appear to reduce sensitivity of
this axis to upstream stimuli. One study on humans described how Dexa inhibits
branched chain amino acids ability to induce phosphorylation of mTOR
substrates eukaryotic translation initiation factor 4E (eIF4E) binding protein
(4E-BP) and p70-S6K [122]. In the same study, Dexa had no effect on another
translation regulator, the &#945; subunit of the eukaryotic initiation factor 2
(eIF2). More evidence has been obtained from animal models (discussed in a
dedicated section).</p>

<p class=MsoNormal>In addition to GC excess, muscle weakness is observed with GC
withdrawal [123], and by GC deficiency, illustrated by the Addisonian crisis [124].
In both hypercortisolism and hypocortisolism, effects on human muscle remain
understudied. Animal models have been essential for the study of GC-induced
muscle loss (discussed in the dedicated section). Human studies agree that
GC-induced loss of muscle force is an objective finding caused by an increased
proteolytic activity. Indirect evidence indicates that human GAML is associated
with changes in protein synthesis. Current guidelines suggest GC
discontinuation if myopathy develops, because proven mitigating interventions
have not been developed.</p>

<h2><a name="_Toc421412245">Muscle protection with androgen therapy</a></h2>

<p class=MsoNormal>A series of historical circumstances brought anabolic
androgenic steroids (AAS) in the attention of clinicians treating
hypercortisolism in muscle. The same circumstances meant that utility of AAS
therapy in glucocorticoid myopathy has never been fully explored.</p>

<p class=MsoNormal>Male hormones have been considered an efficacious anabolic
therapy long before they were purified and tested. The effects of male
castration, such as reductions in aggressiveness and muscle force, were
discovered independently by many human civilizations, starting more than three
thousand years ago. Castration is omnipresent in ancient mythology, and, more
mundanely, in primitive farming. For almost as long, people perceived testis
ingestion as a reversal of castration, thought to improve muscle force. Such
perceptions were caused by the placebo effect alone, given that this testis active
principle is almost completely degraded by liver.</p>

<p class=MsoNormal>Testis extract benefits received more attention starting
around 1889, when Brown-Squard published his theory about rejuvenating
abilities of sperm. He thought that loss of sperm during aging or masturbation
causes degradation in muscle and brain performance, and hypothesized that
chemicals from sperm may pass into blood where they have a most-essential use
in giving strength to the nervous system and to other parts. Consequently, he
injected himself with a combination of sperm and testis extracts, which led to
self-reported improvements in physical and intellectual abilities [125]. He
describes how, at the age of 72, a single injection enables him stand for
hours, or write longer scientific papers. Later on, he describes how testis
extracts appeared to alleviate serious affections of any kind, including
cachexia, pulmonary tuberculosis, cancer and leprosy ulcers [126]. Because the
active principle in testis is made as needed, rather than stored in high-concentration
depots, Brown-Squards injections must have contained very little male
hormones. His observations were likely caused by the placebo effect.</p>

<p class=MsoNormal>The cultural context in which Brown-Squard worked
introduced multiple biases in his experiments and conclusions. His mistaken
theses were constrained into rather low-quality experiments, which luckily
provided useful, testable, and eventually proven scientific hypotheses. First,
the logical conclusion for Brown-Squards theory would have been endorsement
for semen therapy. Instead, due to the semen taboo, Brown-Squard and his
disciples resorted to surrogate interventions, such as vasectomy, believed to
preserve sperm in the body, and injections with testis extracts. The
introduction of injections gave a new lease of life to the therapeutic use of
organ extracts, called organotherapy, which had been banished from the
British Pharmacopoeia in 1788 after failing the test of oral administration.
Some organotherapies were shams or even harmful. Yet a few of them provided
evidence that specific parts of the body store or release into the blood stream
chemicals, which subsequently induce changes in other specific parts of the
body. This conjecture led the discovery of endocrine glands and the
establishment of endocrinology as a science. In fact, androgen organotherapy
provided the blueprint for GC discovery.</p>

<p class=MsoNormal>Second, the Victorian era was an age of body rediscovery.
Georgian pastimes, such as cock fighting, horse racing, or cricket, were
replaced by more muscular sports, such as football, rugby, gymnastics, and
swimming. Bodybuilding became fashionable, with the first professional
competition selling out Royal Albert Hall in 1901. Brown-Squards promise of
muscle without effort made testis organotherapy a widespread, well-earning
business. When Voronoff was barred from practicing in Paris and judged as
fraudulent by the Royal Society of Medicine, he took his testis transplant
business to Algiers, where he received patients from all over the world
(reviewed in [127]). Private sponsorship led to investment in androgen
research, but with a focus on commercial rather than clinical efficacy.</p>

<p class=MsoNormal>Finally, Brown-Squards era tolerated unscientific
theories, which ignored the physical and intellectual ability of women.
Brown-Squard claimed that ovary extracts provide some benefits, but with less
power than testis extracts [126]. Such conclusions stemmed from cultural
biases rather than comparative experiments. In 1849, Berthold showed that, through
testis implants, roosters regain male characteristics they lost through
castration, such as aggressiveness, libido, and larger combs [128]. With
maintenance of secondary sex characteristics as its sole ability, Bertholds
secreted agent was therefore androgenic. In contrast, Brown-Squard claimed
that his extract increases muscle force, without mentioning any virilizing side
effects. Moreover, in 1935, Kochakian proved that urine-extracted male
hormone stimulates muscle accretion in castrated dogs, that is, that it is
anabolic [129]. While ultimately proven correct, the idea that male hormones
were simultaneously androgenic, anabolic, and ergogenic was based on a cultural
construct that confounded manliness and physical force, rather than the product
of direct scientific evidence.</p>

<p class=MsoNormal>The belief in a male-secreted ergogenic substance inspired
many commercial enterprises to sponsor research in male endocrinology, through
the decades where the evidence was confined to changes in the combs of
roosters. These dark ages ended in 1927, when McGee and Koch extracted a
lipophilic virilizing mixture from rooster testis [130, 131]. A pure and even
more androgenic chemical was extracted in 1935 from bull testis by Laqueur,
working for Organon [132]. Laqueur named his discovery testosterone (Testo).
Three months later, Butenandt and Ruzicka, sponsored by Schering and Ciba
respectively, announced the development of manufacturing methods for synthetic
testosterone, an achievement that brought them the 1939 Nobel Chemistry Prize
(reviewed in [133]). The first beneficiaries of the new drug were hypogonadal
men, that is, adult males with pathological decreases in circulating Testo. At
the University of Chicago, Kenyon tested Testo on four eunuchoid patients of
testicular and pituitary etiology. Daily injections of 25 mg testosterone
propionate (Tp) cause an doubling in prostate and penis size [134] after less
than two weeks, thus establishing the efficacy of Testo replacement therapy in
hypogonadal men. Except for a few, narrow exceptions, this population was and
remains the sole generally accepted, FDA-approved indication for Testo therapy
[135, 136, 137]. Recent Testo preparations are also recommended for some breast
cancers, but this indication is describes as having small, unpredictable
efficacy.</p>

<p class=MsoNormal>Due to manufacturing costs, limited commercial target, and
governments lack of interest, Testo therapy traversed a very long experimental
stage, which could easily be called the second dark age of androgens. Only in
1953, did the FDA gives its first approval for an androgenic therapy, a Testo
enanthate injection. Then, as now, FDAs approval was based on Testo ability to
restore normal levels of androgens, rather than other, more functional or
curative, outcomes [136]. However, in 18 years of life as experimental drugs,
androgenic steroids have been trialed in diverse diseases, including male
functional impotence [138], unwanted lactation [139], uterine bleeding and
dysmenorrhea [140], or osteoporosis [141]. These early studies share the
extremely small sample size, and the scarcity of controls, blinding, and
objective outcomes. For example, a study found that 14-35 injections of Tp
(cumulative dose 255-455 mg) caused an improvement of acne in half of the male
participants [142]. Such findings are at odds with more modern trials, where
weekly i.m. androgen injection lead to an increase in absolute risk of acne by
15%, in healthy males [143], and are possibly explained by the variability in
the androgen arm, small sample size (n = 12), lack of blinding, and early
stopping in the placebo arm. Nevertheless, these trials are, in many cases, the
only source of information about the action of Testo in the normogonadal
population. For example, early trials of oral methyltestosterone revealed its
hepatic toxicity. Fifty years later, those limited trials are still the main
factor discouraging the development of oral synthetic androgenic therapies.</p>

<p class=MsoNormal>The second dark age of Testo was a time of poor knowledge
and poor clinical study design. Yet in these years, androgenic steroids first
gained their reputation as ergogenics. Kenyon noted in his studies on eunuchoid
men that Testo injections helped them gain weight through protein accretion, as
demonstrated by a reduction in urinary nitrogen despite fixed dietary intake.
Other trials evidenced benefits from androgenic therapy in muscle-depleting
conditions, including thyrotoxic myopathy [144] and muscular dystrophy [145].
By 1940, Kenyon confirmed that Tp caused nitrogen retention, caused by increased
protein accretion, even in healthy men and women [146]. In 1942, Samuels and
colleagues concluded that Testo does not change grip strength in healthy males
[147]. According to a meta-analysis [148] and my literature search, no other
test of androgens effect on muscle strength was published until 1968. Despite
the lack of evidence, androgens were used as ergogenics in healthy people,
starting with Olympic athletes around 1954 [149].</p>

<p class=MsoNormal>As exemplified by the ergogenic hypothesis, benefits of
androgen therapy on men with Testo deficiency have been extrapolated by
clinicians and theoreticians to other muscle-depleting conditions, and even to
healthy humans. One of the conditions associated with loss of muscle mass that
clinicians hoped to improve was hypercortisolism. In 1941, Albright showed that
the newly discovered Tp, in 25 mg daily injections, was better than estradiol
benzoate, progesterone, or vitamin D in restoring nitrogen balance in three
cases of Cushings disease [150]. Similarly, in 1950, the Mayo Clinic team who
discovered cortisone remarked that, in one case, 25 mg Tp daily injections
reduced urinary nitrogen losses caused by 200 mg cortisone administration [13].
Some of the aforementioned researchers publish similar case reports, sharing the
small sample size and the use of surrogate outcomes [151]. These shortcomings
do not prevent each investigator from subjective claims of improvements in
physical function.</p>

<p class=MsoNormal>During the 1950s, AAS became part of the standard of care
for endogenous hypercortisolism during the gap between diagnosis and curative
surgery. However, this gap narrowed to a few weeks, due to improvements in
differential diagnosis. Today, development of accurate cortisol assays allowed
the measurement of its changes in response to Dexa, thus discriminating
conditions where feedback mechanisms fail (mainly endocrine neoplasms) from
cortisol-stimulating non-endocrine conditions. ACTH assays differentiate
ACTH-independent cases (typically adrenal tumors) from the ACTH-dependent ones
(usually localized in the pituitary). Modern imaging, including computed
tomography of the adrenal and magnetic resonance imaging of the pituitary, rapidly
identify the target for surgery. AAS therapy is now confined to inoperable
cases, including unidentified ectopic sources of ACTH or cortisone. Even these
cases benefit from more targeted interventions (see Table 1).</p>

<p class=MsoNormal style='text-indent:0in'><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'></span>SHAPE <span
style='mso-spacerun:yes'></span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1051"
 type="#_x0000_t202" style='width:6in;height:294.55pt;visibility:visible;
 mso-wrap-style:square;mso-left-percent:-10001;mso-top-percent:-10001;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:char;
 mso-position-vertical:absolute;mso-position-vertical-relative:line;
 mso-left-percent:-10001;mso-top-percent:-10001;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <table class=TableGrid border=0 cellspacing=0 cellpadding=0
     style='margin-left:.2pt;border-collapse:collapse;mso-yfti-tbllook:1184;
     mso-padding-alt:1.25pt 5.75pt 0in 6.2pt'>
     <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes'>
      <td valign=top style='border:solid black 1.0pt;mso-border-alt:solid black .5pt;
      padding:.05in .05in .05in .05in'>
      <p class=MsoNormal align=center style='text-align:center;text-indent:
      0in;line-height:150%'>Class</p>
      </td>
      <td valign=top style='border:solid black 1.0pt;border-left:none;
      mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;
      padding:.05in .05in .05in .05in'>
      <p class=MsoNormal align=center style='text-align:center;text-indent:
      0in;line-height:150%'>Medications</p>
      </td>
     </tr>
     <tr style='mso-yfti-irow:1'>
      <td valign=top style='border:solid black 1.0pt;border-top:none;
      mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
      padding:.05in .05in .05in .05in'>
      <p class=MsoNormal style='text-indent:0in;line-height:150%'>ACTH</p>
      <p class=MsoNormal style='text-indent:0in;line-height:150%'>inhibitors</p>
      </td>
      <td valign=top style='border-top:none;border-left:none;border-bottom:
      solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;
      mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;
      padding:.05in .05in .05in .05in'>
      <p class=MsoNormal style='text-indent:0in;line-height:150%'>Subtype 5
      somatostatin receptor agonists: pasireotide (FDA-approved) [152]</p>
      <p class=MsoNormal style='text-indent:0in;line-height:150%'>Dopamine D2
      receptor blockers: cabergoline</p>
      </td>
     </tr>
     <tr style='mso-yfti-irow:2'>
      <td valign=top style='border:solid black 1.0pt;border-top:none;
      mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
      padding:.05in .05in .05in .05in'>
      <p class=MsoNormal style='text-indent:0in;line-height:150%'>11-&#946;
      hydroxylase inhibitors</p>
      </td>
      <td valign=top style='border-top:none;border-left:none;border-bottom:
      solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;
      mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;
      padding:.05in .05in .05in .05in'>
      <p class=MsoNormal style='text-indent:0in;line-height:150%'>Metyrapone,
      mitotane, ketoconazole.</p>
      </td>
     </tr>
     <tr style='mso-yfti-irow:3'>
      <td valign=top style='border:solid black 1.0pt;border-top:none;
      mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
      padding:.05in .05in .05in .05in'>
      <p class=MsoNormal style='text-indent:0in;line-height:150%'>Inhibitor of
      3 &#946;hydroxysteroid dehydrogenase</p>
      </td>
      <td valign=top style='border-top:none;border-left:none;border-bottom:
      solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;
      mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;
      padding:.05in .05in .05in .05in'>
      <p class=MsoNormal style='text-indent:0in;line-height:150%'>Trilostane
      (EMA-approved, FDA-withdrawn) [153]</p>
      </td>
     </tr>
     <tr style='mso-yfti-irow:4'>
      <td valign=top style='border:solid black 1.0pt;border-top:none;
      mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
      padding:.05in .05in .05in .05in'>
      <p class=MsoNormal style='text-indent:0in;line-height:150%'>Inhibitor of
      the cholesterol side-chain cleavage enzyme</p>
      </td>
      <td valign=top style='border-top:none;border-left:none;border-bottom:
      solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;
      mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;
      padding:.05in .05in .05in .05in'>
      <p class=MsoNormal style='text-indent:0in;line-height:150%'>Aminoglutethimide</p>
      </td>
     </tr>
     <tr style='mso-yfti-irow:5;mso-yfti-lastrow:yes'>
      <td valign=top style='border:solid black 1.0pt;border-top:none;
      mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
      padding:.05in .05in .05in .05in'>
      <p class=MsoNormal style='text-indent:0in;line-height:150%'>GR antagonist</p>
      </td>
      <td valign=top style='border-top:none;border-left:none;border-bottom:
      solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;
      mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;
      padding:.05in .05in .05in .05in'>
      <p class=MsoNormal style='text-indent:0in;line-height:150%'>Mifepristone
      (FDA-approved) [154]</p>
      </td>
     </tr>
    </table>
    <p class=MsoNormal style='text-indent:0in;line-height:150%'>Table 1:
    Pharmacological agents used in Cushings disease of unidentified ectopic,
    or diffuse localization (reviewed in [1, 2])</p>
    <p class=MsoNormal style='text-indent:-135.0pt'><o:p>&nbsp;</o:p></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><![if !vml]><img width=582 height=6
src="thesis-github_files/image001.gif"
alt="Text Box: Class	Medications&#13;&#10;ACTH&#13;&#10;inhibitors	Subtype 5 somatostatin receptor agonists: pasireotide (FDA-approved) [152]&#13;&#10;Dopamine D2 receptor blockers: cabergoline&#13;&#10;11-&#946; hydroxylase inhibitors	Metyrapone, mitotane, ketoconazole.&#13;&#10;Inhibitor of 3 &#946;hydroxysteroid dehydrogenase	Trilostane (EMA-approved, FDA-withdrawn) [153]&#13;&#10;Inhibitor of the cholesterol side-chain cleavage enzyme	Aminoglutethimide&#13;&#10;GR antagonist	Mifepristone (FDA-approved) [154]&#13;&#10;Table 1: Pharmacological agents used in Cushings disease of unidentified ectopic, or diffuse localization (reviewed in [1, 2])&#13;&#10;&#13;&#10;"
v:shapes="Text_x0020_Box_x0020_2"><![endif]><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1085" type="#_x0000_t75" style='width:6in;height:294.55pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p>

<p class=MsoNormal>Similarly, the opportunities for AAS as adjuvant to GC
therapy are very limited. Many of the diseases previously treated by high-dose
GC are now treated with higher- specificity drugs. As practitioners became more
accustomed with the risks of GC therapy, doses and durations were reduced. With
the exception of life-threatening conditions, typical GC prescriptions switched
to lower-potency compounds, such as prednisone or even cortisol. In particular,
practitioners became well aware of the issues of GC withdrawal syndrome, where
adrenal atrophy is aggravated by some other, still undiscovered, component [123].
By mid-1970s, it became common advice that prescriptions for [glucocorticoid]
steroids should not be refillable [155]. By the time modern trials with AAS
began, the incidence of overt hypercortisolism decreased significantly. Despite
a potential epidemic of covert hypercortisolism, with deleterious effects of
life quality and expectancy, the interest for studies on hypercortisolism has
largely waned. Clinical studies investigating the benefits of AAS in
hypercortisolism are scarce and small-scale. For example, there are no
significant-size clinical studies analyzing the effect of AAS on the muscle
strength of the endogenous CS patient.</p>

<p class=MsoNormal>An unblinded trial observed AAS-induced increases in lean
body mass and appendicular muscle mass, in men already receiving an average of
6 mg prednisone a day over 9 years [156]. Another, randomized, blinded,
placebo-controlled trial by Crawford and colleagues tested the benefits of
testosterone or nandrolone decanoate as an adjuvant to chronic GC therapy for
diverse pathologies [157]. The exposure to GC was an average of 12 mg
prednisone a day, over more than 8 years, and was already causing osteopenia,
hyperlipidemia, hypercholesterolemia, and a reduction in quality of life
compared to historical controls [158]. Such side effects could arguably be
considered evidence for mild iatrogenic CS. After six months of 200 mg
testosterone injections every other week, the AAS group had higher bone
density, muscle mass and strength, and a better quality of life, compared to
the placebo group. To date, Crawfords study is the best evidence for
effectiveness of AAS as adjuvant in GC therapy.</p>

<p class=MsoNormal>In a subset of CS patients, androgen administration improves
muscle mass and quality of life. There are no published human trials describing
in molecular terms the interaction of GCs and AAS at muscle level. Most of our
knowledge is derived from animal models (discussed later).</p>

<h2><a name="_Toc421412246">Hypercortisolism-induced changes in endogenous
androgens levels</a></h2>

<p class=MsoNormal>AAS therapy does not change circulating cortisol levels [159].
However, the opposite interaction, where hypercortisolism interferes with
endogenous AAS secretion, is a common finding, with a complex physiological
basis. The interaction of GC with endogenous AAS distinguishes male from female
hypercortisolism, to the point that the two syndromes are qualitatively
different.</p>

<p class=MsoNormal>A series of trials observed the effect of short-term (hours
or days) hypercortisolism in healthy volunteers. Experimental acute
hypercortisolism represses circulating levels of Testo, in a reversible manner,
in males and, to a lesser degree, in females [160, 161]. The mechanisms through
which acute hypercortisolism causes Testo downregulation, also termed
hypoandrogenism, are debated. Some studies suggested that acute
hypercortisolism downregulates the pituitary-secreted, T-upregulating,
luteinizing hormone (LH) [162, 163, 164]. Others found that GC induce hypoandrogenism
even when LH is unchanged, thus locating the repression at gonad level [165].
Another hypothesis is that the negative feedback loop repressing ACTH in
hypercortisolism has a side effect of androgen suppression [166]. A few groups
have even hypothesized the existence of another, still unknown hormone,
synthesized from ACTH precursor, pro-opiomelanocortin (POMC), with the ability
to stimulate androstenedione synthesis and secretion [167, 168]. GC-induced
repression of POMC would also repress this unknown androgen-stimulating
hormone, but its existence was never proven.</p>

<p class=MsoNormal>In males, chronic hypercortisolism is also associated with
hypoandrogenism. Long-term prednisone therapy reduces circulating Testo levels
[169]. Similar observations have been made in endogenous CS, where exposure is
longer and, depending on etiology, ACTH may be higher than normal. As with
acute studies, multiple competing explanations were suggested. A study found
that hypercortisolism impairs hypothalamic GnRH secretion of gonadotropin-releasing
hormone (GnRH), the main regulator of LH [170]. Others found that that CS is
correlated with pathologically low levels of LH and of the other
gonad-stimulating pituitary hormone, follicle stimulating hormone (FSH),
despite normal GnRH secretion [171, 172]. This scenario suggests that
hypercortisolism reduces pituitarys GnRH responsiveness. Finally, a small
study found that male asthma patients receiving long-term prednisone have lower
circulating Testo levels despite increases in LH and FSH, and concluded that
prednisone has a direct inhibitory action on the testes [173]. Despite
disagreeing on the mechanism, all these studies agree that chronic
hypercortisolism represses testicular androgen secretion.</p>

<p class=MsoNormal>In adult women, the regulation of AAS is more complex.
During reproductive age and a few years afterwards, the main source of
androgenic stimulation is the ovary [174], where Testo is an intermediate
product in the synthesis of estrogens (reviewed in [175]). A feedback loop
links LH and estrogens levels, with LH directly stimulating synthesis and
secretion of estrogens from the developing and atretic follicles [176]. The
reverse link is more complex, with estrogens inhibiting LH for most of the
menstrual cycle [177], with the possible exception of ovulation.</p>

<p class=MsoNormal>In the direct link, LH must stimulate ovarian Testo
synthesis in order to achieve estrogen upregulation, but a reverse link, where
Testo directly inhibits LH, is absent in women [178, 179]. Although measurement
methods and normal ranges are still to be perfected, it appears that
circulating Testo level in women are reflecting the menstruation-related
cyclical interplay of estrogen and LH, rather than being independently
controlled [180, 181].</p>

<p class=MsoNormal>This sexual dimorphism differentiates male and female AAS
response to chronic hypercortisolism. Women with CS have lower muscle mass
compared to general population [182]. Decreased libido, a sign of
hypoandrogenism in both genders, is reported by 40% of female CS patients [65].
However, in contrast to males, females with CS have normal or even increased
AAS synthesis and levels, compared to healthy controls [183, 184]. Four fifths
of women with CS have menstrual irregularities, which has been attributed to
hyperandrogenism, direct cortisol action, or depletion of LH or estradiol [170].
More than 75% of CS cases present with hirsutism, that is, male-patterned body
and face hair growth in female patients, and a clear sign of hyperandrogenism [1,
65]. Women with CS-related hirsutism have androgen levels higher than healthy
controls [185]. Other signs of hyperandrogenism, such as voice changes or acne,
are rare in female CS.</p>

<p class=MsoNormal>Indirect evidence suggests that apparent hyperandrogenism is
also present in children with hypercortisolism. In pediatric hypercortisolism, virilization
signs such as change in voice, penile or clitoridian overgrowth, and hirsutism
are common [#joshi2005cushings, #kanter2005single-center]. Published studies do
not describe muscle changes in these children, possibly due to difficulties in
assessment and scarcity of cases.</p>

<p class=MsoNormal>In adult female CS, muscle catabolism increase contrasts
with virilization and circulating androgens changes. This suggests that
relative hyperandrogenism in some tissues is coincident with relative
hypoandrogenism in others. For example, it has been shown that in cultured
prostate cells excess GC improves the sensitivity of <span
style='mso-spacerun:yes'></span>the androgen receptor (AR) [187], the nuclear
receptor mediating the action of AAS. In contrast, in womens muscle, short-term
Dexa inhibits AR expression [188]. It may be the case that GCs interfere with
Testo signals in a tissue- or sex-specific manner.</p>

<p class=MsoNormal>In both sexes, the most concentrated circulating steroids
are dehydroepiandrosterone (DHEA) and its ester, DHEA sulfate (DHEAS), which
originate from the adrenal and, to a lesser degree, from gonads. Their most
important role appears to be that of precursors for synthesis, in glands and
peripheral tissue, of androgens and estrogens. DHEA has some affinity for the
AR, which suggested it might be an AAS. Recent studies indicate that, in human
female tissue, DHEA may in fact be a partial agonist, hindering the action of T
[189]. DHEA and DHEAS, now termed adrenal androgen precursors (AAP), are
upregulated by ACTH, through increased synthesis of DHEA in the adrenal and
rapid bidirectional interconversion [190, 191]. Therefore, Cushings disease
and other conditions associated with increases in ACTH will present with
increases in AAPs, while primary hypercortisolism will be associated with ACTH
repression and consequent AAP decrease [192, 193, 167, 194]. Both types of
hypercortisolism are associated with GAML, despite opposite effects on AAPs,
suggesting that AAPs changes do not cause GAML directly. Understanding
causality in the case of simultaneous muscle loss and hirsutism is complicated
by dose- and compound-dependent crossconversion of GCs to AAS and interference
of GCs in AAS synthesis and degradation.</p>

<p class=MsoNormal>Loss of endogenous AAS is associated with loss of muscle
mass and strength [195, 196]. Perhaps for this reason, muscle wasting is more
common in males than in females with endogenous CS [197]. At least in adult
males, muscle loss in CS may be aggravated by the reductions in endogenous AAP
and AAS. An AAS replacement strategy in hypoandrogenic hypercortisolism appears
intuitively beneficial for the muscle. Moreover, Crawford and colleagues
observed the muscle protection by AAS as adjuvant to GC therapy extended to men
who had low-normal circulating Testo [157]. Androgen therapy for muscle
protection in CS is predicted to benefit adult males, especially in the
frequent cases of patent hypogonadism.</p>

<h2><a name="_Toc421412247">Molecular mechanisms of androgenic myoprotection in
humans</a></h2>

<p class=MsoNormal>GAML is a well-studied phenomenon, with its molecular
mechanisms dissected in human studies. In contrast, the effect of AAS in GAML
was studied in a few case reports, marred by the absence of objective physical
outcomes and of molecular analysis. More information can be gleaned from the
effect of AAS in other muscle-depleting conditions.</p>

<p class=MsoNormal>Most commonly, studies of AAS on muscle are carried on
hypogonadal men. In male primary hypogonadism, rates of cortisol synthesis and
degradation are typically normal [198]. In this population, AAS therapy, even
with low, replacement doses, causes an increase in muscle mass and force [199,
200]. The gain in muscle mass is caused mainly by an increase in protein
synthesis, as evidenced by increased nonoxidative uptake of labeled leucine [200].
Moreover, Testo causes an increase in FSR of myosin heavy chain (MyHC),
indicating that protein accretion is localized in the myotubes. The referenced
studies also measured leucine flux, a proxy for protein degradation, but failed
to detect significant changes as a result to Testo therapy.</p>

<p class=MsoNormal>Typical naturally-occurring male hypogonadism is usually
associated with pleiotropic pathology, such as Klinefelters syndrome, where
deficient androgen synthesis may be complicated by other peripheral defects.
For this reason, some studies were conducted in males with iatrogenic
hypogonadism, induced by administration of GnRH agonists, such as goserelin or
leuprolide, which disrupts and eventually abolishes LH secretion.
Leuprolide-induced hypoandrogenism causes loss of muscle mass in healthy
volunteers and in prostate cancer patients [201, 202]. This form of chemical
castration causes decreases in both protein synthesis and degradation [203],
indicating that loss of muscle is caused by translation changes. In the
prostate cancer study, correction of leuprolide-induced hypoandrogenism by
co-administration of Testo reversed most of the muscle mass losses, although
mechanisms were not studied.</p>

<p class=MsoNormal>The protective action of AAS therapy in iatrogenic
hypoandrogenism is not affected by co-administration of an aromatase inhibitor
such as anastrozole [204]. Aromatase converts Testo in estradiol. The
continuing muscle protection when Testo cannot be converted to estrogens
demonstrates that muscle protection is an intrinsic ability of Testo. A more
plausible mediator for AAS is the insulin-like growth factor I (IGF-I), whose
muscle expression is decreased by iatrogenic hypogonadism [203].</p>

<p class=MsoNormal>Another well-studies group comprises older men, whose Testo
levels and muscle mass are naturally declining [205, 206]. An argument has been
made about benefits of Testo replacement therapy in this population. Multiple
clinical studies tested this hypothesis. In older men with low bioavailable
Testo, muscle mass and strength is improved by 200 mg Testo every other week [207,
208]. As in hypogonadal men, muscle recovery can be localized to the contractile
cells, as indicated by increases in the CSA of fast- and slow-twitching fibers
[209]. No evidence of fiber type switching or fiber type-specific effects in
response to AAS therapy has been seen. Instead, histological studies reveal
that elderly treated with AAS have significantly more satellite cells [209].</p>

<p class=MsoNormal>Testo improves the net balance between protein synthesis and
degradation at muscle level [210]. The cause of protein accretion is an
increase in protein synthesis, as shown by an augmentation of mixed-muscle FSR
[211]. The increase in muscle fiber protein is correlated with an upregulation
of circulating N-terminal propeptide of type III procollagen [212], indicating
that cellular hypertrophy is paralleled by extracellular matrix remodeling.</p>

<p class=MsoNormal>Ferrando and colleagues made the case for an anti-catabolic
action of AAS in older men [213]. They tested a variable, moderate dose of
Testo on normogonadal older men, with the goal of maintaining a physiological
Testo level over six months. This moderate Testo therapy caused an improvement
in muscle mass, strength, and net protein balance, in the absence of an
improvement in protein FSR. Therefore, muscle protein accretion could be
attributed to decreased protein degradation. Moreover, Ferrando and colleagues
showed a significant decrease in the proteasome enzymatic activity following
Testo therapy. The same group found a similar pattern of net gain in muscle
protein, correlated with reduced catabolism and unchanged protein synthesis, in
a short-term trial of Testo on men with severe burns [214]. It is unclear why
the anti-catabolic action of Testo did not garner more attention. The
hypothesis that Testo inhibits protein degradation remains tempting, but better
studies are needed.</p>

<p class=MsoNormal>Perhaps provocatively, the protection of muscle force
provided by Testo to the older hypogonadal men is not hindered by
co-administration of finasteride, an inhibitor of 5&#945;-reductase, which
causes the transformation of Testo to 5&#945;-dihydrotestosterone (DHT) [215]. Similarly,
Testo muscle protection was present when another 5&#945;-reductase inhibitor,
dutasteride, was co-administered to a younger, possibly less hypoandrogenic
cohort [216]. In human males, conversion to DHT is not required or Ts
regulation of muscle mass. Once more, a more plausible mediator of AAS is
IGF-I, the peptide hormone upregulated by Testo in the muscle and in the serum
of the older men [210, 217].</p>

<p class=MsoNormal>There is no agreement on the balance of benefits and
deleterious effects of Testo therapy for women [218, 219]. There is no
FDA-approved Testo preparation for women. Therefore, the action of Testo in
women losing muscle remains an area of research requiring further investigation.</p>

<p class=MsoNormal>The best molecular observations on the action of Testo on
muscle loss have been obtained from studies of HIV-positive men, who have
significantly lower circulating Testo levels [220]. AAS delays loss of muscle
mass in AIDS wasting syndrome, leading to better quality of life [221].
Microarray analysis indicated that T-treated muscle upregulated expression of
genes from the IGF-I- and AR-stimulated signaling pathways [222]. Immunoblot
confirmatory studies indicated that Testo caused the activation of a key
component of the IGF-I signaling pathway, the protein kinase B, also known as
Akt, by increasing its Ser-473 phosphorylation. Other genes upregulated by
Testo are muscle development regulators, such as the myocyte enhancer factor 2A
(MEF2A) and a host of macrophage-associated markers. In addition, Testo
stimulated expression of genes from other pathways, including transcription
factor 4 (TCF4) from the Wnt / &#946;-catenin pathway, AMP kinase (AMPK), and
the guanine nucleotide exchange factor Sos, involved in the mitogen-activated
protein kinase (MAPK) pathway. In the same study, MAPK protein levels did not
appear to be modulated by AAS therapy. The referenced microarray study failed
to find a change in expression of the major muscle regulator myostatin
(described in [223, 224]), or of the two E3 ligases typically associated with
muscle loss, MAFbx and MuRF-1 (described in [225, 226]).</p>

<p class=MsoNormal>The histological and molecular findings from hypogonadal and
HIV-positive males receiving AAS have been confirmed in many other pathologies
that cause loss of muscle. AAS therapy improves muscle mass and strength in
males with chronic kidney disease and liver cirrhosis [227, 228]. In men with
COPD, 100 mg Testo enanthate injected weekly led to improvements in muscle mass
and strength, potentially augmenting quality of life [229]. These improvements include
an increase in fiber CSA, regardless of fiber type, and by an upregulation of
the IGF-I mRNA isoforms IGF-IEa and IGF-IEc [230]. In both COPD and HIV-positive
men, Testo upregulated isoform 3, also known as embryonic, MyHC.</p>

<p class=MsoNormal>A cross-sectional study split a cohort of males with heart
failure, without cachexia and with normal circulating cortisol, Testo and ACTH
levels in two halves based on their cortisol level. The subgroup with lower
circulating cortisol achieved a higher peak work rate, suggestive of GC-induced
muscle damage [231]. A randomized trial showed that heart failure patients
improve their muscle force with AAS therapy [232, 233]. However, a series of
recent studies found deleterious cardiovascular effects of AAS [234, 235],
which will discourage the use of Testo in heart failure and, in general, in
populations at risk. In 2014, FDA required manufacturers to include on Testo
labels a warning regarding increased heart attack and stroke, thus pressing the
need for more specific anabolic adjuvants. To this end, a deeper understanding
of AAS therapy at molecular level is required.</p>

<p class=MsoNormal>In various conditions that cause muscle loss, AAS benefits
share a pattern including improved muscle mass and strength, fiber hypertrophy,
tissue remodeling, and increased protein synthesis. In some conditions,
AAS-driven muscle rehabilitation is associated with an increase in satellite
cells and / or an inhibition of protein degradation. Putative molecular
mediators known from animal models have not been confirmed in humans, with the
exception of IGF-I upregulation. Better clinical studies are required. In their
absence, our insights into glucocorticoid myopathy and AAS muscle protection
come from animal and in vitro experiments, discussed in the next section.</p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

</div>

<span style='font-size:12.0pt;mso-bidi-font-size:11.0pt;line-height:200%;
font-family:"Georgia",serif;mso-fareast-font-family:Georgia;mso-bidi-font-family:
Georgia;color:black;mso-ansi-language:EN-US;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA'><br clear=all style='page-break-before:always;
mso-break-type:section-break'>
</span>

<div class=WordSection3>

<h1><a name="_Toc421412248">2. BIOLOGICAL PREMISES</a></h1>

<h2><a name="_Toc421412249">Skeletal muscle histology</a></h2>

<p class=MsoNormal>Muscles are specialized for their main ability,
contractility. For mammalians, ability to move is vital for survival, meaning
that a large portion of their bodies is muscle. In a cohort of 300 borderline
overweight US Americans, skeletal muscle as a proportion of body weight was on
average 41% for men and 31% for women [236]. Three fifths of the human bodys
protein is confined to the muscle contractile and support structures [237].</p>

<p class=MsoNormal>For the most part, the skeletal muscles confer the
three-dimensional intricate conformation of the body, suggesting a complex,
detailed organization, at least at macroscopic level. In contrast, at cell
level, the relatively high specialization of the skeletal muscle leaves little
space for diversity or inhomogeneity. Muscles diverse shapes are conferred by
non-contractile proteinic auxiliary structures. The largest of these
structures, tendons and aponeuroses. attach the muscle to other body structures
(reviewed in [238]). The tendons are dense connective tissue structure, which
extend into the epimysium, a connective tissue sheath surrounding the muscle.
In turn, epimysium emits connective septing structures termed perimysium,
splitting muscles into subunits termed fascicles. At an even lower level, a
thin, sparse connective structure called endomysium coats each multinucleated,
elongated cell (termed myofiber). The connective tissue inside the muscle
provides mechanical anchoring between fibers, longitudinally, laterally and
with the tendons. This is particularly true of perimysium, which is almost
acellular, at 95% collagen content [239]. Intramuscular connective structures
carry terminal branches of the nervous, circulatory and lymphatic systems. In
addition, muscles include adipose and immune cells. Muscle mass changes require
remodeling of all these connective structures and may confound in vivo studies.
For example, collagen synthesis or macrophage proliferation may misleadingly
increase during slow muscle atrophy.</p>

<p class=MsoNormal>The elongated, multinucleate myofiber is the histological
base unit of contractile tissue. A large majority of the myofiber cytosol is
the contractile apparatus, in the shape of bundles of protein filaments termed
myofibrils. Within myofibrils, myosin and actin filaments alternate, held
together by multi-protein complexes containing titin. Myofibril proteins are
about two thirds of the total myofiber protein [240]. Therefore, any myofiber
size change with functional relevance should correlate with changes in myosin
II and actin protein content. The sizable actin content poses a challenge to
muscle studies. Traditionally, in biological studies, actin is considered a
housekeeping, unregulated, invariable protein, and is used in level
normalization. In muscle, especially in atrophy, actin cannot be invariable. For
example, in rat muscles atrophying due to streptozotocin-induced acute
diabetes, an actin degradation fragment is upregulated to detectable levels [241].
Therefore, in atrophy studies, normalization to actin may misleadingly reduce
the apparent rate of depletion for other proteins. Similar issues govern the
use of 3MH as a marker for myofibril protein catabolism. Given that the main
correlate of urinary 3MH is muscle mass [242], 3MH measurement may lack
sensitivity when used as an indicator for muscle catabolic rate. On one hand,
increased catabolism is expected to cause increased 3MH output, but on the
other, an atrophic muscle has less 3MH to release.</p>

<p class=MsoNormal>Myofibers acquire nuclei by fusion with surrounding
proliferative mononucleate cells, or with neighboring myofibers. Two classes of
mononucleate cells are relevant for muscle structure and development. Satellite
cells are Pax7-positive, mononuclear, nearly devoid of cytosol, sitting in
close proximity to the fiber, under the proteinic external lamina (reviewed in
[243]). In contrast to the above histological definition, myoblasts are defined
in a functional manner, as proliferating cells able to fuse with myofibers. In
vivo, myoblasts are derived from a subset of satellite cells. A transplant of
seven satellite cells from an adult mouse is capable of yielding more than a
hundred multinucleate myofibers, thus demonstrating formers ability to regenerate
muscle [244]. The transformation of quiescent satellite cells into
proliferating myoblast is regulated by the interplay of growth factors,
external lamina, and contact with myofibers [245]. Alternate extra-muscular
sources of nuclei in the myofiber are subject of ongoing research, but their
relative importance is expected to be minor at best (reviewed in [246]).</p>

<p class=MsoNormal>Experimentally, &#945;7 integrin is an effective marker for
selecting proliferative precursors from muscle [247]. Many in vitro muscle
models are based on the formation of multinucleate fibers from isolated
myoblasts. In vivo, myofiber nuclei are typically peripheral, while in vitro
multinucleate cells are characterized by central nuclei, akin to regenerating
fibers. The latter are typically termed myotubes.</p>

<p class=MsoNormal>The proliferative niche can play an important role in muscle
atrophy and recovery. However, muscle hypertrophy may occur without cell
division. For example, the muscles of mice receiving clenbuterol and of rats
undergoing eccentric training gain 20-30% muscle mass without apparent DNA
changes [248, 249], suggesting hypertrophy of existing fibers, but not
additional cell division. Quail muscles depleted of proliferating cells by
irradiation still undergo hypertrophy in response to stretch-overload [250].
These examples of amitotic hypertrophy demonstrate that, in some circumstances,
the number of nuclei is not limiting muscle growth. Conversely, it is plausible
that a moderate degree of muscle atrophy occurs without loss of nuclei.</p>

<p class=MsoNormal>During experiments that perturb muscle mass equilibrium, the
level of the regulators, of typical housekeeping proteins, and of non-myofiber
proteins may fluctuate in manners that convolve their specific modulation with
overall muscle protein kinetics. Investigation of recovery from muscle loss is
burdened by the fact that it aims to dissect protein regulation, when the
regulators are proteins themselves.</p>

<h2><a name="_Toc421412250">Pre-adult muscle development</a></h2>

<p class=MsoNormal>In humans, immediately after birth, the number of satellite
cells is much higher than in the adult, but drops by an order of magnitude
between birth and 10 years [251]. This decay carries on throughout the lifetime
at a slower rate. In mice, muscle growth at puberty is associated with a
massive shift of nuclei from the satellite cells to the myofibers [252].
Perinatal Pax7 knockout reduces muscle ability to regenerate, while its genetic
depletion in utero or at adulthood does not exhibit pathological traits [253],
suggesting that juvenile muscle growth is distinct from muscle development at
other ages.</p>

<p class=MsoNormal>Even earlier, de novo muscle development is remarkable for
its accretion of new nuclei to the myofiber. Pre-adulthood muscle growth
appears reliant on hyperplasia, that is, cell proliferation. Cell proliferation
regulators are crucial in determination of muscle mass in before and soon after
birth. In utero, the mesoderm, which is the source of muscle progenitor cells,
undergoes segmentation and differentiation to form somites, dermomyotomes, and
eventually myotomes (reviewed in [254]). The latter contain the earliest cells
expressing muscle regulatory factors (MRF). These embryonic epaxial and
hypaxial muscles develop into trunk and limb muscles. Early on, limb muscle
precursors express myogenic factor (Myf) 5, due to stimulation from the
transcription factor Pax3 [255, 256]. Myf5 is a strong inductor of the muscle
phenotype, with the ability to convert embryonic fibroblasts to
myosin-containing syncytia [257]. Cranial muscle formation is coordinated in a
slightly different manner, through the transcription factors T-box (Tbx) 1 and
paired-like homeodomain (Pitx) 2 (reviewed in [258]). Once this early stage is
completed, later fetal muscle progenitors converge to a phenotype remarkable
for the expression of the MRF MyoD, due to stimulation by the transcription
factor Pax7 [259]. MyoD knockout mice are normal, with Myf5 supplanting its
absence [260]. In the Online Mendelian Inheritance in Man (OMIM) database,
there is no reported case of human mutation of Myf5 or MyoD, further supporting
the idea of duplicate function.</p>

<p class=MsoNormal>Neither Myf5, nor MyoD induce muscle attributes. However,
the expression of either will promote expression of another MRF, myogenin,
which marks the transition from specification to differentiation. Initiation of
myogenin expression marks the transition from specification to differentiation
stage. In cultured cells, myogenin expression is followed by p21 expression,
which removes the muscle precursor from the cell cycle [261]. Subsequent
changes include expression of muscle-specific enzymes and contractile proteins
[262], of a fourth MRF, the myogenic regulatory factor 4 (Mrf4) [263], and,
finally, acquisition of fusogenic abilities. In humans, by the seventh week of
gestation, the initial wave of myoblast fusion slows down, and a second
proliferative stage starts. The latter tapers off, leading to formation of
secondary myotubes within the same laminar sheath with a primary myotube.
Around the seventeenth week, some secondary myotubes migrate to form
independent centers of coalescence for a third set of myotubes [264].</p>

<p class=MsoNormal>Overall, muscle formation in utero and in early childhood
relies heavily on nuclei accretion and, as a consequence, on precursor
proliferation. A series of other factors cooperate to improve embryonic muscle
formation, including myostatin and IGF-I. Experimental myostatin perturbations
in chicken embryos alter the number of muscle precursor cells [265]. Phenotypic
differences between myostatin-null and wild-type mice develop by the second
week of embryogenesis, prior to the moment when differences in protein
synthesis would become relevant [266]. Similarly, the few reports of viable
human mutations in the myostatin gene concern newborns with unusually large
muscles [267]. Because myostatin defects cause even ampler increases in muscle
mass after birth [268, 267], it is possible that myostatin acts through
parallel, mitotic and non-mitotic, mechanisms.</p>

<p class=MsoNormal>IGF-I has a similar composite effect. In chick embryos,
overexpression of IGF-I induces a rapid increase in the ratio of myoblast to
myofiber nuclei, while fiber density is unchanged [269]. In addition to the
hyperplastic effect, IGF-I stimulates protein anabolism in prenatal muscle [270].
Defects in IGF-1R signaling determine low birth weight and subsequent growth
retardation in humans and transgenic mice [271, 272]. As in myostatins case,
it is difficult to separate mitotic and non-mitotic effects of IGF-I.</p>

<p class=MsoNormal>The adult satellite cells are derived from a subset of fetal
Pax3<sup>+</sup>Pax7<sup>+ </sup>cells. Because some cells, such as bone marrow
stem cells and pericytes, have the ability to fuse with myotubes in vitro, the
muscle stem cell population was hypothesized to include extra-muscular
self-renewing cells [273, 274]. However, after the age of 20, human muscle
nuclei maintain an almost constant length of telomeres, suggesting that mitosis
and recruitment of extramuscular cells are rare phenomena [275]. Moreover, the
proportion of resident satellite cells with proliferating abilities decreases
with age, as more of them approach the Hayflick limit [276]. As evidenced by
studies such as the New Mexico Elder Health Survey, 1993-1995, aging is
associated with accelerated loss of muscle mass [277]. Muscle growth mechanisms
based on mitosis become the exception, rather than the rule, in adult muscle. This
may be underlie a difference between juvenile and adult in the atrophying
effect of GC on muscle. The reduced rate of mitosis in adult muscle suggests
that GAML and its alleviation by AAS should not be mediated by changes in
nuclei density.</p>

<h2><a name="_Toc421412251">Physiological muscle metabolism</a></h2>

<p class=MsoNormal>Muscle is a major energy user in the body, with a skewed use
of fat during rest and glucose during exercise (reviewed in [278, 279]).
Because its capacity to synthesize fatty acid is negligible, muscle is a
consumer and a minor store, but not a generator, of fatty acids. During fast,
more than half of infused non-esterified fatty acids (NEFA) are taken up by
muscle, with a higher rate of incorporation in type I oxidative muscle [280].
In contrast, after feeding, oversupply of NEFA is compensated mainly by
increased uptake, in absolute terms, in the visceral adipose tissue, with minor
contributions from other adipose tissue, liver, and muscle. After repeated
exercise, muscle lipoprotein lipase expression is increased, indicative of an adaptive
improvement in muscle ability to extract NEFA from circulating triglycerides [281].
Ongoing studies suggest that muscle oxidative (catabolic) uptake of NEFA is
upregulated by peroxisome proliferator-activated receptor (PPAR) &#946;/&#948;,
which stimulates expression of the lipolysis rate-limiting enzyme, carnitine
palmitoyltransferase I [282, 283]. This hypothesis is supported by fast- and
exercise-induced upregulation of muscle PPAR &#948; [284, 285]. Moreover, PPAR
&#948; overexpression leads to increase in type I fibers and subsequent
resistance to high-fat diet [282]. Organ-level studies are impaired by the
existence of nontrivial intramuscular adipose tissue.</p>

<p class=MsoNormal>The work described in this dissertation relies extensively on
the C2C12 cell line, an immortalized female mouse muscle progenitor line
obtained from a muscle recovering after mechanical injury. Treatment of
confluent C2C12 cells with Dexa and 3-isobutyl-1-methylxanthine (IBMX) causes
their differentiation into adipocytes [286]. Some pre-adipocyte traits, such as
upregulation of PPAR &#947;, Krppel-like factor-15 (Klf15), and
CCAAT-enhancer-binding protein (C/EBP) &#946; and &#948; ([287]; reviewed in [288]),
may surface in cell culture experiments where muscle differentiation did not
complete, and residual potential for adipogenesis remains (see, for example, [289]).
An in vitro shift to a more adipose-like phenotype may be associated with
diminished cell fusion ability, lower protein synthesis, and lower
mitochondrial content, which may be misinterpreted as muscle atrophy.</p>

<p class=MsoNormal>In humans, up to 90% of the glucose absorbed after a meal is
removed from circulation by the skeletal muscles [290, 291], meaning that
muscles should have a paramount role in the development of insulin resistance
and eventually diabetes mellitus. After normal feeding, muscle builds
polysaccharides reserves, in part because it can synthesize and deposit the
largest glycogen stores in the body, and because it cannot release glucose.</p>

<p class=MsoNormal>Muscle work is generated at such high rates, that most
glucose is processed solely through glycolysis, in the cytosol, to the
three-carbon pyruvate. Some of the pyruvate is further oxidized in the muscle,
through the tricarboxylic acid cycle, but a significant amount is converted to
lactate and released in the blood stream. As part of the Cori cycle,
circulating lactate is reassembled into glucose by the liver, and re-released
into the blood stream, for muscle use. A similar gluconeogenetic mechanism employs
the intramuscular transamination of excess pyruvate to the amino acid alanine. Muscle-released
alanine is converted by liver to glucose, especially at times when dietary
carbohydrate intake is inadequate. Pyruvate transamination requires the amino
acid glutamate. Muscle uses glutamate for other metabolic processes, including
the synthesis of non-essential amino acids, including proline and arginine.
Therefore, at rest, human muscle uptakes significant amounts of glutamate, less
serine, while releasing alanine, glutamine, and smaller amounts of the other
amino acids [292]. Glutamine is synthesized in muscle in order to release the
excess nitrogen yielded by amino acid release during protein degradation.
Muscles glutamine is then converted by the liver to urea and excreted. The
aforementioned amino acids, with important roles outside protein metabolism,
are not suitable for labeling and protein tracking experiments.</p>

<p class=MsoNormal>Among the amino acids with a trend for release between
meals, isoleucine, leucine, methionine, phenylalanine, threonine, and valine
cannot be synthesized by humans. Their net release indicates that, at rest,
basal level of protein degradation slightly surpasses protein synthesis.
Conversely, for a steady muscle mass, there must be net protein synthesis in
the fed state. Muscle protein synthesis is stimulated by feeding in multiple
ways. One of these mechanisms employs effects of branched-chain amino acids
(BCAA), that is, valine, isoleucine, and leucine. BCAA stimulate protein
accretion in muscle through a complex mechanism. Some studies show that BCAA
ingestion or infusion increase protein synthesis rate [293], while others claim
that BCAA solely reduce protein degradation [294]. The effect of BCAA
supplementation is three-fold, combining increased caloric intake, reflex
hyperinsulinemia, and an autonomous, insulin-independent effect. One study
investigated the molecular effects of BCAA at clamped normal insulin levels [295].
In young, healthy men, BCAA alone were able to increase the fractional
synthesis rate for myofibrilar protein. At the same time, BCAA caused
intramuscular hyperphosphorylation of 4E-BP and of the ribosomal protein S6
kinase, 70 kDa (p70-S6K). Both are substrates of mTOR complex 1 (mTORC1), an
integrator of nutrients, energy, and growth factor signaling (reviewed in [296]).
Hyperphosphorylation of 4E-BP is the canonical way by which mTORC1 stimulates
protein synthesis, by abolishing the formers ability to bind and inhibit the
mandatory translation initiation factor eIF4E. The activation of p70-S6K leads
to the activation of a feedback phosphorylation of mTOR at Ser 2448 [297]. Some
of these three posttranslational modifications are paradoxically found in acute
atrophy settings, when BCAA sudden release increases their circulating levels.</p>

<p class=MsoNormal>In vivo, BCAA are used by muscle as protein precursors,
signaling molecules, and energetic substrates, when preferred energetic
substrates are not available [298]. In studies that measure leucine
disappearance from the bloodstream or culture medium, a distinction must be
made between the leucine used in non-oxidative, anabolic reactions, and the
alpha-ketoisocaproate-forming, ergogenic usage. An argument has been made for
using phenylalanine as a tracer, because muscle catabolism is negligible, and
because it has a lower insulin secretagogue effect [299, 300].</p>

<h2><a name="_Toc421412252">Adult muscle remodeling</a></h2>

<p class=MsoNormal>With aging, muscle gradually shifts from a mitotic to a
postmitotic profile, with muscle growth achieved increasingly through
hypertrophy, that is, cell size growth. While the typical middle-aged or
elderly adult is undergoing net loss of muscle mass, muscle re-growth and
remodeling is still possible in two common circumstances, exercise and injury.</p>

<p class=MsoNormal>Humans achieve muscle mass growth following exercise. Some
forms of exercise are more suitable at increasing strength or resistance than
mass per se, but in most cases, mass will increase in pace with force. In
animals, muscle growth is induced by muscle overload, or muscle unloading and
reloading, which may be conceived as forms of aerobic exercise. In healthy
volunteers, the acute response to exercise includes increased intramuscular
expression of MRFs MyoD and myogenin, and increased circulating IGF-I and IL-6
[301, 302, 303]. These signals are associated with increased proliferation of
satellite cells and recruitment of neutrophils to the muscle [304, 305]. In the
acute phase, the satellite cells co-localize with IGF-I [301]. The negative
muscle regulator myostatin is not correlated with the phenotype, that is, it is
not decreased by acute exercise [305, 306]. Acute exercise increases the
fractional protein synthesis rate in muscle [307, 308]. Interestingly, a single
bout of exercise during fast leads to increases circulating cortisol levels and
the release of 3-MH, indicative of increased stimulation of protein degradation
[309]. Concomitant amino acid feeding counters GC and catabolic response to
exercise. Variations in regimens of exercise and timing and composition of diet
have led to a plethora of studies. Just as most of the short-term exercise
routines do not lead to muscle hypertrophy, literature is rich with examples of
short exercise studies, where molecular changes have not been detected
(reviewed in [310]). An important future direction in exercise science is
establishing what distinguishes an effective brief exercise routine from an
ineffective one. In this context, GCs may be interesting noninvasive markers.</p>

<p class=MsoNormal>In the long term, exercise increases fiber CSA, density of
satellite cells, and the number of myofiber nuclei, while the level of
intramuscular MyoD and IGF-I return to normal [311]. On the other hand,
long-term exercise induces the expression of catabolic markers, such as the E3
ligases MAFbx and MuRF-1 [312]. Taken together, these molecular findings
indicate exercise causes muscle remodeling, which manifests as increased muscle
turnover, with upregulation of both protein degradation and synthesis.
Moreover, post-exercise muscle accretion combines hyperplasia and hypertrophy.</p>

<p class=MsoNormal>A similar biphasic response is yielded by injury. In the
immediate stage after injury, the muscle is infiltrated by pro-inflammatory M1
macrophages, while at later stage, anti-inflammatory (M2) subclass dominates
(reviewed in [313]). Although the studies are rather incomplete, it appears
that, similar to exercise adaptations, injury triggers a burst of growth
factors, probably including IGF-I, basic fibroblast growth factor (bFGF), and
transforming growth factor-beta (TGF-&#946;)[314]. Most of the studies of
regeneration provide circumstantial evidence, such as improved healing in the
presence of a presumed mediator, rather than impairment in its absence. Still
unidentified molecules from crushed muscle are able to cause myoblast hyperplasia,
above the levels caused by stimulation with known growth factors [315].</p>

<p class=MsoNormal>Less than half of the C2C12 cells in their proliferating,
undifferentiated, form express MyoD or Pax7 [316]. Limited evidence suggests
these myoblast-like cells do not express Pax3 either [317]. Therefore, the
C2C12 line is an incomplete model of hyperplastic muscle accretion.</p>

<p class=MsoNormal>Generation and regeneration of muscle in common scenarios,
such as development and adaptation, remain an object of study, due to their
complexity. The variable importance of the immune cells, of MRFs, and of IGF-I,
and concurring redundancy remain to be fully worked out to identify a common
pattern for muscle hypertrophy.</p>

<h2><a name="_Toc421412253">Hormonal control of muscle mass</a></h2>

<p class=MsoNormal>The variability of muscle mass within population is
reflective of the variable needs for muscle strength. Muscle mass and strength
are adjusted to the needs of the organism mostly through hormonal, rather than
neural, mechanisms. Multiple classical hormones regulate muscle mass. The acute
phase of insulin response poses a conundrum, with some studies showing it
stimulates protein synthesis in human muscle [318], while others demonstrating
that its effect is limited to anti-catabolism [319]. In male rat muscle, 30
minutes in 30 nM insulin or IGF-I are equally able to stimulate protein
synthesis and to inhibit protein degradation [320].</p>

<p class=MsoNormal>Insulin and IGF-I pathways overlap to some degree. For both
hormones, physiological concentrations are tens of times higher than the half
maximal effective concentration (EC50) for their receptor, suggesting that
physiological fluctuations cause marginal effects downstream [321, 322]. On the
other hand, insulin has the ability to bind and activate IGF-I receptor
(IGF-1R), with an EC50 of about an order of magnitude lower than physiological
insulinemia. The converse is true, with IGF-I being able to bind and activate
insulin receptor (IR), isoforms A and B. There is a small, but real, potential
for interference between insulin and IGF-I signals. Therefore, IGF-I and
insulin emerge as hybrids between metabolic stimuli and growth factors. The
liver is the main source of circulating IGF-I, under the pituitary stimulation
with growth hormone (GH). However, auto- and paracrine secretions fully
supplant the absence of hepatic IGF-I in adult conditional knockout mice [323].
In contrast, insulin is secreted solely by one organ, the pancreas. This sets a
more important distinction between insulin and IGF-I, with the former embracing
a systemic, integrative role, while the latter carries more localized
regulatory tasks. Our understanding of the regulation of insulin secretion is
improving, dispelling the simplistic view that nutrients alone are its sole
modulators (reviewed in [324]).</p>

<p class=MsoNormal>The levels of bioavailable IGF-I are under complex
regulation (reviewed in [325, 326]). IGF-I may be sequestered by IGF-I binding
proteins (IGFBP), which are secreted by muscle under IGF-I stimulation[327].
The interaction with IGFBP may prevents IGF-I from interacting with receptor,
or it may extend its circulating half-life by protecting it from degradation.
Depending on the isoform and location of IGFBP, the interaction may result in
extinction or amplification of the IGF-I signal. IGFBPs levels are modulated by
insulin, while their availability is modified competitively by insulin-like
growth factor 2 (IGF2). The latter can also stimulate IGF-1R, thus providing
its own anabolic and pro-myogenic signals [328]. IGF2 plays other, independent
roles, suggested by the lethality of its knockout [329].</p>

<p class=MsoNormal>There is no consensus concerning the ability of GH to
stimulate muscular secretion of IGF-I. Multiple studies found an upregulation
of IGF-I mRNA in response to GH stimulation [330, 331], but protein data are
lacking. Medium conditioned by GH-stimulated C2C12 cells fails to elicit
hypertrophy in other C2C12 myotubes [332], suggesting that IGF-I is not
secreted in the cell culture medium. Alternatively, the hypertrophic action of
IGF-I may be exerted by an intracellular autocrine mechanism. In addition to
the indirect effect mediated by hepatic and the putative muscular IGF-I, GH has
an IGF-I-independent effect on muscle. For example, knockout of GH receptor
impairs body growth further beyond IGF-1R knockout [333]. In the context of
pituitary pathology associated with Cushings disease, the associated GH
perturbations may contribute to loss of muscle.</p>

<p class=MsoNormal>Hypothyroidism is often associated with muscle weakness and
pseudohypertrophy [334]. Other hormones, such as the parathormone, have small
effects on muscle protein metabolism, essentially irrelevant outside their
respective pathologies [335]. In conclusion, muscle mass homeostasis is under a
tight, multifactorial hormonal control, whose study is complicated by
significant redundancy. The absence of third-party organs, such as glands, from
reductionist cell-culture may limit their ability to replicate in vivo
phenomena.</p>

<h2><a name="_Toc421412254">Interaction of muscle mass and vascularization</a></h2>

<p class=MsoNormal>Muscle vascularization is a modulator of muscle mass and
contractility. Mice whose muscle VEGF-A secretion was genetically depleted
still express a tenth of the muscle VEGF-A protein, but have only half of the
capillaries per muscle fiber, compared to their Cre<sup>-/- </sup>siblings [336].
The muscle-restricted VEGF-A-depleted mice have 12% lighter gastrocnemii,
although the muscle loss disappears when muscle mass is normalized to total
body weight. The loss does not affect specific fibers. Therefore, the muscle
depleted of VEGF-A is less able of endurance effort (80% shorter time to
exhaustion on the inclined treadmill) and of brief anaerobic exercise (34%
lower maximal running speed).</p>

<p class=MsoNormal>Conversely, murine muscles injected with VEGF-A-expressing
retroviruses display a higher proportion of hypertrophic fibers than those
expressing bacterial &#946;-galactosidase [337]. Moreover, in the
VEGF-A-overexpressing muscle, many of the fibers have central nuclei, a sign of
increased fusion with myoblasts. In the murine C2C12 cell line, VEGF-A causes
faster differentiation, into longer myotubes, with more nuclei per fiber,
although mitotic rates are in fact diminished. These observations are
consistent with direct anti-apoptotic and profusogenic effects.</p>

<p class=MsoNormal>It has been suggested that the most direct effect of VEGF-A
depletion is partial segregation of muscle from blood-carried endocrine
signals. For example, VEGF-A-depleted muscle has lower glucose uptake, a defect
that is reversed by explantation [338]. In addition, vascularization defects
may induce relative intramuscular hypoxia, which is an independent atrophying,
pro-proteolytic factor [339].</p>

<p class=MsoNormal>The relative importance of VEGF overexpression during
myogenesis is still open to debate, as muscle-restricted VEGF receptor (VEGFR)
knockout animals were not studied yet. Multiple effects concur to obfuscate VEGF
action in hypertrophying muscle. First, VEGF promoter contains three binding
sites for MyoD, meaning that growing muscle will express more VEGF [340].
Development of vasculature in growing muscle may be a physiologically
meaningful way to ensure vasculature remains competent upon increase
circulatory demands.</p>

<p class=MsoNormal>Second, although the canonical positive regulator of VEGF is
hypoxia-induced factor 1&#945; (HIF 1a), muscle VEGF is also stimulated by PPAR
&#947; coactivator 1 (PGC-1) [341, 342]. Even in the absence of VEGF, PGC-1
coactivators facilitate mitochondria biosynthesis, leading to oxidative fiber
hypertrophy and improvements in endurance capacity [343]. Therefore, it is
difficult to distinguish VEGF-induced muscle changes from the common muscle remodeling
program. Finally, VEGFR activation has multiple effects, including
phosphorylation of Src family proteins [344], of phospholipase C (PLC) &#947; [345],
and, indirectly, of regulatory subunits of PI3K [346] and of the Signal
Transducers and Activators of Transcription (STAT) STAT3 and STAT5 [347]. Most
of these VEGF effects overlap with the effects of many other muscle anabolic
agents. It is possible that VEGF plays a central mediating role in muscle
hypertrophy. Alternatively, VEGF changes may be reactive, merely adjusting the
vasculature to fiber ratio to a constant level, after changes in either muscle
or vasculature caused by other factors.</p>

<h2><a name="_Toc421412255">Control of muscle mass through innervation</a></h2>

<p class=MsoNormal>Current understanding and future directions for the study of
GAML are guided, to a large extent, by the data obtained in denervation
experiments. From the earliest study of protein synthesis and degradation in
atrophying muscle to the discovery of atrogenes, denervation has been compared
with GAML in many studies. Denervation of a hindlimb or hemidiaphragm is a
relatively simple procedure, with the advantage of having an animal as its own
control.</p>

<p class=MsoNormal>Limb and trunk muscles are controlled by the lower (alpha)
motor neuron, located in the ventral horn of the spinal cord. Their main point
of contact is a chemical synapse, the neuro-muscular junction (NMJ). In
addition to the direct synaptic activity, muscles and lower motor neurons are
involved in a mutually beneficial life-long interaction.</p>

<p class=MsoNormal>Motor neuron precursors from the embryo spinal cord degenerate
and die if they cannot engage in significant interactions with myofibers [348].
Eliminated motor neurons include neurons whose axons fail to reach myotubes,
and neurons that eventually fail to maintain contact with myotubes, due to
synapse elimination. The latter is a selective, competitive process, whose
molecular basis is still unknown, and which ensures injectivity of the
correspondence between lower motor neurons and myofibers (reviewed in [349]).
For a few days after birth, rat motor neurons go into a particularly sensitive
state, when axotomy determines motor neuron death [350]. Thence, axotomy
elicits the reprogramming of the neuron into a less differentiated state,
followed by axonal regrowth (reviewed in [351, 352]). The re-establishment of contact
between the motor neuron and muscle causes the reverse molecular changes,
suggesting the existence of muscle-secreted neurotrophic factors. The NMJ loses
functionality with aging, although it is not clear whether NMJ dysfunction
causes or is caused by aging-related muscle loss [353]. Factors that improve
muscles ability to exercise or even mimic exercise, such as IGF-I or
androgens, have been shown to benefit NMJ recovery or to slow down its
degradation during aging [354, 355, 356].</p>

<p class=MsoNormal>The loss of contact with the lower motor neuron elicits
similar detrimental changes in muscle, with clinical relevance in the
understanding and treatment of spinal cord injury and spinal muscular atrophy.
Conceptually, denervation is distinct from disuse, such as that induced by
damage to the upper motor neuron. Clinically, the latter manifests differently,
through a syndrome termed pyramidal weakness, which mainly affects muscles
opposing gravity [357]. In humans, after upper motor neuron damage, disuse
response occurs in a few days after injury, and leads to exaggerated spasticity
[358]. Understandably, literature does not describe any animal model of disuse
by experimental damage to the upper motor neuron. In fact, literature contains
multiple examples where disuse is taken to mean absence of action
potentials, due to denervation, lack of work, due to denervation, unloading,
immobilization, or even both (see for example [359]). Consequently, there are
no experimental attempts to disentangle muscle-maintaining effects of work, of
the NMJ transmitter, acetylcholine, and of any other musculotrophic
neuron-released factor.</p>

<p class=MsoNormal>In utero, experimental destruction of motor neurons with
bungarotoxin abolishes formation of secondary myotubes, although it has limited
effect on the formation of primary fibers [360].</p>

<p class=MsoNormal>Experimental denervation causes rapid and ample loss of
muscle mass. For example, three weeks after sciatic nerve removal, the tibialis
anterior muscle halves in weight [361]. Fewer than one in 7,000 myofiber nuclei
undergo apoptosis in this time [362], demonstrating how atrophy can occur
without changes in nuclei density.</p>

<p class=MsoNormal>In a seminal study, Goldberg demonstrated that denervation
leads to increased loss of prelabeled muscle protein, proving that denervation
upregulates protein degradation [363]. Moreover, denervation increases urinary
3MH, indicating activation of myofibril catabolism [364]. The rate of muscle
loss in denervated muscle is halved by the proteasome inhibitor bortezomib [365].
Denervation stimulates persistently proteasome enzymatic activity [366], and
upregulates all the ubiquitin-proteasome pathway components, including
ubiquitin, the E3 ligases MuRF-1 and MAFbx, and the proteasome subunit A1 [367,
225]. The upregulation of the E3 ligases is induced by multiple independent
transcription factors, including myogenin and the Foxo class [368, 369, 370,
371].</p>

<p class=MsoNormal>The temporal evolution of muscle loss following denervation
comprises two stages. In the first few days of denervation, the atrophic
response is correlated with myogenin upregulation by histone deacetylase (HDAC)
4 [372]. After the first week, Foxo activation is attributed to the
downregulation of its negative regulator, Akt [370, 373].</p>

<p class=MsoNormal>Because the mTOR inhibitor rapamycin prevents fiber
hypertrophy that normally follows in vivo injections with a plasmid coding
constitutively active Akt [373], the scientific community assumed, since the
beginning of century, that atrophy is a mere reverse of hypertrophy. Commonly,
reviews still state that atrophy, including denervation, requires Akt
inactivation, followed by loss of downstream mTOR-mediated effects (for
example, [374, 375]). Recent studies contradicted this paradigm. In 2013, Quy
and colleagues found that denervation increased Thr 389 phosphorylation and
catalytic activity of p70-S6K, indicating that denervation causes in fact
activation of mTORC1 [376]. In 2014, Tang and colleagues proved that rapamycin,
an inhibitor of mTORC1, which lacks intrinsic anabolic properties, abolishes
denervation-induced loss of muscle mass [370].</p>

<p class=MsoNormal>These experiments prove that mTORC1 should be activated for
denervation-associated muscle atrophy to proceed in its later stage. Tang
showed that denervation causes phosphorylation of insulin receptor substrate
(IRS) 1, proving that, in denervation, activated mTORC1 inhibits Akt through a
p70-S6K - IRS 1-mediated negative feedback loop. Quy found that mTORC1
activation is lost upon proteasome inhibition with bortezomib. One can
hypothesize the existence of an mTOR negative regulator, which is specifically
targeted by the ubiquitin-proteasome system during denervation. Alternatively,
mTORC1 activation may be caused by the preceding upregulation of proteasome,
which is stimulating BCAA release. The mechanism by which mTORC1 is stimulated
by denervation remains to be established, but its consequences, including
activation of p70-S6K, phosphorylation of IRS1, inhibition of Akt, and
increased Foxo activity, appear well-supported by evidence.</p>

<p class=MsoNormal>Establishing the role for mTORC1 in denervation-induced loss
of muscle mass is crucial. In the conceptual frame before Quy and Tang
experiments, mTORC1 inhibition was intuitively attractive, as it would
simultaneously downregulate protein synthesis, and remove a restriction on
autophagy. In particular, denervation-induced autophagy appealed to the muscle
biologists of the 2000s. For example, one group claimed that the lysosome
inhibitor chloroquine prevents denervation-induced muscle loss [377]. Others
showed that denervation upregulates lysosome enzyme cathepsin L [378]. A third
group claimed that denervation causes buildup of the autophagosome marker,
microtubule-associated protein 1 light chain 3 (LC3) [379]. These studies were
published even as others clearly refuted the role of autophagy in denervation.
The lysosome inhibitors leupeptin, methylamine, and E64-c have minimal effects
on the release of free tyrosine from denervated muscle [364]. Transgenic mice
expressing LC3 fused with green fluorescent protein (GFP) exhibit a loss of
autophagosomes in denervated muscles [376]. The example of denervation
illustrates the barriers in the study of autophagy, a challenge equally present
in GAML study.</p>

<p class=MsoNormal>A similar debate surrounds protein synthesis regulation in
denervation. In Goldbergs 1969 experiment, the specific activity of the
remaining muscle protein in denervated limbs was essentially the same as in
control limbs. He conjectured that increased or even unchanged protein
synthesis rates would have caused a reduction in specific activity, as new,
tracer-free protein would build up. By exclusion, Goldberg concluded that
denervation causes protein synthesis decreases, thus opening a debate that is
still unsettled. However, Goldbergs observation could have been explained in
other ways. For example, specific activity may be preserved if tracer amino
acids increasingly released due to denervation would not freely diffuse out of
muscle, but would be preferentially reused in new protein. More recent
functional studies, including some from Goldbergs group, found that denervation
stimulates translation [380, 376, 366, 381, 364]. Unlike the 1969 study,
contemporary studies measured protein synthesis rate directly and over shorter
time intervals (hours, rather than weeks). Both Tang and Quy found that
denervation causes increased phosphorylation of 4E-BP, thus potentially causing
protein synthesis upregulation. A sizable number of articles show that protein
synthesis is either increased, decreased, or unchanged by denervation.</p>

<p class=MsoNormal>Given that rapamycin has essentially no effect on adult
muscle mass, it may be that mTOR is not the crucial effector of
denervation-induced muscle atrophy once thought. Current evidence suggests that
it is activated in late stages of denervation, with inconsequential, or perhaps
compensatory, downstream activation of protein synthesis and inhibition of
autophagy. In contrast, denervation-induced muscle loss is correlated
systematically, and requires, the activation of ubiquitin-proteasome system.
The predicaments of denervation research epitomize similar dilemmas in the
study of muscle atrophy due to other, less studied etiologies, including GAML.</p>

<h2><a name="_Toc421412256">Animal models of glucocorticoid myopathy</a></h2>

<p class=MsoNormal>In the 75 years since the discovery of iatrogenic
glucocorticoid myopathy, scientists attempted, with variable success, to
develop multiple animal models. In dogs, seven days of 0<i style='mso-bidi-font-style:
normal'><span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>.</span></i>44
mg<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>/(</span>kg
d<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>) </span>prednisone
increased nitrogen excretion [382]. In horses, the action of Dexa on glycogen
regulating pathways was replicated, but muscle mass was not measured [383]. In
cows, GAML is undetectable at macroscopic level. Any putative change in
myofibers is compensated by bovines unusually rich intramuscular adipose
component, further hypertrophied by Dexa [384]. In rabbits, four days of 1 mg<span
style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>/(</span>kg
d<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>) </span>did
not change muscle mass and reduced urinary 3MH, despite the upregulation of
some catabolic markers [385]. For large animals, cats, or dogs, practical and
humane reasons prevailed, meaning that experiments did not end with
dissections, and data about muscle mass changes are unavailable. For many of
these species, the genome was not known, and specific antibodies are not
manufactured, meaning that signaling pathways could not have been analyzed.
Especially in the early years, studies did not record most relevant outcomes,
such as muscle mass and / or force, putting into question their validity. In
conclusion, literature does not describe any effective non-rodent model of
GAML.</p>

<p class=MsoNormal>In the era of genome sequencing, studies of GAML focused on
mice and rats. The first study of mouse GAML was published in 1964 [386].
However, for a long time, rats were the preferred model. Muscle mass in mice is
smaller, making dissection harder and changes closer to detection threshold,
compared to rats. In terms of glucose metabolism, mice are more GC-resistant
than rats [387]. Mice studies became interesting with the advent of transgenic
studies, starting with the MuRF-1 and MAFbx knockouts created by Bodine and
colleagues [225]. To my knowledge, at the start of this work, there was no
published account of muscle atrophy in mouse, which showed changes in
individual muscle mass, and which stated the effective Dexa dose.</p>

<p class=MsoNormal>Myofiber-restricted knockout of GR abolishes GAML, while
having no effect on denervation atrophy [388]. In rat muscle, chronic Dexa
treatment upregulates expression of the NMJ essential component,
muscle-specific nicotinic acetylcholine receptor, and resistance to
NMJ-specific non-depolarizing muscle relaxants [389]. GAML appears associated
with an improved NMJ, excluding the role of neurons, and confirming the
phenotype that led to the myopathy designation in humans.</p>

<p class=MsoNormal>There is no evidence of satellite cell dysfunction in GAML.
In one report, Dong and colleagues hypothesize a glucocorticoid-induced
satellite cell dysfunction, but describe solely that Dexa reduces the number
of satellite cells in a post-injury regenerating muscle [390]. In conclusion,
GAML is the direct effect of Dexa on myofibers.</p>

<p class=MsoNormal>The perception that myotubes response to Dexa is a complete
model of GAML inspired many reductionist in vitro models. Many published
studies document the effect of Dexa on the mouse cell line C2C12 and the rat
cell line L6. However, these and other myogenic cell lines have significant
limitations, which may cause divergence between in vitro models and the glucocorticoid
myopathy they aim to describe. As mentioned earlier, in the case of primary
cells, experiments with Dexa are outright impossible, because primary cell
survival is GC-dependent.</p>

<p class=MsoNormal>Moreover, Dexa has hyperplastic and hypertrophic effects on
myogenic cell lines. Commonly tested doses of Dexa, in the range of tens of nM,
have been shown to synergize with IGF-I [391] and even to act directly towards
improved proliferation of L6 myoblasts [392, 393]. C2C12 fusion is more
efficient when Dexa is added to IGF-I [90].</p>

<p class=MsoNormal>Until the end of the 1990s, Dexa was a common ingredient in
myogenic culture media [394]. Even contemporary standard proliferation media,
containing 10% fetal bovine serum, provide significant and unpredictable
concentrations of GC, insulin, and IGF-I, impairing their study at
physiological concentrations. In fusing C2C12 cells, IGF-I and Dexa synergize
to amplify some Dexa catabolic signals, such as the expression of REgulated in
Development and DNA damage responses-1 (REDD1) [90]. Conversely, the synergy
with Dexa amplifies some of insulin and IGF-I effects, such as Akt
phosphorylation on Ser 473 [394]. In addition to myotubes, C2C12 may
differentiate into adipose-like or osteoblast-like cells. To avoid histological
ambiguities, this chapter will refer mainly to in vivo studies.</p>

<p class=MsoNormal>With this caveat, in vitro studies have been vital in
excluding third-party organs, such as the pancreas, from the analysis of GAML,
at the time when genome manipulations were not available. Some molecular
features of GAML have been initially described in cell culture, and confirmed
in vivo later. Fully differentiated myotubes from L6 and C2C12 cell lines lose
more than a quarter of their diameter when treated with 100 nM [395]. Evidence
from in vitro studies on myogenic cell lines will be used in this chapter, but
will be limited to studies where multi-nucleate myotubes were obtained and
myoblasts were depleted.</p>

<p class=MsoNormal>The effects of 7-day, 5 mg<span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>/(</span>kg d<span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>) </span>treatment on rats allow the
classification of GCs in two subsets [396]. Members of the short-acting subset,
including prednisolone and corticosterone, cause net gains in body weight,
through increased adiposity, MR-mediated water retention, and a net neutral
effect on muscle mass. Long-acting, specific GCs, such as Dexa, betamethasone,
and triamcinolone, cause loss of body weight, and an even more rapid loss of
muscle mass. The muscle mass loss is paralleled by reductions in maximal twitch
and tetanic force [397]. GAML is an organized process, lacking the microscopic
features of necrosis [398]. Although Dexa temporarily reduces food intake,
possibly through stimulation of leptin secretion [399], pair-feeding
experiments demonstrated that the GAML is not the effect of appetite changes [400,
401]. In response to Dexa, rat myofibers undergo reductions in CSA, to an
ampler degree in fast twitch fibers [402, 403]. Dexa-induced loss of muscle
mass is present, although less manifest, in female rats, possibly because, in
males, hypercortisolism is compounded by a reduction in circulating Testo levels
[402].</p>

<p class=MsoNormal>In rats, the nitrogen imbalance induced by Dexa slows down
by the third day, and is compensated around the seventh day of treatment [404,
405]. Given that later time points are marred by feedback mechanisms and by
animal mortality, almost no published experiment on rats extends past two
weeks. For an animal weighing 300 times less and aging 20 times faster than
humans, the common 5-10 days experiments should be comparable to chronic
exposure in humans. Rats appear more resistant than humans to GAML, given that
reported experiments start at about 0<i style='mso-bidi-font-style:normal'><span
style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>.</span></i>5
mg<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>/(</span>kg
d<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>) </span>Dexa,
more than twice the muscle-impairing dose in humans. Illustrating the higher
resistance to Dexa, recently published mouse experiments used even higher doses
(3 mg<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>/(</span>kg
d<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>) </span>to
10 mg<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>/(</span>kg
d<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>)</span>
[406, 407]).</p>

<p class=MsoNormal>Unless specified, the next sections refer to studies with
chronic (5-10 days) Dexa on adult (not aged) male rodents, which are the best
model from human male glucocorticoid myopathy.</p>

<h2><a name="_Toc421412257">Glucocorticoid stimulation of ubiquitin-proteasome
system</a></h2>

<p class=MsoNormal>The loss of muscle in the Dexa-treated adult rat is mainly
the result of an increase in protein degradation. The 1969 Goldberg study on
atrophy revealed that cortisone induced an even ampler upregulation of
proteolysis than denervation [363]. His comparison of fast-twitch plantaris
and slow-twitch soleus found that the latter did not exhibit lower muscle
mass, not increased proteolysis. Goldberg found that cortisone increases in
equal manner the degradation of older and newer proteins, and of myofibril and
sarcoplasmic proteins. A search begun for an undiscriminating proteolytic
machine stimulated by GC.</p>

<p class=MsoNormal>In rats receiving 0<i style='mso-bidi-font-style:normal'><span
style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>.</span></i>5
mg<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>/(</span>kg
d<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>) </span>Dexa
for six days, epitrochlearis muscle proteolysis rate increased by 50%, while
protein synthesis was essentially unchanged [400]. Dexa-stimulated proteolysis
affects the contractile apparatus, as indicated by the doubling of urinary 3-MH
output [408]. The upregulation of proteolysis occurs even when explants, rather
than animals, are treated with Dexa, suggesting that GAML does not require
extramuscular inputs [409].</p>

<p class=MsoNormal>In vivo GAML is best correlated with an upregulation of the
ubiquitin-proteasome system. The increase in proteolytic rate is unchanged when
explants are treated with the lysosome inhibitor methylamine and the lysosome /
calpain inhibitor E-64. On the other hand, the Dexa-stimulated increase in
proteolysis is abrogated when the explant is treated the proteasome inhibitor
MG132 [410], or depleted of ATP by a combination of the mitochondrial
decoupling agent dinitrophenol and the unlysable glucose homologue,
2-deoxyglucose [411]. Proteasome chymotrypsin-like catalytic activity is
doubled by Dexa [412]. Dexa upregulates proteasome subunits such as C1, C2, C4,
C5 [400, 410].</p>

<p class=MsoNormal>In cultured myotubes treated with 100 nM to 1000 nM Dexa,
the loss of diameter is reliably correlated with a 20% increase in protein
degradation rate [413, 395]. Between 78% and 95% of the Dexa-induced
proteolysis augmentation is lost, when proteasome inhibitors, such as
beta-lactone or MG-132, are co-administered [413, 414]. Demonstrating
proteasomes primacy, MG-132 has this overriding effect even co-administered as
an addition to a cocktail of lysosome and calpain inhibitors [410].
Co-administration of dinitrophenol essentially abolishes Dexa-induced
proteolysis [413]. GAML dependence on ATP reinforces the idea that
GC-stimulated proteolysis takes place in the proteasome. In contrast, lysosome
inhibitors had no effect, while E-64 has minimal effect [413].</p>

<p class=MsoNormal>In L6 myotubes, Dexa causes increased expression of the
ubiquitin gene UbC, through a putative SV40 promoter-specific 1 (Sp1) response
element [415]. In vivo, upregulation of UbC was confirmed only for acute Dexa
treatment [409] and in diabetic rats [416].</p>

<p class=MsoNormal>One of the most tempting hypotheses attributed a role to
nuclear factor kappa - light-chain enhancer of activated B cells (NF-&#954;B),
a mediator of muscle loss in conditions such as cancer cachexia (reviewed in [417])
and a regulator of multiple inflammatory genes (reviewed in [#peterson2008skeletal]).
However, the few published reports are contradictory. In L6 myotubes, Dexa
stimulates acetylation and nuclear translocation of the translational activator
p65 [418], seemingly paralleling cancer cachexia. In contradiction to such
parallels, Dexa was shown to inhibit NF-&#954;B signals by upregulating
inhibitory &#954;B&#945; (I&#954;B&#945;) [419]. Moreover, Dexas inhibition of
NF-&#954;B was shown to be necessary for proteasome subunit C3 upregulation in
the same L6 cells [420].</p>

<p class=MsoNormal>Unbiased searches in atrophying mouse muscles revealed two
upregulated genes, termed atrogenes, MAFbx and MuRF-1 [225]. Both are E3
ligases, pointing to an important role for the proteasome-ubiquitin system in
muscle atrophy. Studies on cultured myotubes confirmed that GCs induce the two
atrogenes directly, without a third-party organ mediation [421]. In contrast to
other muscle atrophy models, GAML is associated with stronger reliance on
MuRF-1 than on MAFbx. Indicating a lower amplitude and / or higher variability
in MAFbx, some unbiased searches in rat GAML failed to identify MAFbx as a
target of Dexa [422]. While genetic depletion of either atrogene leads to
muscle sparing in the denervation model [225], only MuRF-1, but not MAFbx
genetic depletion spares muscle treated with Dexa [423]. The incomplete sparing
of the MuRF-1 knockout indicates genetic redundancy. The main candidates for
supplanting MuRF-1 are homologs MuRF-2 and MuRF-3, rather than MAFbx.</p>

<p class=MsoNormal>One distinction between the two atrogenes is set by their
promoters. MuRF-1 promoter includes a GC response element, which MAFbx promoter
appears to lack [424, 425]. In contrast, MAFbx promoter is activated by
myogenin [369], a MRF involved in muscle regeneration. In C2C12 cells, MAFbx is
upregulated by differentiation [426]. MAFbx is induced in muscle during
hypertrophy from reloading [427]. Moreover, MAFbx knockout abolishes
hypertrophy of loading [428]. Denervation leads to a stronger myogenin
upregulation compared to GAML [429]. It is possible that GAML represses
regeneration to a higher degree, thus leading to a less ample activation of the
myogenin - MAFbx axis.</p>

<p class=MsoNormal>Substrate specificity is also distinguishing the two
ligases. The only two known MAFbx ubiquitination substrates are MyoD and the
eukaryotic initiation factor 3f (eIF3-f), identified in C2C12 ([430, 431],
reviewed in [107]). This suggests that MAFbx may be an initiator, neutralizing
a few specific muscle-protecting factors, belonging to multiple metabolic
pathways. Because MAFbx neutralizes a translation initiation factor, it has
been suggested that MAFbx relative importance is augmented in conditions where
muscle loss relies more on loss of protein synthesis.</p>

<p class=MsoNormal>Two-yeast hybrid experiments revealed two classes of
putative MuRF-1 substrates [432]. The first includes structural myofibrilar
proteins, such as titin, nebulin, troponin-I, troponin-T, myosin light chain 2.
The second class comprises components of ATP-generating machinery, including
NADH dehydrogenase 1a, NADH-ubiquinone oxidoreductase, pyruvate dehydrogenase,
and ATP synthase beta-subunit. In transgenic mouse overexpressing MuRF-1,
proteins from the second class were downregulated [433]. In vitro, MuRF-1
ubiquitinates myosin heavy chains [434] and actin [435]. MuRF-1 is therefore a
more plausible effector of bulk protein degradation, as it is a better fit for
the undiscriminating proteolytic machine postulated by Goldberg.</p>

<p class=MsoNormal>The mechanisms by which MuRF-1 is induced are still under
study. Transgenic mice with a defective GR still exhibit upregulated atrogenes
in denervation and fasting, thus demonstrating the multiplicity of
atrogene-stimulating mechanisms. A sizable body of indirect evidence suggests
that the main positive regulators of atrogenes in GAML are FOXO transcription
factors. Foxo transcripts are reliably upregulated by Dexa in muscle. In
addition, Dexa may inhibit their kinase, Akt, thus protecting them from
ubiquitination and degradation. Experimentally, atrogenes are also modulated by
myostatin, through SMAD3 transcription factor, and by AMPK. The E3 ligase
TRAF6, whose expression is increased by Dexa, appears necessary for GAML and
atrogene upregulation [436].</p>

<p class=MsoNormal>In cultured cells, Dexa upregulates the nuclear cofactor
p300 [437]. Dexa also upregulates acetylation and nuclear translocation of
C/EBP &#946;, in a p300 dependent-manner [418]. Because atrogenes promoters
contain putative binding sites for C/EBP transcription factors, p300 was
hypothesized to be yet another mechanism by which GCs stimulate atrogenes.
Interestingly, p300 is a histone acetyltransferase (HAT). Dexa increases HAT
activity and reduces HDAC activity in muscle [438]. Because HDAC 3 and 6 are
repressed by Dexa and because trichostatin A, an HDAC inhibitor, upregulates
MAFbx, it has been hypothesized that Dexa acts by increased histone
acetylation. The importance of histone acetylation in in vivo GAML and the
specific genes affected by epigenetic mechanisms are still to be determined. Therefore,
the hypothesis that Dexa-induced histone acetylation stimulates MuRF-1 remains
a speculation.</p>

<p class=MsoNormal>In conclusion, explant models suggest that GAML is, to a
wide extend, but not exclusively, the result of upregulation of the
proteasome-ubiquitin system. The absence of specific anti-MAFbx and anti-MuRF-1
antibodies prevents the study of their protein flux and their intracellular localization
[107]. Next sections will describe the various pathways that are hypothesized
to upregulate the ubiquitin-proteasome system. Each of them has
proteasome-unrelated side effects, including activation of other proteolytic
and anti-translational pathways.</p>

<h2><a name="_Toc421412258">Glucocorticoid-induced loss of sensitivity on the
IRS - Akt axis</a></h2>

<p class=MsoNormal>Surprisingly, the most comprehensive account on GC-induced
changes on protein metabolic regulation comes from the study of glucose
metabolism changes. The latter is more easily measured in muscle, because it comprises
only catabolic, but no anabolic, components (detailed in the dedicated section).</p>

<p class=MsoNormal>Dexa causes systemic insulin resistance, manifested as
uncompensated hyperglycemia [401]. Dexa induces concerted catabolic changes,
which eventually converge to hyperglycemia, and consequent hyperinsulinemia.
Together, these yield a higher index of homeostatic model assessment - insulin
resistance (HOMA-IR) [439]. However, Dexa overrides insulin to reduce muscle
glucose uptake [440, 320, 441]. Dexa does not alter expression and activity of
hexokinase, and of glucose transporter (GLUT) 4 expression [442], but inhibits
GLUT4 recruitment to the cell membrane [440, 442]. Because translocation of
GLUT4 in response to insulin is critically dependent on Akt [443], its
suppression by Dexa is strong evidence for Dexa-induced Akt inactivation.
Dexa-induced inhibition of Akt is surprising, because it occurs during
hyperinsulinemia, which causes Akt activation in normal muscle. The
disconnection between the extracellular hyperinsulinemia and the intracellular
signaling is achieved by Dexa in a multi-step process.</p>

<p class=MsoNormal>The end result of Dexa interference, inhibition of Akt, was
the subject of debates in the 2000s. Proving Akt inactivation by Dexa is a
complex endeavor, due to the extremely low Akt activation in basal state.
Insulin or IGF-I, in concentrations close to the physiological levels, increase
glucose uptake about 10-fold in muscle explants [440]. The fact that there is
significant leeway for amplification of anabolic pathways demonstrates that, at
basal state, muscle Akt-mediated signals are far below maximum. In immunoblots,
active, that is, phosphorylated Akt is often below detection threshold in basal
state [400]. Unsurprisingly, observations on basal state muscle frequently
failed to identify further repression of Akt by Dexa. Many studies
misinterpreted this failure to detect as an actual absence of effect.</p>

<p class=MsoNormal>The opposite situation may also be true. Experimental
studies on the Akt pathway are conceptually challenged by its extremely low
basal activity. In a molecular biology experiment, in order to prove causality
by inhibition, one must reverse the inhibition, and observe that the final
effect is lost. In the case of a putative inhibition of Akt by Dexa, genetic
reversal of inhibition will never be able to merely reverse the inhibition.
Most often, overexpression of IGF-I, IGF-1R, Akt, or other mediators on this
pathway overcompensates Dexas effect, thus causes overriding Akt activation
far above the basal level. A long series of reports from overexpression studies
mistakenly concluded that Akt pathway is the only mechanism by which Dexa
causes atrophy, whereas in fact, they were describing non-specific hypertrophy.</p>

<p class=MsoNormal>Dexa interference on the Akt pathway begins at IRS 1. Dexa
treatment does not change basal levels of autophosphorylated insulin receptor
in absolute or stoichiometric terms [439, 444, 445]. Similarly, Dexa alone does
not appear to change the basal level of phosphorylated IRS. However, in response
to insulin, mice treated for 5 days with 1 mg<span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>/(</span>kg d<span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>) </span>Dexa exhibit only a third of the
IRS 1 and 2 phosphorylation, compared to untreated animals [446]. The mechanism
by which Dexa interferes with IRS 1 is unknown. Based on observational studies,
the interference was attributed to an improved protection of IRS by calmodulin
[447], to an inhibitory phosphorylation on another residue, possibly by PKC [448,
445], or to the upregulated phosphatase C1-Ten [449]. In C2C12 myotubes, Dexa
may downregulate IRS through caveolin repression [407].</p>

<p class=MsoNormal>The notion that Dexa interferes with IGF-I signaling
suggested that GAML also attenuates downstream, IRS-independent, MAPK response
(reviewed in [450]). Activated receptors for growth factors, such as IGF-1R,
phosphorylate and assemble a transduction complex, including Src homology 2
domain containing (Shc) and Growth factor receptor-bound protein 2 (Grb2). Dexa
reduces insulins ability to cause Shc phosphorylation and association with
Grb2 [451]. Paralleling the findings in sugar metabolism, Dexa has no
detectable effect in basal state. Further downstream, the effect of Dexa wanes.
The canonical MAPK pathway is activated when the complex including Shc and Grb2
binds and activates Son of sevenless homolog (Sos), the GTPase exchange factor
for Ras. Ras-GTP activates a cascade of kinases, including Raf, Mek, and Erk,
eventually leading to cell proliferation. A report describes that Dexa
upregulates phosphorylation of Mek and Erk in diabetic rats [416]. Others
describe increased Erk phosphorylation in L6 myotubes during acute Dexa [452].
No reports describe such changes in wild-type healthy animals. Measurements of
changes in activation of another MAPK, p38, are contradictory [453, 454].
Together with the limited role of hyperplasia in adult muscle, available
evidence suggests that MAPK cascades do not mediate GAML. Moreover, absence of
sizable changes in the MAPK cascades reinforces the idea that insulin and IGF-I
signaling is extinguished by Dexa at IRS, rather than receptor, level.</p>

<p class=MsoNormal>Next interference by Dexa occurs at the level of PI3K, whose
recruitment to the membrane complex containing insulin receptor and IRS1 is
hindered [439, 446]. One PI3K-inhibiting mechanism is based on transcriptional
effects, with Dexa upregulating transcription of the PI3K regulatory subunit
p85 &#945; [422]. It was hypothesized that p85 &#945; sequesters PI3K catalytic
subunit, p110, in the cytosol, and away from the IRS-containing membrane
complex [439, 455, 456]. Another putative mechanism contends that activated GR
binds p85 in a competitive manner, thus displacing it from IRS1 [457]. This
non-transcriptional effect has not been fully explored in GAML in vivo, but is
supported by the unusual persistence of IRS1-PI3K complexes during diabetes in
GR knockout mice muscle [457].</p>

<p class=MsoNormal>The next step in the Akt pathway is the formation of a
membrane complex comprising the receptor, IRS, p85, and p110 (reviewed in [458]).
The latter acts on the membrane lipids to synthesize 3-phosphoinositides. In
muscle cell lines treated with Dexa in vitro, the depletion of membrane-bound
PI3K and of 3-phosphoinositides leads to lower activation of
3-phosphoinositide-dependent protein kinase 1 (PDK1). In turn, the reduction in
PDK1 lowers the phosphorylation on its substrate, Thr 308 on the activation
loop of Akt. While Thr 308 phosphorylation is not detectable in rat muscle in
basal state, its sensitivity to insulin is depressed by Dexa [459].</p>

<p class=MsoNormal>Akt has another important phosphorylation site at Ser 473.
Historically, Ser 473 phosphorylation was seen as a non-limiting step towards
Akt activation, occurring automatically after Thr 308 phosphorylation. In GAML,
Ser 473 appears to closely mimic Thr 308, with Dexa lowering insulins ability
to upregulate Ser 473 phosphorylation [459, 446, 460, 388]. The introduction of
phospho-specific antibodies brought about the first distinction between Thr 308
and Ser 473 phosphorylation. The latter appears phosphorylated to a detectable
degree even at basal state. In vivo, Dexa was shown to also repress Ser 473
phosphorylation in the basal state [461, 462, 463].</p>

<p class=MsoNormal>A second distinction between Thr 308 and Ser 473 is the
difference in stimuli and enzymes causing their phosphorylation. Ser 473
phosphorylation is nominally stimulated by growth factors, through mTOR complex
2, and through little-known, mTOR-independent, 3-phosphoinositide-stimulated
mechanisms [464]. Extracellular stimuli that activate Thr 308 are expected to
cause 3-phosphoinositide synthesis, and simultaneous Ser 473 activation.
However, Ser 473 and Thr 308 phosphorylation may occur separately (see examples
in the next section). In this case, it may be the case that Dexa impedes Ser
473 phosphorylation through another, yet undiscovered, mechanism.</p>

<p class=MsoNormal>The interdependence between Ser 473 and Thr 308 is
illustrated by the fact that non-mutagenic in vivo experiments rarely describe
Akt activation without phosphorylation at both residues (reviewed in [465]). In
vivo, the scarcity of segregation reports leads to lack of knowledge regarding
potential independent specializations for the two sites. However, in vitro
manipulations indicate that the two sites synergize for maximal Akt activation
[466]. Mutagenic abolition of Ser 473 phosphorylation abrogates Akt activity on
substrates belonging to the Foxo class, but does not change Akt ability to
phosphorylate tuberin (Tuberous Sclerosis Complex 2; TSC2) and glycogen
synthase kinase 3 (GSK3) [467]. Such changes in substrate imply that Ser 473
controls specificity. Because Foxo is at the core of atrogene regulation in
muscle atrophy, Ser 473 status has been of greater interest for GAML studies.</p>

<p class=MsoNormal>More evidence for Dexa-induced inhibition of Akt comes from
its substrates, such as Ser 9 on GSK3-&#946;. Chronic Dexa reduces GSK3-&#946;
phosphorylation at Ser 9, thus leading to GSK3-&#946; activation [459]. The
activation of GSK3-&#946; in GAML is confirmed by increased phosphorylation of
its substrate glycogen synthase at Ser 645, 649, 653, 657, and decreases
intramuscular glycogen synthesis rate [468, 469, 459]. Among the many substrates
of GSK3-&#946;, the subunit &#949; of eukaryotic initiation factor 2B (eIF2B)
may mediate an anti-anabolic effect [470]. In cultured myotubes, GSK3-&#946;
knockdown reduces Dexa ability to upregulate MAFbx [471]. While inactivation of
GSK3-&#946; is typically attributed to latent Akt inhibition, the Ser 9 site is
also a target for ribosomal protein S6 kinase, 90 kDa (p90-RSK), serum and
glucocorticoid-inducible kinase-like kinase (SGKL), and p70-S6K [472, 473,
474]. The role of GSK3-&#946; in muscle atrophy was briefly the subject of
research at the turn of the century, in the context of a hypothesized atrophic
mechanism involving calcineurin and nuclear factor of activated T-cells (NFAT).
Since then, evidence that calcineurin is not involved in muscle anabolism [475]
led to an unjustified neglect of GSK3-&#946;.</p>

<p class=MsoNormal>In conclusion, Dexa interferes with IRS / Akt pathway in
multiple ways, thus inhibiting glucose uptake. The inhibition of this pathway is
difficult to detect in basal conditions, but consistently observed during challenge
tests with insulin or IGF-I. Because the model of GAML centered on Akt is
derived from experiments with acute states, cell models, and intrinsic anabolic
interventions, it is perfectible. The best-studied downstream targets of Akt
are mTOR and FOXO.</p>

<h2><a name="_Toc421412259">Glucocorticoid inhibition of mTOR</a></h2>

<p class=MsoNormal>One of the most effective pathways for Akt to induce its
anabolic program is mTORC1 (reviewed in [476, 477, 478]). The latters modulation
in acute Dexa administration is proven by reduced phosphorylation in its
substrates, 4E-BP (Thr 37/46) and p70-S6K (Thr 389) [479]. More commonly, 4E-BP
and p70-S6K phosphorylation are reported to behave in a manner similar to Akt
activation, with no detectable Dexa effect on their basal phosphorylation, and
a Dexa-induced loss of sensitivity to insulin [480, 441].</p>

<p class=MsoNormal>The mechanism by which mTOR is modulated by Dexa is not
elucidated yet. Cell models established that activated Akt phosphorylates and
inhibits proline-rich Akt substrate of 40-kDa (PRAS40), a negative regulator of
mTORC1 [481]. The same cell models showed that activated Akt phosphorylates
TSC2, thus causing its sequestration with a cytosol partner, 14-3-3, and away
from its transmembrane partner, hamartin (Tuberous Sclerosis Complex 1; TSC1) [482].
The destruction of TSC1-TSC2 complexes relieves the negative regulation from
Rheb, a small GTPase, which can induce activation of mTORC1. Therefore, in
theory, Dexa-induced repression of Akt should inhibit mTORC1 in two distinct
ways. In practice, there is little evidence for TSC2 or PRAS40 based mechanisms
in GAML in vivo.</p>

<p class=MsoNormal>The scarcity of evidence for PRAS40 or TSC2 mediation
suggested that other mechanisms might lead to mTORC1 inactivation in GAML.
Moreover, an Akt-mediated Dexa effect on mTORC1 would be subtle, with sizable
amplitude only during hyperinsulinemia. Alternative Akt-independent pathways
have been hypothesized. A well-studied negative regulator of mTOR is the energy
sensor AMPK [483, 484]. However, Dexa inhibits muscle AMPK phosphorylation and
activity [460, 485], probably as a consequence of intramuscular ATP
upregulation [486]. The surge in intramuscular ATP is caused by Dexa-induced
improvements in mitochondrial function, exemplified by upregulation of
cytochrome c oxidase expression and activity [487] and of Na(+)-K(+)-ATPase
expression and maximal activity [488]. Chronic Dexa or corticosterone do not
alter Liver Kinase B1 (LKB1) [460, 489], the main AMPK kinase, indicating that
ATP availability causes AMPK inhibition by another, unknown mediator. In
conclusion, in GAML, mTOR suppression does not employ AMPK. Moreover, GAML does
not involve mitochondrial dysfunction.</p>

<p class=MsoNormal>A third putative mTORC1 inactivating mechanism is centered
on the stress sensor REDD1. Dexa upregulates REDD1 expression in muscle [422]. Demonstrating
its key role, genetic depletion of REDD1 abolishes GAML and Dexa-induced
myotube atrophy [490, 491]. In cell culture, REDD1 interferes with 14-3-3 in
order to release TSC2, restore TSC1-TSC2 complexes, and eventually inhibit mTORC1
[492]. Moreover, REDD1 is in epistasis with AMPK [493], at times overriding its
action on mTORC1. Interestingly, a REDD1-based mechanism could explain the few
observations on mTORC1 changes just as well as an Akt-centered model would.</p>

<p class=MsoNormal>Finally, limited evidence suggests that Dexa impedes mTORC1
ability to act on its substrate p70-S6K, through the depletion of a putative
scaffold, eIF3f [494].</p>

<p class=MsoNormal>Another way to gauge the role of mTORC1 is to use its
inhibitor, rapamycin. One group reported that the Dexa-induced decrement in
protein synthesis is unmodified, in absolute terms, upon rapamycin
co-administration [441], suggesting that mTOR signaling is dispensable. In a
C2C12 microarray study, interference of IGF-I transcriptional program with PI3K
inhibitor was virtually identical to the interference induced by rapamycin [495],
indicating that, on the contrary, mTOR is indispensable for PI3K effects. Most
likely, both hypotheses are based on reductionist models that do not reflect
true in vivo phenomena.</p>

<p class=MsoNormal>Discovery of novel mTORC1 substrates such as UNC-51-like
kinase 1 (ULK1) [496] led to speculations about additional contributions to the
GAML phenotype from autophagy. In vivo evidence for mTOR-mediated autophagy
upregulation in GAML is indirect and inconclusive (discussed in a later
section). Similarly, Dexa-induced mTORC1 repression is expected to lead to
simultaneous downregulation of protein synthesis via 4E-BP (discussed later).</p>

<p class=MsoNormal>A recent study on acute Dexa [491] opens the perspective for
a paradigm-changing situation. It provides the most complete mechanistic
explanation for Dexa-induced inhibition of mTORC1. In wild-type mouse muscle,
Britto and colleagues found that acute Dexa caused mTORC1 inhibition, as
demonstrated by lower phosphorylation of 4E-BP1. While Dexa reduced
phosphorylation of PRAS40, it unexpectedly led to hyperphosphorylation of the
other Akt substrate, TSC2. These mice also exhibited simultaneous
hyperphosphorylation at Ser 473 and hypophosphorylation at Thr 308, thus
providing a rare evidence for Akt specificity switching. Britto concluded that
Dexa-induced mTORC1 inactivation is mediated by hypophosphorylation of PRAS40,
which is in turn caused by hypophosphorylation of Akt at Thr 308. Britto found
more evidence for the REDD1 - Akt - PRAS40 axis in the REDD1 knockout mice,
which are resistant to chronic Dexa. In these mice, acute Dexa fails to induce
hypophosphorylation on PRAS40, and on Thr 308 of Akt.</p>

<p class=MsoNormal>Britto's model remains beset by incompleteness. In this
report, acute Dexa failed to upregulate protein degradation, suggesting its
extrapolation to chronic GAML may be debatable. Britto also speculated that Akt
Ser 473 hyperphosphorylation is caused by a feedback loop responding to mTORC1
inhibition, a rather unlikely occurrence after only 5 hours from oral
administration. The mechanism by which REDD1 inhibits Akt activity on PRAS40
remains unknown. Studies on transformed cells support the hypothesis that REDD1
impairs Akt Thr 308 phosphorylation, while disagreeing on molecular mechanisms ([497];
reviewed in [498]).</p>

<p class=MsoNormal>The hypothesis that REDD1 suppresses Akt and mTORC1 is very
attractive, because, in contrast to IRS1, REDD1 would be an active and
permanent repressor. The mechanism by which Dexa stimulates REDD1 remains to be
found. In neurons, the most robust inducer of REDD1 is hypoxia, through HIF
transcription factors [498]. In contrast, in muscle, Dexa downregulates VEGF
[499], a downstream effector of HIF (described in the section on
vascularization). This suggests that Dexa causes REDD1 upregulation independent
of HIF1a and of hypoxia. Other putative positive regulators of REDD1 include
ATF4 and NFAT, discussed in other sections of this chapter.</p>

<p class=MsoNormal>While it is certain that GAML is correlated with mTORC1
downregulation, it is still unclear how mTORC1 repression is achieved, and what
is its relative importance. Based on the published evidence, the recent change
of paradigm, which placed p70-S6K at the forefront of denervation atrophy,
appears unlikely in GAML. For now, our understanding of GAML places Akt upstream
of mTORC1. Better transgenic models, a deeper understanding of mTOR pathway,
and more in vitro / recombinant experiments are required for a definitive
conclusion.</p>

<h2><a name="_Toc421412260">Glucocorticoid activation of Foxo transcriptional
program</a></h2>

<p class=MsoNormal>The evidence for the role of Foxo in GAML is not as direct
and compelling as that gathered in denervation atrophy. Given the partial
redundancy between the three regulatable Foxo transcription factors, only a
triple knockout will give the true measure of their relative importance.
Nevertheless, an impressive body of indirect evidence supports their
involvement in GAML.</p>

<p class=MsoNormal>The importance of Foxo transcription factors is supported intuitively
by their role as integrators of multiple atrophy signaling pathways. Multiple
mechanisms converge to induce Foxo upregulation in GAML. First, chronic Dexa
doubles Foxo expression [422]. Foxo1 promoter contains a GR response element [500].
In C2C12 myotubes, the response is biphasic, combining a short-lived ample and
rapid increase, with a gentler long-term augmentation [426]. Foxo promoters
contain GR-binding sites [501]. In vitro, Foxo induction by GR is facilitated
by the histone acetyl transferases p300 and CREB-binding protein, which are
independently upregulated by Dexa [438]. Consequently, GR knockout reduces
expression of FOXO1 and FOXO3a in muscle [424].</p>

<p class=MsoNormal>Second, Foxo transcription factors are thought to be
potentiated by Dexa through post-translational means involving the
earlier-described Akt pathway (reviewed in [502]). When active, Akt
phosphorylates Foxo1 at Tyr 32 and Ser 253, thus creating binding sites for
14-3-3. Phosphorylated Foxo transcription factors are exported from the nucleus,
and eventually marked for ubiquitin-proteasome-mediated degradation.
Intuitively, Dexa-induced impairment of Akt is expected to contribute to an
increase in Foxo activity in GAML. Finding evidence for this mechanism has been
challenging. In C2C12 myotubes, the expected Foxo hypophosphorylation in
response to Dexa has been frequently reported [374, 503]. In vivo, evidence for
Dexa-induced Foxo hypophosphorylation is limited to a few experiments,
performed in unusual conditions, such as diabetes [504, 461, 505]. Given that
phosphorylated Foxo is degraded, the ability to observe and quantify it is
limited.</p>

<p class=MsoNormal>Third, PGC nuclear cofactors may facilitate the Dexa-induced
Foxo surge. Loss of sensitivity to insulin causes PGC-1 repression in muscle [506].
In particular, Dexa represses muscle PGC-1&#945; [453, 505] and PGC-1&#946; [507].
In cultured myotubes, PGC-1&#946; overexpression and knockdown cause changes in
the reverse direction for Foxo3a and atrogenes mRNA. Because PGC-1&#945;
overexpression drives conversion of fast to slow twitch fibers [343], it has
been speculated that differences in PGC-1&#945; levels make different types of
muscle fiber more or less sensitive to Dexa [375]. A whole higher level of
regulation, centered on PGC-1&#945; splicing, is yet to be studied. For example,
isoform 1, and not 4, of PGC-1&#945; is correlated with muscle hypertrophy [508].</p>

<p class=MsoNormal>Fourth, indirect evidence links Foxo1 to PPAR&#946;/&#948;.
Dexa stimulates simultaneously PPAR&#946;/&#948; DNA binding and Foxo1
acetylation [509]. PPAR&#946;/&#948; inhibition reduces GAML and, at the same
time, prevents Dexa-stimulated acetylation of Foxo1. While the direct effects
of this post-transcriptional modification is not elucidated (reviewed in [510,
511]), it was speculated that PPAR&#946;/&#948; changes induce physiologically
relevant alterations in Foxo1.</p>

<p class=MsoNormal>Finally, the microRNA miR-182, whose expression is inhibited
by Dexa, is a negative regulator of Foxo3 [512]. Other mechanisms, such as
AMPK, have been hypothesized, based on the latters ability to upregulate
atrogenes.</p>

<p class=MsoNormal>The net result of these mechanisms is that Dexa treatments
upregulates nuclear Foxo [453]. More convincing evidence towards Foxo
activation comes from its downstream effects. For example, tens of reports
describe how Dexa upregulates glutamine synthetase expression and activity [513].
Glutamine synthetase promoter contains a FOXO response element. Dexa-induced
expression of muscle glutamine synthetase is absent in Foxo1 knockout [514].</p>

<p class=MsoNormal>Manipulations of Foxo have supported their role in GAML.
Transfection with dominant negative Foxo3A partially prevents diameter
reduction in disuse of rat soleus and Dexa-treated C2C12 myotubes [503, 515].</p>

<p class=MsoNormal>Among the Foxo-induced genes, a special importance was given
to the E3 ligases associated with muscle loss, MAFbx and MuRF-1 [421]. Both
atrogenes contain FOXO-binding regions in their promoter [503, 516, 424]. These
Foxo-responsive elements are in close proximity of SMAD3-binding elements, in a
shared response element, which facilitates synergistic interactions between the
two classes of transcription factors [517]. MuRF-1 promoter facilitates another
synergistic interaction, between FOXO1 and GR [424]. A positive feedback loop
links MuRF-1 and FOXO1, as indicated by downregulation of FOXO1 in late GAML in
the MuRF-1 knockout [406].</p>

<p class=MsoNormal>In both atrogenes promoter, a Klf15 response element is
located, near the FOXO binding site [518]. Klf15 is a direct transcriptional
target of GR, and interferes with mTOR signaling. A gene network is centered on
Klf15, which upregulates expression of FOXO transcription factors, and
synergizes with them to upregulate atrogenes. Overall, atrogenes appear to be
under a strong control of Foxo, favored by concomitant activation of
synergistic factors. Dominant negative Foxo3A transfection in rat soleus leads
to loss of atrogene upregulation [519]. In cultured myotubes, transfection of
constitutively active FOXO3a upregulates MAFbx [503], while knocking down FOXO1
causes a reduction in the atrogene response to GC [520].</p>

<p class=MsoNormal>A majority of the effectors described in this chapter appear
to be under the control of Foxo pathway. In addition to atrogenes, Foxo targets
include 4E-BP1, cathepsin L, and another effector of denervation atrophy,
Growth Arrest and DNA Damage 45 (Gadd45) [521].</p>

<h2><a name="_Toc421412261">Glucocorticoid activation of myostatin</a></h2>

<p class=MsoNormal>In rodents, Dexa upregulates myostatin, a strong negative
regulator of muscle mass [522]. In myostatin knockout mice, Dexa induces most
of its transcriptional program, including modulations of IGF-I, MuRF-1, MAFbx,
FOXO3A, but Dexa-induced muscle loss does not occur [412]. These findings
suggest that myostatin is an important mediator of Dexa.</p>

<p class=MsoNormal>Myostatins promoter contains GR response element [522], a
FOXO responsive element [523], and a CCAAT sequence [524], all known to be
stimulated by Dexa. Myostatin expression is also upregulated by the histone
methyltransferase SMYD 3, which in turn is upregulated in muscle by Dexa [525].
The stability of the myostatin transcript is improved by Dexa-exerted
repression of its negative regulators, miR-27 [526].</p>

<p class=MsoNormal>Glutamine supplementation reduces GAML and myostatin
expression in muscle [527]. This finding suggests that, in the context of GAML,
myostatin may double as a nutrient sensor.</p>

<p class=MsoNormal>Myostatins effects are manifold, and not completely
understood. While myostatin inhibition in utero leads to doubling of muscle
mass in adult animals [223], its overexpression in adult animals causes a more
moderate effect [528]. This split in action indicates that myostatin modulates
both hyperplasia- and hypertrophy-based pathways of muscle growth. In explanted
adult mouse myofibers, where proliferation has been minimized, expression of a
dominant negative form of activin A receptor, type IIB (ActRIIB), the receptor
for myostatin, causes an increase in CSA, which is halved by rapamycin [529].</p>

<p class=MsoNormal>Therefore, proliferation-independent mechanisms of
myostatin-induced atrophy may include both mTOR-dependent and -independent
pathways. The extensive, multifactorial action of myostatin on muscle suggests
that it may override any atrophic stimulus, in non-specific ways.</p>

<p class=MsoNormal>A series of experiments describe Akt inhibition in response
to myostatin treatments. In vivo electroporation with myostatin-encoding
plasmids led to 10% loss in tibialis anterior mass in the transfected muscle,
in the absence of any changes at the level of atrogenes [530]. The atrophy was
associated with loss of phosphorylation on TSC2 and p70-S6K, suggesting that
Akt was inhibited, and that myostatin affected protein metabolism. However, in
regenerating, scarred, electroporated muscle, the number of proliferating cells
is likely larger than in normal muscle, suggesting that myostatin might have
acted through proliferative rather than anabolic means. This report is
consistent with the well-documented myostatin-induced impairment of muscle
regeneration [531, 532]. Repression of Akt in proliferating myoblasts is not
expected to mediate GAML.</p>

<p class=MsoNormal>Another study describes Akt inhibition in human myotubes
differentiated from cultured myoblasts. In this system, myostatin treatments
lead to reductions in diameter and atrogene downregulation [533]. In contrast,
GAML is characterized by an upregulation of atrogenes, possibly facilitated by
Akt inhibition. The authors of this study pinpoint the myostatin-induced Akt
inhibition to changes in proliferating myoblasts. In conclusion, there is no
evidence for adult GAML mediation through a myostatin - Akt axis.</p>

<p class=MsoNormal>Myostatin-induced or -associated models of atrophy do not
upregulate protein degradation. For example, microgravity atrophy is associated
myostatin upregulation, but no changes in 3MH excretion [534]. This contrasts
again with GAML, which strongly relies on upregulation of protein degradation.</p>

<p class=MsoNormal>Myostatin is particularly adept at modulating the fusion of
myoblast to myotubes [535]. Myostatins action appears more relevant for
processes where myoblasts or satellite cells are involved, such as muscle
development and regeneration (reviewed in [536, 537]). However, normal adult
muscle maintenance is more dependent on protein accretion than on satellite
cells. In adult GAML, loss of satellite cells regenerative action may play a
minor role, at most.</p>

<p class=MsoNormal>Myostatins relative importance for GAML remains
incompletely explored. The typical experiments, using qualitative alterations
of myostatin, may override any endogenous mechanism, and yield non-specific
anti-atrophic effects.</p>

<h2><a name="_Toc421412262">Glucocorticoid modulation of protein synthesis</a></h2>

<p class=MsoNormal>Goldbergs [363] 1969 study on cortisone-induced atrophy of
rat muscle brought one more important theme for the field of GAML. In that
experiment, the specific activity, that is, the ratio between tracer and total
protein, was the same in GC-treated muscle as in control animals, despite
decreased muscle mass and decreased total tracer in the GC-treated group.
Goldberg conjectured that an equal rate of protein synthesis in the two groups
would have caused a faster dilution of the tracer in the GC-treated muscle.
Failing to find that was interpreted as evidence for decreased protein
synthesis in cortisone-treated muscle. This was an elegant way of bypassing the
denominator effect from the typical experiments, where synthesis rate would be
measured over hours, in muscles that already underwent atrophy in the prior
days. In these cases, a loss in protein synthesis rate might be underestimated
or even factored out, after normalization to a lower muscle mass.</p>

<p class=MsoNormal>As in human studies, the role of protein synthesis
modulation during chronic hypercortisolism is still debated, because chronic
Dexa effect is superimposed by acute effects. A single 20 mg<span
style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>/(</span>kg
d<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>) </span>triamcinolone
dose nearly halves incorporation of labeled precursors in rat muscle protein at
8 hours, yet has no effect after 24 hours [538]. Similar acute effects may be
expected from feeding, which causes fluctuations of insulin and possibly of the
Akt / mTOR / 4E-BP axis in muscle.</p>

<p class=MsoNormal>Variability in the time from feeding and treatment to biopsy
is a significant source of experimental noise, which must contribute to
inconsistencies in literature. For example, some of the most exhaustive studies
of protein metabolism in GAML came from Grizard laboratory. In two studies,
they found that protein synthesis rate was unchanged after 0<i
style='mso-bidi-font-style:normal'><span style='mso-fareast-font-family:Cambria;
mso-bidi-font-family:Cambria'>.</span></i>5 mg<span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>/(</span>kg d<span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>) </span>Dexa for 6 days, compared to
pair-fed animals, in the epitrochlearis muscle [400, 539]. In two other
studies, assaying other glycolytic muscles or quadrupling the Dexa dose, led to
observable reductions in protein FSR [540, 441].</p>

<p class=MsoNormal>In cell culture, studies of Dexa inhibition of protein
synthesis are similarly equivocal, although Dexa causes 4E-BP
hypophosphorylation directly, even in basal state [541]. In the most glaring
example, the same group, using the same methods and working on the same L6
line, found that protein synthesis is not altered by Dexa in one article, and
decreased in the next [395, 542].</p>

<p class=MsoNormal>Even when detected, the amplitude of changes in protein
synthesis in vitro [542, 543, 544] and in vivo [320] is lower than that on
protein degradation, when Dexa is given at the dose that causes muscle loss. In
contrast, doses of Dexa below the apparent EC50 are unable to change protein
degradation rate, while still lowering protein synthesis rate [327].</p>

<p class=MsoNormal>In the MuRF-1 knockout mouse, Dexa fails to change FSR [423],
suggesting a temporal order, with proteolytic processes preceding changes in
protein translation. The temporal order is suggestive of a causal mechanism,
where protein synthesis changes in GAML have a reactive, less central, nature,
compared to protein degradation.</p>

<p class=MsoNormal>While direct evidence has been rarely obtained, indirect
evidence showing that Dexa modulates muscle protein synthesis is rich. For
example, acute GC administration causes a reduction in the proportion of
polyribosomes [545]. The proportion of polysomes recovers to basal level in
less than 24 hours, when the GC is short-acting prednisone [396]. In contrast,
polysome downregulation lasts about two days after Dexa. No published accounts
describe polysome profile changes after longer GC exposure.</p>

<p class=MsoNormal>Dexa has a dual effect on 4E-BP, the inhibitor of protein
synthesis that binds and inhibits the eukaryotic initiation eIF4E. First, Dexa upregulates
4E-BP mRNA [422]. It was long believed 4E-BP induction is direct, and based on
a Foxo response element in 4E-BP promoter [546]. As of 2015, this response
element is proven only in Drosophila. The only replication in mouse cells, in
culture, was withdrawn during the preparation of this work, for unspecified
reason. While the transcriptional upregulation of 4E-BP is certain, the
mechanisms by which Dexa achieves it remain unknown.</p>

<p class=MsoNormal>Second, Dexa may regulate 4E-BP through post-translational
modifications. As shown earlier, Dexa reduces 4E-BP phosphorylation on residues
that are usually phosphorylated by mTORC1. The direct reduction is less
salient, with reductions in response to insulin being more commonly reported.
This mechanism is expected to impede protein synthesis rate mainly after
feeding. The study of mTOR action is challenged by the existence of multiple
phosphorylation sites, inability of antibodies to discern them, and inability
of rapamycin to inhibit mTORC1 action on 4E-BP1 [547].</p>

<p class=MsoNormal>Dexa upregulates mitogen-activated protein
kinaseinteracting kinase 2 (MNK2) expression [548]. Dexa reduces eIF4G Ser
1108 phosphorylation in wild type mice, but not in MNK2 knockout mice. This
posttranslational modification correlates with nutrient availability, but its
role in GAML was not studied (reviewed in [549]).</p>

<p class=MsoNormal>In C2C12 myotubes, GAML may repress protein synthesis by
MAFbx-initiated neutralization of eIF3f [431]. Overexpression of eIF3f causes
hypertrophy, and eIF3f knockout induces atrophy, supporting the hypothesis that
loss of an initiation factor causes reductions in the rate of protein
synthesis. Moreover, further data from the same group shows that loss of eIF3f
impairs the ability of mTOR to bind and phosphorylate p70-S6K, suggesting that
eIF3f pro-anabolic action is more complex [494]. The role of eIF3f in GAML has
not been confirmed in vivo.</p>

<p class=MsoNormal>Canonical control of protein synthesis includes
translational derepression, a cytosol-based mechanism for sensing amino acid
starvation (reviewed in [550]). Relative lack of amino acids enriches uncharged
tRNA, which bind and activates General Control Nonderepressible 2 (GCN2) [551].
Activated GCN2 phosphorylates eIF2&#945; at Ser 51, leading to the formation of
an inactivating complex with eIF2B [552]. The inactivation of eIF2B, the
guanine exchange factor for eIF2, leads to general translation shutdown [553].
The lack of eIF2-GTP complexes leads to start codon skipping, which, for
transcripts including multiple open reading frames (ORF), determines
extraordinary translation from downstream start ORFs. In eukaryotes, a
physiologically relevant downstream ORF is Activating transcription factor 4
(ATF4), which upregulates genes involved in transport of essential amino acids
and synthesis of non-essential amino acids, such as asparagine synthetase [554].
Overall, the translational derepression pathway is a mechanism for inhibiting
protein synthesis, initiated by apparent depletion of free amino acids, and
leading to ATF4 upregulation.</p>

<p class=MsoNormal>The study of translational derepression in mammalians is
still in its beginnings. The ATF4 knockout mouse has normal weight, but
exhibits some sparing from muscle atrophy in response to starvation [555]. ATF4
knockout mice exhibit a normal atrogene response to starvation, indicating that
ATF4 is part of a novel atrophy pathway. The only study that measured chronic
Dexa effect on phosphorylation of eIF2 reported negative results [122].
However, Dexa abrogated amino acid infusion ability to reduce eIF2
phosphorylation, a situation reminiscent of Dexas action on Akt. In a
fibroblastic cell line, Dexa upregulated ATF4 translation as long as insulin
was withheld from the medium [556].</p>

<p class=MsoNormal>Unexpectedly, in C2C12 myotubes, ATF4 protein levels are
upregulated by insulin in a rapamycin-dependent manner [556]. A plausible
explanation is that ATF4 is upregulated by apparent amino acid deficits,
including cases when mTOR-stimulated protein translation depletes the free
amino acid pool.</p>

<p class=MsoNormal>Changes in 4E-BP1 and perhaps some other pathways regulating
protein synthesis are induced by Dexa in a manner consistent with GAML. The
mild alterations of translation molecular markers correlate with the moderate
loss in protein synthesis rate. While the overall effect is not negligible, its
reduced amplitude and its downstream relation to MuRF-1 indicate that anabolism
adjustments play a complementary role to the activation of the
ubiquitin-proteasome system in GAML.</p>

<h2><a name="_Toc421412263">The effects of glucocorticoids on autophagy</a></h2>

<p class=MsoNormal>Proteasome inhibition does not abolish completely
Dexa-activated proteolysis, indicating that some other catabolic mechanisms
must be involved. Based on newly discovered role of mTOR as a major modulator
of autophagy, the second most important effector of GAML was presumed to be
autophagosome. Moreover, in L6 myotubes, 100 M chloroquine or 200 mM E-64
reduce the rate at which Dexa amplifies proteolytic tracer release [413].</p>

<p class=MsoNormal>A series of molecular markers further support the idea that
autophagy is upregulated by Dexa. In C2C12 myotubes, Dexa may induce the
formation of double-membrane autophagic vesicles, although evidence is limited
to unquantified micrographs [557].</p>

<p class=MsoNormal>Dexa reliably upregulates the family of lysosome proteases
known as cathepsins. In vivo, Dexa doubles the lysosome proteases cathepsin L
and D <span style='mso-spacerun:yes'></span>[400, 558, 426]. In L6 myotubes,
Dexa upregulates cathepsin B [413].</p>

<p class=MsoNormal>A new modality for investigating autophagy hinges on one of
the longest-living markers on its surface, LC3. Transgenic mice with expressing
LC3-GFP have been developed, and are regularly used for tracking autophagosomes,
including in denervation atrophy. Unfortunately , there are no reports of this
model being used in the study of GAML. Alternatively, endogenous LC3 is tracked
through immunofluorescence microscopy. Some reports describe an accumulation of
punctate LC3-containing structures in L6 myotubes treated with Dexa for 6 hours
[452]. Another way of tracking LC3 is based on immunoblot. A lipidated form of
LC3, termed LC3-II, migrates faster than its precursor, LC3-I, during
electrophoresis. Various indices, such as the amount of LC3-II, or the ratio
between LC3 electrophoretic forms, are used for estimating the number of
autophagosomes (reviewed in [559]). LC3-II is enriched in C2C12 myotubes
overexpressing LC3 [557] and in L6 myotubes [452].</p>

<p class=MsoNormal>Similar to the microscopy experiments, these reports use
acute Dexa treatments. Moreover, a time course reveals that in L6 myotubes,
LC3-II peaks at 6 hours and is extinguished at 24 hours after Dexa
administration [560]. Such findings are consistent with a rapid formation of
autophagosomes, followed by a slower fusion with lysosomes and clearance.</p>

<p class=MsoNormal>In vivo, LC3 changes are rarely documented. Acute Dexa
causes accumulation of LC3-II protein [491]. Recently, the enrichment of LC3-II
after chronic Dexa has been reported in rats [561].</p>

<p class=MsoNormal>In contrast with the limited body of evidence we have for
autophagy upregulation, there is a significant amount of literature describing
what would drive autophagy up in GAML. In C2C12 myotubes, overexpression of a
constitutively active FoxO3 or chemical inhibition of Akt upregulate lysosome -attributable
proteolysis [374]. As mentioned earlier, mTORC1 is a negative regulator of
autophagy, whose inhibition in GAML is hypothesized to stimulate autophagy.
Acute Dexa administration reduces ULK1 phosphorylation at Ser 575, the
mTOR-specific, inhibitory site [491].</p>

<p class=MsoNormal>Other lines of evidence provide indirect support for
autophagy upregulation in GAML. Acute Dexa downregulates p62, one of the
shortest-lived markers on the autophagosome, thus suggesting that autophagic
flux is upregulated [491].</p>

<p class=MsoNormal>Acute Dexa increases expression of the mitophagy effector
Bnip3 [491, 452]. In C2C12, acute Dexa upregulates expression of lysosome
markers such as autophagy-related 12 (Atg12) [512].</p>

<p class=MsoNormal>Given the spatial segregation between lysosomes internal and
outer space, autophagy must rely on a selective mechanism for any protein that
it is processing. Therefore, it is likely that autophagy acts only on a few
specific, perhaps limiting, proteins. For example, Dexa-induced depletion of
sialidase Neu2 is prevented by 3-MA [557].</p>

<p class=MsoNormal>Autophagy may play a significant role in triggering and
regulating GAML. Current evidence, based on cell culture experiments, is far
from satisfactory. Given its limited amplitude in vivo, it is improbable that
autophagy is responsible for bulk protein elimination.</p>

<h2><a name="_Toc421412264">Other proteolytic systems modulated by
glucocorticoids</a></h2>

<p class=MsoNormal>In 1986, it was discovered that proteolysis in muscle is
increased when explants are soaked in 2.5 mM calcium [562, 563]. The
calcium-stimulated proteolysis subsides upon co-administration of leupeptin, a
wide-spectrum protease inhibitor. The discovery of a class of calcium-dependent
proteases, called calpains, suggested that they might be contributing to muscle
atrophy. The calpain system includes &#956;-calpain, which is activated by
micromolar concentrations of calcium, m-calpain, which is activated by
millimolar concentrations of calcium, and their inhibitor, calpastatin
(reviewed in [564]). Transgenic mice overexpressing calpastatin have 30% lower
loss of muscle upon unloading [565], proving that the calpain system is
important in some atrophy models.</p>

<p class=MsoNormal>There is limited evidence for calpains involvement in GAML,
beyond the experiments from 1980s. In vivo, expression of the calcium-dependent
protease m-calpain is trebled by Dexa [400]. In L6 myotubes, calpastatin overexpression
halves Dexa-induced proteolysis [566]. Also in L6 myotubes, Dexa promotes
store-operated calcium entry, the mechanism by which intracellular Ca
concentration is increased when ER stores are depleted [567].</p>

<p class=MsoNormal>It has been speculated that activations of calpains is an
initial step in GAML, allowing myofibril protein to interact with MuRF-1 [568].
Calpains are important for some atrophy models, but their role in GAML is
understudied.</p>

<p class=MsoNormal>Many unbiased studies found that a family of proteases,
metallothioneins, are upregulated in GAML [569]. However, they contribution to
GAML has not been analyzed.</p>

<p class=MsoNormal>With the advent of new genome technology, enzymatic and
functional studies that brought the proteasome in the center of GAML have been
abandoned. The example of calpains illustrates how non-transcriptional events
can contribute to GAML, and testifies to a blind spot in GAML research.</p>

<h2><a name="_Toc421412265">Alleviation of glucocorticoid myopathy by IGF-I</a></h2>

<p class=MsoNormal>Upon finding that, in L6 myoblasts, Dexa-stimulated
proteolysis is abated by co-administration of insulin, Ballard hypothesized in
1983 that Dexa acts indirectly, by depleting the bodys supply of IGF-I [570].
While the use of non-fusing myoblasts is certain to introduce confounding
changes in proliferation, and the equivalence between IGF-I and insulin lacks
subtlety, his hypothesis captured the attention of many investigators. The
interest it garnered was even more surprising given that another common
research theme in those times was the hyperplastic synergy between IGF-I and GC
[571, 572]. Many reports describe the easily measurable interaction between
Dexa and IGF-I on muscle cells, rather than focus on the more subtle changes
induced by Dexa alone. For example, the above sections on Akt and mTOR were
informed mostly by studies of the interaction. Lately, the interpretation of
such experiments shifted from mechanism-explaining to a therapeutic paradigm.
In mice, electroporation of IGF-I plasmid in tibialis protected solely the
transformed fibers from Dexa-induced atrophy [573]. In Dexa-treated rats,
co-administration of IGF-I reduces loss of muscle mass, fiber atrophy, and 3MH
release [574], thus providing a blueprint for the ideal anti-GAML therapy.</p>

<p class=MsoNormal>Co-administration of IGF-I reverses upregulation of
ubiquitin, and of proteasome subunits C2 C3, C8 [575, 576], thus blunting one
of the major effectors of GAML, the ubiquitin-proteasome system. However, Dexa
antagonizes IGF-I on many other downstream effects, such as glutamine synthesis
[577].</p>

<p class=MsoNormal>In vivo, Dexa reduces muscle expression of IGF-I [578, 188],
and possibly interferes by altering IGFBP secretion [422]. Therefore, GAML
manifests as an absolute loss of IGF-I exacerbated by a downstream inhibition.
Intuitively, IGF-I supplementation may provide GAML alleviation.</p>

<p class=MsoNormal>Despite the positive results seen in rodents, few studies
analyzed molecular mechanisms by which IGF-I works in vivo. Because
co-administration of GH cannot reverse muscle loss from Dexa or triamcinolone [579,
576], it was hypothesized that, similar to Dexa, IGF-I action on muscle is
cell-autonomous, and may be modeled by cell cultures. In cell culture, IGF-I
alone improves protein synthesis, but has no effect on protein degradation [580].
In contrast, on myotubes treated with Dexa, co-administration of IGF-I has an
anti-proteolytic effect [580]. The reduction in proteolysis covers all domains,
but, in acute settings, appears more effective in repressing lysosome than proteasome
activity [581]. IGF-I co-administration reverses MAFbx and MuRF-1 upregulation
[475, 424], in a Foxo dependent manner. During co-administration, Foxo
regulation is split. Dexa upregulates Foxo protein levels, while IGF-I counters
by increasing their phosphorylation [421] and reducing its ability to bind
MuRF-1 promoter [424].</p>

<p class=MsoNormal>The IGF-I-induced Foxo phosphorylation is consistent with
upstream modulations of the Akt axis. Among those, myoprotective
phosphorylation of Akt, GSK-3&#946;, p70-S6K and 4E-BP1 is seen with IGF-I
co-administration in cells [582, 583]. Studies with chemical inhibitors
revealed that IGF-I protective effect is mediated by Akt and PI3K [582]. It is
not known which of these downstream mediators is in fact relevant for
myoprotection. Muscle hypertrophy and recovery are halved by rapamycin,
indicating that other anabolic mediators are as important as the mTOR pathway [584,
373, 585]. From the similarity between muscle protection conferred by IGF-I and
by GSK-3&#946; inhibitors, it was speculated that IGF-I acts by inhibiting
GSK-3&#946; [586, 462].</p>

<p class=MsoNormal>Based on the current evidence, it appears that IGF-I
alleviating action is not completely overlapping with the wide spectrum of
atrophic actions of Dexa. The putative mediator of muscle loss REDD1 is
upregulated by acute insulin or IGF-I [587]. It is possible that REDD1
upregulation contributes to the incompleteness in reversal of GAML by IGF-I.</p>

<p class=MsoNormal>IGF-I is only one of the many determinants of muscle mass.
For example, myostatin knockout mice have double muscle size, yet lower
circulating IGF-I levels, compared to wild type mice [588]. However, the
changes induced by Dexa in IGF-I are consistent with its involvement in the
atrophy program. As our understanding of GAML improved, studies on its
alleviation by IGF-I are lagging. A large number of publications focus on the
balance of GC and IGF-I on Akt in cultured cells. Given the reduced number of
co-administration in vivo studies, our understanding of how IGF-I could
alleviate glucocorticoid myopathy is incomplete.</p>

<h2><a name="_Toc421412266">Alleviation of glucocorticoid myopathy by anabolic
steroids</a></h2>

<p class=MsoNormal>Human studies demonstrated that AAS addition to chronic Dexa
benefits male adult patients, by reducing their loss of muscle and improving
their quality of life [157]. The idea of alleviating the CS by AAS therapy came
two years after the discovery of an affordable source of Testo. In the case of
exogenous hypercortisolism, the same idea surfaced less than a year after the
discovery of GC. Two years later, Courier and Marois report the first
replication of the myoprotective effect in rats [589]. For a long time, during
the second dark age of steroids, the combination of AAS and GC, with
androgenic, but without anabolic potency, was investigated, in the hope that it
would show the way towards splitting the anabolic from the androgenic principle
in Testo.</p>

<p class=MsoNormal>A related theoretic question was the nature of the nuclear
receptor. At the time when it was not clear how many species of nuclear
receptors there are, precise measurements tried to find putative interference
between the various steroids, with Dexa and Testo among the most studied
compounds. In vitro studies have quantified androgens ability to interfere with
the binding of Dexa to GR. The dissociation constant (Kd) for GR-Dexa
association is below nanomolar range [590]. In vitro Dexa doses used in muscle
atrophy experiments range in the tens of hundred nanomolar. Similar
concentrations are likely in the blood of mice injected with the 0<i
style='mso-bidi-font-style:normal'><span style='mso-fareast-font-family:Cambria;
mso-bidi-font-family:Cambria'>.</span></i>5 g<span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>/</span>kg to 1 g<span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>/</span>kg doses described before. At a
concentration of 2 pM in rat skeletal muscle [591], virtually all GR should be
bound to Dexa. On the other hand, inhibitory constant (Ki) for Testo competing
with Dexa for binding to muscle protein extracts is 10 M [592]. While the
referenced report does not distinguish non-specific binding for T, Ki is tens
or hundreds of times higher than typical Testo concentrations used in
literature for biological reversal of GAML. Testo binding affinity to Dexa
binding sites in rat muscle cytosol is less than 100 times lower than Dexas
affinity [593]. Therefore, barring allosteric effects, direct competition
between the two steroids remains only of theoretical importance.</p>

<p class=MsoNormal>The experiments in the 1980s and 1990s tested the
interaction of AAS and GC on the diaphragm. While these studies could not have
measured the yet-undiscovered mediators of GAML, they established that
myoprotection provided by AAS manifests in both muscle mass and force [594,
595, 596].</p>

<p class=MsoNormal>The mechanism by which AAS accomplishes muscle protection in
GAML remains unknown to date. One early study found that, in vivo, Testo
re-establishes the percentage of ribosomes that are involved in translation [597].
Two later studies on L6 myotubes found that AAS could not reverse the
downregulation of protein synthesis induced by Dexa [570, 598]. A study on
C2C12 myotubes also rejected an action of Testo on protein metabolism, despite
trends for restored protein synthesis and degradation when 1 M Testo is added
to 100 nM Dexa [543]. Given the limited number of attempts, the failure of in
vitro systems to replicate in vivo benefits may be ascribed to reduced
sensitivity rather than to fundamental shortcomings of the in vitro model.</p>

<p class=MsoNormal>A few studies investigated the interaction of AAS and GC, by
measuring the changes in one signal when the other is altered. An interaction
at the level of receptors cannot be excluded. In skeletal muscle, GR mRNA and
binding activity are increased upon castration [599, 600], suggesting a way by
which castration causes muscle atrophy. Conversely, Dexa reduces the expression
of AR in skeletal muscle [188]. Hypercortisolism reduces endogenous Testo
levels in male rats, thus leading to ampler loss of muscle than in females,
which experience Testo upregulation [402]. Sexual dimorphism in animal models
confirms that males stand to benefit more from AAS therapy in GAML.</p>

<p class=MsoNormal>In the absence of direct interference, studies sought
downstream effectors at which Testo could prevent Dexas program. One putative
interaction is centered on myostatin. Myostatin promoter contains putative
androgen responsive elements [522]. In intact animals and even in atrophic
muscle after spinal cord injury, Testo does not alter myostatin [601, 602].
Myostatin changes in co-administration of AAS and GC has not been investigated.
Given myostatins limited role in GAML, it is unlikely myostatin repression
could contribute to the ample alleviation provided by Testo.</p>

<p class=MsoNormal>Another promising point of interaction is at the level of
the Akt axis. Testo upregulates IGF-I in muscle, potentially leading to
reversal of Dexa-induced Akt inhibition. In other atrophy models, including castration,
AAS administration had an IGF-I-dependent myoprotective action [603]. Of note,
this protection was correlated with increased Foxo3a phosphorylation,
indicating restoration of Akt pathway.</p>

<p class=MsoNormal>In the era of immunoblot, only three laboratories published
studies of co-administration of AAS and GC. All three converged towards
describing a reversal of Akt pathway inhibition. Sheng laboratory describes the
effect of 10-day 1 mg<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:
Cambria'>/(</span>kg d<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:
Cambria'>) </span>Dexa and/or 13-day 5 mg<span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>/(</span>kg d<span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>) </span>T [604] on rat gastrocnemius.
With these regimen, Testo reliably, but incompletely, reverses losses in body
weight, muscle mass, and fiber CSA, induced by Dexa. Molecular pathways largely
confirm an Akt centered disruption of GAML. Muscle IGF-I expression is repressed
by Dexa, and returned to basal level by Testo co-administration. Downstream,
similar AAS-induced restorations are seen in Akt phosphorylation at Ser 473,
p70-S6K phosphorylation at Thr 389, and atrogenes expression. The only
difference from the canonical pattern is at GSK-3&#946; level, where Dexa has
no effect. These findings are consistent with AAS-driven restoration of Foxo
and mTORC1 pathways to basal level.</p>

<p class=MsoNormal>Dalton laboratory account describes the effect of 8-day 600
g<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>/(</span>kg
d<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>) </span>Dexa
and/or 25 mg<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:
Cambria'>/(</span>kg d<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:
Cambria'>) </span>T [504] on rat muscles. This study is focused on the
anabolic-androgenic split, and therefore compares levator to extraperitoneal
muscles. At these doses, Testo co-administration restores levator ani, but not
other muscles. This is a surprising finding, given that muscle atrophy caused
by a higher Dexa dose was reversed by a much lower dose of Testo, in the study
from Sheng and collaborators.</p>

<p class=MsoNormal>In Daltons study, the difference between levator ani and
extraperitoneal muscles is ascribed to the fact that Testo co-administration
upregulates IGF-I beyond basal levels in the former, and only partially in the
latter. Possibly as a consequence, Testo addition reduces atrogene expression
to a larger extent in levator ani. In levator ani and C2C12 myotubes, Testo reverses
Dexa-induced hypophosphorylation of Akt (Ser 473), GSK-3&#946; (Ser 9), FOXO3a
(Ser 253), and p70-S6K (Thr 389).</p>

<p class=MsoNormal>The series of studies from Cardozo laboratory is the most
informative. This was also the first group to show that 28 mg<span
style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>/(</span>kg
d<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>) </span>Testo
reverses losses in rat gastrocnemius induced by simultaneous 700 g<span
style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>/(</span>kg
d<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>) </span>Dexa
[605]. They ascribed this alleviation to a reduction in proteolysis and
atrogenes expression. In studies on L6 and C2C12 myotubes overexpressing AR,
they found that Testo co-administration reverses transcriptional upregulation
of REDD1 and MAFbx [606, 422].</p>

<p class=MsoNormal>Arguably, the most important contribution Cardozo made is
the first microarray study on alleviation of GAML with T [422], using
gastrocnemii treated as above. This is also the first published microarray
study of GAML, generating many hypotheses still untested. Many of the genes
found in the unbiased approach are consistent with the above description of
GAML, including transcriptional reversal at the levels of IGFBP, IRS1, FOXO1, p85,
and 4E-BP1. These changes point to a pleiotropic program through which AAS
re-establish signaling on the Akt axis. The overlap is not perfect, with
important presumptive effectors, including IGF-I and MAFbx, failing to pass
amplitude and statistical significance thresholds. The reversal of GAML is also
correlated with a repression of REDD1 to basal levels, suggesting that mTOR is
also restored by Testo. Testo also reversed the surge of MuRF-1, proteasome
subunit D8, cathepsin L, LC3, M-type calpain, C/EBP &#946; and &#948;, and
metallothionein 1, exhibiting a wide-spectrum anti-atrophic action.</p>

<p class=MsoNormal>Among the novel putative mediators, the microarray study
revealed that Testo reversed Dexa-induced changes in B-cell leukemia/lymphoma 3
(Bcl3), I&#954;B, and CD36. The latter is a fatty acid translocase. Its changes
suggest that GAML and its reversal have opposite effects on muscles ability to
use lipids as fuel [607].</p>

<p class=MsoNormal>Testo reversed the upregulation of the stress sensor Gadd45,
isoform &#946;. Recently, it has been shown that Gadd45&#946; is an autophagy
blocker [608]. This suggests that in 7-day treated muscle autophagy could be
downregulated, and goes against many other molecular markers that indicate the
opposite.</p>

<p class=MsoNormal>In conclusion, the mechanisms by which Testo prevents GAML
appear manifold. Many of the putative myoprotective actions of Testo are only
suggested by Cardozos microarray, but have never been confirmed in
quantitative assays and require further studies to clarify overall mechanism.</p>

</div>

<span style='font-size:12.0pt;mso-bidi-font-size:11.0pt;line-height:200%;
font-family:"Georgia",serif;mso-fareast-font-family:Georgia;mso-bidi-font-family:
Georgia;color:black;mso-ansi-language:EN-US;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA'><br clear=all style='page-break-before:always;
mso-break-type:section-break'>
</span>

<div class=WordSection4>

<h1><a name="_Toc421412267">3. HYPOTHESES</a></h1>

<p class=MsoNormal>The example of Gadd45, at the end of the previous section,
illustrates the issues GAML research is confronted with. On one hand, we have
macroscopic certainties, such the loss of muscle mass following GC therapy. On
the other, we have invariable molecular correlates of Dexa treatment, such as
augmented proteolysis, increased Foxo transcriptional activity, reduced insulin
sensitivity at Akt and mTORC1 level, and upregulation of MuRF-1 and REDD1. For
many of these, inhibition or interference experiments showed a reduction in
muscle atrophy, but none was found to be indispensable for GAML. The hierarchy
of molecular events in GAML is not known. Progresses made in the study of
denervation atrophy, greatly favored by the use of transgenic models, are yet
to be replicated in the study of GAML. Our understanding of androgen
alleviation of GAML is even more incomplete.</p>

<p class=MsoNormal>One reason why key mediators of GC and AAS actions have not
been identified is the lack of transgenic models. Muscle-localized conditional
knockout experiments are needed. For this purpose, studies on the most common
target of genome manipulation, the mouse, are needed. Surprisingly few studies
describe GAML in the mouse. Moreover, to my knowledge, no study of AAS
alleviation of GAML in mice has been published. While some parallels with rat
studies may help, higher resistance to Dexa in mouse suggests there must be
differences. This work sets out to determine whether AAS can alleviate GAML in
mice. Upon identifying the conditions that lead to GAML and to its alleviation
by AAS, the focus will switch to understanding of the molecular mechanisms
underlying them. Based on the published evidence available at the initiation of
this project, I set forth the following hypotheses:</p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'>1. Testosterone
alleviates dexamethasone-induced muscle atrophy in mice. </b>GAML has been
frequently reported in rats and infrequently in mice. A series of studies
describe reductions in CSA of mouse myofiber upon Dexa treatment. On the other
hand, Testo has been used to reverse loss of muscle in mice and other species.
Based on the information published prior to this work, there was a strong
probability for Testo to prevent GC-induced loss of mouse muscle.</p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'>2. Testosterones
myoprotective action in the context of dexamethasone is based on inhibiting
dexamethasones proteolytic effects</b>. Studies of<b style='mso-bidi-font-weight:
normal'> </b>GAML suggest that it involved a strong upregulation of
proteolysis, aggravated by a decrease in protein synthesis. Protein degradation
mechanisms upregulated by Dexa are diverse, including the proteasome, the
autophagosome, and soluble proteases. Microarray studies showed that Testo
reverses GC-induced changes in markers of each of the three proteolytic
pathways and of protein translation. Given that the amplest changes induced by
Dexa are on the proteasome ubiquitin system, there was a good probability that
specific reversal of GAML by Testo will include proteasomes repression.</p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'>3. Testosterones
myoprotective action in glucocorticoid-induced loss of muscle mass is
facilitated by the activation of IGF-I / Akt / mTOR axis.<span
style='mso-tab-count:1'> </span></b>The few studies on GAML reversal by AAS
revealed that Testo action alters mTOR and Akt signaling. Based on the
microarray studies that showed that Testo reverses changes in IGF-I and IGFBP
induced by Dexa, and on the castration reversal studies indicating that AAS
replacement causes IGF-I upregulation, there was a good probability that the
myoprotective action of Testo involved the modulation of IGF-I signaling.</p>

<span style='font-size:12.0pt;mso-bidi-font-size:11.0pt;line-height:107%;
font-family:"Georgia",serif;mso-fareast-font-family:Georgia;mso-bidi-font-family:
Georgia;color:black;mso-ansi-language:EN-US;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA'><br clear=all style='mso-special-character:line-break;
page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:8.0pt;text-indent:0in;line-height:107%;
mso-pagination:widow-orphan'><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<h1><a name="_Toc421412268">4. METHODS</a></h1>

<h2><a name="_Toc421412269">Ethical considerations</a></h2>

<p class=MsoNormal>All animal procedures have been described in protocols
drafted by the author, and submitted with Dr. Carlo Serra as principal
investigator to the Institutional Animal Care and Use Committee at the Boston
University School of Medicine and Harvard Medical Area Standing Committee on
Animals. Experiments were performed solely after approval was obtained.</p>

<h2><a name="_Toc421412270">Animal studies</a></h2>

<p class=MsoNormal>Male, 6-8 week old (young adult), C57Bl/6J mice were purchased
from The Jackson Laboratories (Bar Harbor, Maine). Mice were acclimated for 3 d
to 7 d between delivery and initiation of the experimental interventions.
Before and during the experiments, mice were maintained in a
temperature-controlled facility, at 21 <sup><span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>&#9702;</span></sup>C, with 12 h light /
12 h dark cycles. Mice were offered water and chow (Purina, Richmond, Indiana)
ad libitum.</p>

<p class=MsoNormal>Experiments involved steroid administration for 1, 3, or 7
days. Every morning, between 9 and 11 AM, mice were weighted, then injected subcutaneously
with 200 L corn-oil based solution, including 14 L ethanol, which delivered
either (A) 0<i style='mso-bidi-font-style:normal'><span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>.</span></i>7 mg Testo propionate (T), or
(B) 0<i style='mso-bidi-font-style:normal'><span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>.</span></i>25 mg Dexa (D), or (C) both T
and Dexa in the above doses (DT), or (D) neither drug. This latter group will
be designated Vehicle (V). Testo propionate and Dexa were from Sigma-Aldrich
(St. Louis, Missouri). Research-grade corn oil was purchased from MP
Biomedicals (Solon, Ohio). Unless specified, chemical reagents used in this
work were from Fisher (Pittsburgh, Pennsylvania), including
pharmaceutical-grade ethanol used here.</p>

<p class=MsoNormal>Before the first injection and 24 h after the last
injection, mice lean and fat body mass was measured by nuclear magnetic
resonance (NMR), using an Echo-MRI whole body composition analyzer (Echo Medical
Systems, Houston, Texas). In this procedure, mice were restrained inside a
transparent methacrylate tube for 90 s, without sedation or anesthesia.</p>

<p class=MsoNormal>Mice were euthanized humanely by Euthasol (pentobarbital
sodium and phenytoin sodium solution; 200 mg<span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>/</span>kg pentobarbital; Diamond Animal
Health, Des Moines, Iowa) intraperitoneal, followed by quick cervical
dislocation. Blood was collected immediately after death through thoracotomy
and cardiac puncture, incubated 15 min at room temperature, centrifuged 15 min,
at 10,000 g, 4 <sup><span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:
Cambria'>&#9702;</span></sup>C. Levator ani, gastrocnemius, tibialis anterior,
quadriceps, and triceps brachii muscles were collected, weighted in wet state,
flash-frozen by submersion in liquid nitrogen, and stored at <span
style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>&#8722;</span>80
<sup><span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>&#9702;</span></sup>C.</p>

<p class=MsoNormal>Muscles were crushed under liquid nitrogen, using a mortar
and pestle pre-chilled in liquid nitrogen, and muscle powder was stored at <span
style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>&#8722;</span>80
<sup><span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>&#9702;</span></sup>C.
Small quantities of muscle powder (25 g to 30 g) were lyzed for enzymatic
activity assays, immunoblot, or quantitative real-time polymerase chain reaction
(qRT-PCR), as described in dedicated sections.</p>

<h2><a name="_Toc421412271">Enzymatic assays</a></h2>

<p class=MsoNormal>Chymotrypsin-like proteasome enzymatic activity was measured
using the 20S Proteasome Activity Assay kit (Chemicon International, Temecula,
California). For each animal and muscle, 25 mg powdered muscle was extracted
with 8 mL<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:
Cambria'>/</span>g tissue of lysis buffer containing 150 mM sodium chloride, 50
mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonate HEPES (pH 7.4), 5 mM sodium
ethylenediaminetetraacetate (EDTA), and 10  Triton X-100, by nutation at 4 <sup><span
style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>&#9702;</span></sup>C
for 30 min, with vortexing every 10 min. The extract was clarified by
centrifugation at 10,000 g, 10 min, 4 <sup><span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>&#9702;</span></sup>C. The clarified
extract was collected and stored at <span style='mso-fareast-font-family:Cambria;
mso-bidi-font-family:Cambria'>&#8722;</span>20 <sup><span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>&#9702;</span></sup>C for 1 h, while its
total protein concentration was determined using the bicinchoninic acid (BCA)
method (detailed in the immunoblot section). Next, the clarified extract was
diluted to match the lowest total protein concentration with lysis buffer. Per
kit manufacturer instructions, 80 L clarified extract (depending on muscle,
300 g to 600 g total protein) were mixed, in 96-well plate wells, with 10 L
proprietary assay buffer and 10 L fluorogenic proteasome substrate,
Succynyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin, 500 M stock. This was done
in duplicates for each sample, and for a negative control (background),
containing lysis buffer instead of muscle extract. The plate was sealed and
incubated at 37 <sup><span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:
Cambria'>&#9702;</span></sup>C for 30 min. Next, fluorescence was measured with
a Saphire multi-well plate reader (Tecan, Mnnedorf, Switzerland) with excitation
at 380 nm and emission at 460 nm. Background fluorescence, including substrate,
was subtracted from sample measurements. Preliminary tests with manufacturers
positive control and muscle lysate indicated that 30 min fluorescence measured
with optimal gain and with background subtraction is proportional with the rate
of fluorescence change and with the amount of measured enzyme. Thus, more
detailed kinetics were not needed.</p>

<p class=MsoNormal>Lysosome enzymatic activity was measured in a similar
protocol, using Cathepsin L Activity Fluorometric Assay kit (Abcam plc,
Cambridge, England). For each animal and muscle, 25 mg powdered muscle was
extracted with 8 mL<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:
Cambria'>/</span>g tissue of proprietary lysis buffer, clarified, stored, and
assayed for total protein, in the same manner as for the proteasome activity
assay. Extracts were diluted to the lowest total protein concentration, using
the same lysis buffer that was used to extract them. Per kit manufacturer
instructions, 48 L clarified extract (depending on muscle, 100 g to 300 g total
protein) were mixed, in 96-well plate wells, with 50 L proprietary assay
buffer and 2 L fluorogenic cathepsin substrate, FR-amino-4-trifluoromethyl
coumarin, 10 mM stock. This was done in duplicates for each sample, and for a
negative control (background), containing lysis buffer instead of muscle
extract. The plate was sealed and incubated at 37 <sup><span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>&#9702;</span></sup>C for 30 min.
Fluorescence was measured with excitation at 400 nm and emission at 505 nm.
Background fluorescence, including substrate, was subtracted from sample
measurements.</p>

<p class=MsoNormal>Calpain enzymatic activity was measured in a similar
protocol, using Cathepsin L Activity Fluorometric Assay kit (Promega, Madison,
Wisconsin). For each animal and muscle, 25 mg powdered muscle was extracted
with 8 mL<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:
Cambria'>/</span>g tissue of lysis buffer containing 150 mM sodium chloride, 10
mM HEPES pH 7.4, 10 mM dithiothreitol (DTT), 1 mM EDTA, and 10  Triton X-100,
as described for proteasome activity assay. Extracts were clarified, and
stored, as described for the proteasome activity assay. Total protein was
measured by Bradford assay.</p>

<p class=MsoNormal>Briefly, 1 L sample was mixed with 300 L Coomassie Plus
(Life Technologies, Carlsbad, California) in duplicate wells of a 96-well
plate, incubated 10 min at room temperature, and measured spectrophotometrically
for absorption at 595 nm. Extracts were diluted to the lowest total protein
concentration, using the same lysis buffer that was used to extract them. Per
kit manufacturer instructions, 50 L clarified extract (depending on muscle, 100
g to 300 g total protein) were mixed, in 96-well plate wells, with 50 L
proprietary assay buffer, containing lyophilized luciferase, ATP, 80 M
pro-luminescent calpain substrate, Suc-Leu-Leu-Val-Tyr-aminoluciferase, and 8
M calcium chloride. This was done in duplicates for each sample, and for a
negative control (background), containing lysis buffer instead of muscle
extract. After 10 min of incubation at room temperature, steady state was
reached, with a constant rate of free aminoluciferase production, which is
immediately converted to free luciferin by the excess luciferase. Luminescence
was measured with a GeniosPro multi-well plate reader (Tecan, Mnnedorf,
Switzerland) set to integrate signal over 100 ms. Background luminescence,
including substrate, was subtracted from sample measurements.</p>

<h2><a name="_Toc421412272">Immunoblot</a></h2>

<p class=MsoNormal>For each animal and muscle, 25 mg powdered muscle was
extracted with 4 mL<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:
Cambria'>/</span>g tissue of radioimmunoprecipitation assay (RIPA) buffer,
containing 150 mM sodium chloride, 20 mM Tris pH 7.5, 100  v/v glycerol, 10 
v/v NP-40, 10 g<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:
Cambria'>/</span>L sodium deoxycholate, 1 g<span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>/</span>L sodium dodecyl sulfate (SDS), 1
mM EDTA, 1 mM sodium ethyleneglycol tetraacetate, 10 mg<span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>/</span>L leupeptin, 10 mg<span
style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>/</span>L
pepstatin, 10 mg<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:
Cambria'>/</span>L aprotinin, 1 mM phenylmethanesulfonylfluoride, 1 mM sodium
orthovanadate, 5 mM sodium fluoride. The mixture was nutated at 4 <sup><span
style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>&#9702;</span></sup>C
for 30 min, with vortexing every 10 min. The suspensions were clarified by
centrifugation at 12,000g, 15 min, at 4 <sup><span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>&#9702;</span></sup>C. The supernatant
was collected, aliquoted, and stored for months at <span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>&#8722;</span>80 <sup><span
style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>&#9702;</span></sup>C.</p>

<p class=MsoNormal>Total protein content was measured with a BCA proprietary
kit (Thermo Scientific Pierce, Rockford, Illinois). First, a 50:1 combination
of reagents VW A and B was prepared. Next, 200 L VW reagent mix was combined
with 2 L unknown solution in a 96-well plate well. This was done in duplicates
for each sample, and for a series of standards of 0<i style='mso-bidi-font-style:
normal'><span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>.</span></i>5
g<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>/</span>L
to 10 g<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>/</span>L
bovine serum albumin (BSA) prepared with the same lysis buffer as the unknowns.
The plate was incubated 30 min at 37 <sup><span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>&#9702;</span></sup>C. Light absorbance
was measured with a Saphire multi-well plate reader (Tecan, Mnnedorf,
Switzerland) with absorption at 562 nm. The standard curve was fitted to a
quadratic equation. Typically, extracts were diluted to the lowest total
protein concentration, using the same lysis buffer that was used to extract
them.</p>

<p class=MsoNormal>The lysates were resolved by polyacrylamide gel
electrophoresis (PAGE). The gels were cast in the morning of the
electrophoresis. The stacking section was a 5 g<span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>/</span>dL acrylamide gel, with 125 mM
Tris pH 6.8. The separating section has a variable concentration of acrylamide
(12 g<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>/</span>dL
for low molecular weight unknowns, 8 g<span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>/</span>dL for others), and 400 mM Tris
pH 8.8. Both sections included 1 g<span style='mso-fareast-font-family:Cambria;
mso-bidi-font-family:Cambria'>/</span>L SDS, and polymerized by the addition of
1 g<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>/</span>L
ammonium persulfate and 0<i style='mso-bidi-font-style:normal'><span
style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>.</span></i>4
 v/v tetramethylethylenediamine. In order to settle and migrate, lysates were
mixed 1:1 with PAGE sample buffer, which contained 30 mM Tris pH 6.8,</p>

<p class=MsoNormal>10 g<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:
Cambria'>/</span>L SDS, 100  v/v glycerol, 50 mg<span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>/</span>L bromophenol blue, and 350 mM
DTT. The mixture of sample and sample buffer was incubated for 5 min at 95 <sup><span
style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>&#9702;</span></sup>C,
then loaded on the gel, with equal volumes and masses of total protein in each
well. Electrophoresis was performed in a Miniprotean Tetra cell (Bio-rad,
Hercules, California), at constant 80 V, using an electrode buffer with 14<i
style='mso-bidi-font-style:normal'><span style='mso-fareast-font-family:Cambria;
mso-bidi-font-family:Cambria'>.</span></i>4 g<span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>/</span>L glycine, 3 g<span
style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>/</span>L
Tris base, 10 g<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:
Cambria'>/</span>L SDS.</p>

<p class=MsoNormal>From the gel, resolved proteins were transferred to
nitrocellulose membranes using a Bio-rad Mini-trans blot cassette, at 8 V<span
style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>/</span>cm
constant overnight at 4 <sup><span style='mso-fareast-font-family:Cambria;
mso-bidi-font-family:Cambria'>&#9702;</span></sup>C. The Towbin transfer buffer
had 200  v/v methanol, 25 mM Tris pH 8.3, 192 mM glycine.</p>

<p class=MsoNormal>Quality of transfer was assessed by temporary Ponceau
staining (20 g<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:
Cambria'>/</span>L Ponceau S in 300 g<span style='mso-fareast-font-family:Cambria;
mso-bidi-font-family:Cambria'>/</span>L trichloroacetic acid and 300 g<span
style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>/</span>L
sulfosalicylic acid). At this time, using indications from the molecular weight
standards, the membrane was sectioned, thus allowing probing with multiple
antibodies.</p>

<p class=MsoNormal>Ponceau was removed by washing twice, with shaking 5 min at
room temperature, in TBST (130 mM sodium chloride, 20 mM Tris pH 7.5, 1  v/v
Tween-20). The membranes were blocked by shaking for one hour in blocking
solution (TBST with 5 g<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:
Cambria'>/</span>dL fat-free instant milk) at room temperature. Next, membranes
were probed by shaking overnight at 4 <sup><span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>&#9702;</span></sup>C in TBST with 50 g<span
style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>/</span>L
BSA and primary antibodies of choice (listed later). Next day, the membranes
were washed in TBST, twice briefly and three times with 5 min shaking at room
temperature. The washed membranes were then probed by shaking at room
temperature for an hour in a solution with TBST, 5 g<span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>/</span>dL fat-free instant milk, and the
secondary antibody of choice (listed later). The membranes were washed as
before.</p>

<p class=MsoNormal>Next, the membranes were probed with proprietary Amersham
ECL Western Blotting Detection Reagent (GE Healthcare, Wilmington,
Massachusetts). Briefly, the two reagent components were warmed to room
temperature, mixed 1:1, and layered on the nitrocellulose membrane. The
membrane was incubated for 1 min, and then excess liquid was drained. The
membrane was placed in the film cassette. In a dark room, under red light, a
X-Omat photographic film (Kodak, Rochester,</p>

<p class=MsoNormal>New York) was placed on the nitrocellulose membrane.
Exposure was between 10 s and 5 min, depending on the strength of the signal.
After developing the first image, longer or shorter exposures were used, as
needed.</p>

<p class=MsoNormal>Photographic films were digitized using a FluorChem-SP
Imaging System (Alpha Innotech, San Leandro, California), using automatic
exposure. Band densitometry was performed with the Image Studio Lite
application (Li-Cor, Lincoln, Nebraska).</p>

<p class=MsoNormal>At times, antibodies were stripped by incubation with
shaking for 45 min at 50 <sup><span style='mso-fareast-font-family:Cambria;
mso-bidi-font-family:Cambria'>&#9702;</span></sup>C in a tight container with
pre-warmed stripping buffer (20 g<span style='mso-fareast-font-family:Cambria;
mso-bidi-font-family:Cambria'>/</span>L SDS, 60 mM Tris pH 6.8, 100 mM
beta-mercaptoethanol). Stripped membranes were rinse with water, washed with
TBST, re-blocked, and re-probed.</p>

<p class=MsoNormal>Primary antibodies used were: anti-myosin heavy chain
(in-house, from MF20 hybridoma cells), anti-GAPDH (Pierce), anti-calpain 1
(Abcam), anti-eIF3f (Rockland), anti-LC3, anti-phospho-eIF2, anti-4EBP,
anti-phospho-4EBP, anti-ATF4, anti-cathepsin L, anti-calpastatin, anti-IGF-1R,
anti-phospho-IGF1-R, anti-Akt, anti-phospho-Ser473 Akt (all from Cell Signaling
Technologies). Anti-mouse and anti-rabbit secondary antibodies were from Cell
Signaling Technologies.</p>

<h2><a name="_Toc421412273">Quantitative real-time polymerase chain reaction</a></h2>

<p class=MsoNormal>Total RNA was purified by a combination of
phenol-chlorophorm fractionation and spin column chromatography. For each
animal and muscle, 25 mg powdered muscle was homogenized briefly in 1 mL Trizol
(Life Technologies). The suspension was incubated 5 min at room temperature,
then supplemented with 200 L chloroform. The tube was shaken vigorously for 15
s, and then incubated 3 min at room temperature. Phase separation was induced
by centrifugation, 15 min, 12,000 g, at 4 <sup><span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>&#9702;</span></sup>C. The top, aqueous
fraction (500 L) was collected, and then passed through a gDNA exclusion
column, by centrifugation for 30 s, 8,000 g. The recovered solution was
supplemented 1:1 with 700  v/v ethanol, then passed through an RNeasy column,
by centrifugation, 10 s at 8,000 g. The column was washed with 700 L
proprietary, guanidine and ethanol-containing, RW1buffer, and twice with 500 L
proprietary RPE buffer, each time by centrifugation, 15 s at 8,000 g. The
column was dried by centrifugation 2 min at 8,000 g. RNA was eluted with 40 L
water, by centrifugation, 1 min at 8,000 g.</p>

<p class=MsoNormal>Total RNA concentration was measured with an ND-1000
spectrophotometer (Nanodrop, Wilmington, Delaware) at 260 nm, using its Windows
proprietary application.</p>

<p class=MsoNormal>To obtain cDNA using AccuScript 1st Strand cDNA synthesis
kit, 320 ng total RNA was combined with 300 ng random primers, 20 nmol of each
triphosphate nucleotide, and the proprietary AccuScript RT Buffer 10. After
incubation for 5 min at 65 <sup><span style='mso-fareast-font-family:Cambria;
mso-bidi-font-family:Cambria'>&#9702;</span></sup>C, and cooling towards room
temperature another 5 min, the RNA mix was supplemented with 2 nmol DTT, 20
units RNAse Block ribonuclease inhibitor, and 1 L reverse transcriptase
(AccuScript RT) proprietary stock. For negative control purposes, the same
mixture was prepared, while withholding the RT Buffer and the RT stock. This
no-RT tube provided a measurement of the leaked DNA, which, in the course of
this work, was negligible. Reverse transcription was performed by incubating 10
min at 25 <sup><span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:
Cambria'>&#9702;</span></sup>C, then 60 min at 42 <sup><span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>&#9702;</span></sup>C. Reverse transcription
was terminated by incubating 15 min at 70 <sup><span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>&#9702;</span></sup>C. The product was
stored at 20 <sup><span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:
Cambria'>&#9702;</span></sup>C between measurements.</p>

<p class=MsoNormal>Specific cDNA amounts were measured with an 7500 Fast
Real-Time PCR cycler (Applied Biosystems, Foster City, California), using
96-well plates. Each unknown was measured in duplicates. Each well contained 1
L cDNA stock, 10 pmol each sense and anti-sense primer (listed later), and
proprietary SybrGreen 2X. The qRT-PCR cycler incubates samples 2 min at 50 <sup><span
style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>&#9702;</span></sup>C,
then 10 min at 95 <sup><span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:
Cambria'>&#9702;</span></sup>C. Then, 40 cycles were run, comprising 15 sat 95 <sup><span
style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>&#9702;</span></sup>C,
and 60 s at 60 <sup><span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:
Cambria'>&#9702;</span></sup>C, with measurements of DNA after each cycle. The
amount of specific cDNA was estimated from the number of cycles (Ct; cycle
threshold) required to reach a DNA concentration threshold, automatically
chosen by the Applied Biosystems software at midway between the lag phase and
the end plateau DNA concentrations. Moreover, the Applied Biosystems software
may interpolate the number of cycles, thus providing, for each well, a
non-integer number of cycles that will yield the threshold DNA concentration.</p>

<p class=MsoNormal>Duplicates were averaged for each unknown. Next, from the
cycle count required to reach the threshold DNA concentration for the specific
cDNA of interest, the cycle count for a housekeeping gene was subtracted, thus
providing a relative measurement of expression for the gene of interest within
the transcriptome of that animal. Statistics were computed on these
differences, also known as &#916;Ct. To enable comparisons, these &#916;Ct
measurements were further re-based, by subtracting from each the average
measurement in the V group. (This double-rebasing method is also referred to as
the &#916;&#916;Ct.) Primers used are listed in table 2.</p>

<p class=MsoNormal style='margin-top:0in;margin-right:.75pt;margin-bottom:.2pt;
margin-left:.75pt'><!--[if gte vml 1]><v:shape id="_x0000_s1050" type="#_x0000_t202"
 style='position:absolute;left:0;text-align:left;margin-left:0;margin-top:14.4pt;
 width:6in;height:462.45pt;text-indent:0;z-index:251667456;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:200;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:3.6pt;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:3.6pt;
 mso-position-horizontal:center;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:200;mso-width-relative:margin;
 mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-fit-shape-to-text:t'>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <table class=TableGrid border=0 cellspacing=0 cellpadding=0 width=513
     style='width:384.7pt;margin-left:.2pt;border-collapse:collapse;mso-yfti-tbllook:
     1184;mso-padding-alt:1.25pt 5.75pt 0in 6.2pt'>
     <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;height:14.85pt'>
      <td width=112 valign=top style='width:84.35pt;border:solid black 1.0pt;
      mso-border-alt:solid black .5pt;padding:1.25pt 5.75pt 0in 6.2pt;
      height:14.85pt'>
      <p class=MsoNormal align=center style='margin-right:.4pt;text-align:center;
      text-indent:0in;line-height:107%'>Gene</p>
      </td>
      <td width=400 valign=top style='width:300.35pt;border:solid black 1.0pt;
      border-left:none;mso-border-left-alt:solid black .5pt;mso-border-alt:
      solid black .5pt;padding:1.25pt 5.75pt 0in 6.2pt;height:14.85pt'>
      <p class=MsoNormal style='text-indent:0in;line-height:107%'>Primers</p>
      </td>
     </tr>
     <tr style='mso-yfti-irow:1;height:29.3pt'>
      <td width=112 valign=top style='width:84.35pt;border:solid black 1.0pt;
      border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
      padding:1.25pt 5.75pt 0in 6.2pt;height:29.3pt'>
      <p class=MsoNormal align=center style='margin-right:.4pt;text-align:center;
      text-indent:0in;line-height:107%'>Trim63</p>
      </td>
      <td width=400 valign=top style='width:300.35pt;border-top:none;
      border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
      mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
      mso-border-alt:solid black .5pt;padding:1.25pt 5.75pt 0in 6.2pt;
      height:29.3pt'>
      <p class=MsoNormal style='margin-right:32.15pt;text-indent:0in;
      line-height:107%'>Forward: TCTCTCAGCTGGAGGACTCC Reverse:
      CTGTACTGGAGGATCAGAGC</p>
      </td>
     </tr>
     <tr style='mso-yfti-irow:2;height:29.3pt'>
      <td width=112 valign=top style='width:84.35pt;border:solid black 1.0pt;
      border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
      padding:1.25pt 5.75pt 0in 6.2pt;height:29.3pt'>
      <p class=MsoNormal align=center style='margin-right:.4pt;text-align:center;
      text-indent:0in;line-height:107%'>Fbxo32</p>
      </td>
      <td width=400 valign=top style='width:300.35pt;border-top:none;
      border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
      mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
      mso-border-alt:solid black .5pt;padding:1.25pt 5.75pt 0in 6.2pt;
      height:29.3pt'>
      <p class=MsoNormal style='margin-right:21.45pt;text-indent:0in;
      line-height:107%'>Forward: GGGAAGCTTTCAACAGATTGG Reverse: AATGTTCATGAAGTTCTTTTGGG</p>
      </td>
     </tr>
     <tr style='mso-yfti-irow:3;height:29.3pt'>
      <td width=112 valign=top style='width:84.35pt;border:solid black 1.0pt;
      border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
      padding:1.25pt 5.75pt 0in 6.2pt;height:29.3pt'>
      <p class=MsoNormal align=center style='margin-right:.3pt;text-align:center;
      text-indent:0in;line-height:107%'>Igf1 (IGF-IEa)</p>
      </td>
      <td width=400 valign=top style='width:300.35pt;border-top:none;
      border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
      mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
      mso-border-alt:solid black .5pt;padding:1.25pt 5.75pt 0in 6.2pt;
      height:29.3pt'>
      <p class=MsoNormal style='text-indent:0in;line-height:107%'>Forward:
      GCTTGCTCACCTTTACCAGC Reverse:AAATGTACTTCCTTCTGGGTCT</p>
      </td>
     </tr>
     <tr style='mso-yfti-irow:4;height:29.3pt'>
      <td width=112 valign=top style='width:84.35pt;border:solid black 1.0pt;
      border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
      padding:1.25pt 5.75pt 0in 6.2pt;height:29.3pt'>
      <p class=MsoNormal align=center style='margin-right:.4pt;text-align:center;
      text-indent:0in;line-height:107%'>Foxo1</p>
      </td>
      <td width=400 valign=top style='width:300.35pt;border-top:none;
      border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
      mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
      mso-border-alt:solid black .5pt;padding:1.25pt 5.75pt 0in 6.2pt;
      height:29.3pt'>
      <p class=MsoNormal style='margin-right:40.2pt;text-indent:0in;line-height:
      107%'>Forward: CACCCTGTCGCAGATCTAG Reverse: CGAATAAACTTGCTGTGAAGG</p>
      </td>
     </tr>
     <tr style='mso-yfti-irow:5;height:29.3pt'>
      <td width=112 valign=top style='width:84.35pt;border:solid black 1.0pt;
      border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
      padding:1.25pt 5.75pt 0in 6.2pt;height:29.3pt'>
      <p class=MsoNormal align=center style='margin-right:.4pt;text-align:center;
      text-indent:0in;line-height:107%'>Foxo3a</p>
      </td>
      <td width=400 valign=top style='width:300.35pt;border-top:none;
      border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
      mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
      mso-border-alt:solid black .5pt;padding:1.25pt 5.75pt 0in 6.2pt;
      height:29.3pt'>
      <p class=MsoNormal style='margin-right:32.15pt;text-indent:0in;
      line-height:107%'>Forward: GACAAACGGCTCACTTTGCC Reverse:
      GACAGGTTGTTGTGCCGGATGG</p>
      </td>
     </tr>
     <tr style='mso-yfti-irow:6;height:29.3pt'>
      <td width=112 valign=top style='width:84.35pt;border:solid black 1.0pt;
      border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
      padding:1.25pt 5.75pt 0in 6.2pt;height:29.3pt'>
      <p class=MsoNormal align=center style='margin-right:.4pt;text-align:center;
      text-indent:0in;line-height:107%'>Foxo4</p>
      </td>
      <td width=400 valign=top style='width:300.35pt;border-top:none;
      border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
      mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
      mso-border-alt:solid black .5pt;padding:1.25pt 5.75pt 0in 6.2pt;
      height:29.3pt'>
      <p class=MsoNormal style='margin-right:23.15pt;text-indent:0in;
      line-height:107%'>Forward: GCCCTACTTTCAAGGACAAGG Reverse:
      CATCCACCAGAGCTCTTC</p>
      </td>
     </tr>
     <tr style='mso-yfti-irow:7;height:29.3pt'>
      <td width=112 valign=top style='width:84.35pt;border:solid black 1.0pt;
      border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
      padding:1.25pt 5.75pt 0in 6.2pt;height:29.3pt'>
      <p class=MsoNormal align=center style='margin-right:.4pt;text-align:center;
      text-indent:0in;line-height:107%'>Ddit4</p>
      </td>
      <td width=400 valign=top style='width:300.35pt;border-top:none;
      border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
      mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
      mso-border-alt:solid black .5pt;padding:1.25pt 5.75pt 0in 6.2pt;
      height:29.3pt'>
      <p class=MsoNormal style='margin-right:30.6pt;text-indent:0in;line-height:
      107%'>Forward: CTGCGAGTCCCCTGGACAGC Reverse: CACTGAGCAGCTCAAAGTCG</p>
      </td>
     </tr>
     <tr style='mso-yfti-irow:8;height:29.3pt'>
      <td width=112 valign=top style='width:84.35pt;border:solid black 1.0pt;
      border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
      padding:1.25pt 5.75pt 0in 6.2pt;height:29.3pt'>
      <p class=MsoNormal align=center style='margin-right:.4pt;text-align:center;
      text-indent:0in;line-height:107%'>Igf1r</p>
      </td>
      <td width=400 valign=top style='width:300.35pt;border-top:none;
      border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
      mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
      mso-border-alt:solid black .5pt;padding:1.25pt 5.75pt 0in 6.2pt;
      height:29.3pt'>
      <p class=MsoNormal style='margin-right:43.6pt;text-indent:0in;line-height:
      107%'>Forward: GGGCTGACTGGTGGATGC Reverse: CGCTGGGCACGGATAGAGC</p>
      </td>
     </tr>
     <tr style='mso-yfti-irow:9;height:29.3pt'>
      <td width=112 valign=top style='width:84.35pt;border:solid black 1.0pt;
      border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
      padding:1.25pt 5.75pt 0in 6.2pt;height:29.3pt'>
      <p class=MsoNormal align=center style='margin-right:.4pt;text-align:center;
      text-indent:0in;line-height:107%'>Becn1</p>
      </td>
      <td width=400 valign=top style='width:300.35pt;border-top:none;
      border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
      mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
      mso-border-alt:solid black .5pt;padding:1.25pt 5.75pt 0in 6.2pt;
      height:29.3pt'>
      <p class=MsoNormal style='margin-right:38.4pt;text-indent:0in;line-height:
      107%'>Forward: CCACAGCCCAGGCGAAACC Reverse: GATGAATCTTCGAGAGACACC</p>
      </td>
     </tr>
     <tr style='mso-yfti-irow:10;height:29.3pt'>
      <td width=112 valign=top style='width:84.35pt;border:solid black 1.0pt;
      border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
      padding:1.25pt 5.75pt 0in 6.2pt;height:29.3pt'>
      <p class=MsoNormal align=center style='margin-right:.4pt;text-align:center;
      text-indent:0in;line-height:107%'>Map1lc3b</p>
      </td>
      <td width=400 valign=top style='width:300.35pt;border-top:none;
      border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
      mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
      mso-border-alt:solid black .5pt;padding:1.25pt 5.75pt 0in 6.2pt;
      height:29.3pt'>
      <p class=MsoNormal style='margin-right:38.2pt;text-indent:0in;line-height:
      107%'>Forward: GGAAGATGTCCGGCTATCC Reverse: CTCATGTTCACGTGGTCAGG</p>
      </td>
     </tr>
     <tr style='mso-yfti-irow:11;height:29.3pt'>
      <td width=112 valign=top style='width:84.35pt;border:solid black 1.0pt;
      border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
      padding:1.25pt 5.75pt 0in 6.2pt;height:29.3pt'>
      <p class=MsoNormal align=center style='margin-right:.4pt;text-align:center;
      text-indent:0in;line-height:107%'>Ctsl</p>
      </td>
      <td width=400 valign=top style='width:300.35pt;border-top:none;
      border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
      mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
      mso-border-alt:solid black .5pt;padding:1.25pt 5.75pt 0in 6.2pt;
      height:29.3pt'>
      <p class=MsoNormal style='margin-right:24.45pt;text-indent:0in;
      line-height:107%'>Forward: AACCGCTGATGCTTAAGATCC Reverse:
      CACTCAGTGAGATCAGTTTGC</p>
      </td>
     </tr>
     <tr style='mso-yfti-irow:12;height:29.3pt'>
      <td width=112 valign=top style='width:84.35pt;border:solid black 1.0pt;
      border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
      padding:1.25pt 5.75pt 0in 6.2pt;height:29.3pt'>
      <p class=MsoNormal align=center style='margin-right:.4pt;text-align:center;
      text-indent:0in;line-height:107%'>Klf15</p>
      </td>
      <td width=400 valign=top style='width:300.35pt;border-top:none;
      border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
      mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
      mso-border-alt:solid black .5pt;padding:1.25pt 5.75pt 0in 6.2pt;
      height:29.3pt'>
      <p class=MsoNormal style='margin-right:37.3pt;text-indent:0in;line-height:
      107%'>Forward: ACAGGCGAGAAGCCCTTGC Reverse: CTCGCACACGGGACACTGG</p>
      </td>
     </tr>
     <tr style='mso-yfti-irow:13;mso-yfti-lastrow:yes;height:29.3pt'>
      <td width=112 valign=top style='width:84.35pt;border:solid black 1.0pt;
      border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
      padding:1.25pt 5.75pt 0in 6.2pt;height:29.3pt'>
      <p class=MsoNormal align=center style='margin-right:.4pt;text-align:center;
      text-indent:0in;line-height:107%'>Gapdh</p>
      </td>
      <td width=400 valign=top style='width:300.35pt;border-top:none;
      border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
      mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
      mso-border-alt:solid black .5pt;padding:1.25pt 5.75pt 0in 6.2pt;
      height:29.3pt'>
      <p class=MsoNormal style='margin-right:23.85pt;text-indent:0in;
      line-height:107%'>Forward: GCTCACTGGCATGGCCTTCCG Reverse: GTAGGCCATGAGGTCCACA</p>
      </td>
     </tr>
    </table>
    <p class=MsoNormal>Table 2: List of RT-PCR primers.</p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="square"/>
</v:shape><![endif]--><![if !vml]><img width=582 height=6
src="thesis-github_files/image002.gif" align=left hspace=12 vspace=5
alt="Text Box: Gene	Primers&#13;&#10;Trim63	Forward: TCTCTCAGCTGGAGGACTCC Reverse: CTGTACTGGAGGATCAGAGC&#13;&#10;Fbxo32	Forward: GGGAAGCTTTCAACAGATTGG Reverse: AATGTTCATGAAGTTCTTTTGGG&#13;&#10;Igf1 (IGF-IEa)	Forward: GCTTGCTCACCTTTACCAGC Reverse:AAATGTACTTCCTTCTGGGTCT&#13;&#10;Foxo1	Forward: CACCCTGTCGCAGATCTAG Reverse: CGAATAAACTTGCTGTGAAGG&#13;&#10;Foxo3a	Forward: GACAAACGGCTCACTTTGCC Reverse: GACAGGTTGTTGTGCCGGATGG&#13;&#10;Foxo4	Forward: GCCCTACTTTCAAGGACAAGG Reverse: CATCCACCAGAGCTCTTC&#13;&#10;Ddit4	Forward: CTGCGAGTCCCCTGGACAGC Reverse: CACTGAGCAGCTCAAAGTCG&#13;&#10;Igf1r	Forward: GGGCTGACTGGTGGATGC Reverse: CGCTGGGCACGGATAGAGC&#13;&#10;Becn1	Forward: CCACAGCCCAGGCGAAACC Reverse: GATGAATCTTCGAGAGACACC&#13;&#10;Map1lc3b	Forward: GGAAGATGTCCGGCTATCC Reverse: CTCATGTTCACGTGGTCAGG&#13;&#10;Ctsl	Forward: AACCGCTGATGCTTAAGATCC Reverse: CACTCAGTGAGATCAGTTTGC&#13;&#10;Klf15	Forward: ACAGGCGAGAAGCCCTTGC Reverse: CTCGCACACGGGACACTGG&#13;&#10;Gapdh	Forward: GCTCACTGGCATGGCCTTCCG Reverse: GTAGGCCATGAGGTCCACA&#13;&#10;Table 2: List of RT-PCR primers.&#13;&#10;"
v:shapes="_x0000_s1050"><![endif]></p>

<h2><a name="_Toc421412274">Cell culture studies</a></h2>

<p class=MsoNormal>C2C12 cells were obtained from ATCC (Manassas, Virginia).
They were grown on solid substrate, on cell culture coated plates, in
atmospheric air, supplemented to 5% CO2, at 37 <sup><span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>&#9702;</span></sup>C. During
proliferation, cells were maintained under 500 L<span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>/</span>cm<sup>2 </sup>growth medium,
that is, Dulbeccos Modified Eagle Medium (DMEM; VWR International, Radnor,
Pennsylvania), supplemented with 100  fetal bovine serum (FBS), 100 units/mL
penicillin, and 100 mg<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:
Cambria'>/</span>L streptomycin, changed every other day. DMEM contained 400 M
phenylalanine, 4<i style='mso-bidi-font-style:normal'><span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>.</span></i>5 g<span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>/</span>L glucose, 4 mM glutamine, and
lacked pyruvate.</p>

<p class=MsoNormal>Confluence and multiple passages reduce their ability to
proliferate and differentiate. Therefore, cells were propagated in an undifferentiated
state, by splitting 1:40 at confluence, about every 5 days. Early on, frozen
stocks were made, at 1 million cells/mL in growth medium supplemented with 100
 dimethyl sulfoxide (DMSO), stored under liquid nitrogen. For detachment,
cells were rinsed twice with pre-warmed 200 L<span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>/</span>cm<sup>2 </sup>phosphate buffered
saline (PBS), then incubated at 37 <sup><span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>&#9702;</span></sup>C for about 5 minutes
with 50 L<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:
Cambria'>/</span>cm<sup>2 </sup>pre-warmed 0.05% trypsin / EDTA (Life
Technologies). After detachment, cells were tested for viability with trypan
blue, counted on a hemocytometer, and re-seeded at about 5,000 cells/cm2.</p>

<p class=MsoNormal>For experiments, cells were differentiated into myotubes by
seeding at higher density (about 5,000 cells/cm2). Next day, when cells were
nearly confluent, the medium was changed to differentiation medium, that is,
DMEM supplemented with 20  horse serum (HS), which was charcoal / dextran
stripped of hormones (Gemini Bio-Products). After two days in differentiation
medium, myotubes form, while myoblast become quiescent. The medium was then changed
every day for five more days, leading to nearly complete elimination of
undifferentiated and mononuclear cells.</p>

<p class=MsoNormal>Dexa and Testo were delivered from 400X stocks in ethanol,
at various concentrations, as indicated at each experiment in the results section.</p>

<p class=MsoNormal>Protein synthesis was inhibited with 100 M cycloheximide
from 360X water-based stock, or 5 M puromycin dihydrochloride from 500X
water-based stock. Proteasome activity was inhibited in cell culture with 5 M
MG132 from an 80X working stock in differentiation medium, which in turn was
derived from an 8,000X DMSO-based stock. Lysosome activity was inhibited with
25 M chloroquine from a 2,000X water-based stock. Calpain and cathepsin
activity was inhibited by 10 M E-64, from a 100X water-based stock. IGF-1R was
inhibited by 50 nM picropodophyllin (PPP), from a 200X working stock in
differentiation medium, which in turn was derived from a 1,000X DMSO-based
stock.</p>

<h2><a name="_Toc421412275">Immunofluorescence microscopy</a></h2>

<p class=MsoNormal>After the experimental treatments, the adherent cells were
washed twice, on ice, with ice-cold PBS. The cells were covered with cold 1:1
v/v ethanol:acetone, and incubated at 20 <sup><span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>&#9702;</span></sup>C for 20 minutes.
This process both fixated and permeabilized the cells. The liquid was removed,
and the cells were rinsed with PBS.</p>

<p class=MsoNormal>On the first day of staining, PBS was removed, and cells
were washed briefly twice with PBS. For blocking purposes, cells were incubated
for 40 min at room temperature under 1% BSA in PBS. The blocking liquid was
then replaced with the primary antibody solution, that is, the same blocking
solution, supplemented with 1:20 hybridoma cell culture medium containing the
anti-myosin heavy chain antibody MF-20. Cells were probed with the primary
antibody overnight at 4 <sup><span style='mso-fareast-font-family:Cambria;
mso-bidi-font-family:Cambria'>&#9702;</span></sup>C.</p>

<p class=MsoNormal>Next day, the cells were incubated twice 5 min each with the
blocking solution, to wash unbound primary antibody. Cells were then probed
with the secondary antibody, that is, blocking solution supplemented with 1:500
anti-mouse antibody conjugated with rhodamine, and with 1 mg<span
style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>/</span>L
DAPI. The cells were incubated 60 min at room temperature in the dark, and then
briefly washed 4 times with PBS. Cells covered in PBS were store at 4 <sup><span
style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>&#9702;</span></sup>C
or observed with an Eclipse TE2000-E fluorescence microscope (Nikon
Instruments, Melville, New York).</p>

<p class=MsoNormal>Cell contours were obtained using Magnetic Lasso in Adobe
Photoshop CS4. All the cell outlines that could be recognized by Photoshop from
two randomly chosen fields were pasted in another file, which was read in
Matlab 8. An automated script determined multiple estimates of the diameter,
and calculated an average diameter for each fiber.</p>

<h2><a name="_Toc421412276">Measurement of muscle protein synthesis and
degradation</a></h2>

<p class=MsoNormal>Cells were labeled by incubation in differentiation medium
supplemented with 0<i style='mso-bidi-font-style:normal'><span
style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>.</span></i>2
mCi<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>/</span>L
radioactive (H- [ring]) phenylalanine (126 Ci<span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>/</span>mmol; PerkinElmer, Shelton,
Connecticut), starting at the times and for the durations specified at each
experiment in the results section. For removal of non-specific tracer at the
end of labeling stage, cells were rinsed with PBS twice, and then incubated
with 2 mm PBS for 15 min at 37 <sup><span style='mso-fareast-font-family:Cambria;
mso-bidi-font-family:Cambria'>&#9702;</span></sup>C, 5% CO<sub>2</sub>.</p>

<p class=MsoNormal>For chase experiments, PBS was then replaced with
non-radioactive differentiation medium, for the durations specified at each
experiment. Chase experiments ended with a double rinse with PBS. Preliminary
studies revealed that supplementation of differentiation medium with 10 mM
phenylalanine made no difference to the rate of tracer release, compared to
differentiation medium alone (data not shown). This is plausible, because
differentiation medium already contains 0<i style='mso-bidi-font-style:normal'><span
style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>.</span></i>4
mM phenylalanine, and suggested that additional osmotic stress could be avoided
at no cost to sensitivity of the method.</p>

<p class=MsoNormal>In all cases, cells and media were collected separately, and
each was fractionated with trichloroacetic acid (TCA). Medium was removed from
the plate, and then supplemented with 6 M TCA, to a final 0<i style='mso-bidi-font-style:
normal'><span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>.</span></i>6
M TCA. Cells were covered with 0<i style='mso-bidi-font-style:normal'><span
style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>.</span></i>6
M TCA. Both media and cells were then incubated overnight at <span
style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>&#8722;</span>20
<sup><span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>&#9702;</span></sup>C.
Next day, cells and media were thawed at 4 <sup><span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>&#9702;</span></sup>C over two hours.
Cells were scraped. The cell culture wells were further scraped and rinsed with
0<i style='mso-bidi-font-style:normal'><span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>.</span></i>6 M TCA. Protein suspensions
were centrifuged at 15,000 g, for 15 min, at 4 <sup><span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>&#9702;</span></sup>C. Pellets were
washed with 0<i style='mso-bidi-font-style:normal'><span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>.</span></i>6 M TCA, by resuspension,
incubation at 4 <sup><span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:
Cambria'>&#9702;</span></sup>C for 15 min, and centrifugation as above. Next,
pellets were washed once more with acetone, by the same procedure. All two
TCA-based supernatants and the acetone supernatant were pooled. Pellets were
dissolved in 1 M NaOH / 1  Triton, with sonication 15 min at 50 <sup><span
style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>&#9702;</span></sup>C,
followed by incubation 15 min at 50 <sup><span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>&#9702;</span></sup>C.</p>

<p class=MsoNormal>From the supernatant or from the resuspended pellet, 100 L
was mixed with 5 mL Econo-lite scintillation fluid, and then counted in a
TriCarb 3100TR liquid scintillation counter (PerkinElmer) for 3 min per sample.
Counts per minute were converted to disintegrations per minute using a standard
curve generated using 1 Ci<span style='mso-fareast-font-family:Cambria;
mso-bidi-font-family:Cambria'>/</span>L to 80 Ci<span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>/</span>L labeled phenylalanine dissolved
in the same solvents as the samples (2:1 TCA:acetone, or 1 M NaOH / 1  v/v
Triton).</p>

<p class=MsoNormal>From the same protein pellet suspension, aliquots were used
to measure total protein concentration by BCA method, as described in the
immunoblot section, but with standards prepared in the same solvent as the
unknowns.</p>

<h2><a name="_Toc421412277">Statistics</a></h2>

<p class=MsoNormal>Statistics and plots were generated in R 3.2 with ggplot2,
knitr, and Lyx [609]. Raw data, with LibreOffice Calc and R calculations, is
publicly available on Github. Results are presented as means  standard error
of the mean. In plots, points represent means, while error bars are standard
error of the mean. In both cases, error bars include only biological
variability. Experiments with more than two groups were analyzed by
Kruskal-Wallis test for overall non-parametric analysis of variance. Groups
were compared in pairs using post-hoc Dunns test with Bonferroni correction
for multiple comparisons. In the cases where data passed the Shapiro-Wilk test
of normality at significance level of 0.05, parametric tests were used instead,
including analysis of variance (ANOVA) and post-hoc Tukeys honest significant
difference (HSD) test.</p>

<p class=MsoNormal>In a plot, means with the same letter are not significantly
different from each other. Tests were considered statistically significant when
the null hypothesis could not be rejected at any level of significance greater
than or equal to 0.05.</p>

<h2><a name="_Toc421412278">Literature review</a></h2>

<p class=MsoNormal>The introduction section was based on review of all
literature indexed by PubMed. Search expressions included testosterone OR
androgens, dexamethasone OR betamethasone OR triamcinolone OR prednisone OR
prednisolone OR hydrocortisone OR cortisone OR triamcinolone OR
fludrocortisone, Cushing, ribosome OR polysome OR lysosome OR autophagosome
OR proteasome OR ligase OR cathepsin OR FOXO OR IGF1 OR calpain OR mTOR OR AMPK
OR Akt, and combinations thereof. Relevant primary data were summarized.</p>

<p class=MsoNormal style='margin-top:0in;margin-right:.75pt;margin-bottom:.2pt;
margin-left:.75pt;line-height:177%'><o:p>&nbsp;</o:p></p>

</div>

<span style='font-size:12.0pt;mso-bidi-font-size:11.0pt;line-height:200%;
font-family:"Georgia",serif;mso-fareast-font-family:Georgia;mso-bidi-font-family:
Georgia;color:black;mso-ansi-language:EN-US;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA'><br clear=all style='page-break-before:always;
mso-break-type:section-break'>
</span>

<div class=WordSection5>

<h1><a name="_Toc421412279">5. IN VIVO EXPERIMENTS</a></h1>

<h2><a name="_Toc421412280">Testosterone reverses dexamethasone-induced muscle
atrophy</a></h2>

<p class=MsoNormal>At the time when the project started, no published study on
mice described a dose of Dexa that would induce muscle atrophy. To date, there
is still no published report of the effective Testo dose that would prevent
GAML in mice. I attempted to repeat the daily injections protocol described by
Jones as effective on rats [504] (Fig.1 ).</p>

<p class=MsoNormal>Mice treated with the Dexa doses that were reported to
induce muscle atrophy in rats did not exhibit significant muscle loss based on
muscle dissection and NMR (data not shown). Higher doses of Dexa were used.
Effect size on wet muscle weight became stronger than experimental error at a
dose of 10 mg<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:
Cambria'>/(</span>kg d<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:
Cambria'>) </span>Dexa. In contrast, Testo doses that could reverse GAML were
found to be similar to those effective in rats (28 mg<span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>/(</span>kg d<span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>)</span>).</p>

<p class=MsoNormal>Upon finding the Dexa dose effective in inducing muscle
atrophy, I analyzed the body weight at sacrifice. There was no difference
between groups in terms of absolute weight, due to the large variability of the
initial body weight (Kruskal-Wallis p = 0.777) (Fig. 2, right). The difference
became apparent when percent change in body weight was compared (Fig. 3, top,
last time point). In this case, the three treatments (vehicle, Dexa, or the
combination Dexa + Testo) were significantly different (Kruskal-Wallis p =
0.00385). Instead of the expected unchanged body weight over the seven days of
treatment with vehicle alone, there was a trend for growth, with an apparent
gain of 0.212 grams every day during the treatment. A similar trend has been
seen in the other repetitions of the experiment, as well as in other published
studies on young rodents. A sizable contribution to this growth was brought by
the 200 L vehicle injected every day.</p>

<p class=MsoNormal style='text-indent:0in'><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'></span>SHAPE <span
style='mso-spacerun:yes'></span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shape
 id="_x0000_s1049" type="#_x0000_t202" style='width:6in;height:279.45pt;
 visibility:visible;mso-wrap-style:square;mso-left-percent:-10001;
 mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
 v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF
90jcwfIWJU67QAgl6YK0S0CoHGBkTxKLZGx5TGhvj5O2G0SRWNoz/78nu9wcxkFMGNg6quQqL6RA
0s5Y6ir5vt9lD1JwBDIwOMJKHpHlpr69KfdHjyxSmriSfYz+USnWPY7AufNIadK6MEJMx9ApD/oD
OlTrorhX2lFEilmcO2RdNtjC5xDF9pCuTyYBB5bi6bQ4syoJ3g9WQ0ymaiLzg5KdCXlKLjvcW893
SUOqXwnz5DrgnHtJTxOsQfEKIT7DmDSUCaxw7Rqn8787ZsmRM9e2VmPeBN4uqYvTtW7jvijg9N/y
JsXecLq0q+WD6m8AAAD//wMAUEsDBBQABgAIAAAAIQA4/SH/1gAAAJQBAAALAAAAX3JlbHMvLnJl
bHOkkMFqwzAMhu+DvYPRfXGawxijTi+j0GvpHsDYimMaW0Yy2fr2M4PBMnrbUb/Q94l/f/hMi1qR
JVI2sOt6UJgd+ZiDgffL8ekFlFSbvV0oo4EbChzGx4f9GRdb25HMsYhqlCwG5lrLq9biZkxWOiqY
22YiTra2kYMu1l1tQD30/bPm3wwYN0x18gb45AdQl1tp5j/sFB2T0FQ7R0nTNEV3j6o9feQzro1i
OWA14Fm+Q8a1a8+Bvu/d/dMb2JY5uiPbhG/ktn4cqGU/er3pcvwCAAD//wMAUEsDBBQABgAIAAAA
IQAVcSQFJQIAAEwEAAAOAAAAZHJzL2Uyb0RvYy54bWysVNuO0zAQfUfiHyy/06RVWnajpqulSxHS
siDt8gETx2ksfMN2m5SvZ+xkS7XACyIPlsczPp45Zybrm0FJcuTOC6MrOp/llHDNTCP0vqJfn3Zv
rijxAXQD0mhe0RP39Gbz+tW6tyVfmM7IhjuCINqXva1oF4Its8yzjivwM2O5RmdrnIKApttnjYMe
0ZXMFnm+ynrjGusM497j6d3opJuE37achc9t63kgsqKYW0irS2sd12yzhnLvwHaCTWnAP2ShQGh8
9Ax1BwHIwYnfoJRgznjThhkzKjNtKxhPNWA18/xFNY8dWJ5qQXK8PdPk/x8sezh+cUQ0FV1QokGh
RE98COSdGcgistNbX2LQo8WwMOAxqpwq9fbesG+eaLPtQO/5rXOm7zg0mN083swuro44PoLU/SfT
4DNwCCYBDa1TkTokgyA6qnQ6KxNTYXi4LK5WRY4uhr55kRerRdIug/L5unU+fOBGkbipqEPpEzwc
732I6UD5HBJf80aKZiekTIbb11vpyBGwTXbpSxW8CJOa9BW9Xi6WIwN/hcjT9ycIJQL2uxSqolfn
ICgjb+91k7oxgJDjHlOWeiIycjeyGIZ6mBSb9KlNc0JmnRnbG8cRN51xPyjpsbUr6r8fwHFK5EeN
6lzPiyLOQjKK5VukkrhLT33pAc0QqqKBknG7DWl+Em/2FlXcicRvlHvMZEoZWzbRPo1XnIlLO0X9
+glsfgIAAP//AwBQSwMEFAAGAAgAAAAhAKTboUfbAAAABQEAAA8AAABkcnMvZG93bnJldi54bWxM
j8FOwzAQRO9I/IO1SNyo0wiqKsSpEFXPlFIJcXPsbRw1XofYTVO+noULXEYazWrmbbmafCdGHGIb
SMF8loFAMsG21CjYv23uliBi0mR1FwgVXDDCqrq+KnVhw5lecdylRnAJxUIrcCn1hZTROPQ6zkKP
xNkhDF4ntkMj7aDPXO47mWfZQnrdEi843eOzQ3PcnbyCuN5+9uawrY/OXr5e1uODed98KHV7Mz09
gkg4pb9j+MFndKiYqQ4nslF0CviR9KucLRf3bGsFeT7PQVal/E9ffQMAAP//AwBQSwECLQAUAAYA
CAAAACEAtoM4kv4AAADhAQAAEwAAAAAAAAAAAAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBL
AQItABQABgAIAAAAIQA4/SH/1gAAAJQBAAALAAAAAAAAAAAAAAAAAC8BAABfcmVscy8ucmVsc1BL
AQItABQABgAIAAAAIQAVcSQFJQIAAEwEAAAOAAAAAAAAAAAAAAAAAC4CAABkcnMvZTJvRG9jLnht
bFBLAQItABQABgAIAAAAIQCk26FH2wAAAAUBAAAPAAAAAAAAAAAAAAAAAH8EAABkcnMvZG93bnJl
di54bWxQSwUGAAAAAAQABADzAAAAhwUAAAAA
">
 <v:textbox style='mso-fit-shape-to-text:t'>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='text-indent:0in'><span style='mso-no-proof:yes'><v:shape
     id="Picture_x0020_13" o:spid="_x0000_i1061" type="#_x0000_t75" style='width:417pt;
     height:231pt;visibility:visible;mso-wrap-style:square'>
     <v:imagedata src="thesis-github_files/image003.gif" o:title=""/>
    </v:shape></span></p>
    <p class=MsoNormal>Figure 1: Experimental protocol for the in vivo studies.</p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><![if !vml]><img width=582 height=6
src="thesis-github_files/image001.gif"
alt="Text Box:  &#13;&#10;Figure 1: Experimental protocol for the in vivo studies.&#13;&#10;"
v:shapes="_x0000_s1049"><![endif]><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1084" type="#_x0000_t75" style='width:6in;height:279.45pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p>

<p class=MsoNormal style='text-indent:0in'><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'></span>SHAPE <span
style='mso-spacerun:yes'></span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shape
 id="_x0000_s1048" type="#_x0000_t202" style='width:6in;height:310.95pt;
 visibility:visible;mso-wrap-style:square;mso-left-percent:-10001;
 mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
 v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-fit-shape-to-text:t'>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='text-indent:0in'><span style='mso-no-proof:yes'><v:shape
     id="Picture_x0020_197" o:spid="_x0000_i1060" type="#_x0000_t75" style='width:417pt;
     height:208.5pt;visibility:visible;mso-wrap-style:square'>
     <v:imagedata src="thesis-github_files/image004.gif" o:title=""/>
    </v:shape></span></p>
    <p class=MsoNormal>Figure 2: Body weight at sacrifice, following 10 mg<span
    style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>/(</span>kg
    d<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>)
    </span>Dexa and / or 28 mg<span style='mso-fareast-font-family:Cambria;
    mso-bidi-font-family:Cambria'>/(</span>kg d<span style='mso-fareast-font-family:
    Cambria;mso-bidi-font-family:Cambria'>) </span>Testo treatments. Treatments
    designated by the same letter do not differ significantly from each other
    (n=5-6).</p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><![if !vml]><img width=582 height=6
src="thesis-github_files/image001.gif"
alt="Text Box:  &#13;&#10;Figure 2: Body weight at sacrifice, following 10 mg/(kg d) Dexa and / or 28 mg/(kg d) Testo treatments. Treatments designated by the same letter do not differ significantly from each other (n=5-6).&#13;&#10;"
v:shapes="_x0000_s1048"><![endif]><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1083" type="#_x0000_t75" style='width:6in;height:310.95pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p>

<p class=MsoNormal>Once this artifact is taken into account, the gain of a
negligible 0.0333 grams per day in the Dexa-treated group is in fact indicative
of an actual massive loss of body weight.</p>

<p class=MsoNormal>Seven-day weight gain in Dexa-treated group (1.05  1.14% of
initial body weight) was significantly smaller than that of the vehicle-treated
group (6.12  0.879%; Dunns test p = 0.0447). Conversely, co-administration of
Testo, hereafter and in plots abbreviated Comb, brought back the body weight
gain over seven days to levels similar to those in vehicle-treated animals
(8.62  0.674%; Dunns test vs. Dexa alone, p = 0.00167).</p>

<p class=MsoNormal>The time course of body weight changes suggested that both
drugs action had a rapid onset (Fig. 3; Kruskal-Wallis for first day percent
change in body weight, p = 0.0239). Specifically, mice receiving vehicle alone
gained 2.28  0.485% body weight in the 24 hours, due to accretion of
nonresorbable vehicle. In contrast, mice receiving Dexa lost 1.86  0.485% body
weight (Dunns test p = 0.0387).</p>

<p class=MsoNormal>Mice receiving a combination of Dexa and Testo were
essentially indistinguishable from those receiving vehicle alone, having gained
2.61  0.767% body weight. This demonstrated an advantage of the combination
treatment over Dexa alone (Dunns test p = 0.0213).</p>

<p class=MsoNormal>Based on the whole time course, I hypothesized that body
weight changes and muscle atrophy occur in a gradual manner, with significant
metabolic and molecular changes preceding the seven-day end of experiment.
Accordingly, I repeated the above experiment on different cohorts of mice,
which were sacrificed after only 1 or 3 days of treatment. Once more, absolute
changes in body weight could not be correlated with the muscle changes (Fig. 2,
left and middle). When normalized, relative changes in body weight for these
groups of mice were less ample than those seen with 7 days of treatment, to the
point that most parameters (body weight, lean body mass, individual muscles
mass) were not changed in a statistically significant manner (Fig. 3, bottom).
These shorter treatments provided insight into the molecular development of
atrophy, but, because they were run as independent experiments, they will not
be analyzed in conjunction. Because this work is focused on longer-term effects
of Dexa, most of the reported data in the remainder of the section will be
either from mice treated for 7 days with Dexa with / without Testo, or
comparisons of the 1, 3 and 7 day samples.</p>

<p class=MsoNormal style='text-indent:0in'><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'></span>SHAPE <span
style='mso-spacerun:yes'></span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shape
 id="_x0000_s1047" type="#_x0000_t202" style='width:6in;height:448.2pt;
 visibility:visible;mso-wrap-style:square;mso-left-percent:-10001;
 mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
 v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-fit-shape-to-text:t'>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='text-indent:0in'><span style='mso-no-proof:yes'><v:shape
     id="Picture_x0020_199" o:spid="_x0000_i1059" type="#_x0000_t75" style='width:6in;
     height:318.75pt;visibility:visible;mso-wrap-style:square'>
     <v:imagedata src="thesis-github_files/image005.gif" o:title=""/>
    </v:shape></span></p>
    <p class=MsoNormal>Figure 3: Time course of body weight Dexa with / without
    Testo treatments (n=5-6). Stars indicate statistically significant
    differences between Veh and Dexa (p &lt;0.05). Daggers indicate
    statistically significant differences between Dexa and Comb (p &lt;0.05).</p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><![if !vml]><img width=582 height=6
src="thesis-github_files/image006.gif"
alt="Text Box:  &#13;&#10;Figure 3: Time course of body weight Dexa with / without Testo treatments (n=5-6). Stars indicate statistically significant differences between Veh and Dexa (p &lt;0.05). Daggers indicate statistically significant differences between Dexa and Comb (p &lt;0.05).&#13;&#10;"
v:shapes="_x0000_s1047"><![endif]><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1082" type="#_x0000_t75" style='width:6in;height:448.2pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p>

<p class=MsoNormal style='margin-top:0in;margin-right:.75pt;margin-bottom:.2pt;
margin-left:.75pt;line-height:177%'>Body composition analysis indicated that
all animals included in these experiments progressively lost total water. There
was no difference between water loss in the three experimental groups (Fig. 4,
top; Kruskal-Wallis for seven day mass of water lost, p = 0.302). This uniform
loss of water negates a scenario in which the observations could be ascribed to
increased water retention due to non-specific action of either steroid with MR.
In all cases, the losses of total water track the loss of lean body mass,
indicating that muscle atrophy, rather than renal dysfunction, underlies the
loss of water. Fat mass analysis indicated that in the vehicle-alone treated
group, the rate of apparent fat gain was essentially equal with the mass of
injected vehicle accrued over the seven days. This demonstrates that
experiments manipulations, in the absence of pharmacological treatments, have
no effect on lipid metabolism. Dexa-treated mice accrued an additional 0.73 g
fat, compared to vehicle (Dunns test, p = 0.0681. Similarly, mice treated with
the combination accrued 0.922 g additional fat, compared to vehicle (Dunns
test, p = 0.0172). Therefore, Testo co-administration had no effect on lipid
accretion (Dunns test, Dexa vs. combination, p = 0.802).</p>

<p class=MsoNormal style='margin-top:0in;margin-right:.75pt;margin-bottom:0in;
margin-left:.75pt;margin-bottom:.0001pt'>Ampler changes were induced by the two
drugs on lean body mass (Fig. 4, bottom; Kruskal-Wallis for seven day lost lean
mass, p = 0.000811). Vehicle alone has no effect on lean body mass (0.327 
0.203 grams lost over seven days, that is, 1.65% of the total lean body mass).
Dexa alone induce a massive loss of lean body mass (3.21  0.166 grams lost
over seven days; Dunns test p = 0.000242). When Testo was co-administered, the
loss of lean body mass persisted, but there was a trend towards a lower loss
rate (1.57  0.133 grams lost over seven days; Dunns test vs Dexa, p = 0.108).</p>

<p class=MsoNormal style='margin-top:0in;margin-right:.75pt;margin-bottom:0in;
margin-left:.75pt;margin-bottom:.0001pt'>The loss of lean body mass induced by
Dexa was apparent even in the 3-day experiment (1.45  0.152 grams lost over
three days; Dunns test vs. vehicle, p = 0.00961). Interestingly, in that
experiment, Testo protective effect was very small and not statistically
significant (1.28  0.369 grams lost over three days; Dunns test vs. Dexa, p =
0.675).</p>

<p class=MsoNormal style='text-indent:0in'><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'></span>SHAPE <span
style='mso-spacerun:yes'></span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shape
 id="_x0000_s1046" type="#_x0000_t202" style='width:6in;height:396.45pt;
 visibility:visible;mso-wrap-style:square;mso-left-percent:-10001;
 mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
 v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-fit-shape-to-text:t'>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='text-indent:0in'><span style='mso-no-proof:yes'><v:shape
     id="Picture_x0020_200" o:spid="_x0000_i1058" type="#_x0000_t75" style='width:417pt;
     height:321pt;visibility:visible;mso-wrap-style:square'>
     <v:imagedata src="thesis-github_files/image007.gif" o:title=""/>
    </v:shape></span></p>
    <p class=MsoNormal>Figure 4: Changes in water, lean, and fat body mass,
    after Dexa with / without Testo treatments (n=5-6).</p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><![if !vml]><img width=582 height=6
src="thesis-github_files/image001.gif"
alt="Text Box:  &#13;&#10;Figure 4: Changes in water, lean, and fat body mass, after Dexa with / without Testo treatments (n=5-6).&#13;&#10;"
v:shapes="_x0000_s1046"><![endif]><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1081" type="#_x0000_t75" style='width:6in;height:396.45pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p>

<p class=MsoNormal>Dissection of individual muscles confirmed that Dexa
achieved widespread muscle atrophy (Fig. 5). Despite the small sample size
(n=5-6), the atrophying effect of Dexa became statistically significant at day
3 on gastrocnemius (Dunns test, p = 0.0369). At day 7, statistical
significance is also achieved in triceps brachii (Dunns test, p = 0.0209),
quadriceps (Dunns test, p = 0.00205), and levator ani (Dunns test, p =
0.0245). In terms of amplitudes, the five measured muscles ranged from
extremely responsive, such as quadriceps (22.7% muscle weight loss), triceps
(18% muscle weight loss) and gastrocnemius (16.5% muscle weight loss), to the
refractory tibialis anterior (6.2% muscle weight loss). For each muscle and
time point, the average muscle weight in the Dexa group was smaller than the
average weight of the controls.</p>

<p class=MsoNormal>Upon Testo co-administration, four out of five muscles
measured were exhibited a trend towards restoration to their basal weight (Fig.
5). The amplitude of restorative response to Testo co-administration was
strongest in quadriceps (15.2% restoration in muscle weight; Dunns test, p =
0.27), followed by levator (10.2% restoration in muscle weight; Dunns test, p
= 0.134), and gastrocnemius (9.07% restoration in muscle weight; Dunns test, p
= 0.199) appear the most responsive.</p>

<p class=MsoNormal>At the seventh day, Testo co-administration led to an
additional 3.12% loss in tibialis weight (Dunns test, p = 0.523). A similar
trend indicating Testos inability to rescue tibialis mass is also present in
the three-day data (2.63% loss; Dunns test, p =0.975). The small amplitude and
the complete absence of statistical significance suggest that observations
describe lack of Testo effect, rather than a true atrophic effect. Because
tibialis is not manifesting GAML at macroscopic level, molecular analysis will
not include it.</p>

<p class=MsoNormal style='text-indent:0in'><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'></span>SHAPE <span
style='mso-spacerun:yes'></span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shape
 id="_x0000_s1045" type="#_x0000_t202" style='width:6in;height:654.45pt;
 visibility:visible;mso-wrap-style:square;mso-left-percent:-10001;
 mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
 v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-fit-shape-to-text:t'>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='text-indent:0in'><span style='mso-no-proof:yes'><v:shape
     id="Picture_x0020_201" o:spid="_x0000_i1057" type="#_x0000_t75" style='width:417pt;
     height:552pt;visibility:visible;mso-wrap-style:square'>
     <v:imagedata src="thesis-github_files/image008.gif" o:title=""/>
    </v:shape></span></p>
    <p class=MsoNormal>Figure 5: Effects of Dexa with / without Testo
    treatments on the wet weight of levator ani, quadriceps, gastrocnemius,
    triceps brachii, and tibialis anterior muscles (normalized to body weight;
    n=5-6).</p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><![if !vml]><img width=582 height=6
src="thesis-github_files/image001.gif"
alt="Text Box:  &#13;&#10;Figure 5: Effects of Dexa with / without Testo treatments on the wet weight of levator ani, quadriceps, gastrocnemius, triceps brachii, and tibialis anterior muscles (normalized to body weight; n=5-6).&#13;&#10;"
v:shapes="_x0000_s1045"><![endif]><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1080" type="#_x0000_t75" style='width:6in;height:654.45pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p>

<p class=MsoNormal>In conclusion, 10 mg<span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>/(</span>kg d<span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>) </span>Dexa injection led to rapid
onset of muscle atrophy. Similar to humans with hypercortisolism, total body
weight had limited use in assessing atrophy progression. Based on the time
course of lean body mass and individual muscle changes, the atrophy develops
throughout the first week, indicating that this murine model replicates chronic
GC exposure. Some muscles are more responsive than others, with tibialis a
notable refractory exception. In contrast, 28 mg<span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>/(</span>kg d<span style='mso-fareast-font-family:
Cambria;mso-bidi-font-family:Cambria'>) </span>Testo co-administration reduced
the loss of muscle throughout the seven days course. While rat experiments have
described a series of pathways by which Dexa can achieve muscle atrophy, it was
unclear which of them, if any, is reversed by Testo co-administration.</p>

<h2><a name="_Toc421412281">Testosterone reverses glucocorticoid-induced
activation of the ubiquitin-proteasome system</a></h2>

<p class=MsoNormal>The rapid loss of muscle mass induced by Dexa in mice exceeds
the rate of protein turnover in normal adult rodent muscle (about 2.5% per day
[610]). Therefore, Dexas action cannot rely exclusively on translational
shutdown. I attempted to establish which protein degradative pathways could be
mediating the atrophic effect of dexamethasone. Experiments on rats suggest
that Dexa causes protein degradation by stimulating the
proteasome-ubiquitin-related transcriptional program, whereas Testo represses
it.</p>

<p class=MsoNormal style='text-indent:0in'><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'></span>SHAPE <span
style='mso-spacerun:yes'></span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shape
 id="_x0000_s1044" type="#_x0000_t202" style='width:6in;height:658.2pt;
 visibility:visible;mso-wrap-style:square;mso-left-percent:-10001;
 mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
 v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-fit-shape-to-text:t'>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='text-indent:0in'><span style='mso-no-proof:yes'><v:shape
     id="Picture_x0020_202" o:spid="_x0000_i1056" type="#_x0000_t75" style='width:417pt;
     height:555.75pt;visibility:visible;mso-wrap-style:square'>
     <v:imagedata src="thesis-github_files/image009.gif" o:title=""/>
    </v:shape></span></p>
    <p class=MsoNormal>Figure 6: Changes in atrogenes MuRF-1 / Trim63 and MAFbx
    / Fbxo32 expression following Dexa with / without Testo treatments, in
    quadriceps and gastrocnemius muscles (n=3-5, normalized to GAPDH).</p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><![if !vml]><img width=582 height=6
src="thesis-github_files/image006.gif"
alt="Text Box:  &#13;&#10;Figure 6: Changes in atrogenes MuRF-1 / Trim63 and MAFbx / Fbxo32 expression following Dexa with / without Testo treatments, in quadriceps and gastrocnemius muscles (n=3-5, normalized to GAPDH).&#13;&#10;"
v:shapes="_x0000_s1044"><![endif]><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1079" type="#_x0000_t75" style='width:6in;height:658.2pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal>In normal circumstances, the rate-limiting factor in
proteasome-mediated protein degradation is target protein conjugation with
ubiquitin, catalyzed by E3 ligases. In mice treated with Dexa, the E3 ligase
more commonly associated with loss of muscle mass, MuRF-1 (Fig. 6, top), was
upregulated by Dexa at day 1 in gastrocnemius (1.9-fold amplification; Dunns
test, p = 0.116) and in quadriceps (61.5-fold amplification; Dunns test, p =
0.00906). The effect was even more consistent at day 3, with MuRF-1 transcript
in gastrocnemius being 7.58-fold amplified (Dunns test, p =0.0154), and in
quadriceps 4.71-fold amplified (Dunns test, p =0.0726). The effect was
insignificant statistically, and in amplitude, by the seventh day of Dexa
administration.</p>

<p class=MsoNormal>Testo co-administration had an inhibitory effect on MuRF-1,
with a later onset. No significant effect of Testo co-administration was seen
in day 1. In day 3 samples, MuRF-1 was repressed by Testo in gastrocnemius
(1.97-fold reduction; Dunns test, p =0.591) and in quadriceps (5.82-fold
reduction; Dunns test, p =0.0268). Testo repression of MuRF-1 strengthened in
the day 7 samples, with transcripts reduced in gastrocnemius (2.11 fold
reduction; Dunns test, p = 0.116) and in quadriceps (2.13 fold reduction;
Dunns test, p = 0.0748).</p>

<p class=MsoNormal>A similar pattern, although with lower intensity, was seen
in MAFbx gene regulation by the two steroids. MAFbx was reliably upregulated by
Dexa at day 1 in gastrocnemius (2.45 fold amplification; Dunns test, p =
0.175) and quadriceps (50.1 fold amplification; Dunns test, p = 0.00906). At
day 3, only the quadriceps MAFbx response was still present to a significant
degree (4.32 fold amplification; Dunns test, p = 0.113). The effect became
insignificant statistically across muscle groups by the seventh day of Dexa
administration.</p>

<p class=MsoNormal>Testo co-administration had no statistically significant
effect on MAFbx at days 1 and 7. By day 3, MAFbx was repressed by Testo in
gastrocnemius (1.34 fold amplification; Dunns test, p = 0.616) and in
quadriceps (6.29 fold amplification; Dunns test, p = 0.0154).</p>

<p class=MsoNormal style='text-indent:0in'><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'></span>SHAPE <span
style='mso-spacerun:yes'></span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shape
 id="_x0000_s1043" type="#_x0000_t202" style='width:6in;height:380.7pt;
 visibility:visible;mso-wrap-style:square;mso-left-percent:-10001;
 mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
 v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-fit-shape-to-text:t'>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='text-indent:0in'><span style='mso-no-proof:yes'><v:shape
     id="Picture_x0020_205" o:spid="_x0000_i1055" type="#_x0000_t75" style='width:417pt;
     height:278.25pt;visibility:visible;mso-wrap-style:square'>
     <v:imagedata src="thesis-github_files/image010.gif" o:title=""/>
    </v:shape></span></p>
    <p class=MsoNormal>Figure 7: Changes in proteasome chymotrypsin-like
    enzymatic activity following Dexa with / without Testo treatments, in
    quadriceps and triceps muscles (n=4-6).</p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><![if !vml]><img width=582 height=6
src="thesis-github_files/image006.gif"
alt="Text Box:  &#13;&#10;Figure 7: Changes in proteasome chymotrypsin-like enzymatic activity following Dexa with / without Testo treatments, in quadriceps and triceps muscles (n=4-6).&#13;&#10;"
v:shapes="_x0000_s1043"><![endif]><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1078" type="#_x0000_t75" style='width:6in;height:380.7pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p>

<p class=MsoNormal>The other component of the ubiquitin-proteasome system is
the proteasome itself. In cases where E3 ligases are upregulated, it may be the
case that availability of proteasomes is limiting the ubiquitin-proteasome
system. However, in day 3 samples, where atrogene upregulation was at its peak,
Dexa upregulated proteasome chymotrypsin-like enzymatic activity in quadriceps
(18.7% increase; Dunns test, p = 0.157) and triceps (111% increase; Dunns
test, p = 0.0884; Fig. 7). This component of atrophy was also inhibited by
Testo, whose co-administration reduced proteasome activity in quadriceps (24.2%
reduction; Dunns test, p = 0.435) and triceps (30% reduction; Dunns test, p =
0.609) at day 3.</p>

<p class=MsoNormal>Overall, the good correlation with the macroscopic loss of
muscle suggests that the proteasome-ubiquitin system is an effector of GAML and
a target of alleviation by AAS.</p>

<h2><a name="_Toc421412282">Autophagy markers during dexamethasone and
testosterone treatments</a></h2>

<p class=MsoNormal>Rat microarray studies indicated that a series of genes
related to autophagy are upregulated by Dexa and downregulated by Testo.
However, these findings have never been tested in vivo in mice. Having
established a model of GAML, I investigated whether the autophagy markers are
correlated with muscle loss. A panel of three genes indicated that Dexa-induced
gastrocnemius atrophy is associated with a reduction in autophagy-related
transcription (Fig. 8) The repression is ampler in day 3 samples, with mRNA for
beclin / Becn1 reduced 9.81-fold (Dunns test, p = 0.0213), cathepsin L / Ctsl
reduced 3.89-fold (Dunns test, p = 0.304), and LC3 / Map1lc3b reduced
5.61-fold (Dunns test, p = 0.359). Across muscle groups and time points, Testo
co-administration lacked detectable effect.</p>

<p class=MsoNormal style='text-indent:0in'><!--[if gte vml 1]><v:shape id="_x0000_s1042"
 type="#_x0000_t202" style='position:absolute;margin-left:0;margin-top:14.4pt;
 width:6in;height:588.45pt;z-index:251669504;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:200;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:3.6pt;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:3.6pt;
 mso-position-horizontal:center;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:200;mso-width-relative:margin;
 mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-fit-shape-to-text:t'>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='text-indent:0in'><span style='mso-no-proof:yes'><v:shape
     id="Picture_x0020_207" o:spid="_x0000_i1054" type="#_x0000_t75" style='width:417pt;
     height:486pt;visibility:visible;mso-wrap-style:square'>
     <v:imagedata src="thesis-github_files/image011.gif" o:title=""/>
    </v:shape></span></p>
    <p class=MsoNormal>Figure 8: Changes in autophagy-related genes following Dexa
    with / without Testo treatments, in quadriceps and triceps muscles (n=3-4,
    normalized to GAPDH).</p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="square"/>
</v:shape><![endif]--><![if !vml]><img width=582 height=6
src="thesis-github_files/image012.gif" align=left hspace=12 vspace=5
alt="Text Box:  &#13;&#10;Figure 8: Changes in autophagy-related genes following Dexa with / without Testo treatments, in quadriceps and triceps muscles (n=3-4, normalized to GAPDH).&#13;&#10;"
v:shapes="_x0000_s1042"><![endif]></p>

<p class=MsoNormal style='text-indent:0in'><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'></span>SHAPE <span
style='mso-spacerun:yes'></span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shape
 id="_x0000_s1041" type="#_x0000_t202" style='width:6in;height:457.95pt;
 visibility:visible;mso-wrap-style:square;mso-left-percent:-10001;
 mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
 v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-fit-shape-to-text:t'>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='text-indent:0in'><span style='mso-no-proof:yes'><v:shape
     id="Picture_x0020_209" o:spid="_x0000_i1053" type="#_x0000_t75" style='width:417pt;
     height:382.5pt;visibility:visible;mso-wrap-style:square'>
     <v:imagedata src="thesis-github_files/image013.gif" o:title=""/>
    </v:shape></span></p>
    <p class=MsoNormal>Figure 9: Changes in cathepsin L enzymatic activity
    following Dexa with / without Testo treatments, in quadriceps and triceps
    muscles (n=4-6).</p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><![if !vml]><img width=582 height=6
src="thesis-github_files/image001.gif"
alt="Text Box:  &#13;&#10;Figure 9: Changes in cathepsin L enzymatic activity following Dexa with / without Testo treatments, in quadriceps and triceps muscles (n=4-6).&#13;&#10;"
v:shapes="_x0000_s1041"><![endif]><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1077" type="#_x0000_t75" style='width:6in;height:457.95pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p>

<p class=MsoNormal>I tested the hypothesis that autophagy mediates protein
degradation in GAML by measuring lysosome enzymatic activity in muscle lysates
(Fig. 9). Unexpectedly, cathepsin L enzymatic activity was reduced in all the
assayed muscle, in a progressive manner. At day 1, cathepsin L activity was
suppressed by Dexa in gastrocnemius (16.4% reduction; Dunns test, p = 0.02),
quadriceps (14.5% reduction; Dunns test, p = 0.0294), and triceps (26.8%
reduction; Dunns test, p = 0.00219). At day 3, cathepsin L activity was
further suppressed by Dexa in gastrocnemius (19.7% reduction; Dunns test, p =
0.223), quadriceps (44.5% reduction; Dunns test, p = 0.00201), and triceps
(44.5% reduction; Dunns test, p = 0.00107). In day 7 samples, Dexa-induced
repression of cathepsin L activity reached 36.3% in gastrocnemius (Dunns test,
p = 0.00365), 44.4% in triceps (Dunns test, p = 0.0486), and 44.9% in
quadriceps (Dunns test, p = 0.0091). Testo co-administration had no
statistically significant effect on cathepsin L enzymatic activity, although a
trend of reversal to baseline can be seen in day 1 and 3 samples.</p>

<p class=MsoNormal style='text-indent:0in'><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'></span>SHAPE <span
style='mso-spacerun:yes'></span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shape
 id="_x0000_s1040" type="#_x0000_t202" style='width:6in;height:249.45pt;
 visibility:visible;mso-wrap-style:square;mso-left-percent:-10001;
 mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
 v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-fit-shape-to-text:t'>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='text-indent:0in'><span style='mso-no-proof:yes'><v:shape
     id="Picture_x0020_212" o:spid="_x0000_i1052" type="#_x0000_t75" style='width:3in;
     height:2in;visibility:visible;mso-wrap-style:square'>
     <v:imagedata src="thesis-github_files/image014.gif" o:title=""/>
    </v:shape><v:shape id="Picture_x0020_211" o:spid="_x0000_i1051" type="#_x0000_t75"
     style='width:183.75pt;height:147pt;visibility:visible;mso-wrap-style:square'>
     <v:imagedata src="thesis-github_files/image015.gif" o:title=""/>
    </v:shape></span></p>
    <p class=MsoNormal>Figure 10: Changes in hyperlipidated (fast-migrating)
    LC3 isoform following Dexa with / without Testo treatment in gastrocnemius
    muscles (n=4).</p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><![if !vml]><img width=582 height=6
src="thesis-github_files/image001.gif"
alt="Text Box:   &#13;&#10;Figure 10: Changes in hyperlipidated (fast-migrating) LC3 isoform following Dexa with / without Testo treatment in gastrocnemius muscles (n=4).&#13;&#10;"
v:shapes="_x0000_s1040"><![endif]><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1076" type="#_x0000_t75" style='width:6in;height:249.45pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p>

<p class=MsoNormal>In literature, another line of evidence for the putative
upregulation of autophagy during GAML was the increase in lipidated, fast
migrating LC3 protein (also known as LC3-II). In murine muscle, detecting this
form has been difficult, because it is significantly less frequent than its slower
migrated counterpart (Fig. 10). In gastrocnemius at day 7, there was a trend
towards enrichment of LC3-II in absolute terms upon Dexa treatment (91.6%
increase, when normalized to GAPDH; Dunns test, p = 1). However, LC3-II
changes become negligible, when LC3-II is normalized to its precursor, LC3-I
(-0.339% increase; Dunns test, p = 1).</p>

<p class=MsoNormal style='text-indent:0in'><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'></span>SHAPE <span
style='mso-spacerun:yes'></span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shape
 id="_x0000_s1039" type="#_x0000_t202" style='width:6in;height:214.2pt;
 visibility:visible;mso-wrap-style:square;mso-left-percent:-10001;
 mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
 v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-fit-shape-to-text:t'>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='text-indent:0in'><span style='mso-no-proof:yes'><v:shape
     id="Picture_x0020_214" o:spid="_x0000_i1050" type="#_x0000_t75" style='width:417pt;
     height:138.75pt;visibility:visible;mso-wrap-style:square'>
     <v:imagedata src="thesis-github_files/image016.gif" o:title=""/>
    </v:shape></span></p>
    <p class=MsoNormal>Figure 11: &#956;-calpain enzymatic activity, during 7
    days of Dexa with / without Testo treatments, in gastrocnemius muscles
    (n=3-6).</p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><![if !vml]><img width=582 height=6
src="thesis-github_files/image006.gif"
alt="Text Box:  &#13;&#10;Figure 11: &#956;-calpain enzymatic activity, during 7 days of Dexa with / without Testo treatments, in gastrocnemius muscles (n=3-6).&#13;&#10;"
v:shapes="_x0000_s1039"><![endif]><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1075" type="#_x0000_t75" style='width:6in;height:214.2pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p>

<p class=MsoNormal>The trend towards increased absolute LC3-II in gastrocnemius
is reversed by a trend towards basal levels upon Testo co-administration (29.8%
decrease, when normalized to GAPDH; Dunns test, p = 1).</p>

<p class=MsoNormal>Findings like the upregulation of LC3-II may have suggested
to other authors that GAML relies on autophagy. However, the overall evidence
suggests that GAML is correlated with rampant autophagy downregulation, while
AAS co-administration has a limited effect on autophagy. Immunoblots and
enzymatic assays indicated a similar disconnection between the calpain /
calpastatin system and the AAS-induced muscle sparing (Fig. 11). The ubiquitin
- proteasome system emerges as the main effector of GAML and the main target of
its alleviation by AAS, in this model system.</p>

<h2><a name="_Toc421412283">Protein synthesis modulation during Dexa-induced
muscle atrophy</a></h2>

<p class=MsoNormal>Often, literature reports describe how upregulation of
muscle catabolism following Dexa treatments is compounded by repression of
protein synthesis. In order to discern putative changes in protein synthesis in
this model, I investigated a series of its translation regulators. A
well-documented manner of translational shutdown upon various conditions, such
as endoplasmic reticulum stress, is phosphorylation of the initiation factor
eIF2&#945; by a diverse set of kinases. In agreement with published studies,
there was no statistically significant change in phospho-eIF2&#945; in the
gastrocnemius of mice treated with Dexa (Dunns test, p = 1; Fig. 12).</p>

<p class=MsoNormal style='text-indent:0in'><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'></span>SHAPE <span
style='mso-spacerun:yes'></span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shape
 id="_x0000_s1038" type="#_x0000_t202" style='width:6in;height:267.45pt;
 visibility:visible;mso-wrap-style:square;mso-left-percent:-10001;
 mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
 v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF
90jcwfIWJU67QAgl6YK0S0CoHGBkTxKLZGx5TGhvj5O2G0SRWNoz/78nu9wcxkFMGNg6quQqL6RA
0s5Y6ir5vt9lD1JwBDIwOMJKHpHlpr69KfdHjyxSmriSfYz+USnWPY7AufNIadK6MEJMx9ApD/oD
OlTrorhX2lFEilmcO2RdNtjC5xDF9pCuTyYBB5bi6bQ4syoJ3g9WQ0ymaiLzg5KdCXlKLjvcW893
SUOqXwnz5DrgnHtJTxOsQfEKIT7DmDSUCaxw7Rqn8787ZsmRM9e2VmPeBN4uqYvTtW7jvijg9N/y
JsXecLq0q+WD6m8AAAD//wMAUEsDBBQABgAIAAAAIQA4/SH/1gAAAJQBAAALAAAAX3JlbHMvLnJl
bHOkkMFqwzAMhu+DvYPRfXGawxijTi+j0GvpHsDYimMaW0Yy2fr2M4PBMnrbUb/Q94l/f/hMi1qR
JVI2sOt6UJgd+ZiDgffL8ekFlFSbvV0oo4EbChzGx4f9GRdb25HMsYhqlCwG5lrLq9biZkxWOiqY
22YiTra2kYMu1l1tQD30/bPm3wwYN0x18gb45AdQl1tp5j/sFB2T0FQ7R0nTNEV3j6o9feQzro1i
OWA14Fm+Q8a1a8+Bvu/d/dMb2JY5uiPbhG/ktn4cqGU/er3pcvwCAAD//wMAUEsDBBQABgAIAAAA
IQB1j19GKQIAAE8EAAAOAAAAZHJzL2Uyb0RvYy54bWysVNuO0zAQfUfiHyy/01xISzdqulq6FCEt
F2mXD3Acp7FwPMZ2m5SvZ+y0pVrgBZEHy+MZH8+cM5PV7dgrchDWSdAVzWYpJUJzaKTeVfTr0/bV
khLnmW6YAi0qehSO3q5fvlgNphQ5dKAaYQmCaFcOpqKd96ZMEsc70TM3AyM0OluwPfNo2l3SWDYg
eq+SPE0XyQC2MRa4cA5P7ycnXUf8thXcf25bJzxRFcXcfFxtXOuwJusVK3eWmU7yUxrsH7LomdT4
6AXqnnlG9lb+BtVLbsFB62cc+gTaVnIRa8BqsvRZNY8dMyLWguQ4c6HJ/T9Y/unwxRLZVDTP5pRo
1qNIT2L05C2MJA/8DMaVGPZoMNCPeIw6x1qdeQD+zRENm47pnbizFoZOsAbzy8LN5OrqhOMCSD18
hAafYXsPEWhsbR/IQzoIoqNOx4s2IRWOh/NiuShSdHH0ZUVaLPKoXsLK83VjnX8voCdhU1GL4kd4
dnhwPqTDynNIeM2Bks1WKhUNu6s3ypIDw0bZxi9W8CxMaTJU9GaezycG/gqRxu9PEL302PFK9hVd
XoJYGXh7p5vYj55JNe0xZaVPRAbuJhb9WI9Rs+z1WaAamiNSa2HqcJxI3HRgf1AyYHdX1H3fMyso
UR80ynOTFUUYh2gU8zfIJbHXnvrawzRHqIp6SqbtxscRisSZO5RxKyPBQe8pk1PO2LWR99OEhbG4
tmPUr//A+icAAAD//wMAUEsDBBQABgAIAAAAIQCk26FH2wAAAAUBAAAPAAAAZHJzL2Rvd25yZXYu
eG1sTI/BTsMwEETvSPyDtUjcqNMIqirEqRBVz5RSCXFz7G0cNV6H2E1Tvp6FC1xGGs1q5m25mnwn
RhxiG0jBfJaBQDLBttQo2L9t7pYgYtJkdRcIFVwwwqq6vip1YcOZXnHcpUZwCcVCK3Ap9YWU0Tj0
Os5Cj8TZIQxeJ7ZDI+2gz1zuO5ln2UJ63RIvON3js0Nz3J28grjefvbmsK2Pzl6+Xtbjg3nffCh1
ezM9PYJIOKW/Y/jBZ3SomKkOJ7JRdAr4kfSrnC0X92xrBXk+z0FWpfxPX30DAAD//wMAUEsBAi0A
FAAGAAgAAAAhALaDOJL+AAAA4QEAABMAAAAAAAAAAAAAAAAAAAAAAFtDb250ZW50X1R5cGVzXS54
bWxQSwECLQAUAAYACAAAACEAOP0h/9YAAACUAQAACwAAAAAAAAAAAAAAAAAvAQAAX3JlbHMvLnJl
bHNQSwECLQAUAAYACAAAACEAdY9fRikCAABPBAAADgAAAAAAAAAAAAAAAAAuAgAAZHJzL2Uyb0Rv
Yy54bWxQSwECLQAUAAYACAAAACEApNuhR9sAAAAFAQAADwAAAAAAAAAAAAAAAACDBAAAZHJzL2Rv
d25yZXYueG1sUEsFBgAAAAAEAAQA8wAAAIsFAAAAAA==
">
 <v:textbox style='mso-fit-shape-to-text:t'>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='text-indent:0in'><span style='mso-no-proof:yes'><v:shape
     id="Picture_x0020_216" o:spid="_x0000_i1049" type="#_x0000_t75" style='width:3in;
     height:2in;visibility:visible;mso-wrap-style:square'>
     <v:imagedata src="thesis-github_files/image017.gif" o:title=""/>
    </v:shape><v:shape id="Picture_x0020_218" o:spid="_x0000_i1048" type="#_x0000_t75"
     style='width:189.75pt;height:165pt;visibility:visible;mso-wrap-style:square'>
     <v:imagedata src="thesis-github_files/image018.gif" o:title=""/>
    </v:shape></span></p>
    <p class=MsoNormal>Figure 12: Levels of phosphorylated eIF2&#945; (Ser 51)
    following Dexa with / without Testo treatment in gastrocnemius muscles
    (normalized to simultaneously resolved GAPDH; n=4).</p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><![if !vml]><img width=582 height=6
src="thesis-github_files/image001.gif"
alt="Text Box:   &#13;&#10;Figure 12: Levels of phosphorylated eIF2&#945; (Ser 51) following Dexa with / without Testo treatment in gastrocnemius muscles (normalized to simultaneously resolved GAPDH; n=4).&#13;&#10;"
v:shapes="_x0000_s1038"><![endif]><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1074" type="#_x0000_t75" style='width:6in;height:267.45pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p>

<p class=MsoNormal>Another regulator of proteins synthesis that was shown to
play a role in muscle atrophy upon starvation is eIF3f. In levator muscles of
mice treated with Dexa, there was no statistically significant change in the
levels of eIF3f (Dunns test, p = 0.971; Fig. 13).</p>

<p class=MsoNormal>Finally, Dexa was hypothesized to achieve protein synthesis
inhibition by stimulating the negative regulator 4E-BP. In Dexa-treated mice,
gastrocnemius 4E-BP protein levels were upregulated (25.6% increase, when
normalized to GAPDH; Dunns test, p = 0.428; Fig. 14, left). However, Dexa also
stimulated phosphorylated, that is, inactive 4E-BP (62.5% increase, when
normalized to GAPDH; Dunns test, p = 0.00669; Fig. 14, right). The effect of
Dexa on active, that is, unphosphorylated 4E-BP could not be clearly estimated
from these immunoblot data.</p>

<p class=MsoNormal style='text-indent:0in'><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'></span>SHAPE <span
style='mso-spacerun:yes'></span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shape
 id="_x0000_s1037" type="#_x0000_t202" style='width:6in;height:267.45pt;
 visibility:visible;mso-wrap-style:square;mso-left-percent:-10001;
 mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
 v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-fit-shape-to-text:t'>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='text-indent:0in'><span style='mso-no-proof:yes'><v:shape
     id="Picture_x0020_220" o:spid="_x0000_i1047" type="#_x0000_t75" style='width:3in;
     height:2in;visibility:visible;mso-wrap-style:square'>
     <v:imagedata src="thesis-github_files/image019.gif" o:title=""/>
    </v:shape><v:shape id="Picture_x0020_221" o:spid="_x0000_i1046" type="#_x0000_t75"
     style='width:192pt;height:165pt;visibility:visible;mso-wrap-style:square'>
     <v:imagedata src="thesis-github_files/image020.gif" o:title=""/>
    </v:shape></span></p>
    <p class=MsoNormal>Figure 13: Levels of eIF3f following Dexa with / without
    Testo treatment in levator ani muscles (normalized to simultaneously
    resolved GAPDH; n=4).</p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><![if !vml]><img width=582 height=6
src="thesis-github_files/image001.gif"
alt="Text Box:   &#13;&#10;Figure 13: Levels of eIF3f following Dexa with / without Testo treatment in levator ani muscles (normalized to simultaneously resolved GAPDH; n=4).&#13;&#10;"
v:shapes="_x0000_s1037"><![endif]><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1073" type="#_x0000_t75" style='width:6in;height:267.45pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p>

<p class=MsoNormal>After 7 days of Testo co-administration, levels of total
4E-BP were essentially identical to those yielded by Dexa alone (5.6% increase;
Dunns test, p = 0.428; Fig. 14, right). At the same time, Testo
co-administration was associated with lower phosphorylated 4E-BP (9.83%
increase, when normalized to GAPDH; Dunns test, p = 0.49; Fig. 14, left). The
combination of increase in total 4E-BP and decrease in inactivated 4E-BP
suggests an unexpected increase in active 4E-BP, which could have led to
reduction in the rate of protein synthesis. The amplitude of Testo-induced
changes in 4E-BP is small, and the direction opposite to what would be required
to upregulate protein synthesis and facilitate muscle recovery.</p>

<p class=MsoNormal>Overall, regulators of protein synthesis appeared largely
unchanged by Testo at the 7-day stage of their administration, in this model
system.</p>

<p class=MsoNormal style='text-indent:0in'><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'></span>SHAPE <span
style='mso-spacerun:yes'></span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shape
 id="_x0000_s1036" type="#_x0000_t202" style='width:6in;height:413.7pt;
 visibility:visible;mso-wrap-style:square;mso-left-percent:-10001;
 mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
 v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-fit-shape-to-text:t'>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='text-indent:0in'><span style='mso-no-proof:yes'><v:shape
     id="Picture_x0020_223" o:spid="_x0000_i1045" type="#_x0000_t75" style='width:417pt;
     height:138.75pt;visibility:visible;mso-wrap-style:square'>
     <v:imagedata src="thesis-github_files/image021.gif" o:title=""/>
    </v:shape></span></p>
    <p class=MsoNormal style='text-indent:0in'><span style='mso-no-proof:yes'><v:shape
     id="Picture_x0020_10016" o:spid="_x0000_i1044" type="#_x0000_t75" style='width:417pt;
     height:159pt;visibility:visible;mso-wrap-style:square'>
     <v:imagedata src="thesis-github_files/image022.gif" o:title=""/>
    </v:shape></span></p>
    <p class=MsoNormal>Figure 14: Levels of total (left) and phosphorylated
    (right) 4E-BP following Dexa with / without Testo treatment in
    gastrocnemius muscles (normalized to GAPDH; n=4).</p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><![if !vml]><img width=582 height=6
src="thesis-github_files/image006.gif"
alt="Text Box:  &#13;&#10; &#13;&#10;Figure 14: Levels of total (left) and phosphorylated (right) 4E-BP following Dexa with / without Testo treatment in gastrocnemius muscles (normalized to GAPDH; n=4).&#13;&#10;"
v:shapes="_x0000_s1036"><![endif]><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1072" type="#_x0000_t75" style='width:6in;height:413.7pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p>

<h2><a name="_Toc421412284">Foxo pathway response to dexamethasone and
testosterone</a></h2>

<p class=MsoNormal>Previous studies on C2C12 cultured cells showed that the
atrogene response is crucially stimulated by Foxo transcription factors. The
review section describes a series of five hypothetical means by which Dexa is
thought to stimulate Foxo transcriptional program. Most of them converge on
upregulation of Foxo transcripts. I set to test the hypothesis that muscle Foxo
expression is modulated by Dexa and Testo in muscle.</p>

<p class=MsoNormal>In this study, Foxo transcription factors were strongly
induced during the early stages of GAML (Fig. 15). In quadriceps at day 1,
Foxo3a RNA was 78.1-fold upregulated (Dunns test, p = 0.00906). In day 3
samples, Foxo3a activation was less ample (3.17-fold; Dunns test, p = 0.0529).
In the samples from day 7, Dexa treatment was associated with a non-significant
downregulation of Foxo3a (Dunns test, p = 0.175).</p>

<p class=MsoNormal style='text-indent:0in'><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'></span>SHAPE <span
style='mso-spacerun:yes'></span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shape
 id="_x0000_s1035" type="#_x0000_t202" style='width:6in;height:449.7pt;
 visibility:visible;mso-wrap-style:square;mso-left-percent:-10001;
 mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
 v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-fit-shape-to-text:t'>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='text-indent:0in'><span style='mso-no-proof:yes'><v:shape
     id="Picture_x0020_10018" o:spid="_x0000_i1043" type="#_x0000_t75" style='width:417pt;
     height:347.25pt;visibility:visible;mso-wrap-style:square'>
     <v:imagedata src="thesis-github_files/image023.gif" o:title=""/>
    </v:shape></span></p>
    <p class=MsoNormal>Figure 15: Changes in the expression of Foxo3a (top) and
    Klf15 (bottom) transcription factors, during 7 days of Dexa with / without
    Testo treatments in quadriceps muscles (n=4, normalized to GAPDH).</p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><![if !vml]><img width=582 height=6
src="thesis-github_files/image006.gif"
alt="Text Box:  &#13;&#10;Figure 15: Changes in the expression of Foxo3a (top) and Klf15 (bottom) transcription factors, during 7 days of Dexa with / without Testo treatments in quadriceps muscles (n=4, normalized to GAPDH).&#13;&#10;"
v:shapes="_x0000_s1035"><![endif]><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1071" type="#_x0000_t75" style='width:6in;height:449.7pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p>

<p class=MsoNormal>In contrast, Testo downregulated Foxo transcription factors
at later stages of GAML. In day 3 samples, Testo co-administration repressed
Foxo3a 2.99-fold (Dunns test, p = 0.195). The trend was present in day 7
samples too, with Foxo3a repressed 2.04-fold (Dunns test, p = 0.304) by Testo
co-administration. Similar patterns of modulation were seen in Foxo1 and Foxo4
transcripts (data not shown).</p>

<p class=MsoNormal>The changes in Foxo transcription factors were mirrored by
similar changes in their positive regulator Klf15. Dexa stimulated Klf15
expression at day 1 (13.9-fold upregulation; Dunns test, p = 0.00906), and day
3 (2-fold upregulation; Dunns test, p = 0.222). Testo co-administration
reversed Klf15 changes, with the strongest repression, 3.28-fold, in day 3
samples (Dunns test, p = 0.017).</p>

<h2><a name="_Toc421412285">Akt pathway response to dexamethasone and
testosterone</a></h2>

<p class=MsoNormal>An alternative way to achieve Foxo modulation is through
their neutralization by Akt. As described in the literature review section,
activation of Akt is dependent on its phosphorylation on two residues, Ser 473
and Thr 308, with the former being the most important regulator of Foxo
specificity. I therefore investigated the effect of the two steroids on Ser 473
phosphorylation.</p>

<p class=MsoNormal>After 7 days, neither drug changed the level of total Akt in
levator, nor gastrocnemius (Fig. 16, left). At the same time, Dexa repressed
phosphorylation of a large degree in gastrocnemius (35.6% reduction in absolute
densitometry of phospho-Ser473 Akt, when normalized to GAPDH; Dunns test, p =
0.304), and levator ani (46.2% reduction; Dunns test, p = 0.146). However,
Testo co-administration had no significant effect on phospho-Ser473 Akt in
gastrocnemius (0.842% increase, p = 1). Interestingly, in this model system, Testo
co-administration repressed phospho-Ser473 in levator ani, an extremely
AAS-sensitive muscle (33.1% decrease; Dunns test, p = 0.823).</p>

<p class=MsoNormal style='text-indent:0in'><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'></span>SHAPE <span
style='mso-spacerun:yes'></span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shape
 id="_x0000_s1034" type="#_x0000_t202" style='width:6in;height:650.7pt;
 visibility:visible;mso-wrap-style:square;mso-left-percent:-10001;
 mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
 v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-fit-shape-to-text:t'>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='text-indent:0in'><span style='mso-no-proof:yes'><v:shape
     id="Picture_x0020_10020" o:spid="_x0000_i1042" type="#_x0000_t75" style='width:417pt;
     height:125.25pt;visibility:visible;mso-wrap-style:square'>
     <v:imagedata src="thesis-github_files/image024.gif" o:title=""/>
    </v:shape></span></p>
    <p class=MsoNormal style='text-indent:0in'><span style='mso-no-proof:yes'><v:shape
     id="Picture_x0020_10021" o:spid="_x0000_i1041" type="#_x0000_t75" style='width:417pt;
     height:137.25pt;visibility:visible;mso-wrap-style:square'>
     <v:imagedata src="thesis-github_files/image025.gif" o:title=""/>
    </v:shape></span></p>
    <p class=MsoNormal style='text-indent:0in'><span style='mso-no-proof:yes'><v:shape
     id="Picture_x0020_10022" o:spid="_x0000_i1040" type="#_x0000_t75" style='width:417pt;
     height:120pt;visibility:visible;mso-wrap-style:square'>
     <v:imagedata src="thesis-github_files/image026.gif" o:title=""/>
    </v:shape></span></p>
    <p class=MsoNormal style='text-indent:0in'><span style='mso-no-proof:yes'><v:shape
     id="Picture_x0020_10023" o:spid="_x0000_i1039" type="#_x0000_t75" style='width:417pt;
     height:125.25pt;visibility:visible;mso-wrap-style:square'>
     <v:imagedata src="thesis-github_files/image027.gif" o:title=""/>
    </v:shape></span></p>
    <p class=MsoNormal>Figure 16: Levels of total and phosphorylated Akt
    following 7 days of Dexa with / without Testo treatment in gastrocnemius
    (top) and levator (bottom) muscles (normalized to GAPDH; n=4).</p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><![if !vml]><img width=582 height=6
src="thesis-github_files/image006.gif"
alt="Text Box:  &#13;&#10; &#13;&#10; &#13;&#10; &#13;&#10;Figure 16: Levels of total and phosphorylated Akt following 7 days of Dexa with / without Testo treatment in gastrocnemius (top) and levator (bottom) muscles (normalized to GAPDH; n=4).&#13;&#10;"
v:shapes="_x0000_s1034"><![endif]><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1070" type="#_x0000_t75" style='width:6in;height:650.7pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p>

<p class=MsoNormal>The other relevant phosphorylation on Akt, Thr 308, is
controlled by REDD1. I investigated the effects of the two steroids on REDD1 /
Ddit4 transcription (fig. 17). Dexa upregulated Redd1 expression in
gastrocnemius collected at days 1 (7.48-fold; Dunns test, p = 0.0362), 3
(27.8-fold; Dunns test, p = 0.0912), and 7 (2.64-fold; Dunns test, p =
0.255). Confirming the rat microarray studies, at day 7, Testo
co-administration induced a sizable repression of REDD1 (1.85-fold; Dunns
test, p = 0.143).</p>

<p class=MsoNormal style='text-indent:0in'><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'></span>SHAPE <span
style='mso-spacerun:yes'></span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shape
 id="_x0000_s1033" type="#_x0000_t202" style='width:6in;height:255.45pt;
 visibility:visible;mso-wrap-style:square;mso-left-percent:-10001;
 mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
 v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-fit-shape-to-text:t'>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='text-indent:0in'><span style='mso-no-proof:yes'><v:shape
     id="Picture_x0020_10025" o:spid="_x0000_i1038" type="#_x0000_t75" style='width:417pt;
     height:153pt;visibility:visible;mso-wrap-style:square'>
     <v:imagedata src="thesis-github_files/image028.gif" o:title=""/>
    </v:shape></span></p>
    <p class=MsoNormal>Figure 17: Changes in Redd1 transcripts, during 7 days
    of Dexa with / without Testo treatments in gastrocnemius muscles (n=4,
    normalized to GAPDH).</p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><![if !vml]><img width=582 height=6
src="thesis-github_files/image001.gif"
alt="Text Box:  &#13;&#10;Figure 17: Changes in Redd1 transcripts, during 7 days of Dexa with / without Testo treatments in gastrocnemius muscles (n=4, normalized to GAPDH).&#13;&#10;"
v:shapes="_x0000_s1033"><![endif]><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1069" type="#_x0000_t75" style='width:6in;height:255.45pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p>

<h2><a name="_Toc421412286">IGF-I changes during dexamethasone and testosterone
administration</a></h2>

<p class=MsoNormal>As explained in the review section, IGF-I was one of the few
genes whose expression was changed in opposite ways by Dexa and Testo in rat
microarrays. I tested the hypothesis that Dexa and Testo alter IGF-I expression
in mice, in vivo (Fig. 18).</p>

<p class=MsoNormal>In gastrocnemius, Dexa downregulated IGF-I expression in
samples collected at days 1 (4.35-fold; Dunns test, p = 0.0213), 3 (4.03-fold;
Dunns test, p = 0.0105), and 7 (2.25-fold; Dunns test, p = 0.0362).
Dexa-induced downregulation of IGF-I was also detected in quadriceps at days 3
(2.87-fold; Dunns test, p = 0.0319), and 7 (2.41-fold; Dunns test, p =
0.0213).</p>

<p class=MsoNormal>Testo reliably reversed this change. In gastrocnemius, Dexa
downregulated IGF-I expression in samples collected at days 1 (2.23-fold;
Dunns test, p = 0.421), 3 (2.55-fold; Dunns test, p = 0.0825), and 7
(1.85-fold; Dunns test, p = 0.175). A similar trend was seen in quadriceps,
but the amplitude was smaller, perhaps owing to the fact that Dexa-induced
changed in IGF-I were smaller.</p>

<p class=MsoNormal style='text-indent:0in'><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'></span>SHAPE <span
style='mso-spacerun:yes'></span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shape
 id="_x0000_s1032" type="#_x0000_t202" style='width:6in;height:449.7pt;
 visibility:visible;mso-wrap-style:square;mso-left-percent:-10001;
 mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
 v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-fit-shape-to-text:t'>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='text-indent:0in'><span style='mso-no-proof:yes'><v:shape
     id="Picture_x0020_10027" o:spid="_x0000_i1037" type="#_x0000_t75" style='width:417pt;
     height:347.25pt;visibility:visible;mso-wrap-style:square'>
     <v:imagedata src="thesis-github_files/image029.gif" o:title=""/>
    </v:shape></span></p>
    <p class=MsoNormal>Figure 18: Changes in the expression of IGF-I, during 7
    days of Dexa with / without Testo treatments in gastrocnemius muscles (n=4,
    normalized to GAPDH).</p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><![if !vml]><img width=582 height=6
src="thesis-github_files/image006.gif"
alt="Text Box:  &#13;&#10;Figure 18: Changes in the expression of IGF-I, during 7 days of Dexa with / without Testo treatments in gastrocnemius muscles (n=4, normalized to GAPDH).&#13;&#10;"
v:shapes="_x0000_s1032"><![endif]><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1068" type="#_x0000_t75" style='width:6in;height:449.7pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p>

<p class=MsoNormal>Throughout this section, the molecular correlates of GAML,
as found in rats, were confirmed in this novel mouse model. However, few of the
effects of Dexa were reversed by Testo, at the resolution of my experimental
design. However, among the putative mechanisms of alleviation of GAML, there is
good evidence for the repression of the proteasome - ubiquitin system and for
restoration of intramuscular IGF-I. In the next section, I describe my efforts to
better understand these myoprotective mechanisms, using an in vitro model.</p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

</div>

<span style='font-size:12.0pt;mso-bidi-font-size:11.0pt;line-height:200%;
font-family:"Georgia",serif;mso-fareast-font-family:Georgia;mso-bidi-font-family:
Georgia;color:black;mso-ansi-language:EN-US;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA'><br clear=all style='page-break-before:always;
mso-break-type:section-break'>
</span>

<div class=WordSection6>

<h1>6. IN VITRO FINDINGS</h1>

<h2>Testosterone alleviates dexamethasone-induced atrophy of cultured cells</h2>

<p class=MsoNormal style='margin-top:0in;margin-right:.75pt;margin-bottom:0in;
margin-left:.75pt;margin-bottom:.0001pt;text-indent:-.75pt'><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'></span>SHAPE <span
style='mso-spacerun:yes'></span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shape
 id="_x0000_s1031" type="#_x0000_t202" style='width:6in;height:493.95pt;
 visibility:visible;mso-wrap-style:square;mso-left-percent:-10001;
 mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
 v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-fit-shape-to-text:t'>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
     style='border-collapse:collapse;border:none;mso-border-alt:solid windowtext .5pt;
     mso-yfti-tbllook:1184;mso-padding-alt:0in 5.4pt 0in 5.4pt'>
     <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes'>
      <td width=278 valign=top style='width:208.55pt;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
      <p class=MsoNormal style='text-indent:0in'><span style='mso-no-proof:
      yes'><v:shape id="Picture_x0020_10898" o:spid="_x0000_i1036" type="#_x0000_t75"
       style='width:194.25pt;height:129.75pt;visibility:visible;
       mso-wrap-style:square'>
       <v:imagedata src="thesis-github_files/image030.jpg" o:title=""/>
      </v:shape></span></p>
      <p class=MsoNormal style='text-indent:0in'>(Veh)</p>
      </td>
      <td width=278 valign=top style='width:208.6pt;border:solid windowtext 1.0pt;
      border-left:none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:
      solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
      <p class=MsoNormal style='text-indent:0in'><span style='mso-no-proof:
      yes'><v:shape id="Picture_x0020_10900" o:spid="_x0000_i1035" type="#_x0000_t75"
       style='width:194.25pt;height:129.75pt;visibility:visible;
       mso-wrap-style:square'>
       <v:imagedata src="thesis-github_files/image031.jpg" o:title=""/>
      </v:shape></span></p>
      <p class=MsoNormal style='text-indent:0in'>(Dexa)</p>
      </td>
     </tr>
     <tr style='mso-yfti-irow:1;mso-yfti-lastrow:yes'>
      <td width=278 valign=top style='width:208.55pt;border:solid windowtext 1.0pt;
      border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:
      solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
      <p class=MsoNormal style='text-indent:0in'><span style='mso-no-proof:
      yes'><v:shape id="Picture_x0020_10902" o:spid="_x0000_i1034" type="#_x0000_t75"
       style='width:194.25pt;height:129.75pt;visibility:visible;
       mso-wrap-style:square'>
       <v:imagedata src="thesis-github_files/image032.jpg" o:title=""/>
      </v:shape></span></p>
      <p class=MsoNormal style='text-indent:0in'>(Comb)</p>
      </td>
      <td width=278 valign=top style='width:208.6pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
      mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
      <p class=MsoNormal style='text-indent:0in'><span style='mso-no-proof:
      yes'><v:shape id="Picture_x0020_4" o:spid="_x0000_i1033" type="#_x0000_t75"
       style='width:194.25pt;height:165pt;visibility:visible;mso-wrap-style:square'>
       <v:imagedata src="thesis-github_files/image033.gif" o:title=""/>
      </v:shape></span></p>
      </td>
     </tr>
    </table>
    <p class=MsoNormal>Figure 19: Changes in C2C12 myotube diameter following Dexa
    with / without Testo treatments. Micrographs are representative for cells
    receiving (top left) vehicle, or (top right) 50 M Dexa, or (bottom left)
    50 M Dexa and 300 nM Testo. Bottom right image compares average myotube
    diameters for the three treatments (n=510-740).</p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><![if !vml]><img width=582 height=6
src="thesis-github_files/image001.gif"
alt="Text Box:  &#13;&#10;(Veh)	 &#13;&#10;(Dexa)&#13;&#10; &#13;&#10;(Comb)	 &#13;&#10;Figure 19: Changes in C2C12 myotube diameter following Dexa with / without Testo treatments. Micrographs are representative for cells receiving (top left) vehicle, or (top right) 50 M Dexa, or (bottom left) 50 M Dexa and 300 nM Testo. Bottom right image compares average myotube diameters for the three treatments (n=510-740).&#13;&#10;"
v:shapes="_x0000_s1031"><![endif]><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1067" type="#_x0000_t75" style='width:6in;height:493.95pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p>

<p class=MsoNormal>In mouse explanted myofibers and C2C12 cultured myotubes,
muscle atrophy is a cell-autonomous phenomenon, with all its essential
manifestations present in vitro. I hypothesized that the muscle protection by
Testo could be replicated in C2C12 cells. Indeed, fully differentiated C2C12
myotubes treated for 48 h with 50 M Dexa lost 8.66% in diameter (Tukeys HSD,
p = 0.000316)Co-administration of 300 nM Testo re-established basal diameters
(Tukeys HSD vs. Dexa alone, p = 1.02e-05).</p>

<p class=MsoNormal style='text-indent:0in'><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'></span>SHAPE <span
style='mso-spacerun:yes'></span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shape
 id="_x0000_s1030" type="#_x0000_t202" style='width:6in;height:453.45pt;
 visibility:visible;mso-wrap-style:square;mso-left-percent:-10001;
 mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
 v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-fit-shape-to-text:t'>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal align=center style='text-align:center;text-indent:0in'><span
    style='mso-no-proof:yes'><v:shape id="Picture_x0020_7" o:spid="_x0000_i1032"
     type="#_x0000_t75" style='width:5in;height:324pt;visibility:visible;
     mso-wrap-style:square'>
     <v:imagedata src="thesis-github_files/image034.gif" o:title=""/>
    </v:shape></span></p>
    <p class=MsoNormal>Figure 20: Changes in C2C12 myotube total protein
    content following Dexa with / without Testo treatments (Top) Absolute total
    protein density. (Bottom) The same data, after normalization to the average
    of the initial time point for each condition (n=5-6).</p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><![if !vml]><img width=582 height=6
src="thesis-github_files/image001.gif"
alt="Text Box:  &#13;&#10;Figure 20: Changes in C2C12 myotube total protein content following Dexa with / without Testo treatments (Top) Absolute total protein density. (Bottom) The same data, after normalization to the average of the initial time point for each condition (n=5-6).&#13;&#10;"
v:shapes="_x0000_s1030"><![endif]><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1066" type="#_x0000_t75" style='width:6in;height:453.45pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p>

<p class=MsoNormal>In another experiment, I tested the ability of Testo to
preserve protein content in C2C12 cells. In order to determine the time course
of protein content, cells were treated with (A) vehicle, (B) 1 M Dexa, (C) 1
M Dexa and 100 nM Testo, or (D) 1 M Dexa and 500 nM Testo, for up to three
days, in increments of 24 h (Fig. 20, top). All the treatments led to loss of
total protein starting from the third day, presumably due to senescence and /
or loss of viability (ANOVA treatment x time, p = 0.000463 for time variable).
When all the samples were analyzed together, treatment had no significant
effect (ANOVA treatment x time, p = 0.0943 for treatment variable).</p>

<p class=MsoNormal>However, there were differences in total protein density
prior to the third day, which mimicked the in vivo findings. These trends
become apparent when data is represented after normalization to the initial
time point (Fig. 20, top), or when data is analyzed only across days 1-3. In
the first two days, there were no relevant changes in total protein content in
cells treated with vehicle. Total protein concentration was 81.8 g<span
style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>/</span>cm<sup>2
</sup>in the first day, 81.1 g<span style='mso-fareast-font-family:Cambria;
mso-bidi-font-family:Cambria'>/</span>cm<sup>2 </sup>in the second, and 81.6 g<span
style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>/</span>cm<sup>2
</sup>in the third (ANOVA p = 0.957). In contrast, Dexa-treated cells lost
protein, declining from 83.3 g<span style='mso-fareast-font-family:Cambria;
mso-bidi-font-family:Cambria'>/</span>cm<sup>2 </sup>in the first day to 81.4
g<span style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>/</span>cm<sup>2
</sup>in the second and 78.9 g<span style='mso-fareast-font-family:Cambria;
mso-bidi-font-family:Cambria'>/</span>cm<sup>2 </sup>in the third day of the
experiment (5.32% loss; ANOVA p = 0.957). Co-administration of Testo more than
compensated the effect of Dexa.</p>

<p class=MsoNormal>Rather than losing protein, cells receiving a combination of
1 M Dexa and 100 nM Testo gained 4.99 % total protein over the first two days
of the experiment (ANOVA p = 0.957). Moreover, increasing the Testo dose to 500
nM further improved protein accretion, leading to a 7.16 % protein gain during
the first two days of the experiment (ANOVA p = 0.957).</p>

<p class=MsoNormal>Overall, the changes in cell diameter and total protein
content are similar to changes observed in muscle in vivo.</p>

<h2><a name="_Toc421412287">Protein synthesis in cultured cells treated with
dexamethasone and testosterone</a></h2>

<p class=MsoNormal style='margin-top:0in;margin-right:.75pt;margin-bottom:0in;
margin-left:.75pt;margin-bottom:.0001pt;text-indent:-.75pt'><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'></span>SHAPE <span
style='mso-spacerun:yes'></span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shape
 id="_x0000_s1029" type="#_x0000_t202" style='width:6in;height:592.2pt;
 visibility:visible;mso-wrap-style:square;mso-left-percent:-10001;
 mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
 v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-fit-shape-to-text:t'>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='text-indent:0in'><span style='mso-no-proof:yes'><v:shape
     id="Picture_x0020_9" o:spid="_x0000_i1031" type="#_x0000_t75" style='width:417pt;
     height:195.75pt;visibility:visible;mso-wrap-style:square'>
     <v:imagedata src="thesis-github_files/image035.gif" o:title=""/>
    </v:shape></span></p>
    <p class=MsoNormal style='text-indent:0in'><span style='mso-no-proof:yes'><v:shape
     id="Picture_x0020_11" o:spid="_x0000_i1030" type="#_x0000_t75" style='width:417pt;
     height:253.5pt;visibility:visible;mso-wrap-style:square'>
     <v:imagedata src="thesis-github_files/image036.gif" o:title=""/>
    </v:shape></span></p>
    <p class=MsoNormal>Figure 21: Estimates of protein synthesis rate in C2C12
    myotubes treated with Dexa with / without Testo. (Top) Experimental
    timeline. (Middle) Amount of tracer incorporated into protein per well.
    (Bottom) Amount of tracer incorporated into protein per gram of total
    protein (n=6).</p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><![if !vml]><img width=582 height=6
src="thesis-github_files/image006.gif"
alt="Text Box:  &#13;&#10; &#13;&#10;Figure 21: Estimates of protein synthesis rate in C2C12 myotubes treated with Dexa with / without Testo. (Top) Experimental timeline. (Middle) Amount of tracer incorporated into protein per well. (Bottom) Amount of tracer incorporated into protein per gram of total protein (n=6).&#13;&#10;"
v:shapes="_x0000_s1029"><![endif]><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1065" type="#_x0000_t75" style='width:6in;height:592.2pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p>

<p class=MsoNormal>In preliminary experiments, I found that tracer uptake is
minimal during the first two hours. In addition, tracer uptake rate became
essentially equal to the rate of tracer release due to protein synthesis after
the first 18 h of labeling. Therefore, I performed a series of assays where the
rate of protein synthesis was estimated through the rate of tracer uptake over
an intermediate 6 h (Fig. 21, top). In each case, cells were differentiated
over seven days, then treated with (A) vehicle, (B) 1 M Dexa, or (C) 1 M Dexa
and 500 nM Testo, for either 6, 24, 48, or 72 hours. The media with steroids
was refreshed every 24 hours. The tracer was added with a final medium change,
six hours before lysis.</p>

<p class=MsoNormal>After lysis, cells were assayed for protein-bound tracer.
There was no effect of treatment on the amount of tracer taken up by the cells
(Fig. 21, middle). To avoid the confounding influence of the atrophy, data was
also analyzed as specific activity, that is, protein-bound intracellular tracer
normalized to the mass of cell protein (Fig. 21, bottom). The same qualitative
observations could be made after normalization. There was a significant effect
of time on the rate of protein synthesis (ANOVA treatment x time, p = 2.45e-08
for time variable). The time variable was significant due to a downward trend
form days 2 through 4. This trend adds to the notion that C2C12 fully
differentiated myotubes quickly lose their viability. When all the samples were
analyzed together, treatment had no significant effect (ANOVA treatment x time,
p = 0.302 for treatment variable). There is no statistically significant
difference between treatments at each time point. The amplest difference in
translation rate between treatments is in day 4, when, in Dexa cells, protein
synthesis rate is higher than in all other conditions (specific activity 10.6%
higher than vehicle, and 13.5% higher than the combination with testosterone).
The trend toward increased protein synthesis with Dexa cannot explain the
observed myotube atrophy induced by Dexa. Moreover, the late onset of protein
synthesis upregulation indicates that this may be a compensatory response to
the earlier loss of protein.</p>

<p class=MsoNormal>Within the limits of the C2C12 model utilized in these
experiments, protein synthesis changes do not appear to mediate Dexa-induced
loss of protein, nor its alleviation by Testo.</p>

<h2><a name="_Toc421412288">Testosterone prevents protein catabolism
upregulation induced by dexamethasone</a></h2>

<p class=MsoNormal>A series of complementary experiments estimated the rate of
protein degradation in C2C12 myotubes. In each case, cells were differentiated
over seven days, then treated with (A) vehicle, (B) 1 M Dexa, (C) 1 M Dexa
and 100 nM Testo, or (D) 1 M Dexa and 500 nM Testo, for either 6, 24, 48, or
72 hours (Fig. 22, top). The media with steroids was refreshed every 24 hours.
The tracer was added three days before the addition of steroids, and was
maintained in the media until 6 hours before lysis. Because the rate of
incorporation of tracer slows down before the first 24 hours, and therefore it
may be assumed that, with some approximation, the ratio of tracer to tracee in
culture medium is equal to that in the pool of rapid-turnover intracellular
protein.</p>

<p class=MsoNormal>Preliminary experiments revealed that scintillation data
were not completely additive. In this experiment, the amounts of free tracer
from cell extract and protein-bound tracer in the medium proteins are tens of
times lower than the free tracer in the medium, and the protein-bound tracer in
the cells. In order to avoid addition of non-additive data, protein degradation
rate was estimated from the ratio of free tracer in the cell culture medium to
protein-bound tracer in the cell extract (Fig. 22, middle). However, the
results are essentially identical when free tracer from cell extract and protein-bound
tracer in the medium proteins are taken into account. This scintillation-based
method is semi-quantitative, meaning that a doubling of the ratio of free
tracer in the cell culture medium to protein-bound tracer in the cell extract
does not indicate a doubling in protein degradation rate, but merely its
upregulation.</p>

<p class=MsoNormal>Overall, due to sample size, the treatments were not
statistically significant across time points (ANOVA time X treatment, p = 0.401
for time; p = 0.259 for treatment). Nevertheless, the effects of the two
steroids were ample and dose-dependent at the 24 hour time point (ANOVA between
treatments, p = 0.144; fig. 22, bottom). For 24-hour vehicle-treated cells, the
ratio of free medium tracer to protein-bound intracellular was 0.0968. When
cells received 1 M Dexa, the ratio of free medium tracer to protein-bound
intracellular increased to 0.661 (Tukeys HSD vs. vehicle, p = 0.202).
Co-administration of Testo had a dose-dependent inhibitory effect on protein
degradation. When Dexa was supplemented with 100 nM Testo, the ratio of free
medium tracer to protein-bound intracellular was reduced to 0.388 (Tukeys HSD
vs. Dexa alone, p = 0.776). When Dexa was supplemented with 500 nM Testo, the
ratio of free medium tracer to protein-bound intracellular was further reduced
to 0.0713 (Tukeys HSD vs. Dexa alone, p = 0.173).</p>

<p class=MsoNormal>A similar trend was recorded at the 48-hour time point. For 48-hour
vehicle-treated cells, the ratio of free medium tracer to protein-bound
intracellular was 0.062. When cells received 1 M Dexa, the ratio of free
medium tracer to protein-bound intracellular increased to 0.0699 (Tukeys HSD
vs. vehicle, p = 0.182). Co-administration of 100 nM Testo reduced the ratio of
free medium tracer to protein-bound intracellular to 0.0607 (Tukeys HSD vs.
Dexa alone, p = 0.12).</p>

<p class=MsoNormal style='text-indent:0in'><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'></span>SHAPE <span
style='mso-spacerun:yes'></span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shape
 id="_x0000_s1028" type="#_x0000_t202" style='width:6in;height:625.2pt;
 visibility:visible;mso-wrap-style:square;mso-left-percent:-10001;
 mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
 v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-fit-shape-to-text:t'>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='text-indent:0in'><span style='mso-no-proof:yes'><v:shape
     id="Picture_x0020_17" o:spid="_x0000_i1029" type="#_x0000_t75" style='width:417pt;
     height:182.25pt;visibility:visible;mso-wrap-style:square'>
     <v:imagedata src="thesis-github_files/image037.gif" o:title=""/>
    </v:shape></span></p>
    <p class=MsoNormal style='text-indent:0in'><span style='mso-no-proof:yes'><v:shape
     id="Picture_x0020_18" o:spid="_x0000_i1028" type="#_x0000_t75" style='width:417pt;
     height:273pt;visibility:visible;mso-wrap-style:square'>
     <v:imagedata src="thesis-github_files/image038.gif" o:title=""/>
    </v:shape></span></p>
    <p class=MsoNormal>Figure 22: Estimates of protein degradation rate in
    C2C12 myotubes treated with Dexa with / without Testo. (Top) Experimental
    timeline. (Middle) Ratio of tracer in medium to tracer in cells, across
    time points. (Bottom) Ratio of free tracer in medium to protein-bound
    tracer in cells, at day 2 (n=5-6).</p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><![if !vml]><img width=582 height=6
src="thesis-github_files/image006.gif"
alt="Text Box:  &#13;&#10; &#13;&#10;Figure 22: Estimates of protein degradation rate in C2C12 myotubes treated with Dexa with / without Testo. (Top) Experimental timeline. (Middle) Ratio of tracer in medium to tracer in cells, across time points. (Bottom) Ratio of free tracer in medium to protein-bound tracer in cells, at day 2 (n=5-6).&#13;&#10;"
v:shapes="_x0000_s1028"><![endif]><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1064" type="#_x0000_t75" style='width:6in;height:625.2pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p>

<p class=MsoNormal>Overall, Dexa myotube atrophy is correlated with an increase
in tracer release, indicating an upregulation of protein degradation. Testo
protection of myotubes is correlated with an inhibition of protein degradation.</p>

<h2><a name="_Toc421412289">Mechanisms of androgenic myoprotection in cultured
myotubes</a> <a name="_Toc421412290">treated with dexamethasone</a></h2>

<p class=MsoNormal>In previous experiments, I established that loss of C2C12
myotube protein during Dexa treatment is associated with an increase in protein
degradation at 24 hours after the initiation of steroid. Using a series of
chemical inhibitors, I investigated the molecular mechanisms that could mediate
this catabolic upregulation (Fig. 23, top). As in the previous experiment, cells
were differentiated over 7 days. In the final three days of differentiation,
medium with tracer was refreshed daily. For the final 24 hours, the tracer was
removed, and cells were treated with (A) vehicle, (B) 100 nM Dexa, or (C) 100
nM Dexa and 300 nM Testo. In order to interfere with putative proteolytic
pathways, other sets of cells were treated with (D) 100 nM Dexa and 25 M
chloroquine, an inhibitor of autophagy, or (E) 100 nM Dexa and 5 M MG132, an
inhibitor of the proteasome. Finally, in order to interfere with IGF-I
signaling, another set of cells were treated with (F) 100 nM Dexa, 300 nM
Testo, and 50 nM picropodophyllin, an inhibitor of IGF-1R.</p>

<p class=MsoNormal>The medium and the cells were fractionated as in the
previous experiment. Protein degradation rate was estimated via the ratio of
free tracer in the medium to protein-bound tracer in the cells. When cells were
treated with vehicle alone, the ratio of free medium tracer to protein-bound
intracellular was 0.826. When cells received 100 nM Dexa, the ratio of free
medium tracer to protein-bound intracellular increased to 1.55 (Tukeys HSD vs.
vehicle, p = 0.000104).</p>

<p class=MsoNormal style='text-indent:0in'><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'></span>SHAPE <span
style='mso-spacerun:yes'></span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shape
 id="_x0000_s1027" type="#_x0000_t202" style='width:6in;height:519.45pt;
 visibility:visible;mso-wrap-style:square;mso-left-percent:-10001;
 mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
 v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-fit-shape-to-text:t'>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='text-indent:0in'><span style='mso-no-proof:yes'><v:shape
     id="Picture_x0020_20" o:spid="_x0000_i1027" type="#_x0000_t75" style='width:417pt;
     height:125.25pt;visibility:visible;mso-wrap-style:square'>
     <v:imagedata src="thesis-github_files/image039.gif" o:title=""/>
    </v:shape></span></p>
    <p class=MsoNormal style='text-indent:0in'><span style='mso-no-proof:yes'><v:shape
     id="Picture_x0020_21" o:spid="_x0000_i1026" type="#_x0000_t75" style='width:417pt;
     height:278.25pt;visibility:visible;mso-wrap-style:square'>
     <v:imagedata src="thesis-github_files/image040.gif" o:title=""/>
    </v:shape></span></p>
    <p class=MsoNormal>Figure 23: Interference of protein degradation in C2C12
    myotubes treated with Dexa with chemical inhibitors. (Top) Experimental timeline.
    (Bottom) Ratio of tracer in medium to tracer in cells (n=5-6).</p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><![if !vml]><img width=582 height=6
src="thesis-github_files/image001.gif"
alt="Text Box:  &#13;&#10; &#13;&#10;Figure 23: Interference of protein degradation in C2C12 myotubes treated with Dexa with chemical inhibitors. (Top) Experimental timeline. (Bottom) Ratio of tracer in medium to tracer in cells (n=5-6).&#13;&#10;"
v:shapes="_x0000_s1027"><![endif]><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1063" type="#_x0000_t75" style='width:6in;height:519.45pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p>

<p class=MsoNormal>The upregulation in catabolism was dependent on both
proteasome and lysosome actions. When the lysosome was inhibited with
chloroquine, the ratio of free medium tracer to protein-bound intracellular was
brought back to basal levels (0.614; Tukeys HSD vs. Dexa, p = 1.44e-06).
However, proteasome inhibition had a more ample result, with the ratio of free
medium tracer to protein-bound intracellular depressed to 0.132 (Tukeys HSD
vs. Dexa, p = 2.4e-10).</p>

<p class=MsoNormal>Testo repressed the upregulation of catabolism brought by
Dexa to basal levels (free medium tracer to protein-bound intracellular tracer
0.714; Tukeys HSD vs. Dexa, p = 2.35e-05). The protective effect of Testo was
not apparently altered by the inhibition of the IGF-1R pathway (free medium
tracer to protein-bound intracellular tracer 0.701; Tukeys HSD vs. Dexa, p =
1).</p>

<p class=MsoNormal>Overall, in C2C12 cells, Dexa upregulates protein
degradation, mainly through the activation of the proteasome. Testo reverses
the activation of proteolysis in an apparently IGF-1R-independent manner, based
on the experimental sensitivity used in these assays.</p>

<p class=MsoNormal style='margin-top:0in;margin-right:.75pt;margin-bottom:0in;
margin-left:1.25pt;margin-bottom:.0001pt;line-height:107%'><o:p>&nbsp;</o:p></p>

</div>

<span style='font-size:12.0pt;mso-bidi-font-size:11.0pt;line-height:200%;
font-family:"Georgia",serif;mso-fareast-font-family:Georgia;mso-bidi-font-family:
Georgia;color:black;mso-ansi-language:EN-US;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA'><br clear=all style='page-break-before:always;
mso-break-type:section-break'>
</span>

<div class=WordSection7>

<h1><a name="_Toc421412291">7. DISCUSSION</a></h1>

<h2><a name="_Toc421412292">Testosterone alleviates dexamethasone-induced
muscle atrophy in mice</a></h2>

<p class=MsoNormal>The present work investigated the molecular mechanisms
mediating androgen attenuation of GC-induced muscle atrophy in mouse. While the
myoprotective action of Testo was demonstrated in humans and rats, to date the
role of T in GC-mediated atrophy has not been studied in the mouse. In fact,
although some studies investigated transcriptional changes in mouse muscle in
response to Dexa, surprisingly few have described macroscopic (organ level)
atrophy.</p>

<p class=MsoNormal>In this dissertation, I demonstrated that a dose of 10 mg d<span
style='mso-fareast-font-family:Cambria;mso-bidi-font-family:Cambria'>/</span>kg
Dexa induced a significant loss of muscle, as evidenced by decrements in lean
body mass and changes in the weight of individual muscles. The effect was
progressive, with the losses of lean body mass at day 3 being roughly half of
the losses at day 7. The observed time dependence is evidence for a
Dexa-specific effect. As expected, lean body mass was essentially unchanged in
mice treated with vehicle alone. The measurement of fat body mass indicated
that the mice treated with vehicle had essentially unchanged tissue fat during
the experiment. The unchanged lean and fat tissue content is evidence for the
fact that the experimental manipulations had no effect by themselves. The robustness
and quality of the study design was further supported by the fact that Dexa
exerted its expected stimulatory effect on accretion of body fat.</p>

<p class=MsoNormal>The observed change in total body mass was approximately
equal to that in lean body mass. This may explain why changes in body weight
(Fig. 3), rather than body weight at sacrifice (Fig. 2), were significantly
altered by Dexa treatment. No other organ appeared to undergo atrophy upon Dexa
treatment. Dissection revealed no significant changes in the size of viscera.
No detectable changes were seen in the wet weight of the heart (data not
shown).</p>

<p class=MsoNormal>Gastrocnemius and quadriceps were the more sensitive muscles
to Dexa, whereas tibialis was essentially unchanged. The lack of response in
tibialis was surprising, given how common mouse tibialis manipulation, such as
electroporation of DNA, that has been described in literature. A report
published during this work similarly failed to observe tibialis anterior
atrophy following 14 days treatment with a slightly lower Dexa dose [423]. With
54% fast glycolytic fibers in gastrocnemius, compared to 59% in tibialis anterior
[#augusto2004skeletal], the two muscles appear very similar in fiber type
distribution. Therefore, even if fiber typing was not evaluated in my model, it
is unlikely that differences in muscle sensitivity stem from differences in
fiber type. <span style='mso-spacerun:yes'></span>The lack of sensitivity in
tibialis may have been due to the fact that the tendinous component is weighing
more in relative terms, compared to large fleshy muscles.</p>

<p class=MsoNormal>There was a remarkable similarity between the first 3 days
of the in vivo experiment and the in vitro findings at 48 hour time point. Whereas
quadriceps lost 6% of their weight, C2C12 myotubes lost about 5% of their total
protein upon Dexa treatment. This rate is similar to that indicated by Desler
for C2C12 myotubes that had been differentiated over three days and then
treated with Dexa [543].</p>

<p class=MsoNormal>In contrast to the in vivo studies, the in vitro study could
not have been extended beyond the early days. Cells ability to thrive degraded
towards their third day of Dexa treatment, that is, their ninth day of
differentiation. The significant reduction in protein synthesis seen at the
72-hour time point suggests that the cells became less metabolically active
compared to the 48-hour time point, perhaps due to senescence. Therefore, the
in vitro model appears inadequate beyond the 48-hour time point. Moreover, the
atrophic fibers diameter becomes comparable with that of the nucleus after the
first two days (Fig. 19). Further reductions in cell diameter would have
required a shrinkage of the nucleus, which has not been observed in the first
two days of myotube atrophy. It was therefore not possible to develop a longer
term in vitro model of muscle atrophy.</p>

<p class=MsoNormal>Co-administration of Testo alleviated all macroscopic Dexa
effects. Similar to the profile of Dexa action, in absolute terms, the recovery
in lean body mass was approximately equal to that in total body weight. The
percentage by which total body weight, lean body mass, and individual muscles
recovered were similar, indicating that Testo action was limited to muscle.</p>

<p class=MsoNormal>The experimental protocol may not have been ideal for
observing the time course for Testo action. On the one hand, the body weight
changes during the 7-day experiment (Fig. 3, top) suggest that the protective
action of Testo begins with the first day of experiment. On the other hand, the
time course was not reflected in the individual muscle weights (Fig. 5). While
7-day samples appear effectively protected by Testo, 3-day samples displayed a
more limited anabolic response. This discrepancy may be due to the fact that
the mice analyzed in the 7-day study were slightly more developed than those
used in the 3-day sample. This was indicated by the difference in levator
muscles at sacrifice between vehicle-treated animals at each time point.
Moreover, the detection of the Testo protective effect on muscle mass may be
strained by its incomplete nature. Because Dexa effect is progressive, its
amplitude in the early stages is necessarily small. When Dexa-induced atrophy
is hard to detect, its incomplete reversal will be even harder to demonstrate. I
could not exclude a temporal dissociation between the actions of the two steroids,
as the changes surrounding the acute onset of GAML were not investigated in
more detail, which was beyond the scope of this work. At the 7-day time point,
which is the more representative model of chronic glucocorticoid myopathy, the
alleviation of GAML has been well established.</p>

<p class=MsoNormal>The alleviation following Testo was incomplete in terms of
lean body mass and individual muscle weights. In contrast, total body weight
completely recovered. The source of this discrepancy remains unclear.
Dissection revealed no other viscera with an appearance of hypertrophy
following Testo co-administration. The dose of Testo used here was shown to be
effective in rats. However, the Dexa dose used in the rat studies was much
smaller, suggesting that mice studied here may have benefited even more from an
increased dose of Testo. Moreover, mice may be intrinsically less responsive to
Testo than rats, as the former appear to be more resistant to many
pharmacological treatments, such as Dexa (reviewed here) or streptozotocin[#tay2005can].
The most effective dose of Testo to fully prevent GAML should be pursued in future
studies. Within the limits of the present data, it may be the case that no
Testo dose would have overcomed the Dexa-induced atrophy, which would then
imply that atrophy inducing mechanisms of Dexa potentially include pathways
outside the scope of anabolic stimuli.</p>

<p class=MsoNormal>Notably, there were differences in the responsiveness to
Testo between muscle groups. Similar to Dexa sensitivity, an important
component appears to be the tendinous content. Levator ani is more responsive
to Testo than to Dexa, perhaps being explained by the increased presence of AR
compared to other muscles [612]. The apparent dependence of Testo response
amplitude to the expression of AR indicates that alleviation of GAML by AAS is
a specific effect, rather than an interaction at the GR level.</p>

<p class=MsoNormal>In vitro, myoprotective action of Testo was similarly
present at late time-points. The protection of C2C12 myotubes was
dose-dependent, based on the total protein assay. Paralleling the in vivo
system, the myoprotective effect in C2C12 cells was more pronounced when the data
were normalized to the first time point in the experiment (fig. 20 top versus
bottom). <b style='mso-bidi-font-weight:normal'><o:p></o:p></b></p>

<h2><a name="_Toc421412293">Testosterones protective action was driven by the
inhibition of the dexamethasone-induced proteasome upregulation</a></h2>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'>The
mouse model of GAML largely replicated what was known from rat experiments,
where a strong upregulation of the proteasome system is followed by alterations
in protein synthesis.</p>

<p class=MsoNormal>In vivo, the E3 ligases also known as atrogenes were
upregulated in this model system. The upregulation of MuRF-1 was robust, and
reached statistical significance despite a small sample size. Upregulation of
MuRF-1 was confirmed at early stages in gastrocnemius, quadriceps, and triceps
(Fig. 6; the latter not shown). In agreement with published studies, the more
specific ligase, MAFbx, was upregulated by a lesser percentage than MuRF-1. In
combination with the practical limitations on sample sizes, the low-level activation
of MAFbx limited my ability to obtain statistical significance. Nevertheless,
the consistent trend across muscle groups of increased MAFbx expression in response
to Dexa indicates that the second atrogene was also part of the atrophic
transcriptional program. The massive proteasome upregulation observed in day 3
samples increased the probability of the hypothetical scenario in which protein
degradation is limited by proteasome availability, rather than E3 ligases.
However, day 3 also marks the peak of proteasome catalytic activity (Fig. 7).
The synchronized stimulation of the proteasome and of the atrogenes indicates
that the proteasome - ubiquitin system may be at the center of GAML.</p>

<p class=MsoNormal>All these catabolic changes were inhibited by Testo
co-administration. In vitro, atrogenes expression was reduced to basal levels,
and, in the case of day 7 samples, even below baseline levels. The inhibitory
effect of Testo on MuRF-1 was predicted by the microarray study on rat muscle.
Similar to the rat study, the changes in MAFbx were also in agreement with the
phenotype, but of a lesser amplitude. In addition, the proteasome activity was
suppressed at its day 3 peak. This aspect of muscle atrophy, already
demonstrated as a component of male post-castration muscle atrophy [603], has
never been investigated in GAML, nor in its attenuation by Testo.</p>

<p class=MsoNormal>Upregulation of proteasome activity, independent of atrogene
status, has been reported by others [428]. It is unclear how Dexa achieves this
upregulation. In this study, limited evaluation of transcripts for proteasome
subunits A6, B10, or D4 were inconclusive (data not shown).</p>

<p class=MsoNormal>In vitro, proteasome inhibition led to nearly complete suppression
of proteolysis, beyond the basal levels seen in vehicle-treated cells. This
finding indicates that most of the proteolytic activity in C2C12 cells is
dependent on the proteasome.</p>

<p class=MsoNormal>A study by Baehr and colleagues [423], which was published
while my experiments were under way, showed that MAFbx knockout did not reduce
the amplitude of GAML, while MuRF-1 knockout reduced GAML to about half of its
amplitude in wild-type mice. My data show that, instead of rejecting the
proteasome-centered model of GAML, future studies should focus on finding
alternative ways by which the proteasome promotes catabolic activity. For
example, the simplest scenario fitting todays data is one where the proteasome
performs the clearance of the bulk of dispensable proteins. An alternative
explanation, which takes into account the subsiding evolution of the atrogene
surge, is that atrogenes ubiquitinate, and target for degradation, a yet
unidentified myoprotective intracellular factor, thus unleashing a cascade of
proteasome-independent mechanisms. Some limited attempts to detect multiple
ubiquitination states for MuRF-1s putative substrate, myosin heavy chain, were
inconclusive (data not shown). If MuRF-1 has only this limited and limiting
action, disruption of MuRF-1 in Baehrs knockout mice could have been
supplanted by partially homologous genes, such as MuRF-2 or Fbxo40 [613, 432].
The distinction between the two scenarios is difficult, especially in the in
vivo approach. In either scenario, the role of the proteasome is indispensable
for GAML. Nevertheless, proteasome inhibition by Testo co-administration
emerges from this work as an important mechanism of GAML alleviation.</p>

<p class=MsoNormal>The experiments performed in this study clearly exclude a
role for the autophagosome - lysosome system in digestion of bulk myofiber
proteins. The in vivo data indicate a persistent suppression of
autophagy-related genes across muscle groups and time points. Moreover,
lysosome-associated cathepsin L enzymatic activity is suppressed by Dexa in a
statistically significant manner at all time points. The downregulation of
cathepsin activity and expression was more ample than the loss of muscle
protein, indicating that an active process of cathepsin degradation is
activated by Dexa in vivo.</p>

<p class=MsoNormal>The finding of Dexa-induced downregulation of autophagy was
unexpected. Some atrophic conditions, most notably starvation, lead to
autophagy regulation. The rat microarray findings found cathepsin L among the
set of genes upregulated by Dexa. Even in this study, a narrow measurement, the
accumulation of lipidated LC3 appeared upregulated by Dexa (Fig. 10, middle).
However, the microarray results were never validated by qRT-PCR. In the present
work, when the hyperlipidated LC3 form is normalized to its precursor, its
levels appeared essentially unchanged in response to Dexa (Fig. 10, right). The
accumulation of LC3 protein, both in precursor and mature form, indicates
reduced capacity in the autophagolysosome compartment, especially in the
present context of downregulated LC3 protein expression. This line of evidence
corroborates the downregulated enzymatic activity to collectively exclude a
putative role for autophagy in bulk GAML.</p>

<p class=MsoNormal>Intuitively, it is more likely for bulk protein catabolism
to be mediated by the smaller proteasome and atrogenes than the larger
autophagosome. However, autophagy may play a regulatory, initiating role in
GAML. In the in vivo studies, the amplitude and invariability of autophagy
inhibition prove its modulation by Dexa. One could speculate that such changes,
ampler than those in muscle mass, cannot be simple inconsequential side
effects. While the present data solidly exclude a role for bulk protein digestion,
further studies are needed to elucidate which proteins are spared from
autophagy during GAML, and what is the regulatory effect of their sparing from
autophagy.</p>

<p class=MsoNormal>While the in vivo data suggested that downregulation of
autophagy is part of GAML, I found the opposite phenomenon in cell culture
experiments. There, inhibition of lysosomes with chloroquine had a significant
protective effect. The differences between the in vivo and in vitro data underscore
the limitations intrinsic to cell culture models. Many factors absent from the
cell culture experiment may explain the observed contrast, including
myoprotective influences of the motor neuron at neuromuscular junctions and
vascularization of muscle tissue. Moreover, the advanced quiescence of the
cultured myotubes contrasts with the ample in vivo ability for muscle to
regenerate. Given the reductionism of the culture cell experiment, the in vivo
experiment is likely more reflective of what occurs in human glucocorticoid
myopathy. The fact that Testo reversed most of the in vivo effects of Dexa on
autophagy suggests that this pathway may be relevant for GAML attenuation.</p>

<p class=MsoNormal>Prior to this work, the calpain system was the least likely
effector of GAML. In agreement with the literature, this study could not
substantiate Dexa-induced changes in calpain enzymatic activity, calpain, or
calpastatin protein levels (data not shown). Overall, the absence of
Dexa-induced amplification in catabolic activity in the cathepsin and calpain
pathways reduces the scope for AAS myoprotection through inhibition of these
pathways. Moreover, Testo had no reliable effect on the Dexa-induced changes in
the autophagosome - lysosome pathway. Therefore, Testo protection is unlikely
to be mediated by inhibition of cathepsin or calpain.</p>

<p class=MsoNormal>Studies on protein synthesis rate have been strained by the
limited technical abilities of measuring protein synthesis in mice. No study that
I am aware of measured changes in the rate of protein synthesis in mice prior
to this work. The studies on rats indicated that such measurements are fraught
with high variability, and would therefore likely fail to detect any effect. I
did not measure protein synthesis directly in vivo. The measurements of protein
synthesis rate in vitro failed to identify any significant change in response
to Dexa. C2C12 cells are surprisingly dependent on protein synthesis, with
either translational inhibitor cycloheximide and puromycin leading to cell
death and detachment within hours (data not shown). Overall, the lack of
detectable changes in protein synthesis rate agrees with findings in rat L6
cells [395] and in explanted muscle experiments [320].</p>

<p class=MsoNormal>In order to detect subtle changes in protein synthesis, I
investigated a series of its regulators. I failed to identify changes in levels
of phosphorylated eIF2&#945; and eIF3f in response to either Dexa or Testo
(Figs. 12, 13). I could not detect ATF4 protein in muscle lysates (data not
shown). In the 7-day samples, both total and phosphorylated 4E-BP were
upregulated by Dexa. With these data, it was unclear whether the active
negative regulator of protein synthesis, unphosphorylated 4E-BP was increased
or decreased by chronic Dexa exposure. The changes in total and phosphorylated
4E-BP induced by Testo are small, and would be unlikely to lead to increased
inactivation of 4E-BP. Therefore, based on these data and the limitations of
the model system, there was no evidence that, at 7-day time point, that the
protective action of Testo benefited from increased protein synthesis.</p>

<p class=MsoNormal>While the reported experiments were ongoing, Baehr and
colleagues reported that Dexa decreased protein synthesis rate at day 3 and
increased it at day 14 in mouse triceps [423]. Baehr et al. findings suggest
that acute Dexa represses protein synthesis, whereas chronic Dexa is associated
with a compensatory restoration of translational capacities. At the 7-day time
point analyzed in this study, a measurement of protein synthesis by Baehrs
method would have been indecisive, as the muscle would have been midway in the
switch from a low to high translation rate.</p>

<p class=MsoNormal>In conclusion, Testo induced muscle protection through
multiple mechanisms, among which inhibition of the proteasome system stood out
by amplitude and persistence.</p>

<h2><a name="_Toc421412294">Molecular mechanisms linking dexamethasone and
testosterone to protein metabolism</a></h2>

<p class=MsoNormal>In agreement with the rat studies, the present work
demonstrates that Dexa-induced upregulation of atrogenes is coordinated with
increased expression of Foxo transcription factors (Fig. 15, top). A Foxo3a
surge was even more robust than the increase in MuRF-1, with a statistically
significant presence in day 1 samples. Moreover, the transcription factor
Klf15, which is a target of Foxo, and their synergistic partner in the
upregulation of MuRF-1, underwent an equally rapid intensification (Fig. 15,
bottom).</p>

<p class=MsoNormal>In addition to repression of atrogenes, Testo reverses other
actions of Dexa. This efficient, multi-directional action of Testo suggests
that it may act on a higher-level mediator of GAML. Two molecular levers
responded in a uniform, consistent manner to the two steroids, and therefore
may be high-level mediators of AAS and GC. The first is REDD1 / Ddit4, the
negative regulator of mTORC1. Dexa consistently upregulated REDD1 expression in
samples from days 1, 3, and 7. The amplitude of upregulation decreased with time.
A time course where Dexa amplifies REDD1 only for the first week could explain
Baehrs observations on protein synthesis changes during GAML. As REDD1
inhibition of mTORC1 subsides, the 4E-BP-mediated brake on protein synthesis is
gradually reduced. Testo co-administration reversed REDD1 upregulation to a
significant degree at 7-day time point, when Dexa-induced amplification was at
its lowest. Further experiments are needed to analyze the relationship between
REDD1 and protein synthesis, especially at later time points, which have not
been investigated here.</p>

<p class=MsoNormal>The transcriptional upregulation of Foxo by Dexa may have
been compounded by Akt inhibition. GC caused a large decrement in Ser 473
phosphorylation of Akt (Fig. 16), which in turn is expected to protect Foxo
from export to cytosol and proteasome-mediated destruction. AAS had no apparent
effect on Ser 473 phosphorylation. The discrepancy between Ser 473
phosphorylation and muscle recovery may be explained within the model described
by Britto [491], who showed preliminary evidence that Ser 473 is not involved
in Akt inactivation during GAML. Another explanation is based on the ability of
Dexa to disconnect Akt from insulin and IGF-I signals (discussed in a dedicated
section). The only other trait shared between mice receiving Dexa with versus
without Testo is accumulation of fat mass, suggestive of whole-body insulin
resistance. At the level of muscle, Dexa induces insulin resistance by
interference at IRS 1 and p85 levels.</p>

<p class=MsoNormal>The other reliable change in GAML and its alleviation by
Testo was observed in IGF-I expression. In agreement with studies on rats, Dexa
reduced IGF-I expression, while Testo co-administration restored IGF-I
expression to basal levels (Fig. 18). In agreement with all previous studies, I
could not substantiate changes in the phosphorylation of IGF-1R that would
correlate with the IGF-I upregulation (data not show). It is unclear to what
extent IGF-I would mediate AAS myoprotection given the aforementioned interference
by Dexa at IRS 1 and p85.</p>

<p class=MsoNormal>In vitro, I attempted to gauge the role of IGF-1R in Testo
myoprotection. A novel IGF-1R inhibitor, picropodophyllin, had no effect on
Testo protection. However, the same experiment uncovered a series of other
shortcomings of the cell culture experiment, including a higher reliance on
autophagy compared to the in vivo model. Better causal inferences could be made
by employing in vivo transgenic models of interference within the IGF-I / Akt /
mTORC1 axis.</p>

<h2><a name="_Toc421412295">Future directions</a></h2>

<p class=MsoNormal>This work demonstrates that Testo protects mouse muscle in
vivo and in vitro by reversing the Dexa-induced upregulation of proteasome
activity. On the other hand, the set of E3 ligases that cause GAML is
incomplete. The role of candidates such as Fbxo40 remains to be investigated.
Future studies will need to determine whether Testo suppresses the other E3
ligases.</p>

<p class=MsoNormal>At this time, the mechanisms by which Dexa upregulates Foxo
transcription factors is a subject of speculation. Even less is known about the
way in which Testo represses Foxo. Chromatin immunoprecipitation tests using
Foxo promoters would help resolve this question.</p>

<p class=MsoNormal>The in vivo experiment suggest that Testo also reversed
Dexa-induced repression of autophagy. The role of autophagy in GAML would be
better understood by observing the effects of GC and AAS on muscle from LC3-GFP
transgenic mice.</p>

<p class=MsoNormal>Both autophagy and protein synthesis appeared to have
changed in time, during the in vivo experiment. Because they were performed as
three independent experiments, an ability to infer the time course of changes
was limited. A direct exploration of time-dependent changes is required, in
order to establish which changes in protein metabolism are late-onset, reactive
adjustments.</p>

<p class=MsoNormal>I was not able to observe the effect of IGF-I modulation,
due to an overarching suppressive effect of Dexa which disconnects the
transmembrane receptors from their Akt effector. The mechanisms by which Dexa
achieve this disconnection are largely the subject of speculation. Future studies
that establish if and how GR interferes with the IGF-I / Akt pathway are
needed.</p>

<p class=MsoNormal>Transgenic models, such as the triple Foxo knockout, are
needed, in order to determine the relative importance and the eventual
interaction between Foxo and the mTOR pathway.</p>

<h2><a name="_Toc421412296">Conclusions</a></h2>

<p class=MsoNormal style='margin-top:0in;margin-right:.75pt;margin-bottom:0in;
margin-left:.75pt;margin-bottom:.0001pt'>Testo co-administration attenuates the
loss of muscle mass induced by GC administration in mice. Based on the model
systems used in this thesis, Testo myoprotection was exerted through an
inhibition of the proteasome, mediated by Foxo and REDD1. Changes in these, as
well as in IGF-I intramuscular expression, indicate that the two classes of
steroids counter each others effect on the Akt signaling pathway (Fig. 24).
AAS therapy may be beneficial for a subset of male adult patients receiving
chronic GC as a treatment, especially if they present with biochemical and
clinical signs of hypogonadism. The relative importance of the proteasome in glucocorticoid
myopathy suggests that in addition to Testo, other more direct proteasome
inhibitors such as bortezomib, may be useful as adjunctive therapy.</p>

<p class=MsoNormal style='margin-top:0in;margin-right:.75pt;margin-bottom:0in;
margin-left:.75pt;margin-bottom:.0001pt;text-indent:-.75pt'><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'></span>SHAPE <span
style='mso-spacerun:yes'></span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shape
 id="_x0000_s1026" type="#_x0000_t202" style='width:6in;height:282.45pt;
 visibility:visible;mso-wrap-style:square;mso-left-percent:-10001;
 mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
 v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF
90jcwfIWJU67QAgl6YK0S0CoHGBkTxKLZGx5TGhvj5O2G0SRWNoz/78nu9wcxkFMGNg6quQqL6RA
0s5Y6ir5vt9lD1JwBDIwOMJKHpHlpr69KfdHjyxSmriSfYz+USnWPY7AufNIadK6MEJMx9ApD/oD
OlTrorhX2lFEilmcO2RdNtjC5xDF9pCuTyYBB5bi6bQ4syoJ3g9WQ0ymaiLzg5KdCXlKLjvcW893
SUOqXwnz5DrgnHtJTxOsQfEKIT7DmDSUCaxw7Rqn8787ZsmRM9e2VmPeBN4uqYvTtW7jvijg9N/y
JsXecLq0q+WD6m8AAAD//wMAUEsDBBQABgAIAAAAIQA4/SH/1gAAAJQBAAALAAAAX3JlbHMvLnJl
bHOkkMFqwzAMhu+DvYPRfXGawxijTi+j0GvpHsDYimMaW0Yy2fr2M4PBMnrbUb/Q94l/f/hMi1qR
JVI2sOt6UJgd+ZiDgffL8ekFlFSbvV0oo4EbChzGx4f9GRdb25HMsYhqlCwG5lrLq9biZkxWOiqY
22YiTra2kYMu1l1tQD30/bPm3wwYN0x18gb45AdQl1tp5j/sFB2T0FQ7R0nTNEV3j6o9feQzro1i
OWA14Fm+Q8a1a8+Bvu/d/dMb2JY5uiPbhG/ktn4cqGU/er3pcvwCAAD//wMAUEsDBBQABgAIAAAA
IQBmSiCNJgIAAE4EAAAOAAAAZHJzL2Uyb0RvYy54bWysVNuO0zAQfUfiHyy/06RRWrpR09XSpQhp
WZB2+YCp4zQWvmG7TcrXM3baUi3wgsiD5fGMj2fOmcnydlCSHLjzwuiaTic5JVwz0wi9q+nX582b
BSU+gG5AGs1reuSe3q5ev1r2tuKF6YxsuCMIon3V25p2IdgqyzzruAI/MZZrdLbGKQhoul3WOOgR
XcmsyPN51hvXWGcY9x5P70cnXSX8tuUsfG5bzwORNcXcQlpdWrdxzVZLqHYObCfYKQ34hywUCI2P
XqDuIQDZO/EblBLMGW/aMGFGZaZtBeOpBqxmmr+o5qkDy1MtSI63F5r8/4Nlj4cvjoimpkVBiQaF
Gj3zIZB3ZiBFpKe3vsKoJ4txYcBjlDmV6u2DYd880Wbdgd7xO+dM33FoML1pvJldXR1xfATZ9p9M
g8/APpgENLRORe6QDYLoKNPxIk1MheHhrFzMyxxdDH3TMi/nRRIvg+p83TofPnCjSNzU1KH2CR4O
Dz7EdKA6h8TXvJGi2Qgpk+F227V05ADYJ5v0pQpehElN+prezIrZyMBfIfL0/QlCiYANL4Wq6eIS
BFXk7b1uUjsGEHLcY8pSn4iM3I0shmE7jJLNzgJtTXNEap0ZGxwHEjedcT8o6bG5a+q/78FxSuRH
jfLcTMsyTkMyytlb5JK4a8/22gOaIVRNAyXjdh3SBCXi7B3KuBGJ4Kj3mMkpZ2zaxPtpwOJUXNsp
6tdvYPUTAAD//wMAUEsDBBQABgAIAAAAIQCk26FH2wAAAAUBAAAPAAAAZHJzL2Rvd25yZXYueG1s
TI/BTsMwEETvSPyDtUjcqNMIqirEqRBVz5RSCXFz7G0cNV6H2E1Tvp6FC1xGGs1q5m25mnwnRhxi
G0jBfJaBQDLBttQo2L9t7pYgYtJkdRcIFVwwwqq6vip1YcOZXnHcpUZwCcVCK3Ap9YWU0Tj0Os5C
j8TZIQxeJ7ZDI+2gz1zuO5ln2UJ63RIvON3js0Nz3J28grjefvbmsK2Pzl6+Xtbjg3nffCh1ezM9
PYJIOKW/Y/jBZ3SomKkOJ7JRdAr4kfSrnC0X92xrBXk+z0FWpfxPX30DAAD//wMAUEsBAi0AFAAG
AAgAAAAhALaDOJL+AAAA4QEAABMAAAAAAAAAAAAAAAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQ
SwECLQAUAAYACAAAACEAOP0h/9YAAACUAQAACwAAAAAAAAAAAAAAAAAvAQAAX3JlbHMvLnJlbHNQ
SwECLQAUAAYACAAAACEAZkogjSYCAABOBAAADgAAAAAAAAAAAAAAAAAuAgAAZHJzL2Uyb0RvYy54
bWxQSwECLQAUAAYACAAAACEApNuhR9sAAAAFAQAADwAAAAAAAAAAAAAAAACABAAAZHJzL2Rvd25y
ZXYueG1sUEsFBgAAAAAEAAQA8wAAAIgFAAAAAA==
">
 <v:textbox style='mso-fit-shape-to-text:t'>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='text-indent:0in'><span style='mso-no-proof:yes'><v:shape
     id="Picture_x0020_12699" o:spid="_x0000_i1025" type="#_x0000_t75" style='width:416.25pt;
     height:234pt;visibility:visible;mso-wrap-style:square'>
     <v:imagedata src="thesis-github_files/image041.gif" o:title=""/>
    </v:shape></span></p>
    <p class=MsoNormal>Figure 24: Mechanisms of AAS alleviation of GAML</p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><![if !vml]><img width=582 height=6
src="thesis-github_files/image001.gif"
alt="Text Box:  &#13;&#10;Figure 24: Mechanisms of AAS alleviation of GAML&#13;&#10;"
v:shapes="_x0000_s1026"><![endif]><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1062" type="#_x0000_t75" style='width:6in;height:282.45pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p>

<b style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;
mso-bidi-font-size:11.0pt;line-height:200%;font-family:"Georgia",serif;
mso-fareast-font-family:Georgia;mso-bidi-font-family:Georgia;color:black;
mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><br
clear=all style='page-break-before:always'>
</span></b>

<h1><a name="_Toc421412297">Bibliography</a></h1>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal style='line-height:normal'>Added during June 22 review:</p>

<p class=MsoNormal style='line-height:normal'>[tay2005] Tay Y-C, Wang Y,
Kairaitis L, Rangan GK, Zhang C, Harris DCH. Can murine diabetic nephropathy be
separated from superimposed acute renal failure? Kidney Int. 2005
Jul;68(1):391398. PMID: 15954931</p>

<p class=MsoNormal style='line-height:normal'><span lang=IT style='mso-ansi-language:
IT'>[augusto2004] Augusto V, Padovani CR, Campos GR. </span>Skeletal muscle
fiber types in C57BL6J mice. Braz J Morphol Sci. 2004;21(2):8994. </p>

<p class=MsoNormal style='line-height:normal'>[peterson2008] Peterson JM,
Guttridge DC. Skeletal muscle diseases, inflammation, and NF-kappaB signaling:
insights and opportunities for therapeutic intervention. Int Rev Immunol.
2008;27(5):375387. PMID: 18853344</p>

<p class=MsoNormal style='line-height:normal'>[joshi2005] Joshi SM, Hewitt RJD,
Storr HL, Rezajooi K, Ellamushi H, Grossman AB, Savage MO, Afshar F. Cushings
disease in children and adolescents: 20 years of experience in a single
neurosurgical center. Neurosurgery. 2005 Aug;57(2):281285; discussion 281285.
PMID: 16094156</p>

<p class=MsoNormal style='line-height:normal'>[kanter2005] Kanter AS, Diallo
AO, Jane JA, Sheehan JP, Asthagiri AR, Oskouian RJ, Okonkwo DO, Sansur CA,
Vance ML, Rogol AD, Laws ER. Single-center experience with pediatric Cushings
disease. J Neurosurg. 2005 Nov;103(5 Suppl):413420. PMID: 16302612</p>

<p class=MsoNormal style='line-height:normal'>[scelsi1980] Scelsi R, Marchetti
C, Poggi P. Histochemical and ultrastructural aspects of m. vastus lateralis in
sedentary old people (age 65--89 years). Acta Neuropathol. 1980;51(2):99105.
PMID: 7435151</p>

<p class=MsoNormal style='line-height:normal'><o:p>&nbsp;</o:p></p>

<p class=MsoNormal style='line-height:normal'>Originally included:</p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[1]<span
style='mso-tab-count:1'> </span>J. Newell-Price, X. Bertagna, A. B.
Grossman, and L. K. Nieman. Cushings syndrome. Lancet, 367(9522):16051617,
May 2006. PMID: 16698415. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[2]<span
style='mso-tab-count:1'> </span>M. E. Molitch. Current approaches to the
pharmacological management of Cushings disease. Molecular and Cellular
Endocrinology, October 2014. PMID: 25450859. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[3]<span
style='mso-tab-count:1'> </span>H. Cushing. The pituitary body and its
disorders, clinical states produced by disorders of the hypophysis cerebri.
J.B. Lippincott Co., Philadelphia &amp; London, 1912. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[4]<span
style='mso-tab-count:1'> </span>E. A. Schfer and S. Vincent. The
physiological effects of extracts of the pituitary body. The Journal of
Physiology, 25(1):8797, 1899. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[5]<span
style='mso-tab-count:1'> </span>H. Cushing. The basophil adenomas of the
pituitary body and their clinical manifestations (pituitary basophilism).
Bulletin of the Johns Hopkins Hospital, L:137195, 1932. PMID: 16353601. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[6]<span
style='mso-tab-count:1'> </span>E. J. Kepler. Cushings disease; a
primary disorder of the adrenal cortices? Annals of the New York Academy of
Sciences, 50(Art. 6):657678, June 1949. PMID: 18148623. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[7]<span
style='mso-tab-count:1'> </span>G. W. Thorn, R. P. Howard, and K.
Emerson. Treatment of Addisons disease with desoxy-corticosterone acetate, a
synthetic adrenal cortical hormone (preliminary report). Journal of Clinical
Investigation, 18(4):449467, July 1939. PMID: 16694679. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[8]<span
style='mso-tab-count:1'> </span>L. K. Nieman, B. M. K. Biller, J. W.
Findling, J. Newell-Price, M. O. Savage, P. M. Stewart, and V. M. Montori. The
diagnosis of Cushings syndrome: an endocrine society clinical practice
guideline. The Journal of Clinical Endocrinology and Metabolism,
93(5):15261540, May 2008. PMID: 18334580. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[9]<span
style='mso-tab-count:1'> </span>L. K. Nieman. Diagnostic tests for
Cushings syndrome. Annals of the New York Academy of Sciences, 970:112118,
September 2002. PMID:12381546. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[10]<span
style='mso-tab-count:1'> </span>L. F. Kirk, R. B. Hash, H. P. Katner, and
T. Jones. Cushings disease: clinical manifestations and diagnostic evaluation.
American Family Physician, 62(5):11191127, 11331134, September 2000. PMID:
10997535. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[11]<span
style='mso-tab-count:1'> </span>J. Glyn. The discovery and early use of
cortisone. Journal of the Royal Society of Medicine, 91(10):513517, October
1998. PMID: 10070369. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[12]<span
style='mso-tab-count:1'> </span>P. S. Hench. The reversibility of certain
rheumatic and non-rheumatic conditions by the use of cortisone or of the
pituitary adrenocorticotropic hormone. In Nobel Lectures, Physiology or
Medicine 1942-1962. Nobel Media AB, Amsterdam, 1964. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[13]<span
style='mso-tab-count:1'> </span>R. G. Sprague, M. H. Power, H. L. Mason, A.
Albert, D. R. Mathieson, P. S. Hench, E. C. Kendall, C. H. Slocumb, and H. F.
Polley. Observations on the physiologic effects of cortisone and ACTH in man.
Archives of Internal Medicine, 85(2):199258, February 1950. PMID: 15405892. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[14]<span
style='mso-tab-count:1'> </span>A. R. Clark. Anti-inflammatory functions of
glucocorticoid-induced genes. Molecular and Cellular Endocrinology,
275(1-2):7997, September 2007. PMID: 17561338. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[15]<span
style='mso-tab-count:1'> </span>A. E. Coutinho and K. E. Chapman. The
anti-inflammatory and immunosuppressive effects of glucocorticoids, recent
developments and mechanistic insights. Molecular and Cellular Endocrinology,
335(1):213, March 2011. PMID: 20398732. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[16]<span
style='mso-tab-count:1'> </span>M. Truss, G. Chalepakis, and M. Beato.
Contacts between steroid hormone receptors and thymines in DNA: an interference
method. Proceedings of the National Academy of Sciences of the United States of
America, 87(18):71807184, September 1990. <span lang=IT style='mso-ansi-language:
IT'>PMID: 2169621. <o:p></o:p></span></p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'><span lang=IT
style='mso-ansi-language:IT'>[17]<span style='mso-tab-count:1'> </span>F.
Re, M. Muzio, M. De Rossi, N. Polentarutti, J. G. Giri, A. Mantovani, and F.
Colotta. </span>The type II receptor as a decoy target for interleukin 1 in
polymorphonuclear leukocytes: characterization of induction by dexamethasone
and ligand binding properties of the released decoy receptor. The Journal of
Experimental Medicine, 179(2):739743, February 1994. PMID: 8294881. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[18]<span
style='mso-tab-count:1'> </span>F. Paliogianni, A. Raptis, S. S. Ahuja, S.
M. Najjar, and D. T. Boumpas. Negative transcriptional regulation of human
interleukin 2 (IL-2) gene by glucocorticoids through interference with nuclear
transcription factors AP-1 and NF-AT. Journal of Clinical Investigation,
91(4):14811489, April 1993. PMID: 8473495. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[19]<span
style='mso-tab-count:1'> </span>M. M. Chang, M. Juarez, D. M. Hyde, and R.
Wu. Mechanism of dexamethasone-mediated interleukin-8 gene suppression in
cultured airway epithelial cells. American Journal of Physiology. Lung Cellular
and Molecular Physiology, 280(1):L107115, January 2001. PMID: 11133500. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[20]<span
style='mso-tab-count:1'> </span>A. Hafezi-Moghadam, T. Simoncini, Z. Yang,
F. P. Limbourg, J.-C. Plumier, M. C. Rebsamen, C.-M. Hsieh, D.-S. Chui, K. L.
Thomas, A. J. Prorock, V. E. Laubach, M. A. Moskowitz, B. A. French, K. Ley,
and J. K. Liao. Acute cardiovascular protective effects of corticosteroids are
mediated by non-transcriptional activation of endothelial nitric oxide
synthase. Nature Medicine, 8(5):473479, May 2002. PMID: 11984591. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[21]<span
style='mso-tab-count:1'> </span>F. S. Dhabhar and B. S. McEwen. Enhancing
versus suppressive effects of stress hormones on skin immune function.
Proceedings of the National Academy of Sciences of the United States of
America, 96(3):10591064, February 1999. PMID: 9927693. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[22]<span
style='mso-tab-count:1'> </span>N. L. Wendler, R. P. Graber, R. E. Jones,
and M. Tishler. Synthesis of 11-hydroxylated cortical steroids.
17(&#945;)-hydroxycorticosterone. Journal of the American Chemical Society,
72(12):57935794, 1950. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[23]<span
style='mso-tab-count:1'> </span>The Empire Rheumatism Council
Sub-Committee. Multi-centre controlled trial of cortisone acetate and acetyl
salicylic acid in the long-term treatment of rheumatoid arthritis: results of
three years treatment. Annals of the Rheumatic Diseases, 16(3):277289,
September 1957. PMID: 13470729. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[24]<span
style='mso-tab-count:1'> </span>L. H. Sarett. Some aspects of the evolution
of anti-inflammatory steroids. Annals of the New York Academy of Sciences,
82(4):802808, 1959. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[25]<span
style='mso-tab-count:1'> </span>H. L. Herzog, C. C. Payne, M. A. Jevnik, D.
Gould, E. L. Shapiro, E. P. Oliveto, and E. B. Hershberg. 11-oxygenated
steroids. XIII. synthesis and proof of structure of
&#8710;-1,4-pregnadiene-17&#945;,21-diol-3,11,20-trione and
&#8710;-1,4-pregnadiene-11&#946;,17&#945;,21-triol-3,20-dione. Journal of the
American Chemical Society, 77(18):47814784, 1955. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[26]<span
style='mso-tab-count:1'> </span>J. J. Bunim, R. L. Black, A. J. Bollet, and
M. M. Pechet. Metabolic effects of metacortandralone and metacortandracin.
Annals of the New York Academy of Sciences, 61(2):358368, 1955. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[27]<span
style='mso-tab-count:1'> </span>Medical Research Council and Nuffield
Foundation Report. A comparison of prednisolone with aspirin or other
analgesics in the treatment of rheumatoid arthritis. Annals of the Rheumatic
Diseases, 19(4):331337, December 1960. PMID: 14447267. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[28]<span
style='mso-tab-count:1'> </span>J. Fried, K. Florey, E. F. Sabo, J. E. Herz,
A. R. Restivo, A. Borman, and F. M. Singer. Synthesis and biological activity
of 1- and 6-dehydro-9&#945;-halocorticoids. Journal of the American Chemical
Society, 77(15):41814182, 1955. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[29]<span
style='mso-tab-count:1'> </span>J. Fried and E. F. Sabo. Synthesis of
17&#945;-hydroxycorticosterone and its 9&#945;-halo derivatives from
11-epi-17&#945;-hydroxycorticosterone. Journal of the American Chemical
Society, 75(9):22732274, 1953. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[30]<span
style='mso-tab-count:1'> </span>G. E. Arth, D. B. R. Johnston, J. Fried, W.
W. Spooncer, D. R. Hoff, and L. H. Sarett. 16-methylated steroids. I.
16&#945;-methylated analogs of cortisone, a new group of anti-inflammatory
steroids. Journal of the American Chemical Society, 80(12):31603161, 1958. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[31]<span
style='mso-tab-count:1'> </span>G. E. Arth, J. Fried, D. B. R. Johnston, D.
R. Hoff, L. H. Sarett, R. H. Silber, H. C. Stoerk, and C. A. Winter.
16-methylated steroids. II. 16&#945;-methyl analogs of cortisone, a new group
of anti-inflammatory steroids. 9&#945;-halo derivatives. Journal of the
American Chemical Society, 80(12):31613163, 1958. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[32]<span
style='mso-tab-count:1'> </span>R. H. Silber. The biology of
anti-inflammatory steroids. Annals of the New York Academy of Sciences,
82(4):821828, October 1959. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[33]<span
style='mso-tab-count:1'> </span>T. F. Frawley, H. Kistler, and T. Shelley.
Effects of anti-inflammatory steroids on carbohydrate metabolism, with emphasis
on hypo-glycemic and diabetic states. Annals of the New York Academy of
Sciences, 82(4):868885, October 1959. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[34]<span
style='mso-tab-count:1'> </span>A. W. Meikle and F. H. Tyler. Potency and
duration of action of glucocorticoids. Effects of hydrocortisone, prednisone
and dexamethasone on human pituitary-adrenal function. The American Journal of
Medicine, 63(2):200207, August 1977. PMID: 888843. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[35]<span
style='mso-tab-count:1'> </span>C. W. Lin, M. Nakane, M. Stashko, D. Falls,
J. Kuk, L. Miller, R. Huang, C. Tyree, J. N. Miner, J. Rosen, P. R. Kym, M. J.
Coghlan, G. Carter, and B. C. Lane. trans-Activation and repression properties
of the novel nonsteroid glucocorticoid receptor ligand
2,5-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5-(1-methylcyclohexen-3-y1)-1H-
[1]benzopyrano [3,4-f]quinoline (A276575) and its four stereoisomers. Molecular
Pharmacology, 62(2):297303, August 2002. PMID: 12130681. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[36]<span
style='mso-tab-count:1'> </span>M. G. Belvisi, S. L. Wicks, C. H. Battram,
S. E. Bottoms, J. E. Redford, P. Woodman, T. J. Brown, S. E. Webber, and M. L.
Foster. Therapeutic benefit of a dissociated glucocorticoid and the relevance
of in vitro separation of transrepression from transactivation activity.
Journal of Immunology (Baltimore, Md.: 1950), 166(3):19751982, February 2001.
PMID: 11160246. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[37]<span
style='mso-tab-count:1'> </span>M. Baiula, A. Bedini, J. Baldi, M. E.
Cavet, P. Govoni, and S. Spampinato. Mapracorat, a selective glucocorticoid
receptor agonist, causes apoptosis of eosinophils infiltrating the conjunctiva
in late-phase experimental ocular allergy. Drug Design, Development and
Therapy, 8:745757, June 2014. PMID: 24959069. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[38]<span
style='mso-tab-count:1'> </span>G. Johannsson, A. Falorni, S. Skrtic, H.
Lennerns, M. Quinkler, J. P. Monson, and P. M. Stewart. Adrenal insufficiency:
review of clinical outcomes with current glucocorticoid replacement therapy.
Clinical Endocrinology, 82(1):211, January 2015. PMID: 25187037. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[39]<span
style='mso-tab-count:1'> </span>M. Crump, J. Kuruvilla, S. Couban, D. A.
MacDonald, V. Kukreti, C. T. Kouroukis, M. Rubinger, R. Buckstein, K. R. Imrie,
M. Federico, N. Di Renzo, K. Howson-Jan, T. Baetz, L. Kaizer, M. Voralia, H. J.
Olney, A. R. Turner, J. Sussman, A. E. Hay, M. S. Djurfeldt, R. M. Meyer, B. E.
Chen, and L. E. Shepherd. Randomized comparison of gemcitabine, dexamethasone,
and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy
before autologous stem-cell transplantation for relapsed and refractory
aggressive lymphomas: NCIC-CTG LY.12. Journal of Clinical Oncology: Official
Journal of the American Society of Clinical Oncology, 32(31):34903496,
November 2014. PMID: 25267740. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[40]<span
style='mso-tab-count:1'> </span>C.-H. Pui and W. E. Evans. Treatment of
acute lymphoblastic leukemia. The New England Journal of Medicine,
354(2):166178, January 2006. PMID: 16407512. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[41]<span
style='mso-tab-count:1'> </span>A. K. Stewart, S. V. Rajkumar, M. A.
Dimopoulos, T. Masszi, I. pi&#269;ka, A. Oriol, R. Hjek, L. Rosiol, D. S.
Siegel, G. G. Mihaylov, V. Goranova-Marinova, P. Rajnics, A. Suvorov, R.
Niesvizky, A. J. Jakubowiak, J. F. San-Miguel, H. Ludwig, M. Wang, V. Maisnar,
J.<span style='mso-tab-count:1'> </span>Minarik, W. I. Bensinger, M.-V.
Mateos, D. Ben-Yehuda, V. Kukreti, N. Zojwalla, M. E. Tonda, X. Yang, B. Xing,
P. Moreau, A. Palumbo, and ASPIRE Investigators. Carfilzomib, lenalidomide, and
dexamethasone for relapsed multiple myeloma. The New England Journal of
Medicine, 372(2):142152, January 2015. PMID: 25482145. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[42]<span
style='mso-tab-count:1'> </span>I. Marie. Therapy of polymyositis and
dermatomyositis. Presse Mdicale (Paris, France: 1983), 40(4 Pt 2):e257270,
April 2011. PMID: 21334847. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[43]<span
style='mso-tab-count:1'> </span>O. J. Dempsey, E. W. Paterson, K. M. Kerr,
and A. R. Denison. Sarcoidosis. BMJ (Clinical research ed.), 339:b3206, 2009.
PMID: 19717499. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[44]<span
style='mso-tab-count:1'> </span>B. Brazzini and N. Pimpinelli. New and
established topical corticosteroids in dermatology: clinical pharmacology and
therapeutic use. American Journal of Clinical Dermatology, 3(1):4758, 2002.
PMID: 11817968. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[45]<span
style='mso-tab-count:1'> </span>J. B. Christoforidis, S. Chang, A. Jiang,
J. Wang, and C. M. Cebulla. Systemic treatment of vitreous inflammation.
Mediators of Inflammation, 2012, 2012. PMID: 23028205. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[46]<span
style='mso-tab-count:1'> </span>D. Gordon and J. McLean. Effects of
pituitary adrenocorticotropic hormone (ACTH) therapy in ophthalmologic
conditions. Journal of the American Medical Association, 142(16):12711276,
April 1950. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[47]<span
style='mso-tab-count:1'> </span>G. E. Keeney, M. P. Gray, A. K. Morrison,
M. N. Levas, E. A. Kessler, G. D. Hill, M. H. Gorelick, and J. L. Jackson.
Dexamethasone for acute asthma exacerbations in children: a meta-analysis.
Pediatrics, 133(3):493499, March 2014. PMID: 24515516. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[48]<span
style='mso-tab-count:1'> </span>F. Qureshi, A. Zaritsky, and M. P. Poirier.
Comparative efficacy of oral dexamethasone versus oral prednisone in acute
pediatric asthma. The Journal of Pediatrics, 139(1):2026, July 2001. PMID:
11445789. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[49]<span
style='mso-tab-count:1'> </span>B. Crotty and D. P. Jewell. Drug therapy of
ulcerative colitis. British Journal of Clinical Pharmacology, 34(3):189198,
September 1992. PMID: 1389944. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[50]<span
style='mso-tab-count:1'> </span>W. Rosenberg, A. Ireland, and D. P. Jewell.
High-dose methylprednisolone in the treatment of active ulcerative colitis.
Journal of Clinical Gastroenterology, 12(1):4041, February 1990. PMID:
2303687. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[51]<span
style='mso-tab-count:1'> </span>D. Haack, K. Schrer, A. Asam-Tauscher, and
P. Vecsei. Glucocorticoid receptors in idiopathic nephrotic syndrome. Pediatric
Nephrology (Berlin, Germany), 13(8):653656, October 1999. PMID: 10502121. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[52]<span
style='mso-tab-count:1'> </span>Merck &amp; Co., Inc. Dexamethasone tablets
[package insert], 2004. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[53]<span
style='mso-tab-count:1'> </span>Pharmacia and Upjohn and Company.
Prednisone tablets [package insert], 2007. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[54]<span
style='mso-tab-count:1'> </span>West-ward Pharmaceutical Corp.
Hydrocortisone tablets [package insert], 2008. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[55]<span
style='mso-tab-count:1'> </span>C. Kotsarini, P. D. Griffiths, I. D.
Wilkinson, and N. Hoggard. A systematic review of the literature on the effects
of dexamethasone on the brain from in vivo human-based studies: implications
for physiological brain imaging of patients with intracranial tumors.
Neurosurgery, 67(6):17991815; discussion 1815, December 2010. PMID: 21107211. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[56]<span
style='mso-tab-count:1'> </span>B. D. Levine, K. Yoshimura, T. Kobayashi,
M. Fukushima, T. Shibamoto, and G. Ueda. Dexamethasone in the treatment of
acute mountain sickness. The New England Journal of Medicine,
321(25):17071713, December 1989. PMID: 2687688. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[57]<span
style='mso-tab-count:1'> </span>P. Alderson and I. Roberts. Corticosteroids
for acute traumatic brain injury. The Cochrane Database of Systematic Reviews,
(1):CD000196, 2005. PMID: 15674869. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[58]<span
style='mso-tab-count:1'> </span>A. L. Skversky, J. Kumar, M. K. Abramowitz,
F. J. Kaskel, and M. L. Melamed. Association of glucocorticoid use and low
25-hydroxyvitamin D levels: results from the National Health and Nutrition
Examination Survey (NHANES): 2001-2006. The Journal of Clinical Endocrinology
and Metabolism, 96(12):38383845, December 2011. PMID: 21956424. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[59]<span
style='mso-tab-count:1'> </span>T. P. van Staa, H. G. Leufkens, L.
Abenhaim, B. Begaud, B. Zhang, and C. Cooper. Use of oral corticosteroids in
the United Kingdom. QJM: Monthly Journal of the Association of Physicians,
93(2):105111, February 2000. PMID: 10700481. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[60]<span
style='mso-tab-count:1'> </span>World Health Organization. WHO Essential
Medicines List, 2013. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[61]<span
style='mso-tab-count:1'> </span>J. Lindholm, S. Juul, J. O. Jrgensen, J.
Astrup, P. Bjerre, U. Feldt-Rasmussen, C. Hagen, J. Jrgensen, M. Kosteljanetz,
L. Kristensen, P. Laurberg, K. Schmidt, and J. Weeke. Incidence and late
prognosis of Cushings syndrome: a population-based study. The Journal of
Clinical Endocrinology and Metabolism, 86(1):117123, January 2001. PMID:
11231987. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[62]<span
style='mso-tab-count:1'> </span>T. Psaras, M. Milian, V. Hattermann, T.
Freiman, B. Gallwitz, and J.<span style='mso-tab-count:1'> </span>Honegger.
Demographic factors and the presence of comorbidities donot promote early
detection of Cushings disease and acromegaly. Experimental and Clinical
Endocrinology &amp; Diabetes: Official Journal, German Society of Endocrinology
[and] German Diabetes Association, 119(1):2125, January 2011. PMID: 20827660. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[63]<span
style='mso-tab-count:1'> </span>C. M. Plotz, A. I. Knowlton, and C. Ragan.
The natural history of Cushings syndrome. The American Journal of Medicine,
13(5):597614, November 1952. PMID: 12996538. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[64]<span
style='mso-tab-count:1'> </span>E. Valassi, I. Crespo, A. Santos, and S. M.
Webb. Clinical consequences of Cushings syndrome. Pituitary, 15(3):319329,
September 2012. PMID: 22527617. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[65]<span
style='mso-tab-count:1'> </span>E. Valassi, A. Santos, M. Yaneva, M. Tth,
C. J. Strasburger, P. Chanson, J. A. H. Wass, O. Chabre, M. Pfeifer, R. A.
Feelders, S. Tsagarakis, P. J. Trainer, H. Franz, K. Zopf, S. Zacharieva, S. W.
J. Lamberts, A. Tabarin, S. M. Webb, and ERCUSYN Study Group. The European
Registry on Cushings syndrome: 2-year experience. Baseline demographic and
clinical characteristics. European Journal of Endocrinology / European
Federation of Endocrine Societies, 165(3):383392, September 2011. PMID:
21715416. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[66]<span
style='mso-tab-count:1'> </span>M. Muller, T. L. Mazzuco, M. Martinie, I.
Bachelot, and O. Chabre. Diagnosis of Cushings syndrome: A retrospective
evaluation of clinical practice. European Journal of Internal Medicine,
17(5):334338, August 2006. PMID: 16864008. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[67]<span
style='mso-tab-count:1'> </span>J. R. Lindsay, T. Nansel, S. Baid, J.
Gumowski, and L. K. Nieman. Long-term impaired quality of life in Cushings
syndrome despite initial improvement after surgical remission. The Journal of
Clinical Endocrinology and Metabolism, 91(2):447453, February 2006. PMID:
16278266. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[68]<span
style='mso-tab-count:1'> </span>S. M. Ravis and W. H. Eaglstein. Topical
hydrocortisone from prescription to over-the-counter sale: a past controversy:
a cautionary tale. Archives of Dermatology, 143(3):413415, March 2007. PMID:
17372109. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[69]<span
style='mso-tab-count:1'> </span>S. B. Adebajo. An epidemiological survey of
the use of cosmetic skin lightening cosmetics among traders in Lagos, Nigeria.
West African Journal of Medicine, 21(1):5155, March 2002. PMID: 12081345. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[70]<span
style='mso-tab-count:1'> </span>A. France-Presse. Ivory Coast bans
potentially deadly skin-whitening creams. The Guardian, May 2015. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[71]<span
style='mso-tab-count:1'> </span>Y. M. Olumide, A. O. Akinkugbe, D.
Altraide, T. Mohammed, N. Ahamefule, S. Ayanlowo, C. Onyekonwu, and N. Essen.
Complications of chronic use of skin lightening cosmetics. International
Journal of Dermatology, 47(4):344353, April 2008. PMID: 18377596. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[72]<span
style='mso-tab-count:1'> </span>J. N. Rozen, E. Alseddeeqi, and J. Rivera.
Cosmetic agents causing endocrinopathy in an African immigrant. Canadian Family
Physician, 58(2):169171, February 2012. PMID: 22337740. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[73]<span
style='mso-tab-count:1'> </span>M. M. Foisy, E. M. K. Yakiwchuk, I. Chiu,
and A. E. Singh. Adrenal suppression and Cushings syndrome secondary to an
interaction between ritonavir and fluticasone: a review of the literature. HIV
medicine, 9(6):389396, July 2008. PMID: 18459946. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[74]<span
style='mso-tab-count:1'> </span>M. Mann, E. Koller, A. Murgo, S.
Malozowski, J. Bacsanyi, and M. Leinung. Glucocorticoidlike activity of
megestrol. A summary of Food and Drug Administration experience and a review of
the literature. Archives of Internal Medicine, 157(15):16511656, August 1997.
PMID: 9250225. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[75]<span
style='mso-tab-count:1'> </span>J. K. Prague, S. May, and B. C. Whitelaw.
Cushings syndrome. BMJ (Clinical research ed.), 346:f945, 2013. PMID:
23535464. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[76]<span
style='mso-tab-count:1'> </span>L. Fardet, A. Flahault, A. Kettaneh, K. P.
Tiev, T. Gnreau, C. Toldano, C. Lebb, and J. Cabane. Corticosteroid-induced
clinical adverse events: frequency, risk factors and patients opinion. The
British Journal of Dermatology, 157(1):142148, July 2007. PMID: 17501951. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[77]<span
style='mso-tab-count:1'> </span>F. L. Mastaglia. Adverse effects of drugs
on muscle. Drugs, 24(4):304321, October 1982. PMID: 6128217. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[78]<span
style='mso-tab-count:1'> </span>J. A. Douglass, D. V. Tuxen, M. Horne, C.
D. Scheinkestel, M. Weinmann, D. Czarny, and G. Bowes. Myopathy in severe
asthma. The American Review of Respiratory Disease, 146(2):517519, August
1992. PMID: 1362636. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[79]<span
style='mso-tab-count:1'> </span>T. T. Batchelor, L. P. Taylor, H. T.
Thaler, J. B. Posner, and L. M. DeAngelis. Steroid myopathy in cancer patients.
Neurology, 48(5):12341238, May 1997. PMID: 9153449. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[80]<span
style='mso-tab-count:1'> </span>S. L. Bowyer, M. P. LaMothe, and J. R.
Hollister. Steroid myopathy: incidence and detection in a population with
asthma. The Journal of Allergy and Clinical Immunology, 76(2 Pt 1):234242,
August 1985. PMID: 4019954. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[81]<span
style='mso-tab-count:1'> </span>R. Mller and E. Kugelberg. Myopathy in
Cushings syndrome. Journal of Neurology, Neurosurgery, and Psychiatry,
22(4):314319, November 1959. PMID: 14425173. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[82]<span
style='mso-tab-count:1'> </span>I. Rodriguez-Carreno, L. Gila-Useros, and A.
Malanda-Trigueros. Motor unit action potential duration: measurement and
significance. In I. M. Abud Ajeena, editor, Advances in Clinical
Neurophysiology. InTech, October 2012. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[83]<span
style='mso-tab-count:1'> </span>E. J. Dropcho and S. J. Soong.
Steroid-induced weakness in patients with primary brain tumors. Neurology,
41(8):12351239, August 1991. PMID: 1866012. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[84]<span
style='mso-tab-count:1'> </span>A. N. DAgostino and M. Chiga. Cortisone
myopathy in rabbits. A light and electron microscopic study. Neurology,
16(3):257263, March 1966. PMID: 5948610. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[85]<span
style='mso-tab-count:1'> </span>C. J. Vecht, A. Hovestadt, H. B. Verbiest,
J. J. van Vliet, and W. L. van Putten. Dose-effect relationship of
dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized
study of doses of 4, 8, and 16 mg per day. Neurology, 44(4):675680, April
1994. PMID: 8164824. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[86]<span
style='mso-tab-count:1'> </span>C. D. Shee. Risk factors for hydrocortisone
myopathy in acute severe asthma. Respiratory Medicine, 84(3):229233, May 1990.
PMID: 2218007. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[87]<span
style='mso-tab-count:1'> </span>E. N. Coomes. Corticosteroid myopathy. Annals
of the Rheumatic Diseases, 24(5):465472, September 1965. PMID: 5834228. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[88]<span
style='mso-tab-count:1'> </span>P. M. Foye, L. Rispoli, G. E. Hwang, and S.
S. Lim. Corticosteroid-induced myopathy, December 2014. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[89]<span
style='mso-tab-count:1'> </span>F. F. Horber, J. R. Scheidegger, B. E.
Grnig, and F. J. Frey. Thigh muscle mass and function in patients treated with
glucocorticoids. European Journal of Clinical Investigation, 15(6):302307,
December 1985. PMID: 3938399. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[90]<span
style='mso-tab-count:1'> </span>N. A. Pansters, R. C. Langen, E. F. Wouters,
and A. M. Schols. Synergistic stimulation of myogenesis by glucocorticoid and
IGF-I signaling. Journal of Applied Physiology (Bethesda, Md.: 1985),
114(9):13291339, May 2013. PMID: 22936724. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[91]<span
style='mso-tab-count:1'> </span>F. F. Horber, H. Hoopeler, J. R.
Scheidegger, B. E. Grnig, H. Howald, and F. J. Frey. Impact of physical
training on the ultrastructure of midthigh muscle in normal subjects and in
patients treated with glucocorticoids. Journal of Clinical Investigation,
79(4):11811190, April 1987. PMID: 3558821. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[92]<span
style='mso-tab-count:1'> </span>F. F. Horber, J. R. Scheidegger, B. E.
Grnig, and F. J. Frey. Evidence that prednisone-induced myopathy is reversed
by physical training. The Journal of Clinical Endocrinology and Metabolism,
61(1):8388, July 1985. PMID: 3998075. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[93]<span
style='mso-tab-count:1'> </span>B. S. Miller, K. M. Ignatoski, S.
Daignault, C. Lindland, P. G. Gauger, G. M. Doherty, S. C. Wang, and University
of Michigan Analytical Morphomics Group. A quantitative tool to assess degree
of sarcopenia objectively in patients with hypercortisolism. Surgery,
150(6):11781185, December 2011. PMID: 22136838. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[94]<span
style='mso-tab-count:1'> </span>J. A. Simoneau, S. R. Colberg, F. L.
Thaete, and D. E. Kelley. Skeletal muscle glycolytic and oxidative enzyme
capacities are determinants of insulin sensitivity and muscle composition in
obese women. FASEB journal: official publication of the Federation of American Societies
for Experimental Biology, 9(2):273278, February 1995. PMID: 7781930. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[95]<span
style='mso-tab-count:1'> </span>M. Rebuff-Scrive, M. Krotkiewski, J.
Elfverson, and P. Bjrntorp. Muscle and adipose tissue morphology and
metabolism in Cushings syndrome. The Journal of Clinical Endocrinology and
Metabolism, 67(6):11221128, December 1988. PMID: 3142910. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[96]<span
style='mso-tab-count:1'> </span>K. S. Topp, P. L. Painter, S. Walcott, J.
B. Krasnoff, D. Adey, G. K. Sakkas, J.<span style='mso-tab-count:1'> </span>Taylor,
K. McCormick, M. TeNyenhuis, M. Iofina, S. Tomlanovich, andP. Stock.
Alterations in skeletal muscle structure are minimized with steroid withdrawal
after renal transplantation. Transplantation, 76(4):667673, August 2003. PMID:
12973106. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[97]<span
style='mso-tab-count:1'> </span>A. A. Khaleeli, R. H. Edwards, K. Gohil, G.
McPhail, M. J. Rennie, J. Round, and E. J. Ross. Corticosteroid myopathy: a
clinical and pathological study. Clinical Endocrinology, 18(2):155166,
February 1983. PMID: 6851197. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[98]<span
style='mso-tab-count:1'> </span>F. Le Grand and M. A. Rudnicki. Skeletal
muscle satellite cells and adult myogenesis. Current opinion in cell biology,
19(6):628633, December 2007. PMID: 17996437. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[99]<span
style='mso-tab-count:1'> </span>R. G. Ham, J. A. St Clair, C. Webster, and
H. M. Blau. Improved media for normal human muscle satellite cells: serum-free
clonal growth and enhanced growth with low serum. In Vitro Cellular &amp;
Developmental Biology: Journal of the Tissue Culture Association,
24(8):833844, August 1988. PMID: 3045074. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[100]<span
style='mso-tab-count:1'> </span>G. T. Griffing. Serum cortisol, March 2014. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[101]<span
style='mso-tab-count:1'> </span>R. G. Sprague, M. H. Power, and H. L. Mason.
Physiological effects of cortisone and pituitary adrenocorticotropic hormone
(ACTH) in man. Journal of the American Medical Association, 144(16):13411347,
December 1950. PMID: 14778744. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[102]<span
style='mso-tab-count:1'> </span>P. S. Simmons, J. M. Miles, J. E. Gerich, and
M. W. Haymond. Increased proteolysis. An effect of increases in plasma cortisol
within the physiologic range. Journal of Clinical Investigation, 73(2):412420,
February 1984. PMID: 6365973. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[103]<span
style='mso-tab-count:1'> </span>D. J. Brillon, B. Zheng, R. G. Campbell, and
D. E. Matthews. Effect of cortisol on energy expenditure and amino acid
metabolism in humans. The American Journal of Physiology, 268(3 Pt 1):E501513,
March 1995. PMID: 7900796. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[104]<span
style='mso-tab-count:1'> </span>S. Ellero-Simatos, E. Szyma&#324;ska, T.
Rullmann, W. H. Dokter, R. Ramaker, R. Berger, T. M. van Iersel, A. K. Smilde,
T. Hankemeier, and W. Alkema. Assessing the metabolic effects of prednisolone
in healthy volunteers using urine metabolic profiling. Genome Medicine,
4(11):94, November 2012. PMID: 23199229. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[105]<span
style='mso-tab-count:1'> </span>M. Elia, A. Carter, S. Bacon, C. G. Winearls,
and R. Smith. Clinical usefulness of urinary 3-methylhistidine excretion in
indicating muscle protein breakdown. British Medical Journal (Clinical research
ed.), 282(6261):351354, January 1981. PMID: 6780020. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[106]<span
style='mso-tab-count:1'> </span>E. Lfberg, A. Gutierrez, J. Wernerman, B.
Anderstam, W. E. Mitch, S. R. Price, J. Bergstrm, and A. Alvestrand. Effects
of high doses of glucocorticoids on free amino acids, ribosomes and protein
turnover in human muscle. European Journal of Clinical Investigation,
32(5):345353, May 2002. PMID: 12027875. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[107]<span
style='mso-tab-count:1'> </span>S. C. Bodine and L. M. Baehr. Skeletal muscle
atrophy and the E3 ubiquitin ligases MuRF1 and MAFbx/atrogin-1. American
Journal of Physiology. Endocrinology and Metabolism, 307(6):E469484, September
2014. PMID: 25096180. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[108]<span
style='mso-tab-count:1'> </span>Millenium Pharmaceuticals, Inc. Velcade
(bortezomib) for injection<span style='mso-spacerun:yes'> </span>[prescribing
information], 2014. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[109]<span
style='mso-tab-count:1'> </span>Onyx Pharmaceuticals, Inc. Kyprolis
(carfilzomib) for injection<span style='mso-spacerun:yes'> </span>[prescribing
information], 2012. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[110]<span
style='mso-tab-count:1'> </span>P. G. Richardson, P. Sonneveld, M. W.
Schuster, D. Irwin, E. A. Stadtmauer, T. Facon, J.-L. Harousseau, D.
Ben-Yehuda, S. Lonial, J.-F. San Miguel, J. D. Cavenagh, and K. C. Anderson.
Safety and efficacy of bortezomib in high-risk and elderly patients with
relapsed multiple myeloma. British Journal of Haematology, 137(5):429435, June
2007. PMID: 17451408. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[111]<span
style='mso-tab-count:1'> </span>S. Jagannath, P. G. Richardson, B. Barlogie,
J. R. Berenson, S. Singhal, D. Irwin, G. Srkalovic, D. P. Schenkein, D. L.
Esseltine, K. C. Anderson, and SUMMIT/CREST Investigators. Bortezomib in
combination with dexamethasone for the treatment of patients with relapsed
and/or refractory multiple myeloma with less than optimal response to
bortezomib alone. Haematologica, 91(7):929934, July 2006. PMID: 16818280. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[112]<span
style='mso-tab-count:1'> </span>R. K. Amaravadi, J. Lippincott-Schwartz,
X.-M. Yin, W. A. Weiss, N. Takebe, W. Timmer, R. S. DiPaola, M. T. Lotze, and
E. White. Principles and current strategies for targeting autophagy for cancer
treatment. Clinical cancer research : an official journal of the American
Association for Cancer Research, 17(4):654666, February 2011. PMID: 21325294. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[113]<span
style='mso-tab-count:1'> </span>Sanofi Aventis US, LLC. Plaquenil
(hydroxychloroquine sulfate) tablets, U.S.P [prescribing information], 2006. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[114]<span
style='mso-tab-count:1'> </span>H. S. Lee, B. H. Daniels, E. Salas, A. W.
Bollen, J. Debnath, and M. Margeta. Clinical utility of LC3 and p62
immunohistochemistry in diagnosis of drug-induced autophagic vacuolar
myopathies: a case-control study. PLoS ONE, 7(4), April 2012. PMID: 22558391. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[115]<span
style='mso-tab-count:1'> </span>P. S. Ghosh, D. Swift, and A. G. Engel.
Teaching NeuroImages: Hydroxychloroquine-induced vacuolar myopathy. Neurology,
80(23):e248e249, June 2013. PMID: 23733558. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[116]<span
style='mso-tab-count:1'> </span>A. Nucci, L. S. Queiroz, and A. M. Samara.
Chloroquine neuromyopathy. Clinical Neuropathology, 15(5):256258, October
1996. PMID: 8879864. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[117]<span
style='mso-tab-count:1'> </span>K. R. Short, J. Nygren, M. L. Bigelow, and
K. S. Nair. Effect of short-term prednisone use on blood flow, muscle protein
metabolism, and function. The Journal of Clinical Endocrinology and Metabolism,
89(12):61986207, December 2004. PMID: 15579778. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[118] K. R.
Short, M. L. Bigelow, and K. S. Nair. Short-term prednisone use antagonizes
insulins anabolic effect on muscle protein and glucose metabolism in young
healthy people. American Journal of Physiology. Endocrinology and Metabolism,
297(6):E1260E1268, December 2009. PMID: 19738036. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[119]<span
style='mso-tab-count:1'> </span>R. J. Louard, R. Bhushan, R. A. Gelfand, E.
J. Barrett, and R. S. Sherwin. Glucocorticoids antagonize insulins
antiproteolytic action on skeletal muscle in humans. The Journal of Clinical
Endocrinology and Metabolism, 79(1):278284, July 1994. PMID: 8027242. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[120]<span
style='mso-tab-count:1'> </span>Z. Liu, L. A. Jahn, W. Long, D. A. Fryburg,
L. Wei, and E. J. Barrett. Branched chain amino acids activate messenger
ribonucleic acid translation regulatory proteins in human skeletal muscle, and
glucocorticoids blunt this action. The Journal of Clinical Endocrinology and
Metabolism, 86(5):21362143, May 2001. PMID: 11344218. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[121]<span
style='mso-tab-count:1'> </span>D. R. Garrel, P. D. Delmas, C. Welsh, M. J.
Arnaud, S. E. Hamilton, and M. M. Pugeat. Effects of moderate physical training
on prednisone-induced protein wasting: a study of whole-body and bone protein
metabolism. Metabolism: Clinical and Experimental, 37(3):257262, March 1988.
PMID: 3257806. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[122]<span
style='mso-tab-count:1'> </span>Z. Liu, G. Li, S. R. Kimball, L. A. Jahn, and
E. J. Barrett. Glucocorticoids modulate amino acid-induced translation
initiation in human skeletal muscle. American Journal of Physiology.
Endocrinology and Metabolism, 287(2):E275281, August 2004. PMID: 15039148. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[123]<span
style='mso-tab-count:1'> </span>T. T. Amatruda, D. R. Hollingsworth, N. D.
Desopo, G. V. Upton, and P. K. Bondy. A study of the mechanism of the steroid
withdrawal syndrome. Evidence for integrity of the
hypothalamic-pituitary-adrenal system. The Journal of Clinical Endocrinology
and Metabolism, 20:339354, March 1960. PMID: 13793101. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[124]<span
style='mso-tab-count:1'> </span>F. Mor, P. Green, and A. J. Wysenbeek.
Myopathy in Addisons disease. Annals of the Rheumatic Diseases, 46(1):8183,
January 1987. PMID: 3813679. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[125]<span
style='mso-tab-count:1'> </span>C.-. Brown-Squard. Note on the effects
produced on man by subcutaneous injections of a liquid obtained from the
testicles of animals. The Lancet, 134(3438):105107, July 1889. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[126]<span
style='mso-tab-count:1'> </span>C.-. Brown-Squard. On a new therapeutic
method consisting in the use of organic liquids extracted from glands and other
organs. British Medical Journal, 1(1693):12121214, June 1893. PMID: 20754269. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[127]<span
style='mso-tab-count:1'> </span>E. Nieschlag and S. Nieschlag. Testosterone
deficiency: a historical perspective. Asian Journal of Andrology,
16(2):161168, 2014. PMID: 24435052. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[128]<span
style='mso-tab-count:1'> </span>A. A. Berthold. Transplantation der Hoden.
Archiv fr Anatomie, Physiologie und Wissenschaftliche Medicin, pages 4246,
1849. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[129]<span
style='mso-tab-count:1'> </span>C. D. Kochakian and J. R. Murlin. The effect
of male hormone on the protein and energy metabolism of castrate dogs. The
Journal of Nutrition, 10(4):437 459, October 1935. PMID: 0. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[130]<span
style='mso-tab-count:1'> </span>T. F. Gallagher and F. C. Koch. The
testicular hormone. Journal of Biological Chemistry, 84(2):495500, November
1929. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[131]<span
style='mso-tab-count:1'> </span>L. C. McGee, M. Juhn, and L. V. Domm. The
development of secondary sex characters in capons by injections of extracts of
bull testes. American Journal of Physiology  Legacy Content, 87(2):406435,
December 1928. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[132]<span
style='mso-tab-count:1'> </span>K. David, E. Dingemanse, J. Freud, and E.
Laqueur. ber krystallinisches mnnliches Hormon aus Hoden (Testosteron),
wirksamer als aus Harn oder aus Cholesterin bereitetes Androsteron.
Hoppe-Seylers Zeitschrift fur physiologische Chemie, 233(5-6):281283, 1935. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[133]<span
style='mso-tab-count:1'> </span>J. M. Hoberman and C. E. Yesalis. The history
of synthetic testosterone. Scientific American, 272(2):7681, February 1995.
PMID: 7817189. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[134]<span
style='mso-tab-count:1'> </span>A. T. Kenyon, I. Sandiford, H. A. Bryan, K.
Knowlton, and F. C. Koch. The effect of testosterone propionate on nitrogen,
electrolyte, water and energy metabolism in eunuchoidism. Endocrinology,
23(2):135153, August 1938. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[135]<span
style='mso-tab-count:1'> </span>Auxilium Pharmaceuticals, Inc. Testim
(testosterone gel) for topical use<span style='mso-spacerun:yes'>
</span>[prescribing information], 2014. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[136]<span
style='mso-tab-count:1'> </span>Endo Pharmaceuticals Solutions Inc.
Delatestryl (testosterone enanthate) injection [prescribing information], 2014.
</p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[137]<span
style='mso-tab-count:1'> </span>Unimed. Androgel, Physicians Package Insert,
2004. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[138]<span
style='mso-tab-count:1'> </span>A. W. Spence. Testosterone propionate in
functional impotence. British Medical Journal, 2(4160):411413, September 1940.
PMID: 20783311. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[139]<span
style='mso-tab-count:1'> </span>R. Kurzrok and C. P. OConnell. The
inhibition of lactation during the puerperium by testosterone propionate.
Endocrinology, 23(4):476478, October 1938. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[140]<span
style='mso-tab-count:1'> </span>E. F. E. Black. The use of testosterone
propionate in gyncology. Canadian Medical Association Journal, 47(2):124128,
August 1942. PMID: 20322517. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[141]<span
style='mso-tab-count:1'> </span>E. C. Reifenstein and F. Albright. The
metabolic effects of steroid hormones in osteoporosis. Journal of Clinical
Investigation, 26:2456, January 1947. PMID: 21424243. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[142]<span
style='mso-tab-count:1'> </span>M. Molitch. The treatment of acne vulgaris
with testosterone propionate. Endocrinology, 23(6):803804, December 1938. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[143]<span
style='mso-tab-count:1'> </span>E. Mommers, W. M. Kersemaekers, J. Elliesen,
M. Kepers, D. Apter, H. M. Behre, J. Beynon, P. M. Bouloux, A. Costantino,
H.-P. Gerbershagen, L. Grnlund, D. Heger-Mahn, I. Huhtaniemi, E. L. Koldewijn,
C. Lange, S.<span style='mso-tab-count:1'> </span>Lindenberg, M. C.
Meriggiola, E. Meuleman, P. F. A. Mulders, E. Nieschlag, A. Perheentupa, A.
Solomon, L. Visl, F. C. Wu, and M. Zitzmann. Male hormonal contraception: a
double-blind, placebo-controlled study. The Journal of Clinical Endocrinology
and Metabolism, 93(7):25722580, July 2008. PMID: 18413423. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[144]<span
style='mso-tab-count:1'> </span>L. W. Kinsell, S. Hertz, and E. C.
Reifenstein. The effect of testosterone compounds upon the nitrogen balance and
creatine excretion in patients with thyrotoxicosis. Journal of Clinical
Investigation, 23(6):880890, November 1944. PMID: 16695173. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[145]<span
style='mso-tab-count:1'> </span>F. H. Hesser, O. R. Langworthy, and S. A.
Vest. Muscle strength in myotonia atrophica (dystrophia myotonica) improved by
testosterone propionate. Endocrinology, 26(2):241243, February 1940. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[146]<span
style='mso-tab-count:1'> </span>A. T. Kenyon, K. Knowlton, I. Sandiford, F.
C. Koch, and G. Lotwin. A comparative study of the metabolic effects of
testosterone propionate in normal men and women and in eunuchoidism.
Endocrinology, 26(1):2645, January 1940. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[147]<span
style='mso-tab-count:1'> </span>L. T. Samuels, A. F. Henschel, and A. Keys.
Influence of methyl testosterone on muscular work and creatine metabolism in
normal young men. The Journal of Clinical Endocrinology &amp; Metabolism,
2(11):649654, November 1942. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[148]<span
style='mso-tab-count:1'> </span>J. D. Elashoff, A. D. Jacknow, S. G. Shain,
and G. D. Braunstein. Effects of anabolic-androgenic steroids on muscular
strength. Annals of Internal Medicine, 115(5):387393, September 1991. PMID:
1830732. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[149]<span
style='mso-tab-count:1'> </span>V. Cowart. Steroids in sports: after four
decades, time to return these genies to bottle? JAMA, 257(4):421423, 427,
January 1987. PMID: 3795420. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[150]<span
style='mso-tab-count:1'> </span>F. Albright, W. Parson, and E. Bloomberg.
Cushings syndrome interpreted as hyperadrenocorticism leading to
hypergluconeogenesis: results of treatment with testosterone propionate. The Journal
of Clinical Endocrinology &amp; Metabolism, 1(5):375384, May 1941. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[151]<span
style='mso-tab-count:1'> </span>E. H. Keutmann and H. A. Friedman. Metabolic
studies in Cushings syndrome; treatment with various androgens and a 6-year
follow-up. The American Journal of Medicine, 5(4):518531, October 1948. PMID:
18886577. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[152]<span
style='mso-tab-count:1'> </span>A. Colao, S. Petersenn, J. Newell-Price, J.
W. Findling, F. Gu, M. Maldonado, U. Schoenherr, D. Mills, L. R. Salgado, B. M.
K. Biller, and Pasireotide B2305 Study Group. A 12-month phase 3 study of
pasireotide in Cushings disease. The New England Journal of Medicine,
366(10):914924, March 2012. PMID: 22397653. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[153]<span
style='mso-tab-count:1'> </span>P. Komanicky, R. F. Spark, and J. C. Melby.
Treatment of Cushings syndrome with trilostane (WIN 24,540), an inhibitor of
adrenal steroid biosynthesis. The Journal of Clinical Endocrinology and
Metabolism, 47(5):10421051, November 1978. PMID: 233687. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[154]<span
style='mso-tab-count:1'> </span>L. K. Nieman, G. P. Chrousos, C. Kellner, I.
M. Spitz, B. C. Nisula, G. B. Cutler, G. R. Merriam, C. W. Bardin, and D. L.
Loriaux. Successful treatment of Cushings syndrome with the glucocorticoid
antagonist RU 486. The Journal of Clinical Endocrinology and Metabolism,
61(3):536540, September 1985. PMID: 2991327. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[155]<span
style='mso-tab-count:1'> </span>R. K. Bergner and A. Bergner. Rational asthma
therapy for the outpatient. JAMA, 235(3):288293, January 1976. PMID: 811824. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[156]<span
style='mso-tab-count:1'> </span>O. Ragnarsson, M. G. Burt, K. K. Y. Ho, and
G. Johannsson. Effect of short-term GH and testosterone administration on body
composition and glucose homoeostasis in men receiving chronic glucocorticoid
therapy. European Journal of Endocrinology / European Federation of Endocrine
Societies, 168(2):243251, February 2013. PMID: 23169695. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[157]<span
style='mso-tab-count:1'> </span>B. A. L. Crawford, P. Y. Liu, M. T. Kean, J.
F. Bleasel, and D. J. Handelsman. Randomized placebo-controlled trial of androgen
effects on muscle and bone in men requiring long-term systemic glucocorticoid
treatment. The Journal of Clinical Endocrinology and Metabolism,
88(7):31673176, July 2003. PMID: 12843161. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[158]<span
style='mso-tab-count:1'> </span>N. M. van Schoor, D. L. Knol, C. a. W. Glas,
R. W. J. G. Ostelo, A. Leplge, C. Cooper, O. Johnell, and P. Lips. Development
of the Qualeffo-31, an osteoporosis-specific quality-of-life questionnaire.
Osteoporosis international: a journal established as result of cooperation
between the European Foundation for Osteoporosis and the National Osteoporosis
Foundation of the USA, 17(4):543551, 2006. PMID: 16362146. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[159]<span
style='mso-tab-count:1'> </span>N. Baume, Y. O. Schumacher, P.-E. Sottas, C.
Bagutti, M. Cauderay, P. Mangin, and M. Saugy. Effect of multiple oral doses of
androgenic anabolic steroids on endurance performance and serum indices of
physical stress in healthy male subjects. European Journal of Applied
Physiology, 98(4):329340, November 2006. PMID: 16896724. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[160]<span
style='mso-tab-count:1'> </span>D. C. Cumming, M. E. Quigley, and S. S. Yen.
Acute suppression of circulating testosterone levels by cortisol in men. The
Journal of Clinical Endocrinology and Metabolism, 57(3):671673, September
1983. PMID: 6348068. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[161]<span
style='mso-tab-count:1'> </span>M. Fassnacht, N. Schlenz, S. B. Schneider, S.
A. Wudy, B. Allolio, and W. Arlt. Beyond adrenal and ovarian androgen
generation: Increased peripheral 5 alpha-reductase activity in women with
polycystic ovary syndrome. The Journal of Clinical Endocrinology and
Metabolism, 88(6):27602766, June 2003. PMID: 12788885. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[162]<span
style='mso-tab-count:1'> </span>A. Kamischke, D. E. Kemper, M. A. Castel, M.
Lthke, C. Rolf, H. M. Behre, H. Magnussen, and E. Nieschlag. Testosterone
levels in men with chronic obstructive pulmonary disease with or without
glucocorticoid therapy. The European Respiratory Journal: Official Journal of
the European Society for Clinical Respiratory Physiology, 11(1):4145, January
1998. PMID: 9543268. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[163]<span
style='mso-tab-count:1'> </span>V. Corts-Gallegos, A. J. Gallegos, N. B.
Tovar, C. Cervantes, and A. Parra. Effect of paramethasone acetate on ovarian
steroids and gonadotropins. I. Normal menstrual cycle. The Journal of Clinical
Endocrinology and Metabolism, 41(2):215220, August 1975. PMID: 1159039. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[164]<span
style='mso-tab-count:1'> </span>J. M. Kuhn, D. Gay, J. P. Lemercier, M.
Pugeat, A. Legrand, and L. M. Wolf. Fonction testiculaire au cours de la
corticothrapie prolonge. Presse Mdicale (Paris, France: 1983),
15(12):559562, March 1986. PMID: 2939405. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[165]<span
style='mso-tab-count:1'> </span>G. Schaison, F. Durand, and I. Mowszowicz.
Study of plasma androstenedione and testosterone levels in hypercorticism
syndromes. Annales Dendocrinologie, 40(1):5152, February 1979. PMID: 443735. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[166]<span
style='mso-tab-count:1'> </span>R. Yehuda, J. A. Golier, S. L. Halligan, M.
Meaney, and L. M. Bierer. The ACTH response to dexamethasone in PTSD. The
American Journal of Psychiatry, 161(8):13971403, August 2004. <span lang=IT
style='mso-ansi-language:IT'>PMID: 15285965. <o:p></o:p></span></p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'><span lang=IT
style='mso-ansi-language:IT'>[167]<span style='mso-tab-count:1'> </span>L.
Barbetta, C. DallAsta, T. Re, P. Colombo, P. Travaglini, and B. Ambrosi. </span>Androgen
secretion in ectopic ACTH syndrome and in Cushings disease: modifications
before and after surgery. Hormone and Metabolic Research, 33(10):596601,
October 2001. PMID: 11607879. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[168]<span
style='mso-tab-count:1'> </span>S. K. Cunningham and T. J. McKenna.
Dissociation of adrenal androgen and cortisol secretion in Cushings syndrome.
Clinical Endocrinology, 41(6):795800, December 1994. PMID: 7889616. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[169]<span
style='mso-tab-count:1'> </span>H. F. Martens, P. K. Sheets, J. S. Tenover,
C. E. Dugowson, W. J. Bremner, and G. Starkebaum. Decreased testosterone levels
in men with rheumatoid arthritis: effect of low dose prednisone therapy. The
Journal of Rheumatology, 21(8):14271431, August 1994. PMID: 7983641. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[170]<span
style='mso-tab-count:1'> </span>J. Lado-Abeal, J. Rodriguez-Arnao, J. D.
Newell-Price, L. A. Perry, A. B. Grossman, G. M. Besser, and P. J. Trainer.
Menstrual abnormalities in women with Cushings disease are correlated with
hypercortisolemia rather than raised circulating androgen levels. The Journal
of Clinical Endocrinology and Metabolism, 83(9):30833088, September 1998.
PMID: 9745407. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[171]<span
style='mso-tab-count:1'> </span>J. P. Luton, P. Thieblot, J. C. Valcke, J.
A. Mahoudeau, and H. Bricaire. Reversible gonadotropin deficiency in male
Cushings disease. The Journal of Clinical Endocrinology and Metabolism,
45(3):488495, September 1977. <span lang=IT style='mso-ansi-language:IT'>PMID:
198424. <o:p></o:p></span></p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'><span lang=IT
style='mso-ansi-language:IT'>[172]<span style='mso-tab-count:1'> </span>G.
Boccuzzi, A. Angeli, D. Bisbocci, D. Fonzo, G. P. Giadano, and F. Ceresa. </span>Effect
of synthetic luteinizing hormone releasing hormone (LH-RH) on the release of
gonadotropins in Cushings disease. The Journal of Clinical Endocrinology and
Metabolism, 40(5):892895, May 1975. PMID: 1092712. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[173]<span
style='mso-tab-count:1'> </span>I. R. Reid, H. K. Ibbertson, J. T. France,
and J. Pybus. Plasma testosterone concentrations in asthmatic men treated with
glucocorticoids. British Medical Journal (Clinical research ed.),
291(6495):574, August 1985. PMID: 2931151. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[174]<span
style='mso-tab-count:1'> </span>H. L. Judd, G. E. Judd, W. E. Lucas, and S.
S. Yen. Endocrine function of the postmenopausal ovary: concentration of
androgens and estrogens in ovarian and peripheral vein blood. The Journal of
Clinical Endocrinology and Metabolism, 39(6):10201024, December 1974. PMID:
4430702. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[175]<span
style='mso-tab-count:1'> </span>H. G. Burger. Androgen production in women.
Fertility and Sterility, 77 Suppl 4:S35, April 2002. PMID: 12007895. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[176]<span
style='mso-tab-count:1'> </span>K. K. Miller, G. Sesmilo, A. Schiller, D.
Schoenfeld, S. Burton, and A. Klibanski. Androgen deficiency in women with
hypopituitarism. The Journal of Clinical Endocrinology and Metabolism,
86(2):561567, February 2001. PMID: 11158009. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[177]<span
style='mso-tab-count:1'> </span>S. S. C. Yen and C. C. Tsai. The effect of
ovariectomy on gonadotropin release. Journal of Clinical Investigation,
50(5):11491153, May 1971. PMID: 5552412. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[178]<span
style='mso-tab-count:1'> </span>B. Couzinet, G. Thomas, J. C. Thalabard, S.
Brailly, and G. Schaison. Effects of a pure antiandrogen on gonadotropin
secretion in normal women and in polycystic ovarian disease. Fertility and
Sterility, 52(1):4250, July 1989. PMID: 2744186. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[179]<span
style='mso-tab-count:1'> </span>M. Y. Abdel-Rahman. Androgen Excess, April
2014. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'><span lang=IT
style='mso-ansi-language:IT'>[180]<span style='mso-tab-count:1'> </span>A.
Salonia, M. Pontillo, R. E. Nappi, G. Zanni, F. Fabbri, M. Scavini, R. Daverio,
A. Gallina, P. Rigatti, E. Bosi, P. A. Bonini, and F. Montorsi. </span>Menstrual
cycle-related changes in circulating androgens in healthy women with
self-reported normal sexual function. The Journal of Sexual Medicine,
5(4):854863, April 2008. PMID: 18371044. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[181]<span
style='mso-tab-count:1'> </span>R. Guerrero, T. Aso, P. F. Brenner, Z. Cekan,
B. M. Landgren, K. Hagenfeldt, and E. Diczfalusy. Studies on the pattern of
circulating steroids in the normal menstrual cycle. <span lang=IT
style='mso-ansi-language:IT'>I. Simultaneous assays of progesterone,
pregnenolone, dehydroepiandrosterone, testosterone, dihydrotestosterone,
androstenedione, oestradiol and oestrone. </span>Acta Endocrinologica,
81(1):133149, January 1976. PMID: 128969. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[182]<span
style='mso-tab-count:1'> </span>B. L. Wajchenberg, A. Bosco, M. M. Marone, S.
Levin, M. Rocha, A. C. Lerrio, M. Nery, J. Goldman, and B. Liberman.
Estimation of body fat and lean tissue distribution by dual energy X-ray
absorptiometry and abdominal body fat evaluation by computed tomography in
Cushings disease. The Journal of Clinical Endocrinology and Metabolism,
80(9):27912794, September 1995. PMID: 7673425. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[183]<span
style='mso-tab-count:1'> </span>H. Vierhapper, P. Nowotny, and W. Waldhusl.
Production rates of testosterone in patients with Cushings syndrome.
Metabolism: Clinical and Experimental, 49(2):229231, February 2000. PMID:
10690950. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[184]<span
style='mso-tab-count:1'> </span>M. Luisi, F. Franchi, D. Drafta, and E.
Stroe. <span lang=IT style='mso-ansi-language:IT'>Plasma steroid dynamics in Cushings
syndrome. Annales Dendocrinologie, 39(2):107115, 1978. </span>PMID: 686649. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[185]<span
style='mso-tab-count:1'> </span>A. G. Smals, P. W. Kloppenborg, and T. J.
Benraad. <span lang=IT style='mso-ansi-language:IT'>Plasma testosterone
profiles in Cushings syndrome. </span>The Journal of Clinical Endocrinology
and Metabolism, 45(2):240245, August 1977. PMID: 195973. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[186]<span
style='mso-tab-count:1'> </span>F. H. Tyler and C. D. West. Laboratory
evaluation of disorders of the adrenal cortex. The American Journal of
Medicine, 53(5):664672, November 1972. PMID: 4342889. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[187]<span
style='mso-tab-count:1'> </span>V. K. Arora, E. Schenkein, R. Murali, S. K. Subudhi,
J. Wongvipat, M. D. Balbas, N. Shah, L. Cai, E. Efstathiou, C. Logothetis, D.
Zheng, and C. L. Sawyers. Glucocorticoid receptor confers resistance to
antiandrogens by bypassing androgen receptor blockade. Cell, 155(6):13091322,
December 2013. PMID: 24315100. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[188]<span
style='mso-tab-count:1'> </span>W. J. Inder, C. Jang, V. R. Obeyesekere, and
F. P. Alford. Dexamethasone administration inhibits skeletal muscle expression
of the androgen receptor and IGF-1implications for steroid-induced myopathy.
Clinical Endocrinology, 73(1):126132, July 2010. PMID: 19681914. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[189]<span
style='mso-tab-count:1'> </span>F. Chen, K. Knecht, E. Birzin, J. Fisher, H.
Wilkinson, M. Mojena, C. T. Moreno, A. Schmidt, S.-i. Harada, L. P. Freedman,
and A. A. Reszka. Direct agonist/antagonist functions of
dehydroepiandrosterone. Endocrinology, 146(11):45684576, November 2005. PMID:
15994348. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[190]<span
style='mso-tab-count:1'> </span>T. Jones, M. Groom, and K. Griffiths. Steroid
biosynthesis by cultures of normal human adrenal tissue. Biochemical and
Biophysical Research Communications, 38(2):355361, January 1970. PMID: 4313933.
</p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[191]<span
style='mso-tab-count:1'> </span>J. L. Vaitukaitis, S. L. Dale, and J. C.
Melby. Role of ACTH in the secretion of free dehydroepiandrosterone and its
sulfate ester in man. The Journal of Clinical Endocrinology and Metabolism,
29(11):14431447, November 1969. PMID: 4310735. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[192]<span
style='mso-tab-count:1'> </span>R. Kouyama, K. Hiraishi, T. Sugiyama, H.
Izumiyama, T. Yoshimoto, T. Akashi, K. Kihara, K. Homma, H. Shibata, and Y.
Hirata. Clinicopathological features, biochemical and molecular markers in 5
patients with adrenocortical carcinoma. Endocrine Journal, 58(7):527534, 2011.
PMID: 21521927. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[193]<span
style='mso-tab-count:1'> </span>P. Monteleone, M. Luisi, V. Martiadis, C.
Serritella, N. Longobardi, E. Casarosa, A. R. Genazzani, and M. Maj. Impaired
reduction of enhanced levels of dehydroepiandrosterone by oral dexamethasone in
anorexia nervosa. Psychoneuroendocrinology, 31(4):537542, May 2006. PMID:
16229957. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[194]<span
style='mso-tab-count:1'> </span>T. Yamaji, M. Ishibashi, H. Sekihara, A.
Itabashi, and T. Yanaihara. Serum dehydroepiandrosterone sulfate in Cushings
syndrome. The Journal of Clinical Endocrinology and Metabolism,
59(6):11641168, December 1984. PMID: 6238041. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[195]<span
style='mso-tab-count:1'> </span>S. Volpato, L. Bianchi, A. Cherubini, F.
Landi, M. Maggio, E. Savino, S.<span style='mso-tab-count:1'> </span>Bandinelli,
G. P. Ceda, J. M. Guralnik, G. Zuliani, and L. Ferrucci.Prevalence and clinical
correlates of sarcopenia in community-dwelling older people: application of the
EWGSOP definition and diagnostic algorithm. The Journals of Gerontology. Series
A, Biological Sciences and Medical Sciences, 69(4):438446, April 2014. PMID:
24085400. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[196]<span
style='mso-tab-count:1'> </span>E. Ramos, W. R. Frontera, A. Llopart, and D.
Feliciano. Muscle strength and hormonal levels in adolescents: gender related
differences. International Journal of Sports Medicine, 19(8):526531, November
1998. PMID: 9877143. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[197]<span
style='mso-tab-count:1'> </span>F. Pecori Giraldi, M. Moro, F. Cavagnini, and
Study Group on the Hypothalamo-Pituitary-Adrenal Axis of the Italian Society of
Endocrinology. Gender-related differences in the presentation and course of
Cushings disease. The Journal of Clinical Endocrinology and Metabolism,
88(4):15541558, April 2003. PMID: 12679438. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[198]<span
style='mso-tab-count:1'> </span>H. Vierhapper, P. Nowotny, and W. Waldhusl.
Production rates of cortisol in men with hypogonadism. Metabolism: Clinical and
Experimental, 53(9):11741176, September 2004. PMID: 15334380. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[199]<span
style='mso-tab-count:1'> </span>S. Bhasin, T. W. Storer, N. Berman, K. E.
Yarasheski, B. Clevenger, J. Phillips, W. P. Lee, T. J. Bunnell, and R.
Casaburi. Testosterone replacement increases fat-free mass and muscle size in
hypogonadal men. The Journal of Clinical Endocrinology and Metabolism,
82(2):407413, February 1997. PMID: 9024227. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[200]<span
style='mso-tab-count:1'> </span>I. G. Brodsky, P. Balagopal, and K. S. Nair.
Effects of testosterone replacement on muscle mass and muscle protein synthesis
in hypogonadal mena clinical research center study. The Journal of Clinical
Endocrinology and Metabolism, 81(10):34693475, October 1996. PMID: 8855787. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[201]<span
style='mso-tab-count:1'> </span>M. R. Smith, J. S. Finkelstein, F. J.
McGovern, A. L. Zietman, M. A. Fallon, D. A. Schoenfeld, and P. W. Kantoff.
Changes in body composition during androgen deprivation therapy for prostate
cancer. The Journal of Clinical Endocrinology and Metabolism, 87(2):599603,
February 2002. PMID: 11836291. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[202]<span
style='mso-tab-count:1'> </span>R. S. Boxer, A. M. Kenny, R. Dowsett, and P.
Taxel. The effect of 6 months of androgen deprivation therapy on muscle and fat
mass in older men with localized prostate cancer. The Aging Male: The Official
Journal of the International Society for the Study of the Aging Male,
8(3-4):207212, December 2005. PMID: 16390748. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[203]<span
style='mso-tab-count:1'> </span>N. Mauras, V. Hayes, S. Welch, A. Rini, K.
Helgeson, M. Dokler, J. D. Veldhuis, and R. J. Urban. Testosterone deficiency
in young men: marked alterations in whole body protein kinetics, strength, and
adiposity. The Journal of Clinical Endocrinology and Metabolism,
83(6):18861892, June 1998. PMID: 9626114. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[204]<span
style='mso-tab-count:1'> </span>J. S. Finkelstein, H. Lee, S.-A. M.
Burnett-Bowie, J. C. Pallais, E. W. Yu, L. F. Borges, B. F. Jones, C. V. Barry,
K. E. Wulczyn, B. J. Thomas, and B. Z. Leder. Gonadal steroids and body
composition, strength, and sexual function in men. The New England journal of
medicine, 369(11):10111022, September 2013. PMID: 24024838. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[205]<span
style='mso-tab-count:1'> </span>I. H. Rosenberg. Summary comments. The
American Journal of Clinical Nutrition, 50(5):12311233, November 1989. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[206]<span
style='mso-tab-count:1'> </span>H. A. Feldman, C. Longcope, C. A. Derby, C. B.
Johannes, A. B. Araujo, A. D. Coviello, W. J. Bremner, and J. B. McKinlay. Age
trends in the level of serum testosterone and other hormones in middle-aged
men: longitudinal results from the Massachusetts male aging study. The Journal
of Clinical Endocrinology and Metabolism, 87(2):589598, February 2002. PMID:
11836290. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[207]<span
style='mso-tab-count:1'> </span>J. E. Morley, H. M. Perry, F. E. Kaiser, D.
Kraenzle, J. Jensen, K. Houston, M. Mattammal, and H. M. Perry. Effects of
testosterone replacement therapy in old hypogonadal males: a preliminary study.
Journal of the American Geriatrics Society, 41(2):149152, February 1993. PMID:
8426037. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[208]<span
style='mso-tab-count:1'> </span>R. Sih, J. E. Morley, F. E. Kaiser, H. M.
Perry, P. Patrick, and C. Ross. Testosterone replacement in older hypogonadal
men: a 12-month randomized controlled trial. The Journal of Clinical
Endocrinology and Metabolism, 82(6):16611667, June 1997. PMID: 9177359. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[209]<span
style='mso-tab-count:1'> </span>I. Sinha-Hikim, M. Cornford, H. Gaytan, M. L.
Lee, and S. Bhasin. Effects of testosterone supplementation on skeletal muscle
fiber hypertrophy and satellite cells in community-dwelling older men. The
Journal of Clinical Endocrinology and Metabolism, 91(8):30243033, August 2006.
PMID: 16705073. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[210]<span
style='mso-tab-count:1'> </span>A. A. Ferrando, M. Sheffield-Moore, C. W.
Yeckel, C. Gilkison, J. Jiang, A. Achacosa, S. A. Lieberman, K. Tipton, R. R.
Wolfe, and R. J. Urban. Testosterone administration to older men improves
muscle function: molecular and physiological mechanisms. American Journal of
Physiology. Endocrinology and Metabolism, 282(3):E601607, March 2002. PMID:
11832363. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[211]<span
style='mso-tab-count:1'> </span>M. Sheffield-Moore, E. L. Dillon, S. L.
Casperson, C. R. Gilkison, D. Paddon-Jones, W. J. Durham, J. J. Grady, and R.
J. Urban. A randomized pilot study of monthly cycled testosterone replacement
or continuous testosterone replacement versus placebo in older men. The Journal
of Clinical Endocrinology and Metabolism, 96(11):E1831E1837, November 2011.
PMID: 21865352. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[212]<span
style='mso-tab-count:1'> </span>S. Bhasin, E. J. He, M. Kawakubo, E. T.
Schroeder, K. Yarasheski, G. J. Opiteck, A. Reicin, F. Chen, R. Lam, J. A.
Tsou, C. Castaneda-Sceppa, E. F. Binder, S. P. Azen, and F. R. Sattler.
N-terminal propeptide of type III procollagen as a biomarker of anabolic
response to recombinant human GH and testosterone. The Journal of Clinical
Endocrinology and Metabolism, 94(11):42244233, November 2009. PMID: 19837911. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[213]<span
style='mso-tab-count:1'> </span>A. A. Ferrando, M. Sheffield-Moore, D.
Paddon-Jones, R. R. Wolfe, and R. J. Urban. Differential anabolic effects of
testosterone and amino acid feeding in older men. The Journal of Clinical
Endocrinology and Metabolism, 88(1):358362, January 2003. PMID: 12519877. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[214]<span
style='mso-tab-count:1'> </span>A. A. Ferrando, M. Sheffield-Moore, S. E.
Wolf, D. N. Herndon, and R. R. Wolfe. Testosterone administration in severe
burns ameliorates muscle catabolism. Critical Care Medicine, 29(10):19361942,
October 2001. PMID: 11588456. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[215]<span
style='mso-tab-count:1'> </span>S. E. Borst, J. F. Yarrow, C. F. Conover, U.
Nseyo, J. R. Meuleman, J. A. Lipinska, R. W. Braith, D. T. Beck, J. S. Martin,
M. Morrow, S. Roessner, L. A. Beggs, S. C. McCoy, D. F. Cannady, and J. J.
Shuster. Musculoskeletal and prostate effects of combined testosterone and
finasteride administration in older hypogonadal men: a randomized, controlled
trial. American Journal of Physiology. Endocrinology and Metabolism,
306(4):E433442, February 2014. PMID: 24326421. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[216]<span
style='mso-tab-count:1'> </span>S. Bhasin, T. G. Travison, T. W. Storer, K.
Lakshman, M. Kaushik, N. A. Mazer, A.-H. Ngyuen, M. N. Davda, H. Jara, A.
Aakil, S. Anderson, P. E. Knapp, S. Hanka, N. Mohammed, P. Daou, R. Miciek, J.
Ulloor, A. Zhang, B. Brooks, K. Orwoll, L. Hede-Brierley, R. Eder, A. Elmi, G.
Bhasin, L. Collins, R. Singh, and S. Basaria. Effect of testosterone
supplementation with and without a dual 5&#945;-reductase inhibitor on fat-free
mass in men with suppressed testosterone production: a randomized controlled
trial. JAMA: the journal of the American Medical Association, 307(9):931939,
March 2012. PMID: 22396515. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[217]<span
style='mso-tab-count:1'> </span>X. Huang, M. R. Blackman, K. Herreman, K. M.
Pabst, S. M. Harman, and B. Caballero. Effects of growth hormone and/or sex
steroid administration on whole-body protein turnover in healthy aged women and
men. Metabolism: Clinical and Experimental, 54(9):11621167, September 2005.
PMID: 16125527. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[218]<span
style='mso-tab-count:1'> </span>A. M. Traish, R. J. Feeley, and A. T. Guay.
Testosterone therapy in women with gynecological and sexual disorders: a
triumph of clinical endocrinology from 1938 to 2008. The Journal of Sexual
Medicine, 6(2):334351, February 2009. PMID: 19138368. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[219]<span
style='mso-tab-count:1'> </span>M. E. Wierman, W. Arlt, R. Basson, S. R.
Davis, K. K. Miller, M. H. Murad, W. Rosner, and N. Santoro. Androgen therapy
in women: a reappraisal: an Endocrine Society clinical practice guideline. The
Journal of Clinical Endocrinology and Metabolism, 99(10):34893510, October
2014. PMID: 25279570. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[220]<span
style='mso-tab-count:1'> </span>T. S. Croxson, W. E. Chapman, L. K. Miller, C.
D. Levit, R. Senie, and B. Zumoff. Changes in the
hypothalamic-pituitary-gonadal axis in human immunodeficiency virus-infected
homosexual men. The Journal of Clinical Endocrinology and Metabolism,
68(2):317321, February 1989. PMID: 2493026. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[221]<span
style='mso-tab-count:1'> </span>S. Grinspoon, C. Corcoran, H. Askari, D.
Schoenfeld, L. Wolf, B. Burrows, M. Walsh, D. Hayden, K. Parlman, E. Anderson,
N. Basgoz, and A. Klibanski. Effects of androgen administration in men with the
AIDS wasting syndrome. A randomized, double-blind, placebo-controlled trial.
Annals of Internal Medicine, 129(1):1826, July 1998. PMID: 9652995. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[222]<span
style='mso-tab-count:1'> </span>M. Montano, J. N. Flanagan, L. Jiang, P.
Sebastiani, M. Rarick, N. K. LeBrasseur, C. A. Morris, R. Jasuja, and S.
Bhasin. Transcriptional profiling of testosterone-regulated genes in the
skeletal muscle of human immunodeficiency virus-infected men experiencing
weight loss. The Journal of Clinical Endocrinology and Metabolism,
92(7):27932802, July 2007. PMID: 17440010. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[223]<span
style='mso-tab-count:1'> </span>A. C. McPherron, A. M. Lawler, and S. J. Lee.
Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily
member. Nature, 387(6628):8390, May 1997. PMID: 9139826. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[224]<span
style='mso-tab-count:1'> </span>N. F. Gonzalez-Cadavid, W. E. Taylor, K.
Yarasheski, I. Sinha-Hikim, K. Ma, S. Ezzat, R. Shen, R. Lalani, S. Asa, M.
Mamita, G. Nair, S. Arver, and S. Bhasin. Organization of the human myostatin
gene and expression in healthy men and HIV-infected men with muscle wasting.
Proceedings of the National Academy of Sciences of the United States of
America, 95(25):1493814943, December 1998. PMID: 9843994. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[225]<span
style='mso-tab-count:1'> </span>S. C. Bodine, E. Latres, S. Baumhueter, V. K.
Lai, L. Nunez, B. A. Clarke, W. T. Poueymirou, F. J. Panaro, E. Na, K.
Dharmarajan, Z. Q. Pan, D. M. Valenzuela, T. M. DeChiara, T. N. Stitt, G. D.
Yancopoulos, and D. J. Glass. Identification of ubiquitin ligases required for
skeletal muscle atrophy. Science (New York, N.Y.), 294(5547):17041708,
November 2001. PMID: 11679633. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[226]<span
style='mso-tab-count:1'> </span>T. Gustafsson, T. Osterlund, J. N. Flanagan,
F. von Waldn, T. A. Trappe, R. M. Linnehan, and P. A. Tesch. Effects of 3 days
unloading on molecular regulators of muscle size in humans. Journal of Applied
Physiology (Bethesda, Md.: 1985), 109(3):721727, September 2010. PMID:
20538844. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[227]<span
style='mso-tab-count:1'> </span>J. H. Macdonald, S. M. Marcora, M. M. Jibani,
M. J. Kumwenda, W. Ahmed, and A. B. Lemmey. Nandrolone decanoate as anabolic
therapy in chronic kidney disease: a randomized phase II dose-finding study.
Nephron. Clinical Practice, 106(3):c125135, 2007. PMID: 17522475. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[228]<span
style='mso-tab-count:1'> </span>A. Yurci, M. Yucesoy, K. Unluhizarci, E.
Torun, S. Gursoy, M. Baskol, K. Guven, and O. Ozbakir. Effects of testosterone
gel treatment in hypogonadal men with liver cirrhosis. Clinics and Research in
Hepatology and Gastroenterology, 35(12):845854, December 2011. PMID: 22074639.
</p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[229]<span
style='mso-tab-count:1'> </span>R. Casaburi, S. Bhasin, L. Cosentino, J.
Porszasz, A. Somfay, M. I. Lewis, M. Fournier, and T. W. Storer. Effects of
testosterone and resistance training in men with chronic obstructive pulmonary
disease. American Journal of Respiratory and Critical Care Medicine,
170(8):870878, October 2004. PMID: 15271690. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[230]<span
style='mso-tab-count:1'> </span>M. I. Lewis, M. Fournier, T. W. Storer, S.
Bhasin, J. Porszasz, S.-G. Ren, X. Da, and R. Casaburi. Skeletal muscle
adaptations to testosterone and resistance training in men with COPD. Journal
of Applied Physiology (Bethesda, Md.: 1985), 103(4):12991310, October 2007.
PMID: 17673568. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[231]<span
style='mso-tab-count:1'> </span>V. Agapitou, S. Dimopoulos, C. Kapelios, E.
Karatzanos, C. Manetos, A. Georgantas, A. Ntalianis, J. Terrovitis, H. Karga,
and S. Nanas. Hormonal imbalance in relation to exercise intolerance and
ventilatory inefficiency in chronic heart failure. The Journal of Heart and
Lung Transplantation: The Official Publication of the International Society for
Heart Transplantation, 32(4):431436, April 2013. PMID: 23402947. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[232]<span
style='mso-tab-count:1'> </span>A. Mirdamadi, M. Garakyaraghi, A.
Pourmoghaddas, A. Bahmani, H. Mahmoudi, and M. Gharipour. Beneficial effects of
testosterone therapy on functional capacity, cardiovascular parameters, and
quality of life in patients with congestive heart failure. BioMed Research
International, 2014, 2014. PMID: 25110677. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[233]<span
style='mso-tab-count:1'> </span>M. Stout, G. A. Tew, H. Doll, I. Zwierska, N.
Woodroofe, K. S. Channer, and J. M. Saxton. Testosterone therapy during
exercise rehabilitation in male patients with chronic heart failure who have
low testosterone status: a double-blind randomized controlled feasibility
study. American Heart Journal, 164(6):893901, December 2012. PMID: 23194490. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[234]<span
style='mso-tab-count:1'> </span>L. Xu, G. Freeman, B. J. Cowling, and C. M.
Schooling. Testosterone therapy and cardiovascular events among men: a
systematic review and meta-analysis of placebo-controlled randomized trials.
BMC Medicine, 11:108, April 2013. PMID: 23597181. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[235]<span
style='mso-tab-count:1'> </span>S. Basaria, A. D. Coviello, T. G. Travison,
T. W. Storer, W. R. Farwell, A. M. Jette, R. Eder, S. Tennstedt, J. Ulloor, A.
Zhang, K. Choong, K. M. Lakshman, N. A. Mazer, R. Miciek, J. Krasnoff, A. Elmi,
P. E. Knapp, B. Brooks, E. Appleman, S. Aggarwal, G. Bhasin, L. Hede-Brierley,
A. Bhatia, L. Collins, N. LeBrasseur, L. D. Fiore, and S. Bhasin. Adverse
events associated with testosterone administration. The New England Journal of
Medicine, 363(2):109122, July 2010. PMID: 20592293. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[236]<span
style='mso-tab-count:1'> </span>Z. Wang, S. Zhu, J. Wang, R. N. Pierson, and
S. B. Heymsfield. Whole-body skeletal muscle mass: development and validation
of total-body potassium prediction models. The American Journal of Clinical
Nutrition, 77(1):7682, January 2003. PMID: 12499326. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[237]<span
style='mso-tab-count:1'> </span>V. Santilli, A. Bernetti, M. Mangone, and M.
Paoloni. Clinical definition of sarcopenia. Clinical Cases in Mineral and Bone
Metabolism, 11(3):177180, 2014. PMID: 25568649. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[238]<span
style='mso-tab-count:1'> </span>A. L. Mescher and L. C. U. Junqueira.
Junqueiras basic histology: text and atlas. 2013. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[239]<span
style='mso-tab-count:1'> </span>N. Light and A. E. Champion. Characterization
of muscle epimysium, perimysium and endomysium collagens. The Biochemical
journal, 219(3):10171026, May 1984. PMID: 6743238. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[240]<span
style='mso-tab-count:1'> </span>J. C. Waterlow, P. J. Garlick, and D. J.
Millward. Protein turnover in mammalian tissues and in the whole body.
North-Holland Pub. Co. ; Sole distributors for the U.S.A. and Canada, Elsevier
North-Holland, Amsterdam; New York; New York, 1978. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[241]<span
style='mso-tab-count:1'> </span>J. Du, X. Wang, C. Miereles, J. L. Bailey, R.
Debigare, B. Zheng, S. R. Price, and W. E. Mitch. Activation of caspase-3 is an
initial step triggering accelerated muscle proteolysis in catabolic conditions.
The Journal of Clinical Investigation, 113(1):115123, January 2004. PMID:
14702115. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[242]<span
style='mso-tab-count:1'> </span>H. C. Lukaski, J. Mendez, E. R. Buskirk, and
S. H. Cohn. Relationship between endogenous 3-methylhistidine excretion and
body composition. The American Journal of Physiology, 240(3):E302307, March
1981. PMID: 7212061. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[243]<span
style='mso-tab-count:1'> </span>J. Scharner and P. S. Zammit. The muscle
satellite cell at 50: the formative years. Skeletal Muscle, 1(1):28, 2011.
PMID: 21849021. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[244]<span
style='mso-tab-count:1'> </span>C. A. Collins, I. Olsen, P. S. Zammit, L.
Heslop, A. Petrie, T. A. Partridge, and J. E. Morgan. Stem cell function,
self-renewal, and behavioral heterogeneity of cells from the adult muscle
satellite cell niche. Cell, 122(2):289301, July 2005. PMID: 16051152. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[245]<span
style='mso-tab-count:1'> </span>R. Bischoff. Proliferation of muscle
satellite cells on intact myofibers in culture. Developmental Biology,
115(1):129139, May 1986. PMID: 3516758. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[246]<span
style='mso-tab-count:1'> </span>H. Yin, F. Price, and M. A. Rudnicki.
Satellite cells and the muscle stem cell niche. Physiological Reviews,
93(1):2367, January 2013. PMID: 23303905. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[247]<span
style='mso-tab-count:1'> </span>W. E. Blanco-Bose, C. C. Yao, R. H. Kramer,
and H. M. Blau. Purification of mouse primary myoblasts based on alpha 7
integrin expression. Experimental Cell Research, 265(2):212220, May 2001.
PMID: 11302686. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[248]<span
style='mso-tab-count:1'> </span>A. K. Sharma, Y. B. Lee, and J. D. Murray. The
response of transgenic mice to beta-adrenergic agonist administration is
different from that of normal mice. Journal of Animal Science, 75(8):20922099,
August 1997. PMID: 9263056. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[249]<span
style='mso-tab-count:1'> </span>T. S. Wong and F. W. Booth. Protein metabolism
in rat tibialis anterior muscle after stimulated chronic eccentric exercise.
Journal of Applied Physiology (Bethesda, Md.: 1985), 69(5):17181724, November
1990. PMID: 1703146. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[250]<span
style='mso-tab-count:1'> </span>D. A. Lowe and S. E. Alway. Stretch-induced
myogenin, MyoD, and MRF4 expression and acute hypertrophy in quail slow-tonic
muscle are not dependent upon satellite cell proliferation. Cell and Tissue
Research, 296(3):531539, June 1999. PMID: 10370140. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[251]<span
style='mso-tab-count:1'> </span>L. B. Verdijk, T. Snijders, M. Drost, T.
Delhaas, F. Kadi, and L. J. C. van Loon. Satellite cells in human skeletal
muscle; from birth to old age. Age, 36(2):545557, April 2014. PMID: 24122288. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[252]<span
style='mso-tab-count:1'> </span>A. Neal, L. Boldrin, and J. E. Morgan. The
Satellite Cell in Male and Female, Developing and Adult Mouse Muscle: Distinct
Stem Cells for Growth and Regeneration. PLoS ONE, 7(5), May 2012. PMID:
22662253. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[253]<span
style='mso-tab-count:1'> </span>C. Lepper, S. J. Conway, and C.-M. Fan. Adult
satellite cells and embryonic muscle progenitors have distinct genetic requirements.
Nature, 460(7255):627631, July 2009. PMID: 19554048. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[254]<span
style='mso-tab-count:1'> </span>F. Yusuf and B. Brand-Saberi. Myogenesis and
muscle regeneration. Histochemistry and Cell Biology, 138(2):187199, August
2012. PMID: 22644378. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[255]<span
style='mso-tab-count:1'> </span>G. Daston, E. Lamar, M. Olivier, and M.
Goulding. Pax-3 is necessary for migration but not differentiation of limb
muscle precursors in the mouse. Development (Cambridge, England),
122(3):10171027, March 1996. PMID: 8631247. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[256]<span
style='mso-tab-count:1'> </span>T. Francetic and Q. Li. Skeletal myogenesis
and Myf5 activation. Transcription, 2(3):109114, 2011. PMID: 21922054. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[257]<span
style='mso-tab-count:1'> </span>T. Braun, G. Buschhausen-Denker, E. Bober, E.
Tannich, and H. H. Arnold. A novel human muscle factor related to but distinct
from MyoD1 induces myogenic conversion in 10T1/2 fibroblasts. The EMBO Journal,
8(3):701709, March 1989. PMID: 2721498. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[258]<span
style='mso-tab-count:1'> </span>D. M. Noden and P. A. Trainor. Relations and
interactions between cranial mesoderm and neural crest populations. Journal of
Anatomy, 207(5):575601, November 2005. PMID: 16313393. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[259]<span
style='mso-tab-count:1'> </span>S. Tajbakhsh, D. Rocancourt, G. Cossu, and M.
Buckingham. Redefining the genetic hierarchies controlling skeletal myogenesis:
Pax-3 and Myf-5 act upstream of MyoD. Cell, 89(1):127138, April 1997. PMID:
9094721. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[260]<span
style='mso-tab-count:1'> </span>M. A. Rudnicki, P. N. Schnegelsberg, R. H. Stead,
T. Braun, H. H. Arnold, and R. Jaenisch. MyoD or Myf-5 is required for the
formation of skeletal muscle. Cell, 75(7):13511359, December 1993. PMID:
8269513. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[261]<span
style='mso-tab-count:1'> </span>V. Andrs and K. Walsh. Myogenin expression,
cell cycle withdrawal, and phenotypic differentiation are temporally separable
events that precede cell fusion upon myogenesis. The Journal of Cell Biology,
132(4):657666, February 1996. PMID: 8647896. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[262]<span
style='mso-tab-count:1'> </span>D. A. Bergstrom and S. J. Tapscott. Molecular
distinction between specification and differentiation in the myogenic basic
helix-loop-helix transcription factor family. Molecular and Cellular Biology,
21(7):24042412, April 2001. PMID: 11259589. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[263]<span
style='mso-tab-count:1'> </span>P. Hasty, A. Bradley, J. H. Morris, D. G.
Edmondson, J. M. Venuti, E. N. Olson, and W. H. Klein. Muscle deficiency and
neonatal death in mice with a targeted mutation in the myogenin gene. Nature,
364(6437):501506, August 1993. PMID: 8393145. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[264]<span
style='mso-tab-count:1'> </span>A. Draeger, A. G. Weeds, and R. B. Fitzsimons.
Primary, secondary and tertiary myotubes in developing skeletal muscle: a new
approach to the analysis of human myogenesis. Journal of the Neurological
Sciences, 81(1):1943, October 1987. PMID: 2445924. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[265]<span
style='mso-tab-count:1'> </span>M. Manceau, J. Gros, K. Savage, V. Thom, A.
McPherron, B. Paterson, and C. Marcelle. Myostatin promotes the terminal
differentiation of embryonic muscle progenitors. Genes &amp; Development,
22(5):668681, March 2008. PMID: 18316481. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[266]<span
style='mso-tab-count:1'> </span>A. Matsakas, A. Otto, M. I. Elashry, S. C.
Brown, and K. Patel. Altered primary and secondary myogenesis in the
myostatin-null mouse. Rejuvenation Research, 13(6):717727, December 2010.
PMID: 21204650. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[267]<span
style='mso-tab-count:1'> </span>M. Schuelke, K. R. Wagner, L. E. Stolz, C.
Hbner, T. Riebel, W. Kmen, T. Braun, J. F. Tobin, and S.-J. Lee. Myostatin
mutation associated with gross muscle hypertrophy in a child. The New England
Journal of Medicine, 350(26):26822688, June 2004. PMID: 15215484. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[268]<span
style='mso-tab-count:1'> </span>J. Lin, H. B. Arnold, M. A. Della-Fera, M. J.
Azain, D. L. Hartzell, and C. A. Baile. Myostatin knockout in mice increases
myogenesis and decreases adipogenesis. Biochemical and Biophysical Research
Communications, 291(3):701706, March 2002. PMID: 11855847. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[269]<span
style='mso-tab-count:1'> </span>P. J. Mitchell, S. E. Johnson, and K. Hannon.
Insulin-like growth factor I stimulates myoblast expansion and myofiber
development in the limb. Developmental Dynamics: An Official Publication of the
American Association of Anatomists, 223(1):1223, January 2002. PMID: 11803566.
</p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[270]<span
style='mso-tab-count:1'> </span>W. Shen, P. Wisniowski, L. Ahmed, D. W. Boyle,
S. C. Denne, and E. A. Liechty. Protein anabolic effects of insulin and IGF-I
in the ovine fetus. American Journal of Physiology. Endocrinology and
Metabolism, 284(4):E748756, April 2003. PMID: 12488244. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[271]<span
style='mso-tab-count:1'> </span>A. M. Fernndez, J. K. Kim, S. Yakar, J.
Dupont, C. Hernandez-Sanchez, A. L. Castle, J. Filmore, G. I. Shulman, and D.
Le Roith. Functional inactivation of the IGF-I and insulin receptors in
skeletal muscle causes type 2 diabetes. Genes &amp; Development,
15(15):19261934, August 2001. PMID: 11485987. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[272]<span
style='mso-tab-count:1'> </span>M. J. Abuzzahab, A. Schneider, A. Goddard, F.
Grigorescu, C. Lautier, E. Keller, W. Kiess, J. Klammt, J. Kratzsch, D. Osgood,
R. Pfffle, K. Raile, B. Seidel, R. J. Smith, S. D. Chernausek, and
Intrauterine Growth Retardation (IUGR) Study Group. IGF-I receptor mutations
resulting in intrauterine and postnatal growth retardation. The New England
Journal of Medicine, 349(23):22112222, December 2003. PMID: 14657428. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[273]<span
style='mso-tab-count:1'> </span>A. Dellavalle, G. Maroli, D. Covarello, E.
Azzoni, A. Innocenzi, L. Perani, S. Antonini, R. Sambasivan, S. Brunelli, S.
Tajbakhsh, and G. Cossu. Pericytes resident in postnatal skeletal muscle
differentiate into muscle fibres and generate satellite cells. Nature
Communications, 2:499, 2011. PMID: 21988915. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[274]<span
style='mso-tab-count:1'> </span>M. A. LaBarge and H. M. Blau. Biological
progression from adult bone marrow to mononucleate muscle stem cell to
multinucleate muscle fiber in response to injury. Cell, 111(4):589601,
November 2002. PMID: 12437931. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[275]<span
style='mso-tab-count:1'> </span>S. Decary, V. Mouly, C. B. Hamida, A. Sautet,
J. P. Barbet, and G. S. Butler-Browne. Replicative potential and telomere
length in human skeletal muscle: implications for satellite cell-mediated gene
therapy. Human Gene Therapy, 8(12):14291438, August 1997. PMID: 9287143. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[276]<span
style='mso-tab-count:1'> </span>V. Renault, G. Piron-Hamelin, C. Forestier,
S. DiDonna, S. Decary, F. Hentati, G. Saillant, G. S. Butler-Browne, and V.
Mouly. Skeletal muscle regeneration and the mitotic clock. Experimental
Gerontology, 35(6-7):711719, September 2000. PMID: 11053661. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[277]<span
style='mso-tab-count:1'> </span>R. N. Baumgartner, K. M. Koehler, D.
Gallagher, L. Romero, S. B. Heymsfield, R. R. Ross, P. J. Garry, and R. D.
Lindeman. Epidemiology of sarcopenia among the elderly in New Mexico. American
Journal of Epidemiology, 147(8):755763, April 1998. PMID: 9554417. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[278]<span
style='mso-tab-count:1'> </span>J. M. Berg, J. L. Tymoczko, and L. Stryer.
Each organ has a unique metabolic profile. In Biochemistry. W.H. Freeman, 2002.
</p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[279]<span
style='mso-tab-count:1'> </span>D. H. Wasserman. Four grams of glucose.
American Journal of Physiology - Endocrinology and Metabolism, 296(1):E11E21,
January 2009. PMID: 18840763. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[280]<span
style='mso-tab-count:1'> </span>M. Li and P. Bjrntorp. Triglyceride uptake in
muscles in rats. Obesity Research, 3(5):419426, September 1995. PMID: 8521161.
</p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[281]<span
style='mso-tab-count:1'> </span>R. L. Seip, K. Mair, T. G. Cole, and C. F.
Semenkovich. Induction of human skeletal muscle lipoprotein lipase gene
expression by short-term exercise is transient. The American Journal of
Physiology, 272(2 Pt 1):E255261, February 1997. PMID: 9124332. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[282]<span
style='mso-tab-count:1'> </span>Y.-X. Wang, C.-H. Lee, S. Tiep, R. T. Yu, J.
Ham, H. Kang, and R. M. Evans. Peroxisome-proliferator-activated receptor delta
activates fat metabolism to prevent obesity. Cell, 113(2):159170, April 2003.
PMID: 12705865. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[283]<span
style='mso-tab-count:1'> </span>V. A. Narkar, M. Downes, R. T. Yu, E. Embler,
Y.-X. Wang, E. Banayo, M. M. Mihaylova, M. C. Nelson, Y. Zou, H. Juguilon, H.
Kang, R. Shaw, and R. M. Evans. AMPK and PPAR&#948; agonists are exercise
mimetics. Cell, 134(3):405415, August 2008. PMID: 18674809. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[284]<span
style='mso-tab-count:1'> </span>M. J. Watt, R. J. Southgate, A. G. Holmes, and
M. A. Febbraio. Suppression of plasma free fatty acids upregulates peroxisome
proliferator-activated receptor (PPAR) alpha and delta and PPAR coactivator
1alpha in human skeletal muscle, but not lipid regulatory genes. Journal of
Molecular Endocrinology, 33(2):533544, October 2004. PMID: 15525607. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[285]<span
style='mso-tab-count:1'> </span>D. Holst, S. Luquet, V. Nogueira, K.
Kristiansen, X. Leverve, and P. A. Grimaldi. Nutritional regulation and role of
peroxisome proliferator-activated receptor delta in fatty acid catabolism in
skeletal muscle. Biochimica Et Biophysica Acta, 1633(1):4350, July 2003. PMID:
12842194. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[286]<span
style='mso-tab-count:1'> </span>A. Mancini, O. El Bounkari, A.-F. Norrenbrock,
M. Scherr, D. Schaefer, M. Eder, A. H. Banham, K. Pulford, L. Lyne, A. D.
Whetton, and T. Tamura. FMIP controls the adipocyte lineage commitment of C2C12
cells by downmodulation of C/EBP &#945;. Oncogene, 26(7):10201027, February
2007. PMID: 16909111. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[287]<span
style='mso-tab-count:1'> </span>T. Mori, H. Sakaue, H. Iguchi, H. Gomi, Y.
Okada, Y. Takashima, K. Nakamura, T. Nakamura, T. Yamauchi, N. Kubota, T.
Kadowaki, Y. Matsuki, W. Ogawa, R. Hiramatsu, and M. Kasuga. Role of
Krppel-like factor 15 (KLF15) in transcriptional regulation of adipogenesis.
The Journal of Biological Chemistry, 280(13):1286712875, April 2005. PMID:
15664998. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[288]<span
style='mso-tab-count:1'> </span>A. G. Cristancho and M. A. Lazar. Forming
functional fat: a growing understanding of adipocyte differentiation. Nature
Reviews. Molecular Cell Biology, 12(11):722734, November 2011. PMID: 21952300.
</p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[289]<span
style='mso-tab-count:1'> </span>Y. Itoigawa, K. N. Kishimoto, H. Okuno, H.
Sano, K. Kaneko, and E. Itoi. Hypoxia induces adipogenic differentitation of
myoblastic cell lines. Biochemical and biophysical research communications,
399(4):721726, September 2010. PMID: 20692234. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[290]<span
style='mso-tab-count:1'> </span>R. A. DeFronzo, E. Jacot, E. Jequier, E.
Maeder, J. Wahren, and J. P. Felber. The effect of insulin on the disposal of
intravenous glucose. Results from indirect calorimetry and hepatic and femoral
venous catheterization. Diabetes, 30(12):10001007, December 1981. PMID:
7030826. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[291]<span
style='mso-tab-count:1'> </span>L. D. Katz, M. G. Glickman, S. Rapoport, E.
Ferrannini, and R. A. DeFronzo. Splanchnic and peripheral disposal of oral
glucose in man. Diabetes, 32(7):675679, July 1983. PMID: 6862113. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[292]<span
style='mso-tab-count:1'> </span>R. A. Gelfand, M. G. Glickman, R. Jacob, R. S.
Sherwin, and R. A. DeFronzo. Removal of infused amino acids by splanchnic and
leg tissues in humans. The American Journal of Physiology, 250(4 Pt
1):E407413, April 1986. PMID: 3963181. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[293]<span
style='mso-tab-count:1'> </span>W. M. Bennet, A. A. Connacher, C. M.
Scrimgeour, K. Smith, and M. J. Rennie. Increase in anterior tibialis muscle
protein synthesis in healthy man during mixed amino acid infusion: studies of
incorporation of [1-13C]leucine. Clinical Science (London, England: 1979),
76(4):447454, April 1989. PMID: 2714054. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[294]<span
style='mso-tab-count:1'> </span>K. S. Nair, R. G. Schwartz, and S. Welle.
Leucine as a regulator of whole body and skeletal muscle protein metabolism in
humans. The American Journal of Physiology, 263(5 Pt 1):E928934, November
1992. PMID: 1443126. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[295]<span
style='mso-tab-count:1'> </span>D. Cuthbertson, K. Smith, J. Babraj, G.
Leese, T. Waddell, P. Atherton, H. Wackerhage, P. M. Taylor, and M. J. Rennie.
Anabolic signaling deficits underlie amino acid resistance of wasting, aging
muscle. FASEB journal: official publication of the Federation of American
Societies for Experimental Biology, 19(3):422424, March 2005. PMID: 15596483. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[296]<span
style='mso-tab-count:1'> </span>M. Laplante and D. M. Sabatini. mTOR signaling
in growth control and disease. Cell, 149(2):274293, April 2012. PMID:
22500797. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[297]<span
style='mso-tab-count:1'> </span>G. G. Chiang and R. T. Abraham.
Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated
by p70S6 kinase. The Journal of Biological Chemistry, 280(27):2548525490, July
2005. PMID: 15899889. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[298]<span
style='mso-tab-count:1'> </span>A. Suryawan, J. W. Hawes, R. A. Harris, Y.
Shimomura, A. E. Jenkins, and S.<span style='mso-tab-count:1'> </span>M.
Hutson. A molecular model of human branched-chain amino acidmetabolism. The
American Journal of Clinical Nutrition, 68(1):7281, July 1998. PMID: 9665099. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[299]<span
style='mso-tab-count:1'> </span>P. J. Garlick, M. A. McNurlan, and V. R.
Preedy. A rapid and convenient technique for measuring the rate of protein
synthesis in tissues by injection of </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[3H]phenylalanine.
The Biochemical journal, 192(2):719723, November 1980. PMID: 6786283. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[300]<span
style='mso-tab-count:1'> </span>L. A. Cynober. Metabolic &amp; Therapeutic
Aspects of Amino Acids in Clinical Nutrition. CRC Press, Hoboken, 2003. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[301]<span
style='mso-tab-count:1'> </span>A. Grubb, S. Joanisse, D. R. Moore, L. M.
Bellamy, C. J. Mitchell, S. M. Phillips, and G. Parise. IGF-1 colocalizes with
muscle satellite cells following acute exercise in humans. Applied Physiology,
Nutrition, and Metabolism = Physiologie Applique, Nutrition Et Mtabolisme,
39(4):514518, April 2014. PMID: 24669996. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[302]<span
style='mso-tab-count:1'> </span>H. Ullum, P. M. Haahr, M. Diamant, J. Palm,
J. Halkjaer-Kristensen, and B. K. Pedersen. Bicycle exercise enhances plasma
IL-6 but does not change IL-1 alpha, IL-1 beta, IL-6, or TNF-alpha pre-mRNA in
BMNC. Journal of Applied Physiology (Bethesda, Md.: 1985), 77(1):9397, July
1994. PMID: 7961280. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[303]<span
style='mso-tab-count:1'> </span>C. S. Bickel, J. Slade, E. Mahoney, F. Haddad,
G. A. Dudley, and G. R. Adams. Time course of molecular responses of human
skeletal muscle to acute bouts of resistance exercise. Journal of Applied
Physiology (Bethesda, Md.: 1985), 98(2):482488, February 2005. PMID: 15465884.
</p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[304]<span
style='mso-tab-count:1'> </span>R. A. Fielding, T. J. Manfredi, W. Ding, M. A.
Fiatarone, W. J. Evans, and J. G. Cannon. Acute phase response in exercise.
III. Neutrophil and IL-1 beta accumulation in skeletal muscle. The American
Journal of Physiology, 265(1 Pt 2):R166172, July 1993. PMID: 8342683. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[305]<span
style='mso-tab-count:1'> </span>T. Snijders, L. B. Verdijk, B. R. McKay, J. S.
J. Smeets, J. van Kranenburg, B. B. B. Groen, G. Parise, P. Greenhaff, and L.
J. C. van Loon. Acute dietary protein intake restriction is associated with
changes in myostatin expression after a single bout of resistance exercise in
healthy young men. The Journal of Nutrition, 144(2):137145, February 2014.
PMID: 24306214. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[306]<span
style='mso-tab-count:1'> </span>T. Schiffer, S. Geisler, B. Sperlich, and H.
K. Strder. MSTN mRNA after varying exercise modalities in humans. International
Journal of Sports Medicine, 32(9):683687, September 2011. PMID: 21695666. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[307]<span
style='mso-tab-count:1'> </span>H. C. Dreyer, S. Fujita, E. L. Glynn, M. J.
Drummond, E. Volpi, and B. B. Rasmussen. Resistance exercise increases leg
muscle protein synthesis and mTOR signalling independent of sex. Acta
physiologica (Oxford, England), 199(1):7181, May 2010. PMID: 20070283. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[308]<span
style='mso-tab-count:1'> </span>M. P. Harber, A. R. Konopka, B. Jemiolo, S. W.
Trappe, T. A. Trappe, and P. T. Reidy. Muscle protein synthesis and gene
expression during recovery from aerobic exercise in the fasted and fed states.
American Journal of Physiology. Regulatory, Integrative and Comparative
Physiology, 299(5):R12541262, November 2010. PMID: 20720176. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[309]<span
style='mso-tab-count:1'> </span>S. P. Bird, K. M. Tarpenning, and F. E.
Marino. Liquid carbohydrate/essential amino acid ingestion during a short-term
bout of resistance exercise suppresses myofibrillar protein degradation.
Metabolism: Clinical and Experimental, 55(5):570577, May 2006. PMID: 16631431.
</p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[310]<span
style='mso-tab-count:1'> </span>L. J. C. van Loon. Is there a need for protein
ingestion during exercise? Sports Medicine (Auckland, N.z.), 44(Suppl
1):105111, 2014. PMID: 24791922. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[311]<span
style='mso-tab-count:1'> </span>K. E. Hanssen, N. H. Kvamme, T. S. Nilsen, B.
Rnnestad, I. K. Ambjrnsen, F. Norheim, F. Kadi, J. Halln, C. A. Drevon, and
T. Raastad. The effect of strength training volume on satellite cells, myogenic
regulatory factors, and growth factors. Scandinavian Journal of Medicine &amp;
Science in Sports, 23(6):728739, December 2013. PMID: 22417199. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[312]<span
style='mso-tab-count:1'> </span>R. J. Stefanetti, S. Lamon, M. Wallace, M. H.
Vendelbo, A. P. Russell, and K. Vissing. Regulation of ubiquitin proteasome
pathway molecular markers in response to endurance and resistance exercise and
training. Pflugers Archiv: European Journal of Physiology, August 2014. PMID:
25104573. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[313]<span
style='mso-tab-count:1'> </span>E. Rigamonti, P. Zordan, C. Sciorati, P.
Rovere-Querini, and S. Brunelli. Macrophage plasticity in skeletal muscle
repair. BioMed Research International, 2014, 2014. PMID: 24860823. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[314]<span
style='mso-tab-count:1'> </span>T. A. Robertson, M. A. Maley, M. D. Grounds,
and J. M. Papadimitriou. The role of macrophages in skeletal muscle
regeneration with particular reference to chemotaxis. Experimental Cell
Research, 207(2):321331, August 1993. PMID: 8344384. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[315]<span
style='mso-tab-count:1'> </span>K. L. Haugk, R. A. Roeder, M. J. Garber, and
G. T. Schelling. Regulation of muscle cell proliferation by extracts from
crushed muscle. Journal of Animal Science, 73(7):19721981, July 1995. PMID:
7592081. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[316]<span
style='mso-tab-count:1'> </span>H. C. Olguin and B. B. Olwin. Pax-7
up-regulation inhibits myogenesis and cell cycle progression in satellite
cells: a potential mechanism for self-renewal. Developmental Biology,
275(2):375388, November 2004. PMID: 15501225. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[317]<span
style='mso-tab-count:1'> </span>J. A. Epstein, P. Lam, L. Jepeal, R. L. Maas,
and D. N. Shapiro. Pax3 inhibits myogenic differentiation of cultured myoblast
cells. The Journal of Biological Chemistry, 270(20):1171911722, May 1995.
PMID: 7744814. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[318]<span
style='mso-tab-count:1'> </span>G. Biolo, R. Y. Declan Fleming, and R. R.
Wolfe. Physiologic hyperinsulinemia stimulates protein synthesis and enhances
transport of selected amino acids in human skeletal muscle. Journal of Clinical
Investigation, 95(2):811819, February 1995. PMID: 7860765. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[319]<span
style='mso-tab-count:1'> </span>L. S. Chow, R. C. Albright, M. L. Bigelow, G.
Toffolo, C. Cobelli, and K. S. Nair. Mechanism of insulins anabolic effect on
muscle: measurements of muscle protein synthesis and breakdown using
aminoacyl-tRNA and other surrogate measures. American Journal of Physiology.
Endocrinology and Metabolism, 291(4):E729736, October 2006. PMID: 16705065. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[320]<span
style='mso-tab-count:1'> </span>D. Dardevet, C. Sornet, I. Savary, E. Debras,
P. Patureau-Mirand, and J. Grizard. Glucocorticoid effects on insulin- and
IGF-I-regulated muscle protein metabolism during aging. The Journal of
Endocrinology, 156(1):8389, January 1998. PMID: 9496237. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[321]<span
style='mso-tab-count:1'> </span>M. A. Soos, J. Whittaker, R. Lammers, A.
Ullrich, and K. Siddle. Receptors for insulin and insulin-like growth factor-I
can form hybrid dimers. Characterisation of hybrid receptors in transfected
cells. Biochemical Journal, 270(2):383390, September 1990. <span lang=IT
style='mso-ansi-language:IT'>PMID: 1698059. <o:p></o:p></span></p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'><span lang=IT
style='mso-ansi-language:IT'>[322]<span style='mso-tab-count:1'> </span>G.
Pandini, F. Frasca, R. Mineo, L. Sciacca, R. Vigneri, and A. Belfiore. </span>Insulin/insulin-like
growth factor I hybrid receptors have different biological characteristics
depending on the insulin receptor isoform involved. The Journal of Biological
Chemistry, 277(42):3968439695, October 2002. PMID: 12138094. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[323]<span
style='mso-tab-count:1'> </span>K. Sjgren, J.-L. Liu, K. Blad, S. Skrtic, O.
Vidal, V. Wallenius, D. LeRoith, J. Trnell, O. G. P. Isaksson, J.-O. Jansson,
and C. Ohlsson. Liver-derived insulin-like growth factor I (IGF-I) is the
principal source of IGF-I in blood but is not required for postnatal body
growth in mice. Proceedings of the National Academy of Sciences of the United
States of America, 96(12):70887092, June 1999. PMID: 10359843. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[324]<span
style='mso-tab-count:1'> </span>P. Rorsman and M. Braun. Regulation of insulin
secretion in human pancreatic islets. Annual Review of Physiology, 75:155179,
2013. PMID: 22974438. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[325]<span
style='mso-tab-count:1'> </span>W. Chao and P. A. DAmore. IGF2: Epigenetic
regulation and role in development and disease. Cytokine &amp; growth factor
reviews, 19(2):111120, April 2008. PMID: 18308616. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[326]<span
style='mso-tab-count:1'> </span>C. P. Velloso. Regulation of muscle mass by
growth hormone and IGF-I. British Journal of Pharmacology, 154(3):557568, June
2008. PMID: 18500379. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[327]<span
style='mso-tab-count:1'> </span>F. M. Tomas, S. E. Knowles, P. C. Owens, C.
S. Chandler, G. L. Francis, L. C. Read, and F. J. Ballard. Insulin-like growth
factor-I (IGF-I) and especially IGF-I variants are anabolic in
dexamethasone-treated rats. Biochemical Journal, 282(Pt 1):9197, February
1992. PMID: 1371669. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[328]<span
style='mso-tab-count:1'> </span>E. M. Wilson, M. M. Hsieh, and P. Rotwein.
Autocrine growth factor signaling by insulin-like growth factor-II mediates
MyoD-stimulated myocyte maturation. The Journal of Biological Chemistry,
278(42):4110941113, October 2003. PMID: 12941952. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[329]<span
style='mso-tab-count:1'> </span>T. M. DeChiara, E. J. Robertson, and A.
Efstratiadis. Parental imprinting of the mouse insulin-like growth factor II
gene. Cell, 64(4):849859, February 1991. PMID: 1997210. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[330]<span
style='mso-tab-count:1'> </span>M. Imanaka, K. Iida, A. Murawaki, H.
Nishizawa, H. Fukuoka, R. Takeno, Y. Takahashi, Y. Okimura, H. Kaji, and K.
Chihara. Growth hormone stimulates mechano growth factor expression and
activates myoblast transformation in C2C12 cells. The Kobe Journal of Medical
Sciences, 54(1):E4654, 2008. PMID: 18772608. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[331]<span
style='mso-tab-count:1'> </span>E. Resmini, B. Morte, E. Sorianello, E.
Gallardo, N. de Luna, I. Illa, A. Zorzano, J. Bernal, and S. M. Webb.
Identification of novel GH-regulated genes in C2C12 cells. Hormone and
metabolic research = Hormon- und Stoffwechselforschung = Hormones et
mtabolisme, 43(13):919930, December 2011. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[332]<span
style='mso-tab-count:1'> </span>A. Sotiropoulos, M. Ohanna, C. Kedzia, R. K.
Menon, J. J. Kopchick, P. A. Kelly, and M. Pende. Growth hormone promotes
skeletal muscle cell fusion independent of insulin-like growth factor 1
up-regulation. Proceedings of the National Academy of Sciences of the United
States of America, 103(19):73157320, May 2006. PMID: 16670201. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[333]<span
style='mso-tab-count:1'> </span>F. Lupu, J. D. Terwilliger, K. Lee, G. V.
Segre, and A. Efstratiadis. Roles of growth hormone and insulin-like growth
factor 1 in mouse postnatal growth. Developmental Biology, 229(1):141162,
January 2001. PMID: 11133160. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[334]<span
style='mso-tab-count:1'> </span>M. Mastropasqua, G. Spagna, V. Baldini, I.
Tedesco, and A. Paggi. Hoffmans syndrome: muscle stiffness, pseudohypertrophy
and hypothyroidism. Hormone Research, 59(2):105108, 2003. PMID: 12589116. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[335]<span
style='mso-tab-count:1'> </span>A. J. Garber. Effects of parathyroid hormone
on skeletal muscle protein and amino acid metabolism in the rat. Journal of
Clinical Investigation, 71(6):18061821, June 1983. PMID: 6306055. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[336]<span
style='mso-tab-count:1'> </span>I. M. Olfert, R. A. Howlett, K. Tang, N. D.
Dalton, Y. Gu, K. L. Peterson, P. D. Wagner, and E. C. Breen. Muscle-specific
VEGF deficiency greatly reduces exercise endurance in mice. The Journal of
Physiology, 587(Pt 8):17551767, April 2009. PMID: 19237429. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[337]<span
style='mso-tab-count:1'> </span>N. Arsic, S. Zacchigna, L. Zentilin, G.
Ramirez-Correa, L. Pattarini, A. Salvi, G. Sinagra, and M. Giacca. Vascular
endothelial growth factor stimulates skeletal muscle regeneration in vivo.
Molecular Therapy: The Journal of the American Society of Gene Therapy,
10(5):844854, November 2004. PMID: 15509502. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[338]<span
style='mso-tab-count:1'> </span>J. S. Bonner, L. Lantier, C. M. Hasenour, F.
D. James, D. P. Bracy, and D. H. Wasserman. Muscle-specific vascular
endothelial growth factor deletion induces muscle capillary rarefaction
creating muscle insulin resistance. Diabetes, 62(2):572580, February 2013.
PMID: 23002035. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[339]<span
style='mso-tab-count:1'> </span>C. C. de Theije, R. C. J. Langen, W. H.
Lamers, H. R. Gosker, A. M. W. J. Schols, and S. E. Khler. Differential
sensitivity of oxidative and glycolytic muscles to hypoxia-induced muscle
atrophy. Journal of Applied Physiology (Bethesda, Md.: 1985), 118(2):200211,
January 2015. PMID: 25429096. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[340]<span
style='mso-tab-count:1'> </span>B. A. Bryan, T. E. Walshe, D. C. Mitchell, J.
S. Havumaki, M. Saint-Geniez, A. S. Maharaj, A. E. Maldonado, and P. A.
DAmore. Coordinated vascular endothelial growth factor expression and
signaling during skeletal myogenic differentiation. Molecular biology of the
cell, 19(3):9941006, March 2008. PMID: 18094043. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[341]<span
style='mso-tab-count:1'> </span>C. R. Vianna, M. Huntgeburth, R. Coppari, C.
S. Choi, J. Lin, S. Krauss, G. Barbatelli, I. Tzameli, Y.-B. Kim, S. Cinti, G.
I. Shulman, B. M. Spiegelman, and B. B. Lowell. Hypomorphic mutation in
PGC1&#946; causes mitochondrial dysfunction and liver insulin resistance. Cell
metabolism, 4(6):453464, December 2006. PMID: 17141629. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[342]<span
style='mso-tab-count:1'> </span>G. C. Rowe, C. Jang, I. S. Patten, and Z.
Arany. PGC-1beta regulates angiogenesis in skeletal muscle. American journal of
physiology. Endocrinology and metabolism, 301(1):E155163, July 2011. PMID:
21364124. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[343]<span
style='mso-tab-count:1'> </span>J. Lin, H. Wu, P. T. Tarr, C.-Y. Zhang, Z. Wu,
O. Boss, L. F. Michael, P. Puigserver, E. Isotani, E. N. Olson, B. B. Lowell,
R. Bassel-Duby, and B. M. Spiegelman. Transcriptional co-activator PGC-1 alpha
drives the formation of slow-twitch muscle fibres. Nature, 418(6899):797801,
August 2002. PMID: 12181572. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[344]<span
style='mso-tab-count:1'> </span>J. Waltenberger, L. Claesson-Welsh, A.
Siegbahn, M. Shibuya, and C. H. Heldin. Different signal transduction
properties of KDR and Flt1, two receptors for vascular endothelial growth
factor. The Journal of Biological Chemistry, 269(43):2698826995, October 1994.
PMID: 7929439. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[345]<span
style='mso-tab-count:1'> </span>L. Seetharam, N. Gotoh, Y. Maru, G. Neufeld,
S. Yamaguchi, and M. Shibuya. A unique signal transduction from FLT tyrosine
kinase, a receptor for vascular endothelial growth factor VEGF. Oncogene,
10(1):135147, January 1995. PMID: 7824266. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[346]<span
style='mso-tab-count:1'> </span>H. P. Gerber, A. McMurtrey, J. Kowalski, M.
Yan, B. A. Keyt, V. Dixit, and N. Ferrara. Vascular endothelial growth factor
regulates endothelial cell survival through the phosphatidylinositol
3-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR
activation. The Journal of biological chemistry, 273(46):3033630343, November
1998. PMID: 9804796. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[347]<span
style='mso-tab-count:1'> </span>E. I. Korpelainen, M. Krkkinen, Y. Gunji,
M. Vikkula, and K. Alitalo. Endothelial receptor tyrosine kinases activate the
STAT signaling pathway: mutant Tie-2 causing venous malformations signals a
distinct STAT activation response. Oncogene, 18(1):18, January 1999. PMID:
9926914. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[348]<span
style='mso-tab-count:1'> </span>T. M. OConnor and C. R. Wyttenbach. Cell
death in the embryonic chick spinal cord. The Journal of Cell Biology,
60(2):448459, February 1974. PMID: 4855905. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[349]<span
style='mso-tab-count:1'> </span>M. Favero, A. Cangiano, and G. Busetto.
Hebb-based rules of neural plasticity: are they ubiquitously important for the
refinement of synaptic connections in development? The Neuroscientist: A Review
Journal Bringing Neurobiology, Neurology and Psychiatry, 20(1):814, February
2014. PMID: 23753676. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[350]<span
style='mso-tab-count:1'> </span>A. Burls, K. Subramaniam, M. B. Lowrie, and G.
Vrbov. Absence of nerve muscle interaction influences the survival of
developing motoneurons. The European Journal of Neuroscience, 3(3):216221,
1991. PMID: 12106198. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[351]<span
style='mso-tab-count:1'> </span>M. Kuno. Target dependence of motoneuronal
survival: the current status. Neuroscience Research, 9(3):155172, December
1990. PMID: 1963675. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[352]<span
style='mso-tab-count:1'> </span>A. D. Grinnell. Dynamics of nerve-muscle
interaction in developing and mature neuromuscular junctions. Physiological
Reviews, 75(4):789834, October 1995. PMID: 7480163. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[353]<span
style='mso-tab-count:1'> </span>M. Gonzalez-Freire, R. de Cabo, S. A.
Studenski, and L. Ferrucci. The neuromuscular junction: aging at the crossroad
between nerves and muscle. Frontiers in Aging Neuroscience, 6, August 2014.
PMID: 25157231. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[354]<span
style='mso-tab-count:1'> </span>C. Serra, D. Lee, N. L. Sandor, G. Toraldo,
H. Jang, R. Jasuja, and S. Bhasin. Characterization of the neuromuscular
junction in castrated male mice. San Francisco, June 2013. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[355]<span
style='mso-tab-count:1'> </span>H. Nishimune, J. A. Stanford, and Y. Mori.
Role of exercise in maintaining the integrity of the neuromuscular junction.
Muscle &amp; nerve, 49(3):315324, March 2014. PMID: 24122772. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[356]<span
style='mso-tab-count:1'> </span>P. J. Apel, J. Jun, M. Callahan, C. N.
Northam, T. B. Alton, W. E. Sonntag, and Z. Li. Effect of locally delivered
IGF-1 on nerve regeneration during aging: an experimental study in rats. Muscle
&amp; nerve, 41(3):335341, March 2010. PMID: 19802878. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[357]<span
style='mso-tab-count:1'> </span>R. Thijs, N. Notermans, J. Wokke, Y. van der
Graaf, and J. van Gijn. Distribution of muscle weakness of central and
peripheral origin. Journal of Neurology, Neurosurgery, and Psychiatry,
65(5):794796, November 1998. PMID: 9810962. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[358]<span
style='mso-tab-count:1'> </span>D. Purves, G. J. Augustine, D. Fitzpatrick, L.
C. Katz, A.-S. LaMantia, J. O. McNamara, and S. M. Williams. Damage to
descending motor pathways: the upper motor neuron syndrome. In Neuroscience.
Sinauer Associates, Inc., Sunderland, United States, 2 edition, 2001. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[359]<span
style='mso-tab-count:1'> </span>R. W. Jackman and S. C. Kandarian. The
molecular basis of skeletal muscle atrophy. American Journal of Physiology.
Cell Physiology, 287(4):C834843, October 2004. PMID: 15355854. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[360]<span
style='mso-tab-count:1'> </span>A. J. Harris. Embryonic growth and innervation
of rat skeletal muscles. I. Neural regulation of muscle fibre numbers.
Philosophical Transactions of the Royal Society of London. Series B, Biological
Sciences, 293(1065):257277, July 1981. PMID: 6116248. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[361]<span
style='mso-tab-count:1'> </span>E. M. MacDonald, E. Andres-Mateos, R. Mejias,
J. L. Simmers, R. Mi, J.-S. Park, S. Ying, A. Hoke, S.-J. Lee, and R. D. Cohn.
Denervation atrophy is independent from Akt and mTOR activation and is not
rescued by myostatin inhibition. Disease Models &amp; Mechanisms, 7(4):471481,
April 2014. PMID: 24504412. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[362]<span
style='mso-tab-count:1'> </span>J. C. Bruusgaard and K. Gundersen. In vivo
time-lapse microscopy reveals no loss of murine myonuclei during weeks of
muscle atrophy. The Journal of Clinical Investigation, 118(4):14501457, April
2008. PMID: 18317591. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[363]<span
style='mso-tab-count:1'> </span>A. L. Goldberg. Protein turnover in skeletal
muscle. II. Effects of denervation and cortisone on protein catabolism in
skeletal muscle. The Journal of Biological Chemistry, 244(12):32233229, June
1969. PMID: 5792658. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[364]<span
style='mso-tab-count:1'> </span>K. Furuno, M. N. Goodman, and A. L. Goldberg.
Role of different proteolytic systems in the degradation of muscle proteins
during denervation atrophy. The Journal of Biological Chemistry,
265(15):85508557, May 1990. PMID: 2187867. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[365]<span
style='mso-tab-count:1'> </span>B. C. Beehler, P. G. Sleph, L. Benmassaoud,
and G. J. Grover. Reduction of skeletal muscle atrophy by a proteasome
inhibitor in a rat model of denervation. Experimental Biology and Medicine
(Maywood, N.J.), 231(3):335341, March 2006. PMID: 16514182. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[366]<span
style='mso-tab-count:1'> </span>A. V. Gomes, D. S. Waddell, R. Siu, M. Stein,
S. Dewey, J. D. Furlow, and S.<span style='mso-tab-count:1'> </span>C.
Bodine. Upregulation of proteasome activity in muscle RING finger1-null mice
following denervation. The FASEB Journal, 26(7):29862999, July 2012. PMID:
22508689. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[367]<span
style='mso-tab-count:1'> </span>R. Medina, S. S. Wing, and A. L. Goldberg.
Increase in levels of polyubiquitin and proteasome mRNA in skeletal muscle
during starvation and denervation atrophy. Biochemical Journal, 307(Pt
3):631637, May 1995. PMID: 7741690. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[368]<span
style='mso-tab-count:1'> </span>A.-K. Fjllstrm, K. Evertsson, M. Norrby, and
S. Tgerud. Forkhead box O1 and muscle RING finger 1 protein expression in
atrophic and hypertrophic denervated mouse skeletal muscle. Journal of
Molecular Signaling, 9:9, September 2014. PMID: 25276226. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[369]<span
style='mso-tab-count:1'> </span>V. Moresi, A. H. Williams, E. Meadows, J. M. Flynn,
M. J. Potthoff, J. McAnally, J. M. Shelton, J. Backs, W. H. Klein, J. A.
Richardson, R. Bassel-Duby, and E. N. Olson. Myogenin and class II HDACs
control neurogenic muscle atrophy by inducing E3 ubiquitin ligases. Cell,
143(1):3545, October 2010. PMID: 20887891. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[370]<span
style='mso-tab-count:1'> </span>H. Tang, K. Inoki, M. Lee, E. Wright, A.
Khuong, A. Khuong, S. Sugiarto, M. Garner, J. Paik, R. A. DePinho, D. Goldman,
K.-L. Guan, and J. B. Shrager. mTORC1 promotes denervation-induced muscle
atrophy through a mechanism involving the activation of FoxO and E3 ubiquitin
ligases. Science Signaling, 7(314):ra18, February 2014. PMID: 24570486. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[371]<span
style='mso-tab-count:1'> </span>P. C. D. Macpherson, X. Wang, and D. Goldman.
Myogenin regulates denervation-dependent muscle atrophy in mouse soleus muscle.
Journal of cellular biochemistry, 112(8):21492159, August 2011. PMID:
21465538. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[372]<span
style='mso-tab-count:1'> </span>H. Tang, P. Macpherson, M. Marvin, E.
Meadows, W. H. Klein, X.-J. Yang, and D. Goldman. A histone deacetylase
4/myogenin positive feedback loop coordinates denervation-dependent gene
induction and suppression. Molecular Biology of the Cell, 20(4):11201131,
February 2009. PMID: 19109424. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[373]<span
style='mso-tab-count:1'> </span>S. C. Bodine, T. N. Stitt, M. Gonzalez, W. O.
Kline, G. L. Stover, R. Bauerlein, E. Zlotchenko, A. Scrimgeour, J. C.
Lawrence, D. J. Glass, and G. D. Yancopoulos. Akt/mTOR pathway is a crucial
regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in
vivo. Nature Cell Biology, 3(11):10141019, November 2001. PMID: 11715023. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[374]<span
style='mso-tab-count:1'> </span>J. Zhao, J. J. Brault, A. Schild, P. Cao, M.
Sandri, S. Schiaffino, S. H. Lecker, and A. L. Goldberg. FoxO3 coordinately
activates protein degradation by the autophagic/lysosome and proteasome
pathways in atrophying muscle cells. Cell metabolism, 6(6):472483, December
2007. PMID: 18054316. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[375]<span
style='mso-tab-count:1'> </span>S. Schiaffino, K. A. Dyar, S. Ciciliot, B.
Blaauw, and M. Sandri. Mechanisms regulating skeletal muscle growth and
atrophy. The FEBS journal, 280(17):42944314, September 2013. PMID: 23517348. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[376]<span
style='mso-tab-count:1'> </span>P. N. Quy, A. Kuma, P. Pierre, and N.
Mizushima. Proteasome-dependent activation of mammalian target of rapamycin
complex 1 (mTORC1) is essential for autophagy suppression and muscle remodeling
following denervation. The Journal of Biological Chemistry, 288(2):11251134,
January 2013. PMID: 23209294. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[377]<span
style='mso-tab-count:1'> </span>J. Schwartz, L. Rath-Wolfson, D. Varon, E.
Skutelsky, E. Gaton, and M. Wolman. Effects of various drugs on denervation
changes in rat muscles. <span lang=IT style='mso-ansi-language:IT'>Clinical
Neuropathology, 9(6):305309, December 1990. PMID: 2286023. <o:p></o:p></span></p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'><span lang=IT
style='mso-ansi-language:IT'>[378]<span style='mso-tab-count:1'> </span>C.
Mammucari, G. Milan, V. Romanello, E. Masiero, R. Rudolf, P. Del Piccolo, S. J.
Burden, R. Di Lisi, C. Sandri, J. Zhao, A. L. Goldberg, S. Schiaffino, and M.
Sandri. </span>FoxO3 controls autophagy in skeletal muscle in vivo. Cell
metabolism, 6(6):458471, December 2007. PMID: 18054315. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[379]<span
style='mso-tab-count:1'> </span>J.-S. Ju, A. S. Varadhachary, S. E. Miller,
and C. C. Weihl. Quantitation of autophagic flux in mature skeletal muscle.
Autophagy, 6(7):929935, October 2010. PMID: 20657169. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[380]<span
style='mso-tab-count:1'> </span>D. A. P. Gonalves, W. A. Silveira, E. C.
Lira, F. A. Graa, S. Paula-Gomes, N. M. Zanon, I. C. Kettelhut, and L. C. C.
Navegantes. Clenbuterol suppresses proteasome and lysosome proteolysis and
atrophy-related genes in denervated rat soleus muscles independently of Akt.
American Journal of Physiology. Endocrinology and Metabolism, 302(1):E123133,
January 2012. PMID: 21952035. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[381]<span
style='mso-tab-count:1'> </span>S. K. Joshi, H. T. Kim, B. T. Feeley, and X.
Liu. Differential ubiquitin-proteasome and autophagy signaling following
rotator cuff tears and suprascapular nerve injury. Journal of orthopaedic
research : official publication of the Orthopaedic Research Society, 32(1),
January 2014. PMID: 24018537. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[382]<span
style='mso-tab-count:1'> </span>F. Muhlbacher, C. R. Kapadia, M. F. Colpoys,
R. J. Smith, and D. W. Wilmore. Effects of glucocorticoids on glutamine
metabolism in skeletal muscle. The American Journal of Physiology, 247(1 Pt
1):E7583, July 1984. PMID: 6146264. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[383]<span
style='mso-tab-count:1'> </span>H. A. Tiley, R. J. Geor, and L. J. McCutcheon.
Effects of dexamethasone administration on insulin resistance and components of
insulin signaling and glucose metabolism in equine skeletal muscle. American
Journal of Veterinary Research, 69(1):5158, January 2008. PMID: 18167087. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[384]<span
style='mso-tab-count:1'> </span>T. J. Corah, J. D. Tatum, J. B. Morgan, R. G.
Mortimer, and G. C. Smith. Effects of a dexamethasone implant on deposition of
intramuscular fat in genetically identical cattle. Journal of Animal Science,
73(11):33103316, November 1995. PMID: 8586589. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[385]<span
style='mso-tab-count:1'> </span>J. Y. Yeh, B. R. Ou, and N. E. Forsberg.
Effects of dexamethasone on muscle protein homeostasis and on calpain and
calpastatin activities and gene expression in rabbits. The Journal of
Endocrinology, 141(2):209217, May 1994. PMID: 7519233. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[386]<span
style='mso-tab-count:1'> </span>M. Rohdewald and H. Glasmacher. ber die
antianabole Wirkung von Glucocorticoiden. I. Mitteilung: Untersuchungen am
Skelettmuskel von Ratte und Maus. <span lang=IT style='mso-ansi-language:IT'>Enzymologia,
28:4956, November 1964. PMID: 14238775. <o:p></o:p></span></p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'><span lang=IT
style='mso-ansi-language:IT'>[387]<span style='mso-tab-count:1'> </span>A. O.
P. Protzek, J. M. Costa-Jnior, L. F. Rezende, G. J. Santos, T. G. Arajo, J.
F. Vettorazzi, F. Ortis, E. M. Carneiro, A. Rafacho, and A. C. Boschero. </span>Augmented
beta-cell function and mass in glucocorticoid-treated rodents are associated
with increased islet Ir-beta/AKT/mTOR and decreased AMPK/ACC and AS160
signaling. International Journal of Endocrinology, 2014, 2014. PMID: 25313308. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[388]<span
style='mso-tab-count:1'> </span>M. L. Watson, L. M. Baehr, H. M. Reichardt, J.
P. Tuckermann, S. C. Bodine, and J. D. Furlow. A cell-autonomous role for the
glucocorticoid receptor in skeletal muscle atrophy induced by systemic
glucocorticoid exposure. American journal of physiology. Endocrinology and
metabolism, 302(10):E12101220, May 2012. PMID: 22354783. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[389]<span
style='mso-tab-count:1'> </span>D. Chen, M. R. Yang, L. N. Huang, Y. W. Qiu,
and S. T. Li. Different magnitude of resistance to non-depolarizing muscle
relaxants in dexamethasone-treated rat diaphragm associated with altered
acetylcholine receptor expression. Genetics and molecular research: GMR,
13(3):58925900, 2014. PMID: 25117347. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[390]<span
style='mso-tab-count:1'> </span>Y. Dong, J. S. Pan, and L. Zhang. Myostatin
suppression of Akirin1 mediates glucocorticoid-induced satellite cell dysfunction.
PloS One, 8(3):e58554, 2013. PMID: 23516508. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[391]<span
style='mso-tab-count:1'> </span>F. Giorgino and R. J. Smith. Dexamethasone
enhances insulin-like growth factor-I effects on skeletal muscle cell
proliferation. Role of specific intracellular signaling pathways. The Journal
of clinical investigation, 96(3):14731483, September 1995. PMID: 7544807. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[392]<span
style='mso-tab-count:1'> </span>J. R. Florini and S. B. Roberts. A serum-free
medium for the growth of muscle cells in culture. In vitro, 15(12):983992,
December 1979. PMID: 94034. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[393]<span
style='mso-tab-count:1'> </span>P. A. Whitson, C. A. Stuart, M. H. Huls, C. F.
Sams, and N. M. Cintron. Dexamethasone effects on creatine kinase activity and
insulin-like growth factor receptors in cultured muscle cells. Journal of
cellular physiology, 140(1):817, July 1989. PMID: 2544617. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[394]<span
style='mso-tab-count:1'> </span>A. Takahashi, Y. Kureishi, J. Yang, Z. Luo, K.
Guo, D. Mukhopadhyay, Y. Ivashchenko, D. Branellec, and K. Walsh. Myogenic Akt
signaling regulates blood vessel recruitment during myofiber growth. Molecular
and cellular biology, 22(13):48034814, July 2002. PMID: 12052887. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[395]<span
style='mso-tab-count:1'> </span>M. Menconi, P. Gonnella, V. Petkova, S.
Lecker, and P.-O. Hasselgren. Dexamethasone and corticosterone induce similar,
but not identical, muscle wasting responses in cultured L6 and C2C12 myotubes.
Journal of Cellular Biochemistry, 105(2):353364, October 2008. PMID: 18615595.
</p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[396]<span
style='mso-tab-count:1'> </span>G. R. Bullock, E. E. Carter, P. Elliott, R. F.
Peters, P. Simpson, and A. M. White. Relative changes in the function of muscle
ribosomes and mitochondria during the early phase of steroid-induced
catabolism. Biochemical Journal, 127(5):881892, May 1972. PMID: 5076236. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[397]<span
style='mso-tab-count:1'> </span>N. Alamdari, G. Toraldo, Z. Aversa, I. Smith,
E. Castillero, G. Renaud, R. Qaisar, L. Larsson, R. Jasuja, and P.-O.
Hasselgren. Loss of muscle strength during sepsis is in part regulated by glucocorticoids
and is associated with reduced muscle fiber stiffness. American Journal of
Physiology. Regulatory, Integrative and Comparative Physiology,
303(10):R10901099, November 2012. PMID: 23019215. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[398]<span
style='mso-tab-count:1'> </span>S. Nava, G. Gayan-Ramirez, H. Rollier, A.
Bisschop, R. Dom, V. de Bock, and M. Decramer. Effects of acute steroid
administration on ventilatory and peripheral muscles in rats. American Journal
of Respiratory and Critical Care Medicine, 153(6 Pt 1):18881896, June 1996.
PMID: 8665051. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[399]<span
style='mso-tab-count:1'> </span>F. Caldefie-Chzet, C. Moinard, R.
Minet-Quinard, F. Gachon, L. Cynober, and M. Vasson. Dexamethasone treatment
induces long-lasting hyperleptinemia and anorexia in old rats. Metabolism:
Clinical and Experimental, 50(9):10541058, September 2001. PMID: 11555838. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[400]<span
style='mso-tab-count:1'> </span>D. Dardevet, C. Sornet, D. Taillandier, I.
Savary, D. Attaix, and J. Grizard. Sensitivity and protein turnover response to
glucocorticoids are different in skeletal muscle from adult and old rats. Lack
of regulation of the ubiquitin-proteasome proteolytic pathway in aging. The
Journal of Clinical Investigation, 96(5):21132119, November 1995. PMID:
7593595. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[401]<span
style='mso-tab-count:1'> </span>H. Nicastro, B. Gualano, W. M. A. M. de
Moraes, V. de Salles Painelli, C. R. da Luz, A. dos Santos Costa, F. de Salvi
Guimares, A. Medeiros, P. C. Brum, and J. Lancha, Antonio Herbert. Effects of
creatine supplementation on muscle wasting and glucose homeostasis in rats
treated with dexamethasone. Amino acids, 42(5):16951701, May 2012. PMID:
21373767. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[402]<span
style='mso-tab-count:1'> </span>D. J. Prezant, M. L. Karwa, B. Richner, D.
Maggiore, E. I. Gentry, and J. Cahill. Gender-specific effects of dexamethasone
treatment on rat diaphragm structure and function. Journal of Applied
Physiology (Bethesda, Md.: 1985), 82(1):125133, January 1997. PMID: 9029207. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[403]<span
style='mso-tab-count:1'> </span>I. L. Baptista, W. J. Silva, G. G. Artioli, J.
P. L. F. Guilherme, M. L. Leal, M. S. Aoki, E. H. Miyabara, and A. S. Moriscot.
Leucine and HMB differentially modulate proteasome system in skeletal muscle
under different sarcopenic conditions. PloS One, 8(10):e76752, 2013. PMID:
24124592. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[404]<span
style='mso-tab-count:1'> </span>R. Minet-Quinard, C. Moinard, S. Walrand, F.
Villi, B. Normand, M. P. Vasson, J. Chopineau, and L. Cynober. Induction of a
catabolic state in rats by dexamethasone: dose or time dependency? JPEN.
Journal of parenteral and enteral nutrition, 24(1):3036, February 2000. PMID:
10638469. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[405]<span
style='mso-tab-count:1'> </span>S. B. Bowes, N. C. Jackson, D.
Papachristodoulou, A. M. Umpleby, and P. H. Snksen. Effect of corticosterone
on protein degradation in isolated rat soleus and extensor digitorum longus
muscles. The Journal of Endocrinology, 148(3):501507, March 1996. PMID:
8778228. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[406]<span
style='mso-tab-count:1'> </span>J. D. Furlow, M. L. Watson, D. S. Waddell, E.
S. Neff, L. M. Baehr, A. P. Ross, and S. C. Bodine. Altered gene expression
patterns in Muscle Ring Finger 1 null mice during denervation and
dexamethasone-induced muscle atrophy. Physiological genomics, October 2013.
PMID: 24130153. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[407]<span
style='mso-tab-count:1'> </span>Y. H. Son, S.-J. Lee, K.-B. Lee, J.-H. Lee, E.
M. Jeong, S. G. Chung, S.-C. Park, and I.-G. Kim. Dexamethasone downregulates
caveolin-1 causing muscle atrophy via inhibited insulin signaling. The Journal
of Endocrinology, 225(1):2737, April 2015. PMID: 25688118. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[408]<span
style='mso-tab-count:1'> </span>T. Seene, M. Umnova, K. Alev, and A. Pehme.
Effect of glucocorticoids on contractile apparatus of rat skeletal muscle.
Journal of Steroid Biochemistry, 29(3):313317, March 1988. PMID: 3282126. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[409]<span
style='mso-tab-count:1'> </span>S. S. Wing and A. L. Goldberg. Glucocorticoids
activate the ATP-ubiquitin-dependent proteolytic system in skeletal muscle
during fasting. The American Journal of Physiology, 264(4 Pt 1):E668676, April
1993. PMID: 7682781. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[410]<span
style='mso-tab-count:1'> </span>L. Combaret, D. Taillandier, D. Dardevet, D.
Bchet, C. Rallire, A. Claustre, J. Grizard, and D. Attaix. Glucocorticoids
regulate mRNA levels for subunits of the 19 S regulatory complex of the 26 S
proteasome in fast-twitch skeletal muscles. Biochemical Journal, 378(Pt
1):239246, February 2004. PMID: 14636157. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[411]<span
style='mso-tab-count:1'> </span>G. Tiao, J. Fagan, V. Roegner, M. Lieberman,
J. J. Wang, J. E. Fischer, and P. O. Hasselgren. Energy-ubiquitin-dependent
muscle proteolysis during sepsis in rats is regulated by glucocorticoids.
Journal of Clinical Investigation, 97(2):339348, January 1996. PMID: 8567953. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[412]<span
style='mso-tab-count:1'> </span>H. Gilson, O. Schakman, L. Combaret, P.
Lause, L. Grobet, D. Attaix, J. M. Ketelslegers, and J. P. Thissen. Myostatin
gene deletion prevents glucocorticoid-induced muscle atrophy. Endocrinology,
148(1):452460, January 2007. PMID: 17038559. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[413]<span
style='mso-tab-count:1'> </span>L. Wang, G. J. Luo, J. J. Wang, and P. O.
Hasselgren. Dexamethasone stimulates proteasome- and calcium-dependent
proteolysis in cultured L6 myotubes. Shock (Augusta, Ga.), 10(4):298306,
October 1998. PMID: 9788663. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[414]<span
style='mso-tab-count:1'> </span>M. G. Thompson, A. Thom, K. Partridge, K.
Garden, G. P. Campbell, G. Calder, and R. M. Palmer. Stimulation of
myofibrillar protein degradation and expression of mRNA encoding the
ubiquitin-proteasome system in C(2)C(12) myotubes by dexamethasone: effect of
the proteasome inhibitor MG-132. Journal of Cellular Physiology,
181(3):455461, December 1999. PMID: 10528231. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[415]<span
style='mso-tab-count:1'> </span>A. C. Marinovic, W. E. Mitch, and S. R. Price.
Tools for evaluating ubiquitin (UbC) gene expression: characterization of the
rat UbC promoter and use of an unique 3 mRNA sequence. Biochemical and
biophysical research communications, 274(2):537541, August 2000. PMID:
10913373. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[416]<span
style='mso-tab-count:1'> </span>B. Zheng, S. Ohkawa, H. Li, T. K.
Roberts-Wilson, and S. R. Price. FOXO3a mediates signaling crosstalk that
coordinates ubiquitin and atrogin-1/MAFbx expression during
glucocorticoid-induced skeletal muscle atrophy. FASEB journal: official
publication of the Federation of American Societies for Experimental Biology,
24(8):26602669, August 2010. PMID: 20371624. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[417]<span
style='mso-tab-count:1'> </span>M. J. Tisdale. Catabolic mediators of cancer
cachexia. Current Opinion in Supportive and Palliative Care, 2(4):256261,
December 2008. PMID: 19069310. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[418]<span
style='mso-tab-count:1'> </span>W. Chamberlain, P. Gonnella, N. Alamdari, Z.
Aversa, and P.-O. Hasselgren. Multiple muscle wasting-related transcription
factors are acetylated in dexamethasone-treated muscle cells. Biochemistry and
cell biology = Biochimie et biologie cellulaire, 90(2):200208, April 2012.
PMID: 22292478. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[419]<span
style='mso-tab-count:1'> </span>G. Luo, X. Sun, E. Hungness, and P. O.
Hasselgren. Heat shock protects L6 myotubes from catabolic effects of
dexamethasone and prevents downregulation of NF-kappaB. American journal of
physiology. Regulatory, integrative and comparative physiology,
281(4):R11931200, October 2001. PMID: 11557628. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[420]<span
style='mso-tab-count:1'> </span>J. Du, W. E. Mitch, X. Wang, and S. R. Price.
Glucocorticoids induce proteasome C3 subunit expression in L6 muscle cells by
opposing the suppression of its transcription by NF-kappa B. The Journal of
Biological Chemistry, 275(26):1966119666, June 2000. PMID: 10867022. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[421]<span
style='mso-tab-count:1'> </span>T. N. Stitt, D. Drujan, B. A. Clarke, F.
Panaro, Y. Timofeyva, W. O. Kline, M. Gonzalez, G. D. Yancopoulos, and D. J.
Glass. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced
ubiquitin ligases by inhibiting FOXO transcription factors. Molecular Cell,
14(3):395403, May 2004. PMID: 15125842. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[422]<span
style='mso-tab-count:1'> </span>Y. Wu, W. Zhao, J. Zhao, Y. Zhang, W. Qin, J.
Pan, W. A. Bauman, R. D. Blitzer, and C. Cardozo. REDD1 is a major target of
testosterone action in preventing dexamethasone-induced muscle loss.
Endocrinology, 151(3):10501059, March 2010. PMID: 20032058. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[423]<span
style='mso-tab-count:1'> </span>L. M. Baehr, J. D. Furlow, and S. C. Bodine.
Muscle sparing in muscle RING finger 1 null mice: response to synthetic
glucocorticoids. The Journal of physiology, 589(Pt 19):47594776, October 2011.
PMID: 21807613. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[424]<span
style='mso-tab-count:1'> </span>D. S. Waddell, L. M. Baehr, J. van den Brandt,
S. A. Johnsen, H. M. Reichardt, J. D. Furlow, and S. C. Bodine. The
glucocorticoid receptor and FOXO1 synergistically activate the skeletal muscle
atrophy-associated MuRF1 gene. American Journal of Physiology. Endocrinology
and Metabolism, 295(4):E785797, October 2008. PMID: 18612045. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[425]<span
style='mso-tab-count:1'> </span>T. P. Braun and D. L. Marks. The regulation
of muscle mass by endogenous glucocorticoids. Frontiers in Physiology, 6,
February 2015. PMID: 25691871. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[426]<span
style='mso-tab-count:1'> </span>M. Nishimura, M. Mikura, K. Hirasaka, Y.
Okumura, T. Nikawa, Y. Kawano, M. Nakayama, and M. Ikeda. Effects of dimethyl
sulphoxide and dexamethasone on mRNA expression of myogenesis- and muscle
proteolytic system-related genes in mouse myoblastic C2C12 cells. Journal of
biochemistry, 144(6):717724, December 2008. PMID: 18835828. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[427]<span
style='mso-tab-count:1'> </span>L. Slimani, D. Micol, J. Amat, G. Delcros, B.
Meunier, D. Taillandier, C. Polge, D. Bchet, D. Dardevet, B. Picard, D.
Attaix, A. Listrat, and L. Combaret. The worsening of tibialis anterior muscle
atrophy during recovery post-immobilization correlates with enhanced connective
tissue area, proteolysis, and apoptosis. American Journal of Physiology.
Endocrinology and Metabolism, 303(11):E13351347, December 2012. PMID:
23032683. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[428]<span
style='mso-tab-count:1'> </span>L. M. Baehr, M. Tunzi, and S. C. Bodine.
Muscle hypertrophy is associated with increases in proteasome activity that is
independent of MuRF1 and MAFbx expression. Frontiers in Physiology, 5:69, 2014.
PMID: 24600408. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[429]<span
style='mso-tab-count:1'> </span>T. Mozaffar, F. Haddad, M. Zeng, L. Y. Zhang,
G. R. Adams, and K. M. Baldwin. Molecular and cellular defects of skeletal
muscle in an animal model of acute quadriplegic myopathy. Muscle &amp; Nerve,
35(1):5565, January 2007. PMID: 16967495. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[430]<span
style='mso-tab-count:1'> </span>L. A. Tintignac, J. Lagirand, S. Batonnet, V.
Sirri, M. P. Leibovitch, and S. A. Leibovitch. Degradation of MyoD mediated by
the SCF (MAFbx) ubiquitin ligase. The Journal of Biological Chemistry,
280(4):28472856, January 2005. PMID: 15531760. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[431]<span
style='mso-tab-count:1'> </span>J. Lagirand-Cantaloube, N. Offner, A. Csibi,
M. P. Leibovitch, S.<span style='mso-tab-count:1'> </span>Batonnet-Pichon,
L. A. Tintignac, C. T. Segura, and S. A. Leibovitch. Theinitiation factor
eIF3-f is a major target for atrogin1/MAFbx function in skeletal muscle
atrophy. The EMBO journal, 27(8):12661276, April 2008. PMID: 18354498. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[432]<span
style='mso-tab-count:1'> </span>S. H. Witt, H. Granzier, C. C. Witt, and S.
Labeit. MURF-1 and MURF-2 target a specific subset of myofibrillar proteins
redundantly: towards understanding MURF-dependent muscle ubiquitination.
Journal of Molecular Biology, 350(4):713722, July 2005. PMID: 15967462. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[433]<span
style='mso-tab-count:1'> </span>S. Hirner, C. Krohne, A. Schuster, S.
Hoffmann, S. Witt, R. Erber, C. Sticht, A. Gasch, S. Labeit, and D. Labeit.
MuRF1-dependent regulation of systemic carbohydrate metabolism as revealed from
transgenic mouse studies. Journal of Molecular Biology, 379(4):666677, June
2008. PMID: 18468620. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[434]<span
style='mso-tab-count:1'> </span>B. A. Clarke, D. Drujan, M. S. Willis, L. O.
Murphy, R. A. Corpina, E. Burova, S. V. Rakhilin, T. N. Stitt, C. Patterson, E.
Latres, and D. J. Glass. The E3 Ligase MuRF1 degrades myosin heavy chain
protein in dexamethasone-treated skeletal muscle. Cell metabolism,
6(5):376385, November 2007. PMID: 17983583. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[435]<span
style='mso-tab-count:1'> </span>C. Polge, A.-E. Heng, M. Jarzaguet, S.
Ventadour, A. Claustre, L. Combaret, D. Bchet, M. Matondo, S.
Uttenweiler-Joseph, B. Monsarrat, D. Attaix, and D. Taillandier. Muscle actin
is polyubiquitinylated in vitro and in vivo and targeted for breakdown by the
E3 ligase MuRF1. FASEB journal: official publication of the Federation of
American Societies for Experimental Biology, 25(11):37903802, November 2011.
PMID: 21764995. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[436]<span
style='mso-tab-count:1'> </span>H. Sun, Y. Gong, J. Qiu, Y. Chen, F. Ding, and
Q. Zhao. TRAF6 inhibition rescues dexamethasone-induced muscle atrophy.
International Journal of Molecular Sciences, 15(6):1112611141, 2014. PMID:
24955790. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[437]<span
style='mso-tab-count:1'> </span>H. Yang, M. J. Menconi, W. Wei, V. Petkova,
and P.-O. Hasselgren. Dexamethasone upregulates the expression of the nuclear
cofactor p300 and its interaction with C/EBPbeta in cultured myotubes. Journal
of Cellular Biochemistry, 94(5):10581067, April 2005. PMID: 15669015. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[438]<span
style='mso-tab-count:1'> </span>N. Alamdari, I. J. Smith, Z. Aversa, and P.-O.
Hasselgren. Sepsis and glucocorticoids upregulate p300 and downregulate HDAC6
expression and activity in skeletal muscle. American Journal of Physiology.
Regulatory, Integrative and Comparative Physiology, 299(2):R509520, August
2010. PMID: 20538901. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[439]<span
style='mso-tab-count:1'> </span>M. J. Saad, F. Folli, J. A. Kahn, and C. R.
Kahn. Modulation of insulin receptor, insulin receptor substrate-1, and
phosphatidylinositol 3-kinase in liver and muscle of dexamethasone-treated
rats. Journal of Clinical Investigation, 92(4):20652072, October 1993. PMID:
7691892. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[440]<span
style='mso-tab-count:1'> </span>S. P. Weinstein, T. Paquin, A. Pritsker, and
R. S. Haber. Glucocorticoid-induced insulin resistance: dexamethasone inhibits
the activation of glucose transport in rat skeletal muscle by both insulin- and
non-insulin-related stimuli. Diabetes, 44(4):441445, April 1995. PMID:
7698514. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[441]<span
style='mso-tab-count:1'> </span>D. Dardevet, C. Sornet, and J. Grizard.
Glucocorticoid-induced insulin resistance of protein synthesis is independent
of the rapamycin-sensitive pathways in rat skeletal muscle. The Journal of
Endocrinology, 162(1):7785, July 1999. PMID: 10396023. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[442]<span
style='mso-tab-count:1'> </span>G. Dimitriadis, B. Leighton, M.
Parry-Billings, S. Sasson, M. Young, U. Krause, S. Bevan, T. Piva, G. Wegener,
and E. A. Newsholme. Effects of glucocorticoid excess on the sensitivity of
glucose transport and metabolism to insulin in rat skeletal muscle. Biochemical
Journal, 321(Pt 3):707712, February 1997. PMID: 9032457. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[443]<span
style='mso-tab-count:1'> </span>Q. Wang, R. Somwar, P. J. Bilan, Z. Liu, J.
Jin, J. R. Woodgett, and A. Klip. Protein kinase B/Akt participates in GLUT4
translocation by insulin in L6 myoblasts. Molecular and Cellular Biology,
19(6):40084018, June 1999. PMID: 10330141. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[444]<span
style='mso-tab-count:1'> </span>C. Corporeau, C. L. Foll, M. Taouis, J.-P.
Gouygou, J.-P. Berg, and J. Delarue. Adipose tissue compensates for defect of
phosphatidylinositol 3-kinase induced in liver and muscle by dietary fish oil
in fed rats. American Journal of Physiology. Endocrinology and Metabolism,
290(1):E78E86, January 2006. PMID: 16339925. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[445]<span
style='mso-tab-count:1'> </span>T. Ishizuka, M. Yamamoto, T. Nagashima, K.
Kajita, O. Taniguchi, K. Yasuda, and K. Miura. Effect of dexamethasone and
prednisolone on insulin-induced activation of protein kinase C in rat
adipocytes and soleus muscles. Metabolism: Clinical and Experimental,
44(3):298306, March 1995. PMID: 7885273. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[446]<span
style='mso-tab-count:1'> </span>F. A. Rojas, A. E. Hirata, and M. J. A. Saad.
Regulation of insulin receptor substrate-2 tyrosine phosphorylation in animal
models of insulin resistance. Endocrine, 21(2):115122, July 2003. PMID:
12897373. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[447]<span
style='mso-tab-count:1'> </span>Z. Li, J. L. Joyal, and D. B. Sacks. Binding
of IRS proteins to calmodulin is enhanced in insulin resistance. Biochemistry,
39(17):50895096, May 2000. PMID: 10819975. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[448]<span
style='mso-tab-count:1'> </span>S. A. Morgan, M. Sherlock, L. L. Gathercole,
G. G. Lavery, C. Lenaghan, I. J. Bujalska, D. Laber, A. Yu, G. Convey, R.
Mayers, K. Hegyi, J. K. Sethi, P. M. Stewart, D. M. Smith, and J. W. Tomlinson.
11beta-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced
insulin resistance in skeletal muscle. Diabetes, 58(11):25062515, November
2009. PMID: 19675138. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[449]<span
style='mso-tab-count:1'> </span>A. Koh, M. N. Lee, Y. R. Yang, H. Jeong, J.
Ghim, J. Noh, J. Kim, D. Ryu, S.<span style='mso-tab-count:1'> </span>Park,
P. Song, S.-H. Koo, N. R. Leslie, P.-O. Berggren, J. H. Choi, P.-G.Suh, and S.
H. Ryu. C1-Ten is a protein tyrosine phosphatase of insulin receptor substrate
1 (IRS-1), regulating IRS-1 stability and muscle atrophy. Molecular and
cellular biology, 33(8):16081620, April 2013. PMID: 23401856. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[450]<span
style='mso-tab-count:1'> </span>M. C. Mendoza, E. E. Er, and J. Blenis. The
Ras-ERK and PI3K-mTOR Pathways: Cross-talk and Compensation. Trends in
biochemical sciences, 36(6):320328, June 2011. PMID: 21531565. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[451]<span
style='mso-tab-count:1'> </span>E. V. Pez Espinosa, E. M. Rocha, L. A.
Velloso, A. C. Boschero, and M. J. Saad. Insulin-induced tyrosine
phosphorylation of Shc in liver, muscle and adipose tissue of insulin resistant
rats. Molecular and Cellular Endocrinology, 156(1-2):121129, October 1999.
PMID: 10612430. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[452]<span
style='mso-tab-count:1'> </span>M. D. Girn, J. D. Vlchez, S. Shreeram, R. Salto,
M. Manzano, E. Cabrera, N. Campos, N. K. Edens, R. Rueda, and J. M. Lpez
Pedrosa. Beta-hydroxy-beta-methylbutyrate (HMB) normalizes
dexamethasone-induced autophagy-lysosome pathway in skeletal muscle. PLoS ONE,
10(2), February 2015. PMID: 25658432. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[453]<span
style='mso-tab-count:1'> </span>W. Qin, J. Pan, Y. Wu, W. A. Bauman, and C.
Cardozo. Protection against dexamethasone-induced muscle atrophy is related to
modulation by testosterone of FOXO1 and PGC-1&#945;. Biochemical and
Biophysical Research Communications, 403(3-4):473478, December 2010. PMID:
21094144. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[454]<span
style='mso-tab-count:1'> </span>J. M. McClung, A. R. Judge, S. K. Powers, and
Z. Yan. p38 MAPK links oxidative stress to autophagy-related gene expression in
cachectic muscle wasting. American journal of physiology. Cell physiology,
298(3):C542549, March 2010. PMID: 19955483. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[455]<span
style='mso-tab-count:1'> </span>F. Giorgino, M. T. Pedrini, L. Matera, and R.
J. Smith. Specific increase in p85alpha expression in response to dexamethasone
is associated with inhibition of insulin-like growth factor-I stimulated
phosphatidylinositol 3-kinase activity in cultured muscle cells. The Journal of
Biological Chemistry, 272(11):74557463, March 1997. PMID: 9054447. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[456]<span
style='mso-tab-count:1'> </span>J. R. Singleton, B. L. Baker, and A.
Thorburn. Dexamethasone inhibits insulin-like growth factor signaling and
potentiates myoblast apoptosis. Endocrinology, 141(8):29452950, August 2000.
PMID: 10919283. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[457]<span
style='mso-tab-count:1'> </span>Z. Hu, H. Wang, I. H. Lee, J. Du, and W. E.
Mitch. Endogenous glucocorticoids and impaired insulin signaling are both
required to stimulate muscle wasting under pathophysiological conditions in
mice. The Journal of Clinical Investigation, 119(10):30593069, October 2009.
PMID: 19759515. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[458]<span
style='mso-tab-count:1'> </span>B. Geering, P. R. Cutillas, and B.
Vanhaesebroeck. Regulation of class IA PI3Ks: is there a role for monomeric
PI3K subunits? Biochemical Society Transactions, 35(Pt 2):199203, April 2007.
PMID: 17371237. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[459]<span
style='mso-tab-count:1'> </span>J. Burn, Y. C. Lai, M. Lundgren, J. W.
Eriksson, and J. Jensen. Insulin action and signalling in fat and muscle from
dexamethasone-treated rats. Archives of Biochemistry and Biophysics,
474(1):91101, June 2008. PMID: 18328801. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[460]<span
style='mso-tab-count:1'> </span>D. B. Williams, Z. Wan, B. C. Frier, R. C.
Bell, C. J. Field, and D. C. Wright. Dietary supplementation with vitamin E and
C attenuates dexamethasone-induced glucose intolerance in rats. American Journal
of Physiology. Regulatory, Integrative and Comparative Physiology,
302(1):R4958, January 2012. PMID: 22031784. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[461]<span
style='mso-tab-count:1'> </span>A. Fappi, T. S. Godoy, J. R. Maximino, V. R.
Rizzato, J. d. C. Neves, G. Chadi, and E. Zanoteli. The effects of omega-3
fatty acid supplementation on dexamethasone-induced muscle atrophy. BioMed
Research International, 2014:961438, 2014. PMID: 24982916. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[462]<span
style='mso-tab-count:1'> </span>O. Schakman, S. Kalista, L. Bertrand, P.
Lause, J. Verniers, J. M. Ketelslegers, and J. P. Thissen. Role of
Akt/GSK-3beta/beta-catenin transduction pathway in the muscle anti-atrophy
action of insulin-like growth factor-I in glucocorticoid-treated rats.
Endocrinology, 149(8):39003908, August 2008. PMID: 18467435. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[463]<span
style='mso-tab-count:1'> </span>J. E. Cho, M. Fournier, X. Da, and M. I.
Lewis. Time course expression of Foxo transcription factors in skeletal muscle
following corticosteroid administration. Journal of Applied Physiology,
108(1):137145, January 2010. PMID: 19850732. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[464]<span
style='mso-tab-count:1'> </span>D. D. Sarbassov, D. A. Guertin, S. M. Ali, and
D. M. Sabatini. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR
complex. Science (New York, N.Y.), 307(5712):10981101, February 2005. PMID:
15718470. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[465]<span
style='mso-tab-count:1'> </span>B. D. Manning and L. C. Cantley. Akt/PKB
signaling: navigating downstream. Cell, 129(7):12611274, June 2007. PMID:
17604717. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[466]<span
style='mso-tab-count:1'> </span>D. R. Alessi, M. Andjelkovic, B. Caudwell, P.
Cron, N. Morrice, P. Cohen, and B. A. Hemmings. Mechanism of activation of
protein kinase B by insulin and IGF-1. The EMBO Journal, 15(23):65416551,
December 1996. PMID: 8978681. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[467]<span
style='mso-tab-count:1'> </span>E. Jacinto, V. Facchinetti, D. Liu, N. Soto,
S. Wei, S. Y. Jung, Q. Huang, J. Qin, and B. Su. SIN1/MIP1 maintains
rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate
specificity. Cell, 127(1):125137, October 2006. PMID: 16962653. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[468]<span
style='mso-tab-count:1'> </span>J. Ruzzin and J. Jensen. Contraction activates
glucose uptake and glycogen synthase normally in muscles from
dexamethasone-treated rats. American Journal of Physiology. Endocrinology and
Metabolism, 289(2):E241250, August 2005. PMID: 15741240. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[469]<span
style='mso-tab-count:1'> </span>L. Coderre, G. A. Vallega, P. F. Pilch, and S.
R. Chipkin. Regulation of glycogen concentration and glycogen synthase activity
in skeletal muscle of insulin-resistant rats. Archives of Biochemistry and
Biophysics, 464(1):144150, August 2007. PMID: 17509520. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[470]<span
style='mso-tab-count:1'> </span>G. I. Welsh and C. G. Proud. Glycogen synthase
kinase-3 is rapidly inactivated in response to insulin and phosphorylates
eukaryotic initiation factor eIF-2B. Biochemical Journal, 294(Pt 3):625629,
September 1993. PMID: 8397507. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[471]<span
style='mso-tab-count:1'> </span>K. J. P. Verhees, A. M. W. J. Schols, M. C.
J. M. Kelders, C. M. H. Op den Kamp, J. L. J. van der Velden, and R. C. J.
Langen. Glycogen synthase kinase-3&#946; is required for the induction of
skeletal muscle atrophy. American Journal of Physiology. Cell Physiology,
301(5):C995C1007, November 2011. PMID: 21832246. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[472]<span
style='mso-tab-count:1'> </span>H. H. Zhang, A. I. Lipovsky, C. C. Dibble, M.
Sahin, and B. D. Manning. S6K1 regulates GSK3 under conditions of
mTOR-dependent feedback inhibition of Akt. Molecular cell, 24(2):185197,
October 2006. PMID: 17052453. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[473]<span
style='mso-tab-count:1'> </span>F. Dai, L. Yu, H. He, Y. Chen, J. Yu, Y.
Yang, Y. Xu, W. Ling, and S. Zhao. Human serum and glucocorticoid-inducible
kinase-like kinase (SGKL) phosphorylates glycogen syntheses kinase 3 beta
(GSK-3beta) at serine-9 through direct interaction. Biochemical and Biophysical
Research Communications, 293(4):11911196, May 2002. PMID: 12054501. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[474]<span
style='mso-tab-count:1'> </span>S. Frame and P. Cohen. GSK3 takes centre
stage more than 20 years after its discovery. Biochemical Journal, 359(Pt
1):116, October 2001. PMID: 11563964. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[475]<span
style='mso-tab-count:1'> </span>J. M. Sacheck, A. Ohtsuka, S. C. McLary, and
A. L. Goldberg. IGF-I stimulates muscle growth by suppressing protein breakdown
and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1.
American journal of physiology. Endocrinology and metabolism, 287(4):E591601,
October 2004. PMID: 15100091. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[476]<span
style='mso-tab-count:1'> </span>D. A. Guertin and D. M. Sabatini. Defining
the role of mTOR in cancer. Cancer Cell, 12(1):922, July 2007. PMID: 17613433.
</p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[477]<span
style='mso-tab-count:1'> </span>M. Laplante and D. M. Sabatini. mTOR
signaling at a glance. Journal of Cell Science, 122(20):35893594, October
2009. PMID: 19812304. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[478]<span
style='mso-tab-count:1'> </span>K. Inoki, Y. Li, T. Zhu, J. Wu, and K.-L.
Guan. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR
signalling. Nature Cell Biology, 4(9):648657, September 2002. PMID: 12172553. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[479]<span
style='mso-tab-count:1'> </span>O. J. Shah, J. C. Anthony, S. R. Kimball, and
L. S. Jefferson. Glucocorticoids oppose translational control by leucine in
skeletal muscle. American Journal of Physiology. Endocrinology and Metabolism,
279(5):E11851190, November 2000. PMID: 11052975. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[480]<span
style='mso-tab-count:1'> </span>W. Long, L. Wei, and E. J. Barrett.
Dexamethasone inhibits the stimulation of muscle protein synthesis and PHAS-I
and p70 S6-kinase phosphorylation. American Journal of Physiology.
Endocrinology and Metabolism, 280(4):E570575, April 2001. PMID: 11254463. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[481]<span
style='mso-tab-count:1'> </span>Y. Sancak, C. C. Thoreen, T. R. Peterson, R.
A. Lindquist, S. A. Kang, E. Spooner, S. A. Carr, and D. M. Sabatini. PRAS40 is
an insulin-regulated inhibitor of the mTORC1 protein kinase. Molecular Cell,
25(6):903915, March 2007. PMID: 17386266. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[482]<span
style='mso-tab-count:1'> </span>S.-L. Cai, A. R. Tee, J. D. Short, J. M.
Bergeron, J. Kim, J. Shen, R. Guo, C. L. Johnson, K. Kiguchi, and C. L. Walker.
Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane
partitioning. The Journal of Cell Biology, 173(2):279289, April 2006. PMID:
16636147. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[483]<span
style='mso-tab-count:1'> </span>H.-J. Koh, J. Brandauer, and L. J. Goodyear.
LKB1 and AMPK and the regulation of skeletal muscle metabolism. Current opinion
in clinical nutrition and metabolic care, 11(3):227232, May 2008. PMID:
18403917. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[484]<span
style='mso-tab-count:1'> </span>C. Cant and J. Auwerx. AMP-activated protein
kinase and its downstream transcriptional pathways. Cellular and molecular life
sciences : CMLS, 67(20):34073423, October 2010. PMID: 20640476. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[485]<span
style='mso-tab-count:1'> </span>S. L. U. Amaral, J. C. U. de Andrade Louzada,
T. J. Dionisio, B. A. U. Viscelli, E. J. U. Dionisio, J. R. U. Bosqueiro, and
A. M. U. Martuscelli. Opposite effects of exercise and dexamethasone on
skeletal muscle glucose uptake: Role of AMPK and CaMKII. FASEB Journal, page 1,
April 2010. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[486]<span
style='mso-tab-count:1'> </span>J.-F. Dumas, G. Bielicki, J.-P. Renou, D. Roussel,
P.-H. Ducluzeau, Y. Malthiry, G. Simard, and P. Ritz. Dexamethasone impairs
muscle energetics, studied by (31)P NMR, in rats. Diabetologia, 48(2):328335,
February 2005. PMID: 15645207. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[487]<span
style='mso-tab-count:1'> </span>K. Weber, P. Brck, Z. Mikes, J.-H. Kpper, M.
Klingenspor, and R. J. Wiesner. Glucocorticoid hormone stimulates mitochondrial
biogenesis specifically in skeletal muscle. Endocrinology, 143(1):177184,
January 2002. PMID: 11751607. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[488]<span
style='mso-tab-count:1'> </span>N. Nordsborg, C. Goodmann, M. J. McKenna, and
J. Bangsbo. Dexamethasone up-regulates skeletal muscle maximal Na+,K+ pump
activity by muscle group specific mechanisms in humans. The Journal of
physiology, 567(Pt 2):583589, September 2005. PMID: 15975987. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[489]<span
style='mso-tab-count:1'> </span>G. N. Nakken, D. L. Jacobs, D. M. Thomson, N.
Fillmore, and W. W. Winder. Effects of excess corticosterone on LKB1 and AMPK
signaling in rat skeletal muscle. Journal of Applied Physiology,
108(2):298305, February 2010. PMID: 19959768. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[490]<span
style='mso-tab-count:1'> </span>H. Wang, N. Kubica, L. W. Ellisen, L. S.
Jefferson, and S. R. Kimball. Dexamethasone represses signaling through the
mammalian target of rapamycin in muscle cells by enhancing expression of REDD1.
The Journal of Biological Chemistry, 281(51):3912839134, December 2006. PMID:
17074751. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[491]<span
style='mso-tab-count:1'> </span>F. A. Britto, G. Begue, B. Rossano, A. Docquier,
B. Vernus, C. Sar, A. Ferry, A. Bonnieu, V. Ollendorff, and F. B. Favier. REDD1
deletion prevents dexamethasone-induced skeletal muscle atrophy. American
Journal of Physiology. Endocrinology and Metabolism, page ajpendo.00234.2014,
October 2014. PMID: 25315696. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[492]<span
style='mso-tab-count:1'> </span>M. P. DeYoung, P. Horak, A. Sofer, D. Sgroi,
and L. W. Ellisen. Hypoxia regulates TSC1/2mTOR signaling and tumor
suppression through REDD1-mediated 1433 shuttling. Genes &amp; Development,
22(2):239251, January 2008. PMID: 18198340. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[493]<span
style='mso-tab-count:1'> </span>A. Sofer, K. Lei, C. M. Johannessen, and L. W.
Ellisen. Regulation of mTOR and Cell Growth in Response to Energy Stress by
REDD1. Molecular and Cellular Biology, 25(14):58345845, July 2005. PMID:
15988001. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[494]<span
style='mso-tab-count:1'> </span>A. Csibi, K. Cornille, M.-P. Leibovitch, A.
Poupon, L. A. Tintignac, A. M. J. Sanchez, and S. A. Leibovitch. The
translation regulatory subunit eIF3f controls the kinase-dependent mTOR
signaling required for muscle differentiation and hypertrophy in mouse. PloS
One, 5(2):e8994, 2010. PMID: 20126553. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[495]<span
style='mso-tab-count:1'> </span>E. Latres, A. R. Amini, A. A. Amini, J.
Griffiths, F. J. Martin, Y. Wei, H. C. Lin, G. D. Yancopoulos, and D. J. Glass.
Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes
via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin
(PI3K/Akt/mTOR) pathway. The Journal of biological chemistry, 280(4):27372744,
January 2005. PMID: 15550386. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[496]<span
style='mso-tab-count:1'> </span>N. Hosokawa, T. Hara, T. Kaizuka, C. Kishi, A.
Takamura, Y. Miura, S.-i. Iemura, T. Natsume, K. Takehana, N. Yamada, J.-L.
Guan, N. Oshiro, and N. Mizushima. Nutrient-dependent mTORC1 Association with
the ULK1Atg13FIP200 Complex Required for Autophagy. Molecular Biology of the
Cell, 20(7):19811991, April 2009. PMID: 19211835. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[497]<span
style='mso-tab-count:1'> </span>M. D. Dennis, C. S. Coleman, A. Berg, L. S.
Jefferson, and S. R. Kimball. REDD1 enhances protein phosphatase 2A-mediated
dephosphorylation of Akt to repress mTORC1 signaling. Science signaling,
7(335):ra68, July 2014. PMID: 25056877. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[498]<span
style='mso-tab-count:1'> </span>M. Canal, J. Roman Aumedes, N. Martn Flores,
V. Prez Fernndez, and C. Malagelada. RTP801/REDD1: a stress coping regulator
that turns into a troublemaker in neurodegenerative disorders. Frontiers in
Cellular Neuroscience, 8, October 2014. PMID: 25324725. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[499]<span
style='mso-tab-count:1'> </span>M. Barel, O. A. B. Perez, V. A. Giozzet, A.
Rafacho, J. R. Bosqueiro, and S. L. do Amaral. Exercise training prevents
hyperinsulinemia, muscular glycogen loss and muscle atrophy induced by
dexamethasone treatment. European Journal of Applied Physiology,
108(5):9991007, March 2010. PMID: 19967395. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[500]<span
style='mso-tab-count:1'> </span>W. Qin, J. Pan, Y. Qin, D. N. Lee, W. A.
Bauman, and C. Cardozo. Identification of functional glucocorticoid response
elements in the mouse FoxO1 promoter. Biochemical and Biophysical Research
Communications, 450(2):979983, July 2014. PMID: 24971545. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[501]<span
style='mso-tab-count:1'> </span>N. Ltzner, H. Kalbacher, A. Krones-Herzig,
and F. Rsl. FOXO3 is a glucocorticoid receptor target and regulates LKB1 and
its own expression based on cellular AMP levels via a positive autoregulatory
loop. PLoS ONE, 7(7), July 2012. PMID: 22848740. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[502]<span
style='mso-tab-count:1'> </span>D. R. Calnan and A. Brunet. The FoxO code.
Oncogene, 27(16):22762288, April 2008. PMID: 18391970. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[503]<span
style='mso-tab-count:1'> </span>M. Sandri, C. Sandri, A. Gilbert, C. Skurk, E.
Calabria, A. Picard, K. Walsh, S. Schiaffino, S. H. Lecker, and A. L. Goldberg.
Foxo transcription factors induce the atrophy-related ubiquitin ligase
atrogin-1 and cause skeletal muscle atrophy. Cell, 117(3):399412, April 2004.
PMID: 15109499. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[504]<span
style='mso-tab-count:1'> </span>A. Jones, D.-J. Hwang, R. Narayanan, D. D.
Miller, and J. T. Dalton. Effects of a novel selective androgen receptor
modulator on dexamethasone-induced and hypogonadism-induced muscle atrophy.
Endocrinology, 151(8):37063719, August 2010. PMID: 20534726. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[505]<span
style='mso-tab-count:1'> </span>S. R. Jesinkey, M. C. Korrapati, K. A.
Rasbach, C. C. Beeson, and R. G. Schnellmann. Atomoxetine prevents
dexamethasone-induced skeletal muscle atrophy in mice. The Journal of
Pharmacology and Experimental Therapeutics, 351(3):663673, December 2014.
PMID: 25292181. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[506]<span
style='mso-tab-count:1'> </span>C. Ling, P. Poulsen, E. Carlsson, M.
Ridderstrle, P. Almgren, J. Wojtaszewski, H. Beck-Nielsen, L. Groop, and A.
Vaag. Multiple environmental and genetic factors influence skeletal muscle
PGC-1&#945; and PGC-1&#946; gene expression in twins. Journal of Clinical
Investigation, 114(10):15181526, November 2004. PMID: 15546003. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[507]<span
style='mso-tab-count:1'> </span>M. J. Menconi, Z. P. Arany, N. Alamdari, Z.
Aversa, P. Gonnella, P. ONeal, I. J. Smith, S. Tizio, and P.-O. Hasselgren. Sepsis
and glucocorticoids downregulate the expression of the nuclear cofactor
PGC-1beta in skeletal muscle. American journal of physiology. Endocrinology and
metabolism, 299(4):E533543, October 2010. PMID: 20647557. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[508]<span
style='mso-tab-count:1'> </span>J. L. Ruas, J. P. White, R. R. Rao, S.
Kleiner, K. T. Brannan, B. C. Harrison, N. P. Greene, J. Wu, J. L. Estall, B.
A. Irving, I. R. Lanza, K. A. Rasbach, M. Okutsu, K. S. Nair, Z. Yan, L. A.
Leinwand, and B. M. Spiegelman. A PGC-1alpha isoform induced by resistance
training regulates skeletal muscle hypertrophy. Cell, 151(6):13191331,
December 2012. PMID: 23217713. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[509]<span
style='mso-tab-count:1'> </span>E. Castillero, N. Alamdari, Z. Aversa, A.
Gurav, and P.-O. Hasselgren. PPAR&#946;/&#948; regulates glucocorticoid- and
sepsis-induced FOXO1 activation and muscle wasting. PLoS ONE, 8(3), March 2013.
PMID: 23555761. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[510]<span
style='mso-tab-count:1'> </span>H. Daitoku, J.-I. Sakamaki, and A. Fukamizu.
Regulation of FoxO transcription factors by acetylation and protein-protein
interactions. Biochimica Et Biophysica Acta, 1813(11):19541960, November 2011.
PMID: 21396404. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[511]<span
style='mso-tab-count:1'> </span>J. Nakae, M. Oki, and Y. Cao. The FoxO
transcription factors and metabolic regulation. FEBS letters, 582(1):5467,
January 2008. PMID: 18022395. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[512]<span
style='mso-tab-count:1'> </span>M. B. Hudson, J. A. Rahnert, B. Zheng, M. E.
Woodworth-Hobbs, H. A. Franch, and S. R. Price. miR-182 attenuates
atrophy-related gene expression by targeting FoxO3 in skeletal muscle. American
Journal of Physiology. Cell Physiology, May 2014. PMID: 24871856. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[513]<span
style='mso-tab-count:1'> </span>P. A. King, L. Goldstein, and E. A.
Newsholme. Glutamine synthetase activity of muscle in acidosis. Biochemical
Journal, 216(2):523525, November 1983. PMID: 6140920. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[514]<span
style='mso-tab-count:1'> </span>Y. Kamei, M. Hattori, Y. Hatazawa, T.
Kasahara, M. Kanou, S. Kanai, X. Yuan, T. Suganami, W. H. Lamers, T. Kitamura,
and Y. Ogawa. FOXO1 activates glutamine synthetase gene in mouse skeletal
muscles through a region downstream of 3-UTR: possible contribution to ammonia
detoxification. American Journal of Physiology. Endocrinology and Metabolism,
307(6):E485493, September 2014. PMID: 25074987. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[515]<span
style='mso-tab-count:1'> </span>S. M. Senf, S. L. Dodd, and A. R. Judge. FOXO
signaling is required for disuse muscle atrophy and is directly regulated by
Hsp70. American Journal of Physiology. Cell Physiology, 298(1):C3845, January
2010. PMID: 19864323. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[516]<span
style='mso-tab-count:1'> </span>M. Sandri, J. Lin, C. Handschin, W. Yang, Z.
P. Arany, S. H. Lecker, A. L. Goldberg, and B. M. Spiegelman. PGC-1alpha
protects skeletal muscle from atrophy by suppressing FoxO3 action and
atrophy-specific gene transcription. Proceedings of the National Academy of
Sciences of the United States of America, 103(44):1626016265, October 2006.
PMID: 17053067. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[517]<span
style='mso-tab-count:1'> </span>L. M. Bollinger, C. A. Witczak, J. A.
Houmard, and J. J. Brault. SMAD3 augments FoxO3-induced MuRF-1 promoter
activity in a DNA-binding-dependent manner. American Journal of Physiology.
Cell Physiology, 307(3):C278287, August 2014. PMID: 24920680. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[518]<span
style='mso-tab-count:1'> </span>N. Shimizu, N. Yoshikawa, N. Ito, T.
Maruyama, Y. Suzuki, S.-i. Takeda, J. Nakae, Y. Tagata, S. Nishitani, K.
Takehana, M. Sano, K. Fukuda, M. Suematsu, C. Morimoto, and H. Tanaka. Crosstalk
between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle.
Cell Metabolism, 13(2):170182, February 2011. PMID: 21284984. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[519]<span
style='mso-tab-count:1'> </span>S. M. Senf, S. L. Dodd, J. M. McClung, and A.
R. Judge. Hsp70 overexpression inhibits NF-kappaB and Foxo3a transcriptional
activities and prevents skeletal muscle atrophy. FASEB journal: official
publication of the Federation of American Societies for Experimental Biology,
22(11):38363845, November 2008. PMID: 18644837. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[520]<span
style='mso-tab-count:1'> </span>I. J. Smith, N. Alamdari, P. ONeal, P.
Gonnella, Z. Aversa, and P.-O. Hasselgren. Sepsis increases the expression and
activity of the transcription factor Forkhead Box O 1 (FOXO1) in skeletal
muscle by a glucocorticoid-dependent mechanism. The international journal of
biochemistry &amp; cell biology, 42(5):701711, May 2010. PMID: 20079455. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[521]<span
style='mso-tab-count:1'> </span>K. S. Bongers, D. K. Fox, S. M. Ebert, S. D.
Kunkel, M. C. Dyle, S. A. Bullard, J. M. Dierdorff, and C. M. Adams. Skeletal
muscle denervation causes skeletal muscle atrophy through a pathway that
involves both Gadd45a and HDAC4. American Journal of Physiology - Endocrinology
and Metabolism, 305(7):E907E915, October 2013. PMID: 23941879. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[522]<span
style='mso-tab-count:1'> </span>K. Ma, C. Mallidis, S. Bhasin, V. Mahabadi,
J. Artaza, N. Gonzalez-Cadavid, J. Arias, and B. Salehian.
Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation
of myostatin gene expression. American Journal of Physiology. Endocrinology and
Metabolism, 285(2):E363371, August 2003. PMID: 12721153. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[523]<span
style='mso-tab-count:1'> </span>D. L. Allen and T. G. Unterman. Regulation of
myostatin expression and myoblast differentiation by FoxO and SMAD
transcription factors. American Journal of Physiology. Cell Physiology,
292(1):C188199, January 2007. PMID: 16885393. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[524]<span
style='mso-tab-count:1'> </span>D. L. Allen, A. S. Cleary, A. M. Hanson, S.
F. Lindsay, and J. M. Reed. CCAAT/enhancer binding protein-delta expression is
increased in fast skeletal muscle by food deprivation and regulates myostatin
transcription in vitro. American Journal of Physiology. Regulatory, Integrative
and Comparative Physiology, 299(6):R15921601, December 2010. <span lang=IT
style='mso-ansi-language:IT'>PMID: 20844262. <o:p></o:p></span></p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'><span lang=IT
style='mso-ansi-language:IT'>[525]<span style='mso-tab-count:1'> </span>V.
Proserpio, R. Fittipaldi, J. G. Ryall, V. Sartorelli, and G. Caretti. </span>The
methyltransferase SMYD3 mediates the recruitment of transcriptional cofactors
at the myostatin and c-Met genes and regulates skeletal muscle atrophy. Genes
&amp; development, 27(11):12991312, June 2013. PMID: 23752591. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[526]<span
style='mso-tab-count:1'> </span>D. L. Allen and A. S. Loh. Posttranscriptional
mechanisms involving microRNA-27a and b contribute to fast-specific and
glucocorticoid-mediated myostatin expression in skeletal muscle. American
journal of physiology. Cell physiology, 300(1):C124137, January 2011. PMID:
20980549. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[527]<span
style='mso-tab-count:1'> </span>B. Salehian, V. Mahabadi, J. Bilas, W. E.
Taylor, and K. Ma. The effect of glutamine on prevention of
glucocorticoid-induced skeletal muscle atrophy is associated with myostatin
suppression. Metabolism: clinical and experimental, 55(9):12391247, September
2006. PMID: 16919545. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[528]<span
style='mso-tab-count:1'> </span>T. A. Zimmers, M. V. Davies, L. G. Koniaris,
P. Haynes, A. F. Esquela, K. N. Tomkinson, A. C. McPherron, N. M. Wolfman, and
S.-J. Lee. Induction of cachexia in mice by systemically administered
myostatin. Science (New York, N.Y.), 296(5572):14861488, May 2002. PMID:
12029139. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[529]<span
style='mso-tab-count:1'> </span>R. Sartori, G. Milan, M. Patron, C.
Mammucari, B. Blaauw, R. Abraham, and M. Sandri. Smad2 and 3 transcription
factors control muscle mass in adulthood. American Journal of Physiology. Cell
Physiology, 296(6):C12481257, June 2009. PMID: 19357234. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[530]<span
style='mso-tab-count:1'> </span>A. Amirouche, A.-C. Durieux, S. Banzet, N.
Koulmann, R. Bonnefoy, C. Mouret, X. Bigard, A. Peinnequin, and D. Freyssenet.
Down-regulation of Akt/mammalian target of rapamycin signaling pathway in
response to myostatin overexpression in skeletal muscle. Endocrinology,
150(1):286294, January 2009. PMID: 18801898. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[531]<span
style='mso-tab-count:1'> </span>S. McCroskery, M. Thomas, L. Maxwell, M.
Sharma, and R. Kambadur. Myostatin negatively regulates satellite cell
activation and self-renewal. The Journal of Cell Biology, 162(6):11351147,
September 2003. PMID: 12963705. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[532]<span
style='mso-tab-count:1'> </span>T. V. Cohen, H. D. Kollias, N. Liu, C. W.
Ward, and K. R. Wagner. Genetic disruption of Smad7 impairs skeletal muscle
growth and regeneration. The Journal of Physiology, April 2015. PMID: 25854148.
</p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[533]<span
style='mso-tab-count:1'> </span>A. U. Trendelenburg, A. Meyer, D. Rohner, J.
Boyle, S. Hatakeyama, and D. J. Glass. Myostatin reduces Akt/TORC1/p70S6K
signaling, inhibiting myoblast differentiation and myotube size. American
Journal of Physiology. Cell Physiology, 296(6):C12581270, June 2009. PMID:
19357233. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[534]<span
style='mso-tab-count:1'> </span>R. Lalani, S. Bhasin, F. Byhower, R.
Tarnuzzer, M. Grant, R. Shen, S. Asa, S. Ezzat, and N. F. Gonzalez-Cadavid.
Myostatin and insulin-like growth factor-I and -II expression in the muscle of
rats exposed to the microgravity environment of the NeuroLab space shuttle
flight. The Journal of Endocrinology, 167(3):417428, December 2000. PMID:
11115768. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[535]<span
style='mso-tab-count:1'> </span>M. Nozaki, Y. Li, J. Zhu, F. Ambrosio, K.
Uehara, F. H. Fu, and J. Huard. Improved muscle healing after contusion injury
by the inhibitory effect of suramin on myostatin, a negative regulator of
muscle growth. The American Journal of Sports Medicine, 36(12):23542362,
December 2008. PMID: 18725651. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[536]<span
style='mso-tab-count:1'> </span>G. Carnac, B. Vernus, and A. Bonnieu.
Myostatin in the pathophysiology of skeletal muscle. Current Genomics,
8(7):415422, November 2007. PMID: 19412331. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[537]<span
style='mso-tab-count:1'> </span>B. Elliott, D. Renshaw, S. Getting, and R.
Mackenzie. The central role of myostatin in skeletal muscle and whole body
homeostasis. Acta Physiologica (Oxford, England), 205(3):324340, July 2012.
PMID: 22340904. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[538]<span
style='mso-tab-count:1'> </span>R. F. Peters, M. C. Richardson, M. Small, and
A. M. White. Some biochemical effects of triamcinolone acetonide on rat liver
and muscle. Biochemical Journal, 116(3):349355, February 1970. PMID: 5435682. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[539]<span
style='mso-tab-count:1'> </span>I. Rieu, C. Sornet, J. Grizard, and D.
Dardevet. Glucocorticoid excess induces a prolonged leucine resistance on
muscle protein synthesis in old rats. Experimental Gerontology,
39(9):13151321, September 2004. PMID: 15489054. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[540]<span
style='mso-tab-count:1'> </span>I. Savary, E. Debras, D. Dardevet, C. Sornet,
P. Capitan, J. Prugnaud, P. P. Mirand, and J. Grizard. Effect of glucocorticoid
excess on skeletal muscle and heart protein synthesis in adult and old rats.
The British Journal of Nutrition, 79(3):297304, March 1998. PMID: 9577308. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[541]<span
style='mso-tab-count:1'> </span>O. J. Shah, S. R. Kimball, and L. S.
Jefferson. Glucocorticoids abate p70S6k and eIF4E function in L6 skeletal
myoblasts. American Journal of Physiology. Endocrinology and Metabolism,
279(1):E74E82, July 2000. <span lang=IT style='mso-ansi-language:IT'>PMID:
10893325. <o:p></o:p></span></p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'><span lang=IT
style='mso-ansi-language:IT'>[542]<span style='mso-tab-count:1'> </span>Z.
Aversa, N. Alamdari, E. Castillero, M. Muscaritoli, F. Rossi Fanelli, and P.-O.
Hasselgren. </span>Beta-Hydroxy-beta-methylbutyrate (HMB) prevents
dexamethasone-induced myotube atrophy. Biochemical and biophysical research
communications, 423(4):739743, July 2012. PMID: 22705301. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[543]<span
style='mso-tab-count:1'> </span>M. M. Desler, S. J. Jones, C. W. Smith, and
T. L. Woods. Effects of dexamethasone and anabolic agents on proliferation and
protein synthesis and degradation in C2C12 myogenic cells. Journal of animal
science, 74(6):12651273, June 1996. PMID: 8791198. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[544]<span
style='mso-tab-count:1'> </span>K. L. Jones, J. Harty, M. J. Roeder, T. A.
Winters, and W. J. Banz. In vitro effects of soy phytoestrogens on rat L6
skeletal muscle cells. Journal of medicinal food, 8(3):327331, 2005. PMID:
16176142. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[545]<span
style='mso-tab-count:1'> </span>V. R. Young, S. C. Chen, and J. Macdonald.
The sedimentation of rat skeletal-muscle ribosomes. Effect of hydrocortisone,
insulin and diet. Biochemical Journal, 106(4):913919, February 1968. PMID:
5637371. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[546]<span
style='mso-tab-count:1'> </span>H. Bai, P. Kang, A. M. Hernandez, and M.
Tatar. Activin signaling targeted by insulin/dFOXO regulates aging and muscle
proteostasis in drosophila. PLoS Genetics, 9(11), November 2013. PMID:
24244197. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[547]<span
style='mso-tab-count:1'> </span>M. Livingstone and M. Bidinosti.
Rapamycin-insensitive mTORC1 activity controls eIF4E:4E-BP1 binding. F1000Research,
1, July 2012. PMID: 24358826. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[548]<span
style='mso-tab-count:1'> </span>S.-I. Hu, M. Katz, S. Chin, X. Qi, J. Cruz, C.
Ibebunjo, S. Zhao, A. Chen, and D. J. Glass. MNK2 inhibits eIF4G activation
through a pathway involving serine-arginine-rich protein kinase in skeletal
muscle. Science signaling, 5(211):ra14, February 2012. PMID: 22337810. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[549]<span
style='mso-tab-count:1'> </span>T. C. Vary and C. J. Lynch. Nutrient
signaling components controlling protein synthesis in striated muscle. The
Journal of Nutrition, 137(8):18351843, August 2007. PMID: 17634251. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[550]<span
style='mso-tab-count:1'> </span>J. Gallinetti, E. Harputlugil, and J. R.
Mitchell. Amino acid sensing in dietary-restriction-mediated longevity: roles
of signal-transducing kinases GCN2 and TOR. The Biochemical journal,
449(1):110, January 2013. PMID: 23216249. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[551]<span
style='mso-tab-count:1'> </span>J. J. Berlanga, J. Santoyo, and C. De Haro.
Characterization of a mammalian homolog of the GCN2 eukaryotic initiation
factor 2alpha kinase. European journal of biochemistry / FEBS, 265(2):754762,
October 1999. PMID: 10504407. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[552]<span
style='mso-tab-count:1'> </span>M. Gross, M. Wing, C. Rundquist, and M. S.
Rubino. Evidence that phosphorylation of eIF-2(alpha) prevents the
eIF-2B-mediated dissociation of eIF-2 X GDP from the 60 S subunit of complete
initiation complexes. The Journal of Biological Chemistry, 262(14):68996907,
May 1987. PMID: 3646234. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[553]<span
style='mso-tab-count:1'> </span>R. Sood, A. C. Porter, D. A. Olsen, D. R.
Cavener, and R. C. Wek. A mammalian homologue of GCN2 protein kinase important
for translational control by phosphorylation of eukaryotic initiation
factor-2alpha. Genetics, 154(2):787801, February 2000. PMID: 10655230. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[554]<span
style='mso-tab-count:1'> </span>A. Gjymishka, N. Su, and M. S. Kilberg.
Transcriptional induction of the human asparagine synthetase gene during the
unfolded protein response does not require the ATF6 and IRE1/XBP1 arms of the
pathway. The Biochemical journal, 417(3):695703, February 2009. PMID:
18840095. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[555]<span
style='mso-tab-count:1'> </span>S. M. Ebert, M. C. Dyle, S. D. Kunkel, S. A.
Bullard, K. S. Bongers, D. K. Fox, J. M. Dierdorff, E. D. Foster, and C. M.
Adams. Stress-induced skeletal muscle Gadd45a expression reprograms myonuclei
and causes muscle atrophy. The Journal of Biological Chemistry,
287(33):2729027301, August 2012. PMID: 22692209. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[556]<span
style='mso-tab-count:1'> </span>C. M. Adams. Role of the transcription factor
ATF4 in the anabolic actions of insulin and the anti-anabolic actions of
glucocorticoids. The Journal of Biological Chemistry, 282(23):1674416753, June
2007. PMID: 17430894. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[557]<span
style='mso-tab-count:1'> </span>S. Rossi, E. Stoppani, W. Martinet, A.
Bonetto, P. Costelli, R. Giuliani, F. Colombo, A. Preti, S. Marchesini, and A.
Fanzani. The cytosolic sialidase Neu2 is degraded by autophagy during myoblast
atrophy. Biochimica Et Biophysica Acta, 1790(8):817828, August 2009. PMID:
19371771. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[558]<span
style='mso-tab-count:1'> </span>C. Deval, S. Mordier, C. Obled, D. Bechet, L.
Combaret, D. Attaix, and M. Ferrara. Identification of cathepsin L as a
differentially expressed message associated with skeletal muscle wasting. The
Biochemical Journal, 360(Pt 1):143150, November 2001. PMID: 11696001. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[559]<span
style='mso-tab-count:1'> </span>N. Mizushima and T. Yoshimori. How to
interpret LC3 immunoblotting. Autophagy, 3(6):542545, December 2007. PMID:
17611390. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[560]<span
style='mso-tab-count:1'> </span>R. Troncoso, F. Paredes, V. Parra, D. Gatica,
C. Vsquez Trincado, C. Quiroga, R. Bravo-Sagua, C. Lpez Crisosto, A. E.
Rodriguez, A. P. Oyarzn, G. Kroemer, and S. Lavandero. Dexamethasone-induced
autophagy mediates muscle atrophy through mitochondrial clearance. Cell Cycle
(Georgetown, Tex.), 13(14):22812295, July 2014. PMID: 24897381. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[561]<span
style='mso-tab-count:1'> </span>D. Yamamoto, T. Maki, E. H. Herningtyas, N.
Ikeshita, H. Shibahara, Y. Sugiyama, S. Nakanishi, K. Iida, G. Iguchi, Y.
Takahashi, H. Kaji, K. Chihara, and Y. Okimura. Branched-chain amino acids
protect against dexamethasone-induced soleus muscle atrophy in rats. Muscle
&amp; Nerve, 41(6):819827, June 2010. PMID: 20169591. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[562]<span
style='mso-tab-count:1'> </span>H. P. Rodemann, L. Waxman, and A. L.
Goldberg. The stimulation of protein degradation in muscle by Ca2+ is mediated
by prostaglandin E2 and does not require the calcium-activated protease. The Journal
of Biological Chemistry, 257(15):87168723, August 1982. PMID: 6807980. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[563]<span
style='mso-tab-count:1'> </span>K. Furuno and A. L. Goldberg. The activation
of protein degradation in muscle by Ca2+ or muscle injury does not involve a
lysosome mechanism. The Biochemical Journal, 237(3):859864, August 1986. PMID:
3099758. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[564]<span
style='mso-tab-count:1'> </span>E. V. Kachaeva and B. S. Shenkman. Various
jobs of proteolytic enzymes in skeletal muscle during unloading: facts and
speculations. Journal of biomedicine &amp; biotechnology, 2012:493618, 2012.
PMID: 22496611. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[565]<span
style='mso-tab-count:1'> </span>J. G. Tidball and M. J. Spencer. Expression
of a calpastatin transgene slows muscle wasting and obviates changes in myosin
isoform expression during murine muscle disuse. The Journal of Physiology,
545(Pt 3):819828, December 2002. PMID: 12482888. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[566]<span
style='mso-tab-count:1'> </span>M. U. Fareed, A. R. Evenson, W. Wei, M.
Menconi, V. Poylin, V. Petkova, B. Pignol, and P.-O. Hasselgren. Treatment of
rats with calpain inhibitors prevents sepsis-induced muscle proteolysis
independent of atrogin-1/MAFbx and MuRF1 expression. American Journal of
Physiology. Regulatory, Integrative and Comparative Physiology,
290(6):R15891597, June 2006. PMID: 16455766. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[567]<span
style='mso-tab-count:1'> </span>K. Itagaki, M. Menconi, B. Antoniu, Q. Zhang,
P. Gonnella, D. Soybel, C. Hauser, and P.-O. Hasselgren. Dexamethasone
stimulates store-operated calcium entry and protein degradation in cultured L6
myotubes through a phospholipase A(2)-dependent mechanism. American journal of
physiology. Cell physiology, 298(5):C11271139, May 2010. PMID: 20107037. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[568]<span
style='mso-tab-count:1'> </span>D. E. Goll, V. F. Thompson, H. Li, W. Wei, and
J. Cong. The calpain system. Physiological Reviews, 83(3):731801, July 2003.
PMID: 12843408. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[569]<span
style='mso-tab-count:1'> </span>S. H. Lecker, R. T. Jagoe, A. Gilbert, M.
Gomes, V. Baracos, J. Bailey, S. R. Price, W. E. Mitch, and A. L. Goldberg.
Multiple types of skeletal muscle atrophy involve a common program of changes
in gene expression. The FASEB Journal: Official Publication of the Federation
of American Societies for Experimental Biology, 18(1):3951, January 2004.
PMID: 14718385. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[570]<span
style='mso-tab-count:1'> </span>F. J. Ballard and G. L. Francis. Effects of
anabolic agents on protein breakdown in L6 myoblasts. The Biochemical journal,
210(1):243249, January 1983. PMID: 6342615. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[571]<span
style='mso-tab-count:1'> </span>D. Z. Ewton and J. R. Florini. Effects of the
somatomedins and insulin on myoblast differentiation in vitro. Developmental
Biology, 86(1):3139, August 1981. PMID: 6169566. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[572]<span
style='mso-tab-count:1'> </span>P. Elsner, B. Quistorff, T. S. Hermann, J.
Dich, and N. Grunnet. Regulation of glycogen accumulation in L6 myotubes
cultured under optimized differentiation conditions. The American journal of
physiology, 275(6 Pt 1):E925933, December 1998. PMID: 9843733. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[573]<span
style='mso-tab-count:1'> </span>O. Schakman, H. Gilson, V. de Coninck, P.
Lause, J. Verniers, X. Havaux, J. M. Ketelslegers, and J. P. Thissen.
Insulin-like growth factor-I gene transfer by electroporation prevents skeletal
muscle atrophy in glucocorticoid-treated rats. Endocrinology, 146(4):17891797,
April 2005. PMID: 15661854. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[574]<span
style='mso-tab-count:1'> </span>F. Kanda, K. Takatani, S. Okuda, T.
Matsushita, and K. Chihara. Preventive effects of insulinlike growth factor-I
on steroid-induced muscle atrophy. Muscle &amp; Nerve, 22(2):213217, February
1999. PMID: 10024134. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[575]<span
style='mso-tab-count:1'> </span>D. Chrysis, J. Zhang, and L. E. Underwood.
Divergent regulation of proteasomes by insulin-like growth factor I and growth
hormone in skeletal muscle of rats made catabolic with dexamethasone. Growth
hormone &amp; IGF research: official journal of the Growth Hormone Research
Society and the International IGF Research Society, 12(6):434441, December
2002. PMID: 12423629. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[576]<span
style='mso-tab-count:1'> </span>D. Chrysis and L. E. Underwood. Regulation of
components of the ubiquitin system by insulin-like growth factor I and growth
hormone in skeletal muscle of rats made catabolic with dexamethasone.
Endocrinology, 140(12):56355641, December 1999. PMID: 10579327. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[577]<span
style='mso-tab-count:1'> </span>K. Kimura, F. Kanda, S. Okuda, and K.
Chihara. Insulin-like growth factor 1 inhibits glucocorticoid-induced glutamine
synthetase activity in cultured L6 rat skeletal muscle cells. Neuroscience
letters, 302(2-3):154156, April 2001. PMID: 11290410. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[578]<span
style='mso-tab-count:1'> </span>G. Gayan-Ramirez, F. Vanderhoydonc, G.
Verhoeven, and M. Decramer. Acute treatment with corticosteroids decreases
IGF-1 and IGF-2 expression in the rat diaphragm and gastrocnemius. American
Journal of Respiratory and Critical Care Medicine, 159(1):283289, January
1999. PMID: 9872851. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[579]<span
style='mso-tab-count:1'> </span>B. J. Petrof, S. B. Gottfried, J. Eby, J.
Lamanca, and S. Levine. Growth hormone does not prevent corticosteroid-induced
changes in rat diaphragm structure and function. Journal of Applied Physiology
(Bethesda, Md.: 1985), 79(5):15711577, November 1995. PMID: 8594016. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[580]<span
style='mso-tab-count:1'> </span>L. S. Quinn, B. G. Anderson, and S. R.
Plymate. Muscle-specific overexpression of the type 1 IGF receptor results in
myoblast-independent muscle hypertrophy via PI3K, and not calcineurin,
signaling. American journal of physiology. Endocrinology and metabolism,
293(6):E15381551, December 2007. PMID: 17940216. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[581]<span
style='mso-tab-count:1'> </span>B.-G. Li, P.-O. Hasselgren, C.-H. Fang, and
G. D. Warden. Insulin-like growth factor-I blocks dexamethasone-induced protein
degradation in cultured myotubes by inhibiting multiple proteolytic pathways:
2002 ABA paper. The Journal of burn care &amp; rehabilitation, 25(1):112118,
February 2004. PMID: 14726748. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[582]<span
style='mso-tab-count:1'> </span>B.-G. Li, P.-O. Hasselgren, and C.-H. Fang.
Insulin-like growth factor-I inhibits dexamethasone-induced proteolysis in
cultured L6 myotubes through PI3K/Akt/GSK-3beta and PI3K/Akt/mTOR-dependent
mechanisms. The International Journal of Biochemistry &amp; Cell Biology,
37(10):22072216, October 2005. PMID: 15927518. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[583]<span
style='mso-tab-count:1'> </span>O. J. Shah, S. R. Kimball, and L. S. Jefferson.
Among translational effectors, p70S6k is uniquely sensitive to inhibition by
glucocorticoids. The Biochemical Journal, 347(Pt 2):389397, April 2000. PMID:
10749668. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[584]<span
style='mso-tab-count:1'> </span>G. Pallafacchina, E. Calabria, A. L. Serrano,
J. M. Kalhovde, and S. Schiaffino. A protein kinase B-dependent and
rapamycin-sensitive pathway controls skeletal muscle growth but not fiber type
specification. Proceedings of the National Academy of Sciences of the United
States of America, 99(14):92139218, July 2002. PMID: 12084817. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[585]<span
style='mso-tab-count:1'> </span>E. E. Spangenburg, D. Le Roith, C. W. Ward,
and S. C. Bodine. A functional insulin-like growth factor receptor is not
necessary for load-induced skeletal muscle hypertrophy. The Journal of
Physiology, 586(Pt 1):283291, January 2008. PMID: 17974583. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[586]<span
style='mso-tab-count:1'> </span>A. R. Evenson, M. U. Fareed, M. J. Menconi, J.
C. Mitchell, and P.-O. Hasselgren. GSK-3beta inhibitors reduce protein
degradation in muscles from septic rats and in dexamethasone-treated myotubes.
The International Journal of Biochemistry &amp; Cell Biology, 37(10):22262238,
October 2005. PMID: 16051512. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[587]<span
style='mso-tab-count:1'> </span>R. A. Frost, D. Huber, A. Pruznak, and C. H.
Lang. Regulation of REDD1 by insulin-like growth factor-I in skeletal muscle
and myotubes. Journal of cellular biochemistry, 108(5):11921202, December
2009. PMID: 19795384. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[588]<span
style='mso-tab-count:1'> </span>N. G. Williams, J. P. Interlichia, M. F.
Jackson, D. Hwang, P. Cohen, and B. D. Rodgers. Endocrine actions of myostatin:
systemic regulation of the IGF and IGF binding protein axis. Endocrinology,
152(1):172180, January 2011. PMID: 21147879. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[589]<span
style='mso-tab-count:1'> </span>R. Courrier and M. Marois. Relations entre la
testostrone et la cortisone dans leurs effets sur certains organes rcepteurs.
Comptes rendus hebdomadaires des sances de lAcadmie des sciences,
234(3):271, 1952. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[590]<span
style='mso-tab-count:1'> </span>F. O. Levy, A. H. Ree, L. Eikvar, M. V.
Govindan, T. Jahnsen, and V. Hansson. Glucocorticoid receptors and
glucocorticoid effects in rat Sertoli cells. Endocrinology, 124(1):430436,
January 1989. PMID: 2909375. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[591]<span
style='mso-tab-count:1'> </span>E. Dahlberg, M. Snochowski, and J. A.
Gustafsson. Regulation of the androgen and glucocorticoid receptors in rat and
mouse skeletal muscle cytosol. Endocrinology, 108(4):14311440, April 1981.
PMID: 6970661. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[592]<span
style='mso-tab-count:1'> </span>M. Mayer and F. Rosen. Interaction of
anabolic steroids with glucocorticoid receptor sites in rat muscle cytosol. The
American Journal of Physiology, 229(5):13811386, November 1975. PMID: 173192. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[593]<span
style='mso-tab-count:1'> </span>M. Snochowski, E. Dahlberg, and J. A.
Gustafsson. Characterization and quantification of the androgen and
glucocorticoid receptors in cytosol from rat skeletal muscle. European journal
of biochemistry / FEBS, 111(2):603616, October 1980. PMID: 6970125. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[594]<span
style='mso-tab-count:1'> </span>G. T. Ferguson. Effects of cortisone and
testosterone on diaphragmatic function and biochemistry in the rabbit. Journal
of Applied Physiology (Bethesda, Md.: 1985), 78(4):14591468, April 1995. PMID:
7615456. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[595]<span
style='mso-tab-count:1'> </span>R. H. Van Balkom, P. N. Dekhuijzen, H. T.
Folgering, J. H. Veerkamp, H. T. Van Moerkerk, J. A. Fransen, and C. L. Van
Herwaarden. Anabolic steroids in part reverse glucocorticoid-induced
alterations in rat diaphragm. Journal of Applied Physiology (Bethesda, Md.:
1985), 84(5):14921499, May 1998. PMID: 9572790. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[596]<span
style='mso-tab-count:1'> </span>J. M. Eason, S. L. Dodd, and S. K. Powers.
Use of anabolic steroids to attenuate the effects of glucocorticoids on the rat
diaphragm. Physical Therapy, 83(1):2936, January 2003. PMID: 12495410. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[597]<span
style='mso-tab-count:1'> </span>G. Bullock, A. M. White, and J. Worthington.
The effects of catabolic and anabolic steroids on amino acid incorporation by
skeletal-muscle ribosomes. Biochemical Journal, 108(3):417425, July 1968.
PMID: 5673936. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[598]<span
style='mso-tab-count:1'> </span>R. A. Roeder, S. D. Thorpe, F. M. Byers, G. T.
Schelling, and J. M. Gunn. Influence of anabolic agents on protein synthesis and
degradation in muscle cells grown in culture. Growth, 50(4):485495, 1986.
PMID: 3596326. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[599]<span
style='mso-tab-count:1'> </span>F. Ye, S. C. McCoy, H. H. Ross, J. A.
Bernardo, A. W. Beharry, S. M. Senf, A. R. Judge, D. T. Beck, C. F. Conover, D.
F. Cannady, B. K. Smith, J. F. Yarrow, and S. E. Borst. Transcriptional
regulation of myotrophic actions by testosterone and trenbolone on
androgen-responsive muscle. Steroids, 87:5966, September 2014. PMID: 24928725.
</p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[600]<span
style='mso-tab-count:1'> </span>D. C. DuBois and R. R. Almon. Perineal
muscles: possible androgen regulation of glucocorticoid receptor sites in the
rat. The Journal of Endocrinology, 102(2):225229, August 1984. PMID: 6747500. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[601]<span
style='mso-tab-count:1'> </span>A. E. Rigamonti, L. Locatelli, S. G. Cella,
S. M. Bonomo, M. Giunta, F. Molinari, A. Sartorio, and E. E. Mller. Muscle expressions
of MGF, IGF-IEa, and myostatin in intact and hypophysectomized rats: effects of
rhGH and testosterone alone or combined. Hormone and Metabolic Research =
Hormon- Und Stoffwechselforschung = Hormones Et Mtabolisme, 41(1):2329,
January 2009. PMID: 18841527. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[602]<span
style='mso-tab-count:1'> </span>Y. Wu, J. Zhao, W. Zhao, J. Pan, W. A. Bauman,
and C. P. Cardozo. Nandrolone normalizes determinants of muscle mass and fiber
type after spinal cord injury. Journal of Neurotrauma, 29(8):16631675, May
2012. PMID: 22208735. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[603]<span
style='mso-tab-count:1'> </span>C. Serra, N. L. Sandor, H. Jang, D. Lee, G.
Toraldo, T. Guarneri, S. Wong, A. Zhang, W. Guo, R. Jasuja, and S. Bhasin. The
effects of testosterone deprivation and supplementation on proteasome and
autophagy activity in the skeletal muscle of the male mouse: differential
effects on high-androgen responder and low-androgen responder muscle groups.
Endocrinology, 154(12):45944606, December 2013. PMID: 24105483. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[604]<span
style='mso-tab-count:1'> </span>H.-N. Yin, J.-K. Chai, Y.-M. Yu, C.-A. Shen,
Y.-Q. Wu, Y.-M. Yao, H. Liu, L.-M. Liang, R. G. Tompkins, and Z.-Y. Sheng.
Regulation of signaling pathways downstream of IGF-I/insulin by androgen in
skeletal muscle of glucocorticoid-treated rats. The Journal of Trauma,
66(4):10831090, April 2009. PMID: 19359918. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[605]<span
style='mso-tab-count:1'> </span>W. Zhao, J. Pan, Z. Zhao, Y. Wu, W. A. Bauman,
and C. P. Cardozo. Testosterone protects against dexamethasone-induced muscle
atrophy, protein degradation and MAFbx upregulation. The Journal of steroid
biochemistry and molecular biology, 110(1-2):125129, May 2008. PMID: 18436443.
</p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[606]<span
style='mso-tab-count:1'> </span>W. Zhao, J. Pan, X. Wang, Y. Wu, W. A. Bauman,
and C. P. Cardozo. Expression of the muscle atrophy factor muscle atrophy F-box
is suppressed by testosterone. Endocrinology, 149(11):54495460, November 2008.
PMID: 18599544. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[607]<span
style='mso-tab-count:1'> </span>J. T. McFarlan, Y. Yoshida, S. S. Jain, X.-X.
Han, L. A. Snook, J. Lally, B. K. Smith, J. F. C. Glatz, J. J. F. P. Luiken, R.
A. Sayer, A. R. Tupling, A. Chabowski, G. P. Holloway, and A. Bonen. In vivo,
Fatty Acid Translocase (CD36) critically regulates skeletal muscle fuel selection,
exercise performance, and training-induced adaptation of fatty acid oxidation.
The Journal of Biological Chemistry, 287(28):2350223516, July 2012. PMID:
22584574. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[608]<span
style='mso-tab-count:1'> </span>E. Keil, R. Hcker, M. Schuster, F. Essmann,
N. Ueffing, B. Hoffman, D. A. Liebermann, K. Pfeffer, K. Schulze-Osthoff, and
I. Schmitz. Phosphorylation of Atg5 by the Gadd45betaMEKK4-p38 pathway
inhibits autophagy. Cell Death and Differentiation, 20(2):321332, February
2013. PMID: 23059785. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[609]<span
style='mso-tab-count:1'> </span>V. Stodden, F. Leisch, and R. D. Peng.
Implementing Reproducible Research. CRC Press, April 2014. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[610]<span
style='mso-tab-count:1'> </span>D. J. Millward, P. J. Garlick, R. J. Stewart,
D. O. Nnanyelugo, and J. C. Waterlow. Skeletal-muscle growth and protein
turnover. Biochemical Journal, 150(2):235243, August 1975. PMID: 1180916. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[611]<span
style='mso-tab-count:1'> </span>M. D. Delp and C. Duan. Composition and size
of type I, IIA, IID/X, and IIB fibers and citrate synthase activity of rat
muscle. Journal of Applied Physiology (Bethesda, Md.: 1985), 80(1):261270,
January 1996. PMID: 8847313. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[612]<span
style='mso-tab-count:1'> </span>F. M. Bentvelsen, M. J. McPhaul, C. M.
Wilson, J. D. Wilson, and F. W. George. Regulation of immunoreactive androgen
receptor in the adrenal gland of the adult rat. Endocrinology,
137(7):26592663, July 1996. PMID: 8770883. </p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'>[613]<span
style='mso-tab-count:1'> </span>J. Shi, L. Luo, J. Eash, C. Ibebunjo, and D.
J. Glass. The SCF-Fbxo40 complex induces IRS1 ubiquitination in skeletal
muscle, limiting IGF1 signaling. Developmental Cell, 21(5):835847, November
2011. PMID: 22033112. </p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

</div>

<span style='font-size:12.0pt;mso-bidi-font-size:11.0pt;line-height:200%;
font-family:"Georgia",serif;mso-fareast-font-family:Georgia;mso-bidi-font-family:
Georgia;color:black;mso-ansi-language:EN-US;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA'><br clear=all style='page-break-before:always;
mso-break-type:section-break'>
</span>

<div class=WordSection8>

<h1><a name="_Toc421412298">8. CURRICULUM VITAE</a></h1>

<p class=MsoNormal align=center style='text-align:center'><b style='mso-bidi-font-weight:
normal'>Nicolae Lucian Sandor<o:p></o:p></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'>Education</b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:.75pt;margin-bottom:0in;
margin-left:16.35pt;margin-bottom:.0001pt;mso-list:l9 level1 lfo10'><![if !supportLists]><span
style='mso-bidi-font-size:12.0pt;line-height:200%'><span style='mso-list:Ignore'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>PhD candidate, Boston University School of
Medicine, expected graduation 2015</p>

<p class=MsoNormal style='margin-top:0in;margin-right:.75pt;margin-bottom:0in;
margin-left:15.85pt;margin-bottom:.0001pt;mso-list:l9 level1 lfo10'><![if !supportLists]><span
style='mso-bidi-font-size:12.0pt;line-height:200%'><span style='mso-list:Ignore'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>BS (Licentiat in Biofizica), Universitatea
Bucuresti, 2005</p>

<p class=MsoNormal style='margin-top:0in;margin-right:.75pt;margin-bottom:0in;
margin-left:16.35pt;margin-bottom:.0001pt;mso-list:l9 level1 lfo10'><![if !supportLists]><span
lang=IT style='mso-bidi-font-size:12.0pt;line-height:200%;mso-ansi-language:
IT'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=IT style='mso-ansi-language:IT'>BM\DM
(Doctor in Medicina), Universitatea de Medicina si Farmacie Carol Davila
Bucuresti, 2002<o:p></o:p></span></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'>Research experience<o:p></o:p></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:.75pt;margin-bottom:0in;
margin-left:16.35pt;margin-bottom:.0001pt;mso-list:l15 level1 lfo11'><![if !supportLists]><span
style='mso-bidi-font-size:12.0pt;line-height:200%'><span style='mso-list:Ignore'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>2012-2015: Department of Medicine, Boston
University School of Medicine, P.I. Dr. Shalender Bhasin, under the supervision
of Drs. Carlo Serra and Monty Montano</p>

<p class=MsoNormal style='margin-top:0in;margin-right:.75pt;margin-bottom:0in;
margin-left:27.8pt;margin-bottom:.0001pt'><b style='mso-bidi-font-weight:normal'>
</b>Subject: Testosterone alleviating glucocorticoid-induced muscle loss.</p>

<p class=MsoNormal style='margin-top:0in;margin-right:.75pt;margin-bottom:0in;
margin-left:16.35pt;margin-bottom:.0001pt;mso-list:l15 level1 lfo11'><![if !supportLists]><span
style='mso-bidi-font-size:12.0pt;line-height:200%'><span style='mso-list:Ignore'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>2009-2012: Department of Biophysics, Boston
University School of Medicine, P.I. Dr. Assen Marintchev</p>

<p class=MsoNormal style='margin-top:0in;margin-right:.75pt;margin-bottom:0in;
margin-left:41.55pt;margin-bottom:.0001pt'><b style='mso-bidi-font-weight:normal'>
</b>Subject: Interactions between translation initiation factors eIF1A and
eIF5B</p>

<p class=MsoNormal style='margin-top:0in;margin-right:.75pt;margin-bottom:0in;
margin-left:15.85pt;margin-bottom:.0001pt;mso-list:l15 level1 lfo11'><![if !supportLists]><span
style='mso-bidi-font-size:12.0pt;line-height:200%'><span style='mso-list:Ignore'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>2005-2008: Center for the Study of Brain, Mind
and Behavior, Princeton University, P.I. Dr. Anne Treisman, FRS</p>

<p class=MsoNormal style='margin-top:0in;margin-right:4.35pt;margin-bottom:
0in;margin-left:15.4pt;margin-bottom:.0001pt'><b style='mso-bidi-font-weight:
normal'> </b>Subject: Brain mechanisms for statistical processing of visual
scenes</p>

<p class=MsoNormal style='margin-top:0in;margin-right:.75pt;margin-bottom:0in;
margin-left:16.35pt;margin-bottom:.0001pt;mso-list:l15 level1 lfo11'><![if !supportLists]><span
style='mso-bidi-font-size:12.0pt;line-height:200%'><span style='mso-list:Ignore'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Summer 2004: Biology Department, Universitatea
Bucuresti, P.I. Dr. Gordon Reid, under the supervision of Dr. Iurie Barbu</p>

<p class=MsoNormal style='margin-right:5.15pt'><b style='mso-bidi-font-weight:
normal'> </b>Subject: The mediation of thermoception by ionic membrane
channels</p>

<p class=MsoNormal style='margin-top:0in;margin-right:16.9pt;margin-bottom:
0in;margin-left:15.4pt;margin-bottom:.0001pt;mso-list:l15 level1 lfo11'><![if !supportLists]><span
style='mso-bidi-font-size:12.0pt;line-height:200%'><span style='mso-list:Ignore'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>2001-2002: Biophysics Department, Universitatea
de Medicina si Farmacie Carol Davila Bucuresti, P.I. Dr. Dan Eremia, under the
supervision of Dr. Eva Katona,</p>

<p class=MsoNormal style='margin-top:0in;margin-right:.75pt;margin-bottom:0in;
margin-left:41.55pt;margin-bottom:.0001pt'><b style='mso-bidi-font-weight:normal'>
</b>Subject: The effect of non-ionizing radiation of the mobility of the cell
membrane lipids</p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'>Peer-reviewed
publications<o:p></o:p></b></p>

<p class=MsoNormal style='margin-left:15.85pt;mso-list:l2 level1 lfo12'><![if !supportLists]><span
style='mso-bidi-font-size:12.0pt;line-height:200%'><span style='mso-list:Ignore'>1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Serra C, Tangherlini F, Rudy S, Lee D, Toraldo
G, Sandor NL, Zhang A, Jasuja R, Bhasin S. <i style='mso-bidi-font-style:normal'>Testosterone
improves the regeneration of old and young mouse skeletal muscle</i>. J
Gerontol A Biol Sci Med Sci. 2013 Jan;68(1).</p>

<p class=MsoNormal style='margin-left:15.85pt;mso-list:l2 level1 lfo12'><![if !supportLists]><span
style='mso-bidi-font-size:12.0pt;line-height:200%'><span style='mso-list:Ignore'>2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Serra C, Sandor NL, Jang H, Lee D, Toraldo G,
Guarneri T, Wong S, Zhang A, Guo W, Jasuja R, Bhasin S. <i style='mso-bidi-font-style:
normal'>The effects of testosterone deprivation and supplementation on proteasomal
and autophagy activity in the skeletal muscle of the male mouse: differential
effects on high-androgen responder and low-androgen responder muscle groups</i>.
Endocrinology. 2013 Dec;154(12).</p>

<p class=MsoNormal style='margin-left:15.85pt;mso-list:l2 level1 lfo12'><![if !supportLists]><span
style='mso-bidi-font-size:12.0pt;line-height:200%'><span style='mso-list:Ignore'>3.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Guo W, Bachman E, Vogel J, Li M, Peng L, Pencina
K, Serra C, Sandor NL, Jasuja R, Montano M, Basaria S, Gassmann M, Bhasin S. <i
style='mso-bidi-font-style:normal'>The effects of short-term and long-term
testosterone supplementation on blood viscosity and erythrocyte deformability
in healthy adult mice</i>. Endocrinology. 2015 Mar 16;en20141784. PMID:
25774550.</p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'>Other scientific communications<o:p></o:p></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:.75pt;margin-bottom:0in;
margin-left:16.6pt;margin-bottom:.0001pt;mso-list:l14 level1 lfo13'><![if !supportLists]><span
style='mso-bidi-font-size:12.0pt;line-height:200%'><span style='mso-list:Ignore'>1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Sandor NL, Hendrickson E, Sandor D, Wagner G,
Pestova TV, Marintchev A. <i style='mso-bidi-font-style:normal'>Interplay
between intra- and intermolecular interactions involving human eIF1A and eIF5B</i>.
Abstract presented at the 2010 Meeting of Translational Control, Sept. 2010, Cold
Spring Harbor, NY.</p>

<p class=MsoNormal style='margin-top:0in;margin-right:9.55pt;margin-bottom:
0in;margin-left:15.4pt;margin-bottom:.0001pt;mso-list:l14 level1 lfo13'><![if !supportLists]><span
style='mso-bidi-font-size:12.0pt;line-height:200%'><span style='mso-list:Ignore'>2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Sandor NL, Lee D, Toraldo G, Zhang A, Jasuja R,
Bhasin S, Serra C. <i style='mso-bidi-font-style:normal'>The role of
testosterone on the control of muscle protein synthesis and degradation</i>.<span
style='mso-spacerun:yes'> </span>Abstract presented at the 2011 Evans Center
Days, Nov. 2011, Boston, MA.</p>

<p class=MsoNormal style='margin-top:0in;margin-right:.75pt;margin-bottom:0in;
margin-left:16.35pt;margin-bottom:.0001pt;mso-list:l14 level1 lfo13'><![if !supportLists]><span
style='mso-bidi-font-size:12.0pt;line-height:200%'><span style='mso-list:Ignore'>3.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Serra C, Lee D, Sandor NL, Toraldo G, Jang H,
Jasuja R, Bhasin S. <i style='mso-bidi-font-style:normal'>Characterization of
the neuromuscular junction in castrated male mice</i>. Poster presented at
ENDO2013, The Endocrine Societys 95th Annual Meeting &amp; Expo, 2013, San
Francisco, CA.</p>

<p class=MsoNormal style='margin-top:0in;margin-right:.75pt;margin-bottom:0in;
margin-left:16.6pt;margin-bottom:.0001pt;mso-list:l14 level1 lfo13'><![if !supportLists]><span
style='mso-bidi-font-size:12.0pt;line-height:200%'><span style='mso-list:Ignore'>4.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Sandor NL, Jasuja R, Serra C, Bhasin S. <i
style='mso-bidi-font-style:normal'>Testosterone alleviates glucocorticoid
myopathy by inhibiting the proteolytic machinery</i>. Poster presented at the
2013 Evans Center Days, Nov. 2013, Boston, MA.</p>

</div>

</body>

</html>
